IMAX (IMAX) 10-K 22 Feb 23 2022 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Jan. 31, 2023	Jun. 30, 2022
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Registrant Name	IMAX Corporation
Entity Central Index Key	0000921582
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Well-known Seasoned Issuer	Yes
Entity Public Float			$ 781.2
Entity Common Stock, Shares Outstanding		53,969,868
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	IMAX
Security Exchange Name	NYSE
Entity File Number	001-35066
Entity Incorporation, State or Country Code	Z4
Entity Tax Identification Number	98-0140269
Entity Address, Address Line One	2525 Speakman Drive
Entity Address, City or Town	Mississauga
Entity Address, State or Province	ON
Entity Address, Country	CA
Entity Address, Postal Zip Code	L5K 1B1
City Area Code	(905)
Local Phone Number	403-6500
Document Annual Report	true
Document Transition Report	false
Auditor Firm ID	271
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Toronto, Canada
Documents Incorporated by Reference	Portions of the registrant’s definitive Proxy Statement to be filed within 120 days of the close of IMAX Corporation’s fiscal year ended December 31, 2022 , with the Securities and Exchange Commission pursuant to Regulation 14A involving the election of directors and the annual meeting of the stockholders of the registrant (the “Proxy Statement”) are incorporated by reference in Part III of this Form 10-K to the extent described therein.
Other Address [Member]
Document Information [Line Items]
Entity Address, Address Line One	902 Broadway, Floor 20
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Country	US
Entity Address, Postal Zip Code	10010
City Area Code	(212)
Local Phone Number	821-0100

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Assets
Cash and cash equivalents	$ 97,401	$ 189,711
Accounts receivable, net of allowance for credit losses	136,142	110,050
Financing receivables, net of allowance for credit losses	129,384	141,049
Variable consideration receivables, net of allowance for credit losses	44,024	44,218
Inventories	31,534	26,924
Prepaid expenses	12,343	11,802
Film assets, net of accumulated amortization	5,277	4,241
Property, plant and equipment, net of accumulated depreciation	252,896	260,353
Investment in equity securities	1,035	1,087
Other assets	15,665	17,799
Deferred income tax assets, net of valuation allowance	9,900	13,906
Goodwill	52,815	39,027
Other intangible assets, net of accumulated amortization	32,738	23,080
Total assets	821,154	883,247
Liabilities
Accounts payable	25,237	15,943
Accrued and other liabilities	117,286	111,896
Deferred revenue	70,940	81,281
Revolving credit facility borrowings, net of unamortized debt issuance costs	36,111	2,472
Convertible notes and other borrowings, net of unamortized discounts and debt issuance costs	226,912	223,641
Deferred income tax liabilities	14,900	17,642
Total liabilities	491,386	452,875
Commitments, contingencies and guarantees (see Notes 16 and 17)
Non-controlling interests
Non-controlling interests	722	758
Shareholders' equity
Capital stock common shares - no par value. Authorized - unlimited number. 54,148,614 issued and outstanding (December 31, 2021 - 58,653,642 issued and outstanding)	376,715	409,979
Other equity	185,678	174,620
Statutory surplus reserve	3,932	3,932
Accumulated deficit	(293,124)	(234,975)
Accumulated other comprehensive (loss) income	(9,846)	2,527
Total shareholders' equity attributable to common shareholders	263,355	356,083
Non-controlling interests	65,691	73,531
Total shareholders' equity	329,046	429,614
Total liabilities and shareholders' equity	$ 821,154	$ 883,247

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Shareholders' equity
Common stock, par value
Common stock, shares issued	54,148,614	58,653,642
Common stock, shares outstanding	54,148,614	58,653,642

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues
Revenues, total	$ 300,805	$ 254,883	$ 137,003
Costs and expenses applicable to revenues
Cost and expenses applicable to revenues, total	144,450	120,477	115,463
Gross margin	156,355	134,406	21,540
Selling, general and administrative expenses	138,043	117,322	108,485
Research and development	5,300	6,944	5,618
Amortization of intangible assets	4,829	4,877	5,394
Credit loss expense (reversal), net	8,547	(3,951)	18,608
Asset impairments	4,470		1,151
Legal judgment and arbitration awards	0	(1,770)	4,105
(Loss) income from operations	(4,834)	10,984	(121,821)
Realized and unrealized investment gains (losses)	70	5,340	(2,081)
Retirement benefits non-service expense	(556)	(463)	(600)
Interest income	1,428	2,218	2,388
Interest expense	(5,877)	(7,092)	(7,010)
(Loss) income before taxes	(9,769)	10,987	(129,124)
Income tax expense	(10,108)	(20,564)	(26,504)
Equity in losses of investees, net of tax	0	0	(1,858)
Net loss	(19,877)	(9,577)	(157,486)
Net (income) loss attributable to non-controlling interests	(2,923)	(12,752)	13,711
Net loss attributable to common shareholders	$ (22,800)	$ (22,329)	$ (143,775)
Net loss per share attributable to common shareholders - basic and diluted:
Net loss per share - basic	$ (0.40)	$ (0.38)	$ (2.43)
Net loss per share - diluted	$ (0.40)	$ (0.38)	$ (2.43)
Weighted average shares outstanding - basic	56,674	59,126	59,237
Weighted average shares outstanding - diluted	56,674	59,126	59,237
Technology Sales [Member]
Revenues
Revenues, total	$ 69,158	$ 66,153	$ 49,728
Costs and expenses applicable to revenues
Cost and expenses applicable to revenues, total	37,610	37,039	33,170
Image Enhancement and Maintenance Services [Member]
Revenues
Revenues, total	161,379	131,148	59,318
Costs and expenses applicable to revenues
Cost and expenses applicable to revenues, total	81,834	58,062	53,598
Technology Rentals [Member]
Revenues
Revenues, total	61,786	46,790	17,841
Costs and expenses applicable to revenues
Cost and expenses applicable to revenues, total	25,006	25,376	28,695
Finance Income [Member]
Revenues
Revenues, total	$ 8,482	$ 10,792	$ 10,116

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Net loss	$ (19,877)	$ (9,577)	$ (157,486)
Other comprehensive (loss) income, before tax
Unrealized defined benefit plan actuarial gain (loss)	2,901	132	(897)
Unrealized postretirement benefit plans actuarial gain (loss)	754	140	(351)
Amortization of prior service cost	184	185	87
Unrealized net (loss) gain from cash flow hedging instruments	(1,323)	468	500
Realized net loss (gain) from cash flow hedging instruments	596	(1,707)	604
Reclassification of unrealized gain from ineffective cash flow hedging instruments		(318)
Foreign currency translation adjustments	(20,594)	3,364	5,992
Total other comprehensive (loss) income, before tax	(17,482)	2,264	5,935
Income tax (expense) benefit related to other comprehensive income	(818)	286	55
Other comprehensive (loss) income, net of tax	(18,300)	2,550	5,990
Comprehensive loss	(38,177)	(7,027)	(151,496)
Comprehensive loss (income) attributable to non-controlling interests	3,004	(13,763)	11,899
Comprehensive loss attributable to common shareholders	$ (35,173)	$ (20,790)	$ (139,597)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating Activities
Net loss	$ (19,877)	$ (9,577)	$ (157,486)
Adjustments to reconcile net loss to cash provided by (used in) operating activities:
Depreciation and amortization	56,661	56,082	52,704
Amortization of deferred financing costs	3,177	2,513	902
Credit loss expense (reversal), net	8,547	(3,951)	18,608
Write-downs, including asset impairments	7,176	1,764	17,729
Deferred income tax (benefit) expense	(2,073)	2,996	23,618
Share-based and other non-cash compensation	27,573	26,079	22,038
Unrealized foreign currency exchange loss (gain)	1,108	256	(1,355)
Realized and unrealized investment (gains) losses	(70)	(5,340)	2,081
Equity in losses of investees	0	0	1,858
Changes in assets and liabilities:
Accounts receivable	(29,003)	(52,453)	33,597
Inventories	(5,529)	11,451	1,637
Film assets	(19,598)	(14,810)	(7,665)
Deferred revenue	(11,572)	(6,591)	(6,637)
Changes in other operating assets and liabilities	801	(2,354)	(24,640)
Net cash provided by (used in) operating activities	17,321	6,065	(23,011)
Investing Activities
Acquisition of SSIMWAVE Inc., net of cash and cash equivalents acquired	(15,939)
Purchase of property, plant and equipment	(8,424)	(3,590)	(697)
Investment in equipment for joint revenue sharing arrangements	(19,803)	(10,094)	(6,654)
Interest in film classified as a financial instrument	(4,731)
Acquisition of other intangible assets	(4,394)	(4,092)	(1,904)
Proceeds from sale of equity securities		17,769
Net cash used in investing activities	(53,291)	(7)	(9,255)
Financing Activities
Proceeds from issuance of convertible notes, net		223,675
Debt issuance costs related to convertible notes		(1,161)
Purchase of capped calls related to convertible notes		(19,067)
Revolving credit facility borrowings	37,871	3,600	287,610
Repayments of revolving credit facility borrowings	(3,600)	(307,609)
Credit facility amendment fees paid	(2,279)	(527)	(1,073)
Treasury stock purchased for future settlement of restricted share units			(3,086)
Taxes withheld and paid on employee stock awards vested	(3,687)	(3,660)	(512)
Common shares issued - stock options exercised		883
Principal payment under finance lease obligations	(948)
Dividends paid to non-controlling interests	(2,704)	(4,889)	(4,214)
Net cash (used in) provided by financing activities	(58,514)	(132,720)	240,567
Effects of exchange rate changes on cash	2,174	(1,006)	(406)
(Decrease) increase in cash and cash equivalents during year	(92,310)	(127,668)	207,895
Cash and cash equivalents, beginning of year	189,711	317,379	109,484
Cash and cash equivalents, end of year	97,401	189,711	317,379
IMAX Corporation
Financing Activities
Repurchase of common shares	(80,124)	(13,905)	(36,624)
IMAX China
Financing Activities
Repurchase of common shares	$ (3,043)	$ (10,060)	$ (1,534)

Consolidated Statements of Shar

Consolidated Statements of Shareholder's Equity - USD ($) $ in Thousands	Total	Capital Stock [Member]	Other Equity [Member]	Statutory Surplus Reserve [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive (Loss) Income [Member]	Non-controlling Interests [Member]	Common Shares Issued and Outstanding [Member]
Balance, beginning of year at Dec. 31, 2019		$ 419,348	$ 180,225		$ (40,253)	$ (3,190)
Movement of Shareholders' Equity
Amortization of share-based payment expense - stock options			2,426
Amortization of share-based payment expense - restricted share units			13,532
Amortization of share-based payment expense - performance stock units			2,708
Change in shares held in treasury		4,027
Restricted share units vested		1,448	(9,370)
Change in ownership interest related to IMAX China common share repurchases			(676)				$ (858)
Common shares repurchased and retired		(17,803)			(18,821)
Net income (loss) attributable to common shareholders	$ (143,775)				(143,775)
Net income (loss) attributable to non-controlling interests	(13,711)						(8,572)
Other comprehensive (loss) income, net of tax	5,990					4,178
Other comprehensive (loss) income, net of tax							1,812
Share-based compensation attributable to non-controlling interests							779
Dividends paid to non-controlling shareholders							(4,214)
Shares held in treasury								(723)
Balance, end of year at Dec. 31, 2020		407,020	188,845		(202,849)	988
Balance, beginning of year at Dec. 31, 2019							81,057
Balance, end of year at Dec. 31, 2020							70,004
Common shares issued and outstanding, Balance, beginning of year at Dec. 31, 2019								61,175,852
Movement of Shareholders' Equity
Restricted share units and stock option exercises settled from treasury shares purchased on open market								187,020
Restricted share units settled with new treasury shares								42,982
Repurchase of common shares								(2,484,123)
Common shares issued and outstanding, Balance, end of year at Dec. 31, 2020								58,921,008
Movement of Shareholders' Equity
Total shareholders' equity	464,008
Amortization of share-based payment expense - stock options			1,267
Amortization of share-based payment expense - restricted share units			17,116
Amortization of share-based payment expense - performance stock units			5,733
Change in shares held in treasury		11
Restricted share units vested		9,833	(14,740)
Employee stock options exercised, net of shares withheld for employee tax obligations		883
Grant date fair value of stock options exercised		271	(271)
Change in ownership interest related to IMAX China common share repurchases			(4,263)				(5,797)
Purchase of capped calls related to convertible notes			(19,067)
Common shares repurchased and retired		(8,039)			(5,865)
Net income (loss) attributable to common shareholders	(22,329)				(22,329)
Net income (loss) attributable to non-controlling interests	12,752						12,753
Other comprehensive (loss) income, net of tax	2,550					1,539
Other comprehensive (loss) income, net of tax							1,011
Share-based compensation attributable to non-controlling interests							449
Establishment of statutory surplus reserve, IMAX China				$ 3,932			1,699
Statutory surplus reserve deducted from retained earnings, IMAX China					(3,932)
Dividends paid to non-controlling shareholders							(4,889)
Balance, end of year at Dec. 31, 2021	356,083	409,979	174,620	3,932	(234,975)	2,527
Movement of Shareholders' Equity
Statutory surplus reserve deducted from IMAX China retained earnings							(1,699)
Balance, end of year at Dec. 31, 2021	$ 73,531						73,531
Movement of Shareholders' Equity
Employee stock options exercised								41,613
Restricted share units and stock option exercises settled from treasury shares purchased on open market								723
Restricted share units settled with new treasury shares								531,629
Repurchase of common shares								(841,331)
Common shares issued and outstanding, Balance, end of year at Dec. 31, 2021	58,653,642							58,653,642
Movement of Shareholders' Equity
Total shareholders' equity	$ 429,614
Amortization of share-based payment expense - stock options			637
Amortization of share-based payment expense - restricted share units			18,952
Amortization of share-based payment expense - performance stock units			8,495
Restricted share units vested		11,597	(16,441)
Issuance of common shares in acquisition		1,947						$ 160,547
Change in ownership interest related to IMAX China common share repurchases			(585)				(2,458)
Common shares repurchased and retired		(46,808)			(35,349)
Net income (loss) attributable to common shareholders	(22,800)				(22,800)
Net income (loss) attributable to non-controlling interests	2,923						2,959
Other comprehensive (loss) income, net of tax	(18,300)					(12,373)
Other comprehensive (loss) income, net of tax							(5,927)
Share-based compensation attributable to non-controlling interests							290
Dividends paid to non-controlling shareholders							(2,704)
Balance, end of year at Dec. 31, 2022	263,355	$ 376,715	$ 185,678	$ 3,932	$ (293,124)	$ (9,846)
Balance, end of year at Dec. 31, 2022	$ 65,691						$ 65,691
Movement of Shareholders' Equity
Restricted share units settled with new treasury shares								596,277
Repurchase of common shares								(5,261,852)
Common shares issued and outstanding, Balance, end of year at Dec. 31, 2022	54,148,614							54,148,614
Movement of Shareholders' Equity
Total shareholders' equity	$ 329,046

Description of the Business

Description of the Business	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of the Business	1. Description of the Business IMAX Corporation, together with its consolidated subsidiaries (the “Company”, or “IMAX”) is a Canadian corporation that was formed in March 1994 as a result of an amalgamation between WGIM Acquisition Corp. and the former IMAX Corporation (“Predecessor IMAX”). Predecessor IMAX was incorporated in 1967. As of December 31, 2022 , IMAX Corporation indirectly owns 71.73 % of IMAX China Holding, Inc. (“IMAX China”), whose shares trade on the Hong Kong Stock Exchange. IMAX China is a consolidated subsidiary of the Company. IMAX is a premier global technology platform for entertainment and events. Through its proprietary software, theater architecture, patented intellectual property, and specialized equipment, IMAX offers a unique end-to-end solution to create superior, immersive content experiences for which the IMAX ® brand is globally renowned. Top filmmakers, movie studios, artists, and creators utilize the cutting-edge visual and sound technology of IMAX to connect with audiences in innovative ways. As a result, IMAX is among the most important and successful global distribution platforms for domestic and international tentpole films and, increasingly, exclusive experiences ranging from live performances to interactive events with leading artists and creators. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the digital remastering of films and other content into the IMAX format (“IMAX DMR” ® ) and the sale or lease of premium IMAX theater systems (“IMAX System(s)”). IMAX Systems are based on proprietary and patented image, audio and other technology developed over the course of the Company’s history since its founding in 1967. The customers for IMAX Systems are principally theater exhibitors that operate commercial multiplex theaters, and, to a much lesser extent, museums, science centers and destination entertainment sites. The Company generally does not own the locations in the IMAX network, and is not an exhibitor, but instead sells or leases the IMAX System to exhibitor customers along with a license to use its trademarks and ongoing maintenance services. As of December 31, 2022, there were 1,716 IMAX Systems operating in 87 countries and territories, including 1,633 commercial multiplexes, 12 commercial destinations and 71 institutional locations in the Company's global network. This compares to 1,683 IMAX Systems operating in 87 countries and territories as of December 31, 2021 including 1,599 commercial multiplexes, 12 commercial destinations, and 72 institutional locations in the Company's global network. The Company also distributes large-format documentary films, primarily to institutional theaters, and distributes exclusive experiences ranging from live performances to interactive events with leading artists and creators. In addition, the Company provides film post-production and quality control services for large-format films, whether produced by IMAX or third parties, and digital post-production services. The Company has the following reportable segments: (i) IMAX DMR; (ii) Joint Revenue Sharing Arrangements (“JRSA”); (iii) IMAX Systems, (iv) IMAX Maintenance; (v) Other Theater Business; (vi) Film Distribution; and (vii) Film Post-Production, which are described in Note 22 .

Impact of COVID-19 Pandemic

Impact of COVID-19 Pandemic	12 Months Ended
	Dec. 31, 2022
Impact Of Coronavirus Nineteen Pandemic [Abstract]
Impact of COVID-19 Pandemic	2. Impact of COVID-19 Pandemic The COVID-19 pandemic and the measures to prevent its spread have impacted the Company’s business and the global economy. Capacity restrictions and safety protocols were lifted then reinstituted at various points since the third quarter of 2020. Although normal operations have resumed in most key markets and movie theaters throughout the IMAX network, the Company’s business continues to experience impact from COVID-19. For example, following the emergence of the Omicron variant and the rise of COVID-19 cases in China in the first quarter of 2022, the Chinese government reinstituted capacity restrictions and safety protocols on large public gatherings and enforced a zero-COVID policy, which led to the temporary lock-down of various cities and the temporary closure of theaters in these cities. At the end of 2022, the Chinese government relaxed its zero-COVID policies and significantly eased capacity restrictions. As of December 31, 2022, approximately 97 % of the IMAX network in Greater China was open at various capacities. The impact of the COVID-19 pandemic on the Company's business and financial results will continue to depend on numerous evolving factors that cannot be accurately predicted and that will vary by jurisdiction and market.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies The Company prepares its Consolidated Financial Statements in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The significant accounting policies used by the Company are summarized below. (a) Principles of Consolidation The Consolidated Financial Statements include the accounts of the Company together with its consolidated subsidiaries, except for subsidiaries which have been identified as variable interest entities (“VIEs”) where the Company is not the primary beneficiary. All intercompany accounts and transactions have been eliminated. The Company has evaluated its various variable interests to determine whether they are VIEs as required by U.S. GAAP. The Company has interests in ten film production companies, which have been identified as VIEs. The Company is the primary beneficiary of and consolidates five of these entities as it has the power to direct the activities that most significantly impact the economic performance of the VIE, and it has the obligation to absorb losses or the right to receive benefits from the respective VIE that could potentially be significant. The majority of the assets relating to these production companies are held by the IMAX Original Film Fund (the “Original Film Fund”) as described in Note 26 (b). The Company does not consolidate the other five film production companies because it does not have the power to direct their activities and it does not have the obligation to absorb the majority of the expected losses or the right to receive expected residual returns. The Company uses the equity method of accounting for these entities, which are not material to the Company’s Consolidated Financial Statements. A loss in value of an equity method investment that is other than temporary is recognized as a charge in the Consolidated Statements of Operations. As of December 31, 2022 and 2021, total assets and liabilities of the Company's consolidated VIEs are as follows: December 31, December 31, (In thousands of U.S. Dollars) 2022 2021 Total assets $ 1,523 $ 1,576 Total liabilities $ 248 $ 259 (b) Estimates and Assumptions The preparation of financial statements and related disclosures in accordance with U.S. GAAP requires management to make judgments, assumptions, and estimates that affect the amounts reported in the Company’s Consolidated Financial Statements and accompanying notes. Management’s judgments, assumptions, and estimates are based on historical experience, future expectations and other factors that are believed to be reasonable as of the date of the Consolidated Financial Statements. Actual results may ultimately differ from management’s original estimates, as future events and circumstances sometimes do not develop as expected, and the differences may be material. Significant estimates made by management include, but are not limited to: (i) the allocation of the transaction price in an IMAX System arrangement to distinct performance obligations; (ii) the amount of variable consideration to be earned on sales of IMAX Systems based on projections of future box office performance; (iii) expected credit losses on accounts receivable, financing receivables, and variable consideration receivables; (iv) provisions for the write-down of excess and obsolete inventory; (v) the fair values of the reporting units used in assessing the recoverability of goodwill; (vi) the cash flow projections used in testing the recoverability of long-lived assets such as the theater system equipment supporting joint revenue sharing arrangements; (vii) the economic lives of the theater system equipment supporting joint revenue sharing arrangements; (viii) the useful lives of intangible assets; (ix) the ultimate revenue forecasts used to test the recoverability of film assets; (x) the discount rates used to determine the present value of financing receivables and lease liabilities, as well as to determine the fair values of the Company’s reporting units for the purpose of assessing the recoverability of goodwill; (xi) pension plan assumptions; (xii) estimates related to the fair value and projected vesting of share-based payment awards; (xiii) the valuation of deferred income tax assets; (xiv) reserves related to uncertain tax positions; and (xv) the allocation of the purchase price for the acquisition of SSIMWAVE Inc. and its wholly-owned subsidiary (together, “SSIMWAVE”). The COVID-19 pandemic and the measures to prevent its spread have impacted the Company’s business and the global economy, as described in Note 2. Although management is encouraged by the broad reopening of the IMAX network, the continued progress towards the resumption of normal theater operations, normal film release schedules, and recent box office results, there continues to be risk and uncertainty relating to the judgments, assumptions, and estimates used by management in preparing the Company's Consolidated Financial Statements. Commencing in March 2022, in response to numerous sanctions imposed by the United States, Canada and the European Union on companies transacting in Russia and Belarus resulting from ongoing conflict between Russia and Ukraine, the Company suspended its operations in Russia and Belarus. As of December 31, 2022 , the IMAX network includes 54 systems in Russia, eight systems in Ukraine, and one system in Belarus, and the Company's backlog includes 14 systems in Russia, one system in Ukraine, and five systems in Belarus with a total fixed contracted value of $ 22.9 million. In the first quarter of 2022, the Company recorded provisions for potential credit losses against substantially all of its receivables in Russia due to uncertainties associated with the ongoing conflict and resulting sanctions. These receivables relate to existing sale agreements as the Company is not party to any joint revenue sharing arrangements in these countries. In addition, beginning in the first quarter of 2022, exhibitors in Russia, Ukraine, and Belarus were placed on nonaccrual status for maintenance revenue and finance income. Most multiplexes in Ukraine have reopened since the conflict began and the Company remains optimistic that its full network in Ukraine will ultimately resume operations. The Company continues to closely monitor the evolving impacts of this conflict (including the sanctions imposed by the United States, Canada and the European Union) and its effects on the global economy and the Company. (See Note 6 for more information on the impact of the ongoing Russia-Ukraine conflict and resulting sanctions on the Company's receivables and current expected credit losses.) On September 7, 2022, Cineworld Group plc (“Cineworld”), the parent company of Regal, and certain of its subsidiaries and Regal CineMedia Holdings, LLC, filed petitions for reorganization under Chapter 11 of the United States Bankruptcy Code in the Southern District of Texas. The Company had an unsecured pre-petition claim of $ 11.4 million related to receivables from the entities included in the reorganization proceedings. On October 21, 2022, the Company was ratified by the bankruptcy court as a critical vendor of Cineworld, allowing the Company to collect pre-petition amounts owed to it by Cineworld, and requiring Cineworld to stay current on the Company’s post-petition receivables. On November 8, 2022, IMAX Corporation entered into a trade agreement with Cineworld (the “Trade Agreement”), pursuant to which Cineworld affirmed the amount of the receivables owed to the Company and agreed to a payment plan under which all amounts due will be settled over the period from November 9, 2022 to April 12, 2023. As of February 20, 2023, the Company had received payments of $ 7.2 million from Cineworld in accordance with the terms of the Trade Agreement. Based on its evaluation of its contracts with Cineworld, its assessment of the reorganization and its discussions with Cineworld to date, the Company has determined that no additional provision for expected credit losses is required. The Company also does not expect to see a material impact on its IMAX network with Cineworld resulting from this reorganization. There can, however, be no guarantees as to the ultimate outcome of a Chapter 11 proceeding. (c) Cash and Cash Equivalents The Company considers all highly liquid investments convertible to a known amount of cash and with an original maturity of three months or less to be cash equivalents. (d) Receivables The Company develops an estimate of expected credit losses by class of receivable and customer type through a calculation that utilizes historical loss rates which are then adjusted for specific receivables that are judged to have a higher-than-normal risk profile after considering management’s internal credit quality classifications, as well as macro-economic and industry risk factors. The write-off of any billed receivable balance requires the approval of management. (See Note 6 for more information related to the Company’s receivables and current expected credit losses.) (e) Inventories Inventories are carried at the lower of cost, determined on an average cost basis, and net realizable value except for raw materials, which are carried at the lower of cost and replacement cost. Finished goods and work-in-process includes the cost of raw materials, direct labor, theater design costs, and an applicable share of manufacturing overhead costs. The costs related to IMAX Systems under sale and sales-type lease arrangements are transferred from Inventories to Costs and Expenses Applicable to Revenues – Technology Sales in the period when the sale is recognized in the Consolidated Statements of Operations. The costs related to IMAX Systems under joint revenue sharing arrangements are transferred from Inventories to assets under construction in Property, Plant and Equipment when allocated to a signed joint revenue sharing arrangement. The Company records write-downs for excess and obsolete inventory based upon management’s judgments regarding future events and business conditions, including the anticipated installation dates for the current backlog of theater system contracts, contracts in negotiation, technological developments, growth prospects within the customers’ ultimate marketplace and anticipated market acceptance of the Company’s current and pending theater IMAX Systems. Finished goods inventories includes IMAX Systems for which title has passed to the Company’s customer in situations when the IMAX System has been delivered to the customer, but the criteria for revenue recognition were not met as of the balance sheet date. (f) Film Assets Film Assets consist of: (i) capitalized costs associated with the digital remastering of films where the copyright is owned by a third party, including labor and allocated overhead, and (ii) capitalized costs associated with the production of films, including labor, allocated overhead, and the cost of acquiring film rights. Production financing provided by third parties that acquire substantive rights in the film is recorded as a reduction of the cost of the film. Capitalized film costs are amortized and participation costs are accrued to Costs and Expenses Applicable to Revenues using the individual-film-forecast method, which amortizes such costs in the same ratio as the associated ultimate revenue. Estimates of ultimate revenues are prepared on a title-by-title basis and reviewed regularly by management and revised where necessary to reflect the most current information. Ultimate revenues reflect management’s estimates of future revenue over a period not to exceed ten years following the date of the film’s initial release. The recoverability of the Company’s film assets is dependent upon the commercial acceptance of the underlying films and the resulting level of box office results and, in certain situations, ancillary revenues. If management’s projections of future net cash flows resulting from the exploitation of a film indicate that the carrying value of the film asset is not recoverable, the film asset is written down to its fair value. Film exploitation costs, including advertising and marketing, are recorded in Costs and Expenses Applicable to Revenues – Image Enhancement and Maintenance Services as incurred, except for those costs that are made after recognizing revenue, which are recorded when the related revenues are recognized. (g) Property, Plant and Equipment Property, Plant and Equipment is recorded at cost and is depreciated on a straight-line basis over the estimated useful lives of the underlying assets as follows: Theater system components (1) — Over the equipment’s expected useful life ( 7 to 20 years) Camera equipment — Over a period between 5 to 10 years Buildings — Over a period between 20 to 25 years Office and product equipment — Over a period between 3 to 5 years Leasehold improvements — Over the shorter of the initial term of the underlying lease plus any reasonably assured renewal periods, and the useful life of the asset (1) Includes equipment under joint revenue sharing arrangements. The cost of IMAX System components and related equipment expected to be used in future joint revenue sharing arrangements, including related direct labor costs and an allocation of direct production costs, are recorded within assets under construction until the underlying IMAX System is installed and in working condition. These assets are depreciated to Costs and Expenses Applicable to Revenues on a straight-line basis over the lesser of the term of the joint revenue sharing arrangement and the equipment’s expected useful life. The estimated useful lives of the system components and related equipment used in joint revenue sharing arrangements are reviewed periodically to determine if any adjustments are required. Property, Plant and Equipment is grouped at the lowest level for which identifiable cash flows are largely independent and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset (or asset group) may not be recoverable. In such situations, the asset (or asset group) is considered impaired when estimated future cash flows (undiscounted and without interest charges) resulting from the use of the asset (or asset group) and its eventual disposition are less than the carrying value of the asset (or asset group). In such situations, the asset (or asset group) is written down to its fair value, which is the present value of the estimated future cash flows. Factors that are considered when evaluating such assets for impairment include a current expectation that it is more likely than not that the long-lived asset will be sold significantly before the end of its useful life, a significant decrease in the market price of the long-lived asset, and a significant change in the extent or manner in which the long-lived asset is being used. (h) Investment in Equity Securities Equity securities with readily determinable fair values are reported at fair value with changes in fair value recorded within Realized and Unrealized Investment Gains (Losses) in the Consolidated Statements of Operations. (i) Other Assets Other Assets principally includes lease incentives provided to certain exhibitor customers under joint revenue sharing arrangements classified as an operating lease, as well as sales commissions and other deferred selling expenses that directly relate to the acquisition of the revenue generating contract and are incremental to the Company’s other expenses. To a much lesser extent, Other Assets also includes various investments and foreign currency derivatives. Capitalized lease incentives are amortized on a straight-line basis over the term of the lease as a reduction to rental revenue. Sales commissions and other selling expenses paid prior to the recognition of the related revenue are deferred and recognized within Costs and Expenses Applicable to Revenues upon the client acceptance of the IMAX System or the abandonment of the sale arrangement. Foreign currency derivatives are accounted for at fair value using quoted prices in active markets. In periods when there are no outstanding borrowings under the Company’s revolving credit facility arrangements, any related debt issuance costs are recorded within Other Assets and amortized on a straight-line basis over the term of the facility. In periods when there are outstanding borrowings under the Company’s revolving credit facility arrangements, any related debt issuance costs are reclassified to reduce the principal amount of outstanding borrowings and amortized on a straight-line basis over the term of the facility. (See Note 15 for information related to the Company’s borrowings.) (j) Goodwill Goodwill represents the excess of the purchase price paid over the fair value of net assets acquired in a business combination. Goodwill is not amortized, but is tested annually for impairment at the reporting unit level in the fourth quarter of the year and between annual tests if indicators of potential impairment exist. These indicators could include a decline in the Company’s stock price and market capitalization, a significant change in the outlook for the reporting unit's business, including projections of future box office results and IMAX System installations, lower than expected operating results, increased competition, legal factors, or the sale or disposition of a significant portion of a reporting unit. For reporting units with goodwill, an impairment loss is recognized for the amount by which the reporting unit's carrying value, including goodwill, exceeds its fair value. The carrying value of each reporting unit is based on a systematic and rational allocation of certain assets and liabilities. The fair value of each reporting unit is assessed using a discounted cash flow model based on management’s current short-term forecast and estimated long-term projections, against which various sensitivity analyses are performed. The discount rates used in the cash flow model are derived based on the Company’s estimated weighted average cost of capital. These estimates and the likelihood of future changes in these estimates depend on a number of underlying variables and a range of possible outcomes. (k) Other Intangible Assets Other intangible assets with finite lives are generally amortized on a straight-line basis over estimated useful lives ranging from 4 to 20 years, except for intangible assets that have an identifiable pattern of consumption of the economic benefit of the asset. Such intangible assets are amortized over the consumption pattern. Research and development acquired in a business combination is measured at fair value using market-participant assumptions and is initially classified as an indefinite-lived intangible asset. The in-process intangible research and development (IPR&D) assets are considered indefinite-lived until the abandonment or completion of the associated research and development efforts. If the acquired IPR&D project is abandoned, the related intangible would be written off or impaired. Once the IPR&D activities are completed, management would determine the useful lives and the methods of amortization of the related intangible assets. The Company capitalizes costs associated with internally developed and/or purchased software systems for internal use that have reached the application development stage. Capitalized costs include external direct costs of materials and services utilized in developing or obtaining internal-use software and payroll and payroll-related expenses for employees who are directly associated with and devote time to the internal-use software project. Capitalization of such costs begins when the preliminary project stage is complete and ceases no later than the point at which the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages are charged to expense. These capitalized costs are amortized on a straight-line basis over the estimated useful life. Intangible Assets are grouped at the lowest level for which identifiable cash flows are largely independent and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset (or asset group) may not be recoverable. In such situations, the asset (or asset group) is considered impaired when estimated future cash flows (undiscounted and without interest charges) resulting from the use of the asset (or asset group) and its eventual disposition are less than the carrying value of the asset (or asset group). In such situations, the asset (or asset group) is written down to its fair value, which is the present value of the estimated future cash flows. Factors that are considered when evaluating intangible assets for impairment include a current expectation that it is more likely than not that the intangible asset will be sold significantly before the end of its useful life, a significant decrease in the market price of the intangible asset, and a significant change in the extent or manner in which the intangible asset is being used. (l) Deferred Revenue In instances where the Company receives consideration prior to satisfying its performance obligations, the recognition of revenue is deferred. The majority of the Deferred Revenue balance relates to payments received by the Company for IMAX Systems where control of the system has not transferred to the customer. The Deferred Revenue balance related to an individual location increases as progress payments are made and is then derecognized when control of the system is transferred to the customer. To a lesser extent, the Deferred Revenue balance also relates to situations when an exhibitor customer pays the contractual maintenance fee prior to the recognition of revenue. (m) Statutory Surplus Reserve Pursuant to the corporate law of the People’s Republic of China (the “PRC”), entities registered in the PRC are required to maintain certain statutory reserves, which are appropriated from after-tax profits, after offsetting accumulated losses from prior years, before dividends can be declared or paid to equity holders. The Company’s PRC subsidiaries are required to appropriate 10 % of statutory net profits to statutory surplus reserves, upon distribution of their after-tax profits. The Company’s PRC subsidiaries may discontinue the appropriation of statutory surplus reserves when the aggregate sum of the statutory surplus reserve is more than 50 % of their registered capital. The statutory surplus reserve is non-distributable other than during liquidation and may only be used to fund losses from prior years, to expand production operations, or to increase the capital of the subsidiaries. In addition, the subsidiaries may make further contribution to a discretionary surplus reserve using post-tax profits in accordance with resolutions of the Board of Directors. (n) Income Taxes Income taxes are accounted for under the liability method whereby deferred income tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the accounting and tax bases of assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates or laws is recognized in the Company’s Consolidated Financial Statements in the period in which the change is enacted. Investment tax credits are recognized as a reduction of income tax expense. The Company assesses the realization of deferred income tax assets and based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable in the current period. In assessing the need for a valuation allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning strategies. If management determines that sufficient negative evidence exists, then management will consider recording a valuation allowance against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, management’s projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with the benefit of hindsight, to be inaccurate, it could prove more difficult to support the realization of these deferred tax assets. As a result, an additional valuation allowance could be required, which would have an adverse impact on the Company’s effective income tax rate and results. Conversely, if, after recording a valuation allowance, management determines that sufficient positive evidence exists in the jurisdiction in which a valuation allowance is recorded, the Company may reverse all or a portion of the valuation allowance in that jurisdiction. In such situations, the adjustment made to the deferred tax asset would have a favorable impact on the Company’s effective income tax rate and results in the period such determination was made. The Company is subject to ongoing tax exposures, examinations and assessments in various jurisdictions. Tax benefits are recognized only when it is more likely than not, based on the technical merits, that the benefits will be sustained on examination. Tax benefits that meet the more likely than not recognition threshold are measured using a probability weighting of the largest amount of tax benefit that has greater than 50% likelihood of being realized upon settlement. Whether the more likely than not recognition threshold is met for a particular tax benefit is a matter of judgment based on the individual facts and circumstances evaluated in light of all available evidence as of the balance sheet date. Although management believes that the Company has adequately accounted for its uncertain tax positions, tax audits can result in subsequent assessments where the ultimate resolution may result in the Company owing additional taxes above what was originally recognized in its financial statements. Tax reserves for uncertain tax positions are adjusted by the Company to reflect its best estimate of the outcome of examinations and assessments and in light of changing facts and circumstances, such as the completion of a tax audit, expiration of a statute of limitations, the refinement of an estimate, and interest accruals associated with the uncertain tax positions until they are resolved. Some of these adjustments require significant judgment in estimating the timing and amount of the additional tax expense. (o) Revenue Recognition IMAX Systems The Company evaluates each of the performance obligations in an IMAX System arrangement to determine which are considered distinct, either individually or in a group, for accounting purposes and which of the deliverables represent separate performance obligations. The Company’s “System Obligation” consists of the following: (i) an IMAX System, which includes the projector, sound system, screen system and, if applicable, a 3D glasses cleaning machine; (ii) services associated with the IMAX System, including theater design support, the supervision of installation services, and projectionist training; and (iii) a license to use the IMAX brand to market the theater. The System Obligation, as a group, is a distinct performance obligation. The Company is not responsible for the physical installation of the equipment in the customer’s facility; however, it supervises the installation by the customer. The customer has the right to use the IMAX brand from the date the Company and the customer enter into an arrangement. IMAX System arrangements also include a requirement for the Company to provide maintenance services and an extended warranty over the life of the arrangement in exchange for an annual maintenance fee, which is subject to a consumer price index increase on renewal each year. Consideration related to the provision of maintenance services is included in the allocation of the transaction price to the separate performance obligations in the arrangement at contract inception, as discussed in more detail below. The Company’s maintenance services are a stand ready obligation and, as a result, are recognized on a straight-line basis over the contract term. The transaction price in an IMAX System arrangement is allocated to each good or service that is identified as a separate performance obligation based on estimated standalone selling prices. This allocation is based on observable prices when the Company sells the goods or services separately. The Company has established standalone prices for the System Obligation and maintenance and extended warranty services, as well as for film license arrangements. The Company uses an adjusted market assessment approach for separate performance obligations that do not have standalone selling prices or third-party evidence of estimated standalone selling prices. The Company considers multiple factors including its historical pricing practices, product class, market competition and geography. IMAX System arrangements involve either the lease or the sale of an IMAX System. The transaction price for the System Obligation, other than for IMAX Systems delivered pursuant to joint revenue sharing arrangements, consist of upfront or initial payments made before and after the final installation of the system and ongoing payments throughout the term of the arrangement. The Company estimates the transaction price, including an estimate of future variable consideration, received in exchange for the goods delivered or services rendered. The arrangement for the sale of an IMAX System includes indexed minimum payment increases over the term of the arrangement, as well as the potential for additional payments owed by the exhibitor customer if certain minimum box office receipt thresholds are exceeded. In addition, hybrid sales arrangements include amounts owed by the exhibitor customer based on a percentage of their box office receipts over the term of the arrangement. These contract provisions are considered to be variable consideration. An estimate of the present value of such variable consideration is recognized as revenue upon the transfer of control of the System Obligation to the customer, subject to constraints to ensure that there is not a risk of significant revenue reversal. This estimate is based on management’s box office projections for the individual location, which are developed using historical data for the location and, if necessary, comparable theaters and territories (see “Constraints on the Recognition of Variable Consideration” below). Transfer of control of the System Obligation occurs at the earlier of client acceptance of the installation of the IMAX System, including projectionist training, and the opening of the theater to the public, as discussed in more detail below. IMAX System arrangements are non-cancellable unless the Company fails to perform its obligations. In the absence of a material default by the Company, there is no right to any remedy for the customer under the Company’s arrangements. If a material default by the Company exists, the customer has the right to terminate the arrangement and seek a refund only if the customer provides notice to the Company of a material default and only if the Company does not cure the default within a specified period. Sales Arrangements For IMAX System arrangements that qualify as a sale, the transaction price allocated to the System Obligation is recognized in the Consolidated Statements of Operations upon the transfer of control of the system to the customer, which is when all of the following conditions have been met: (i) the projector, sound system, and screen system have been installed and are in full working condition, (ii) the 3D glasses cleaning machine, if applicable, has been delivered, (iii) projectionist training has been completed, and (iv) the earlier of (a) the receipt of written customer acceptance certifying the completion of installation and run-in testing of the equipment and the completion of projectionist training or (b) the public opening of the IMAX System. The initial revenue recognized i

New Accounting Standards and Ac

New Accounting Standards and Accounting Changes	12 Months Ended
	Dec. 31, 2022
Accounting Standards Update and Change in Accounting Principle [Abstract]
New Accounting Standards and Accounting Changes	4. New Accounting Standards and Accounting Changes Adoption of New Accounting Policies In July 2021, the FASB issued ASU No. 2021-05, “Leases (Topic 842): Lessors - Certain Leases with Variable Lease Payments” (“ASU 2021-05”), which requires sales-type or direct financing leases that have variable payments (that do not depend on a rate or an index) and result in a day-one loss to be classified as operating leases. When a lease is classified as operating, the lessor does not recognize a net investment in the lease, does not derecognize the underlying asset, and, therefore, does not recognize a selling profit or loss. The amendments are effective for annual periods beginning after December 15, 2021 including interim periods within those periods. Early adoption is permitted. The Company adopted ASU 2021-05 for the year ended December 31, 2022 and adoption did no t have a material impact on the Company's Consolidated Financial Statements. In October 2021, the FASB issued ASU No. 2021-08, “2021-08: Business Combinations (Topic 850): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (“ASU 2021-08” ). ASU 2021-08 requires that an acquirer recognize and measure contract assets and contract liabilities (e.g., deferred revenue) acquired in a business combination in accordance with Topic 606, as opposed to at fair value. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, including interim periods within those periods. Early adoption is permitted. The Company elected to early adopt ASU 2021-08 in the third quarter of 2022 in connection with its acquisition of SSIMWAVE Inc. (see Note 5). In November 2021, the FASB issued ASU No. 2021-10, “2021-10: Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance” (“ASU 2021-10”). The amendments in ASU 2021-10 require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The amendments are effective for annual periods beginning after December 15, 2021. Early adoption is permitted. The Company adopted ASU 2021-10 for the year ended December 31, 2022 and has provided the required disclosures in Note 25. Recently Issued FASB Accounting Standard Codification Updates Not Yet Adopted In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”). The purpose of ASU 2020-04 is to provide optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2020-04 is effective for all entities from the beginning of an interim period that includes the issuance date of the ASU. An entity may elect to apply ASU 2020-04 prospectively through December 31, 2022. In October 2022, the FASB extended the temporary accounting relief to December 31, 2024 from the current sunset date of December 31, 2022. As of December 31, 2022, the Company is not party to any third party contracts that reference the London Interbank Offered Rate (LIBOR). Accordingly, the Company does not expect ASU 2020-04 to have a material effect on its Consolidated Financial Statements. In March 2022, the FASB issued ASU No. 2022-02, “2022-02: Financial Instruments—Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures” (“ASU 2022-02”). ASU 2022-02 amends and eliminates the accounting guidance for Troubled Debt Restructurings by creditors, while enhancing disclosure requirements for certain loan refinancings and restructurings by creditors when a borrower is experiencing financial difficulty and requires for public business entities, to disclose current-period gross write offs by year of origination for financing receivables and net investments in leases. ASU 2022-02 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. The Company will adopt ASU 2022-02 for the first quarter of 2023 and is in the process of evaluating the accounting and disclosure impact, if any, on the Company's Consolidated Financial Statements. The Company considers the applicability and impact of all recently issued FASB accounting standard codification updates. Accounting standard updates that are not noted above were assessed and determined to be not applicable or not significant to the Company’s Consolidated Financial Statements for the year ended December 31, 2022.

Acquisition

Acquisition	12 Months Ended
	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisition	5. Acquisition On September 22, 2022 , the Company acquired all of the issued and outstanding shares of SSIMWAVE pursuant to a share purchase agreement by and among the Company, SSIMWAVE, and related shareholders (the “Sellers”). SSIMWAVE provides perceptual quality measurement and optimization solutions based on artificial intelligence technologies for leading media and entertainment companies. Following the acquisition, SSIMWAVE became a wholly-owned subsidiary of the Company. As consideration for the acquisition of SSIMWAVE, the Company paid an aggregate purchase price of $ 23.2 million, comprised of: (i) $ 19.5 million in cash, (ii) 160,547 common shares of the Company with a fair value of $ 1.9 million (the “IMAX Share Consideration”), and (iii) contingent consideration with a fair value of $ 1.8 million (the “Earn-Out Payment”). The fair value of the IMAX Share Consideration, which is based on the share price on the date of the acquisition, is reduced to reflect the fair value of certain restrictions on the future transfer of the shares. The Earn-Out Payment may be paid to certain Sellers in an aggregate amount of up to $ 2.0 million in cash, contingent upon and following the achievement of certain commercial and financial milestones during the period from January 1, 2023 to December 31, 2024, or under certain terms March 31, 2025. The fair value of the Earn-Out Payment is based on management's assessment of the likelihood of achieving these milestones. The revenues and earnings of SSIMWAVE for the period post-acquisition through December 31, 2022 were included in All Other for segment reporting and were not material to the Company's Consolidated Financial Statements. During the year ended December 31, 2022 , the Company incurred $ 1.1 million of professional fees in connection with the acquisition of SSIMWAVE, which were recorded within Selling, General and Administrative Expenses on the Company's Consolidated Statements of Operations. The Company has accounted for the acquisition of SSIMWAVE as a business combination and has completed its valuation of the assets acquired and liabilities assumed. In the fourth quarter of 2022, the Company finalized the purchase price allocation and allocated $ 11.2 million from Goodwill to Other Intangible Assets based on its valuation procedures and recognized the $ 2.0 million of deferred tax liability related to this allocation. In addition, in the fourth quarter of 2022, the Company made an additional payment of $ 0.1 million to certain former SSIMWAVE shareholders resulting from customary post-acquisition date working capital adjustments. The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed as of December 31, 2022. (In thousands of U.S. Dollars) Purchase Price : Cash payments $ 19,521 IMAX Share Consideration 1,947 Earn-Out Payment 1,750 Total Purchase Price $ 23,218 Allocation of Purchase Price : Cash and cash equivalents $ 3,582 Accounts receivable 158 Property, plant and equipment 409 Intangible assets (see Note 14) 11,189 Other assets 293 Accounts payable and accrued liabilities ( 1,092 ) Deferred revenue ( 1,300 ) Federal economic development loan, net of unaccreted interest benefit ( 1,772 ) Deferred tax liability ( 2,037 ) Goodwill (see Note 14) 13,788 Total Purchase Price $ 23,218 The allocation of the fair value of identified intangible assets is as follows: (In thousands of U.S. Dollars) Fair Value Weighted Average Useful Life Patent and trademarks 100 2 Years Customer relationships 1,340 7 Years Developed technology 5,779 4 to 7 Years In-process research and development 3,810 Not yet in use Non-compete agreement 160 4 Years Total identifiable intangible assets $ 11,189 Goodwill is the excess of the consideration transferred over the net assets recognized and primarily represents future economic benefits arising from assets acquired that are not individually identified and separately recognized, including synergies and assembled workforce inherent in the acquired business. The goodwill recorded is not expected to be deductible for income tax purposes. The goodwill associated with SSIMWAVE is in a separate reporting unit for goodwill impairment assessment purposes.

Receivables

Receivables	12 Months Ended
	Dec. 31, 2022
Receivables [Abstract]
Receivables	6. Receivables The ability of the Company to collect its receivables is principally dependent on the viability and solvency of individual theater operators which is significantly influenced by consumer behavior and general economic conditions. Theater operators, or other customers, may experience financial difficulties that could result in them being unable to fulfill their payment obligations to the Company. In order to mitigate the credit risk associated with its receivables, management performs an initial credit evaluation prior to entering into an arrangement with a customer and then regularly monitors the credit quality of each customer through an analysis of collections history and aging. This monitoring process includes meetings on at least a monthly basis to identify credit concerns and potential changes in credit quality classification. A customer may improve their credit quality classification once a substantial payment is made on an overdue balance or when the customer has agreed to a payment plan and payments have commenced in accordance with that plan. Changes in credit quality classification are dependent upon management approval. The Company’s internal credit quality classifications for theater operators are as follows: • Good Standing — The theater operator continues to be in good standing as payments and reporting are received on a regular basis. • Credit Watch — The theater operator has demonstrated a delay in payments, but continues to be in active communication with the Company. Theater operators placed on Credit Watch are subject to enhanced monitoring. In addition, depending on the size of the outstanding balance, length of time in arrears, and other factors, future transactions may need to be approved by management. These receivables are in better condition than those in the Pre-Approved Transactions Only category, but are not in as good condition as the receivables in the Good Standing category. • Pre-Approved Transactions Only — The theater operator has demonstrated a delay in payments with little or no communication with the Company. All services and shipments to the theater operator must be reviewed and approved by management. These receivables are in better condition than those in the All Transactions Suspended category, but are not in as good condition as the receivables in the Credit Watch category. In certain situations, a theater operator may be placed on nonaccrual status and all revenue recognition related to the theater may be suspended, including the accretion of Finance Income for Financing Receivables. • All Transactions Suspended — The theater operator is severely delinquent, non-responsive or not negotiating in good faith with the Company. Once a theater operator is classified within the All Transactions Suspended category, the theater is placed on nonaccrual status and all revenue recognitions related to the theater are suspended, including the accretion of Finance Income for Financing Receivables. During the period when the accretion of Finance Income is suspended for Financing Receivables, any payments received from a customer are applied against the outstanding balance owed. If payments are sufficient to cover any unreserved receivables, a reversal of the provision is recorded to the extent of the residual cash received. Once the collectability issues are resolved and the customer has returned to being in good standing, the Company will resume recognition of Finance Income. When a customer’s aging exceeds 90 days, the Company’s policy is to perform an enhanced review to assess collectability of the theater’s past due accounts. The over 90 days past due category may be an indicator of potential impairment as up to 90 days outstanding is considered to be a reasonable time to resolve any issues. The Company develops an estimate of expected credit losses by class of receivable and customer type through a calculation that utilizes historical loss rates which are then adjusted for specific receivables that are judged to have a higher-than-normal risk profile after considering management’s internal credit quality classifications. Additional credit loss provisions are also recorded taking into account macro-economic and industry risk factors. The write-off of any billed receivable balance requires the approval of management. On September 7, 2022, Cineworld, the parent company of Regal, and certain of its subsidiaries and Regal CineMedia Holdings, LLC, filed petitions for reorganization under Chapter 11 of the United States Bankruptcy Code in the Southern District of Texas. The Company had an unsecured pre-petition claim of $ 11.4 million related to receivables from the entities included in the reorganization proceedings. On October 21, 2022, the Company was ratified by the bankruptcy court as a critical vendor of Cineworld, allowing the Company to collect pre-petition amounts owed to it by Cineworld, and requiring Cineworld to stay current on the Company’s post-petition receivables. On November 8, 2022, IMAX Corporation entered into a trade agreement with Cineworld (the “Trade Agreement”), pursuant to which Cineworld affirmed the amount of the receivables owed to the Company and agreed to a payment plan under which all amounts due will be settled over the period from November 9, 2022 to April 12, 2023. As of February 20, 2023, the Company had received payments of $ 7.2 million from Cineworld in accordance with the terms of the Trade Agreement. Based on its evaluation of its contracts with Cineworld, its assessment of the reorganization and its discussions with Cineworld to date, the Company has determined that no additional provision for expected credit losses is required. The Company also does not expect to see a material impact on its IMAX network with Cineworld resulting from this reorganization. There can, however, be no guarantees as to the ultimate outcome of a Chapter 11 proceeding. Management's judgments regarding expected credit losses are based on the facts available to management and involve estimates about the future. Due to the unprecedented nature of the COVID-19 pandemic, its effect on the Company's customers and their ability to meet their financial obligations to the Company is difficult to predict. As a result, the Company's judgments and associated estimates of credit losses may ultimately prove, with the benefit of hindsight, to be incorrect (see Note 2). The impacts of inflation, and rising interest rates may also impact future credit losses. The Company will continue to monitor economic trends and conditions and portfolio performance and adjust its allowance for credit loss accordingly. Accounts Receivable Accounts receivable principally includes amounts currently due to the Company under IMAX System sale and sales-type lease arrangements, contingent fees owed by theater operators as a result of box office performance, and fees for maintenance services. Accounts receivable also includes amounts due to the Company from movie studios and other content creators principally for digitally remastering films into IMAX formats, as well as for film distribution and post-production services. The following tables summarize the activity in the allowance for credit losses related to Accounts Receivable for the years ended December 31, 2022 and 2021: Year Ended December 31, 2022 (In thousands of U.S. Dollars) Theater Studios Other Total Beginning balance $ 8,867 $ 1,994 $ 1,085 $ 11,946 Current period provision (reversal), net 2,687 ( 128 ) 585 3,144 Write-offs ( 43 ) ( 128 ) ( 394 ) ( 565 ) Foreign exchange ( 367 ) ( 39 ) — ( 406 ) Ending balance $ 11,144 $ 1,699 $ 1,276 $ 14,119 Year Ended December 31, 2021 (In thousands of U.S. Dollars) Theater Studios Other Total Beginning balance $ 8,368 $ 4,481 $ 1,446 $ 14,295 Current period provision (reversal), net 793 ( 1,913 ) ( 332 ) ( 1,452 ) Write-offs ( 357 ) ( 551 ) ( 19 ) ( 927 ) Foreign exchange 63 ( 23 ) ( 10 ) 30 Ending balance $ 8,867 $ 1,994 $ 1,085 $ 11,946 For the year ended December 31, 2022, the Company’s allowance for current expected credit losses related to Accounts Receivable increased by $ 2.2 million , principally due to reserves established against its receivables in Russia due to uncertainties associated with the ongoing Russia-Ukraine conflict and resulting sanctions, partially offset by the reversal of provisions associated with the COVID-19 pandemic as the outlook for the theatrical exhibition industry in Domestic and Rest of World markets continues to improve. There remains a $ 1.5 million COVID-19 additional reserve for China. For the year ended December 31, 2021, the Company’s allowance for current expected credit losses related to Accounts Receivable decreased by $ 2.3 million . This decrease is principally due to improved collection experience with respect to foreign studio receivable balances, partially offset by new provisions recorded in the period. Financing Receivables Financing receivables are due from theater operators and consist of the Company’s net investment in sales-type leases and receivables associated with financed sales of IMAX Systems . As of December 31, 2022 and 2021, financing receivables consist of the following: December 31, December 31, (In thousands of U.S. Dollars) 2022 2021 Net investment in leases Gross minimum payments due under sales-type leases $ 29,727 $ 29,953 Unearned finance income ( 619 ) ( 763 ) Present value of minimum payments due under sales-type leases 29,108 29,190 Allowance for credit losses ( 776 ) ( 798 ) Net investment in leases 28,332 28,392 Financed sales receivables Gross minimum payments due under financed sales 141,337 152,315 Unearned finance income ( 29,340 ) ( 34,244 ) Present value of minimum payments due under financed sales 111,997 118,071 Allowance for credit losses ( 10,945 ) ( 5,414 ) Net financed sales receivables 101,052 112,657 Total financing receivables $ 129,384 $ 141,049 Net financed sales receivables due within one year $ 32,366 $ 29,115 Net financed sales receivables due after one year 68,686 83,542 Total financed sales receivables $ 101,052 $ 112,657 As of December 31, 2022 and 2021, the weighted-average remaining lease term and weighted-average interest rate associated with the Company’s sales-type lease arrangements and financed sale receivables, as applicable, are as follows: December 31, December 31, 2022 2021 Weighted-average remaining lease term (in years) Sales-type lease arrangements 9.0 9.6 Weighted-average interest rate Sales-type lease arrangements 8.23 % 6.56 % Financed sales receivables 8.79 % 8.79 % The tables below provide information on the Company’s net investment in leases by credit quality indicator as of December 31, 2022 and 2021. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. (In thousands of U.S. Dollars) By Origination Year As of December 31, 2022 2022 2021 2020 2019 2018 Prior Total Net investment in leases: Credit quality classification: In good standing $ 4,148 $ 6,969 $ 2,494 $ 1,977 $ — $ 1,016 $ 16,604 Credit Watch — — — — — — — Pre-approved transactions — 3,089 1,162 5,401 2,451 — 12,103 Transactions suspended — — — — — 401 401 Total net investment in leases $ 4,148 $ 10,058 $ 3,656 $ 7,378 $ 2,451 $ 1,417 $ 29,108 (In thousands of U.S. Dollars) By Origination Year As of December 31, 2021 2021 2020 2019 2018 2017 Prior Total Net investment in leases: Credit quality classification: In good standing $ 11,030 $ 3,991 $ 7,973 $ 2,574 $ 823 $ 1,928 $ 28,319 Credit Watch — — — — — — — Pre-approved transactions — — — — — — — Transactions suspended — — — — — 871 871 Total net investment in leases $ 11,030 $ 3,991 $ 7,973 $ 2,574 $ 823 $ 2,799 $ 29,190 The tables below provide information on the Company’s financed sale receivables by credit quality indicator as of December 31, 2022 and 2021. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. (In thousands of U.S. Dollars) By Origination Year As of December 31, 2022 2022 2021 2020 2019 2018 Prior Total Financed sales receivables: Credit quality classification: In good standing $ 10,252 $ 8,643 $ 6,280 $ 8,541 $ 9,854 $ 39,912 $ 83,482 Credit Watch — — — — — 1,152 1,152 Pre-approved transactions — 2,318 1,399 1,134 1,449 9,243 15,543 Transactions suspended 272 664 142 1,269 1,197 8,276 11,820 Total financed sales receivables $ 10,524 $ 11,625 $ 7,821 $ 10,944 $ 12,500 $ 58,583 $ 111,997 (In thousands of U.S. Dollars) By Origination Year As of December 31, 2021 2021 2020 2019 2018 2017 Prior Total Financed sales receivables: Credit quality classification: In good standing $ 12,520 $ 8,251 $ 10,593 $ 13,278 $ 12,615 $ 47,950 $ 105,207 Credit Watch — — — — 321 1,292 1,613 Pre-approved transactions — — 743 418 2,098 3,650 6,909 Transactions suspended — — 335 — 680 3,327 4,342 Total financed sales receivables $ 12,520 $ 8,251 $ 11,671 $ 13,696 $ 15,714 $ 56,219 $ 118,071 The balance of financed sale receivables classified within the Transactions Suspended category as of December 31, 2022 includes amounts due from exhibitors in Russia, Ukraine, and Belarus which were reclassified from other credit quality classifications in the first quarter of 2022 as a result of the ongoing Russia-Ukraine conflict and resulting sanctions. The following tables provide an aging analysis for the Company’s net investment in leases and financed sale receivables as of December 31, 2022 and 2021: As of December 31, 2022 (In thousands of U.S. Dollars) Accrued 30-89 90+ Billed Unbilled Recorded Allowance Net Net investment in leases $ 237 $ 216 $ 2,593 $ 3,046 $ 26,062 $ 29,108 $ ( 776 ) $ 28,332 Financed sales receivables 2,269 1,307 12,793 16,369 95,628 111,997 ( 10,945 ) 101,052 Total $ 2,506 $ 1,523 $ 15,386 $ 19,415 $ 121,690 $ 141,105 $ ( 11,721 ) $ 129,384 As of December 31, 2021 (In thousands of U.S. Dollars) Accrued 30-89 90+ Billed Unbilled Recorded Allowance Net Net investment in leases $ 225 $ 156 $ 1,267 $ 1,648 $ 27,542 $ 29,190 $ ( 798 ) $ 28,392 Financed sales receivables 1,750 989 8,378 11,117 106,954 118,071 ( 5,414 ) 112,657 Total $ 1,975 $ 1,145 $ 9,645 $ 12,765 $ 134,496 $ 147,261 $ ( 6,212 ) $ 141,049 The following tables provide information about the Company’s net investment in leases and financed sale receivables with billed amounts past due for which it continues to accrue finance income as of December 31, 2022 and 2021. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. As of December 31, 2022 (In thousands of U.S. Dollars) Accrued 30-89 Days 90+ Days Billed Unbilled Allowance Net Net investment in leases $ 190 $ 181 $ 2,593 $ 2,964 $ 17,070 $ ( 230 ) $ 19,804 Financed sales receivables 1,550 1,115 10,814 13,479 43,172 ( 1,587 ) 55,064 Total $ 1,740 $ 1,296 $ 13,407 $ 16,443 $ 60,242 $ ( 1,817 ) $ 74,868 As of December 31, 2021 (In thousands of U.S. Dollars) Accrued 30-89 Days 90+ Days Billed Unbilled Allowance Net Net investment in leases $ 143 $ 132 $ 825 $ 1,100 $ 12,619 $ ( 176 ) $ 13,543 Financed sales receivables 959 729 6,190 7,878 41,439 ( 1,413 ) 47,904 Total $ 1,102 $ 861 $ 7,015 $ 8,978 $ 54,058 $ ( 1,589 ) $ 61,447 The following table provides information about the Company’s net investment in leases and financed sale receivables that are on nonaccrual status as of December 31, 2022 and 2021: As of December 31, 2022 As of December 31, 2021 (In thousands of U.S. Dollars) Recorded Allowance Net Recorded Allowance Net Net investment in leases $ 401 $ ( 401 ) $ — $ 871 $ ( 309 ) $ 562 Net financed sales receivables 27,364 ( 9,589 ) 17,775 8,642 ( 2,357 ) 6,285 Total $ 27,765 $ ( 9,990 ) $ 17,775 $ 9,513 $ ( 2,666 ) $ 6,847 The balances of net investment in leases and financed sale receivables that are on nonaccrual status as of December 31, 2022 include amounts due from exhibitors in Russia, Ukraine, and Belarus which were placed on nonaccrual status in the first quarter of 2022 as a result of the ongoing Russia-Ukraine conflict and resulting sanctions. For the year ended December 31, 2022, the Company recognized $ 0.1 million (2021 — $ 0.1 million ) in Finance Income related to the net investment in leases with billed amounts past due. For the years ended December 31, 2022 and 2021 , the Company did no t recognize any Finance Income related to the net investment in leases in nonaccrual status. For the year ended December 31, 2022, the Company recognized $ 3.6 million (2021 — $ 3.7 million ) in Finance Income related to the financed sale receivables with billed amounts past due. For the year ended December 31, 2022, the Company recognized $ 0.5 million (2021 – $ 0.2 million ) in Finance Income related to the financed sales receivables in nonaccrual status. The following tables summarize the activity in the allowance for credit losses related to the Company’s net investment in leases and financed sale receivables for years ended December 31, 2022 and 2021: Year Ended December 31, 2022 Net Investment Financed (In thousands of U.S. Dollars) in Leases Sales Receivables Beginning balance $ 798 $ 5,414 Current period provision, net 5 5,783 Foreign exchange ( 27 ) ( 252 ) Ending balance $ 776 $ 10,945 Year Ended December 31, 2021 Net Investment Net Financed (In thousands of U.S. Dollars) in Leases Sales Receivables Beginning balance $ 557 $ 7,274 Current period provision (reversal), net 235 ( 1,947 ) Foreign exchange 6 87 Ending balance $ 798 $ 5,414 For the year ended December 31, 2022, the Company’s allowance for current expected credit losses related to its net investment in leases and financed sale receivables increased by $ 5.5 million . This increase is principally due to reserves established against its receivables in Russia due to uncertainties associated with the ongoing Russia-Ukraine conflict and resulting sanctions, partially offset by the reversal of provisions associated with the COVID-19 pandemic as the outlook for the theatrical exhibition industry in Domestic and Rest of World markets continues to improve. For the year ended December 31, 2021, the Company’s allowance for current expected credit losses related to its net investment in leases and financed sale receivables decreased by $ 1.6 million . This decrease is principally due to the reversal of previously recorded credit loss expense as a result of an improving outlook for theater operators following the reopening of theaters and the resumption of normal film release schedules as the theatrical exhibition industry continues to recover from the COVID-19 pandemic, partially offset by new provisions recorded in the period. Variable Consideration Receivables In sale arrangements, variable consideration may become due to the Company from theater operators if certain annual minimum box office receipt thresholds are exceeded. Such variable consideration is recorded as revenue in the period when the sale is recognized and adjusted in future periods based on actual results and changes in estimates. Variable consideration is only recognized to the extent the Company believes there is not a risk of significant revenue reversal. The following table summarizes the activity in the Allowance for Credit Losses related to Variable Consideration Receivables for the years ended December 31, 2022 and 2021: Year Ended December 31, (In thousands of U.S. Dollars) 2022 2021 Beginning balance $ 1,082 $ 1,887 Current period reversal, net ( 440 ) ( 787 ) Foreign Exchange ( 32 ) ( 18 ) Ending balance $ 610 $ 1,082 For the year ended December 31, 2022, the Company’s allowance for current expected credit losses related to Variable Consideration Receivables decreased by $ 0.5 million . This decrease is principally due to the reversal of provisions associated with the COVID-19 pandemic as the outlook for the theatrical exhibition industry in Domestic and Rest of World markets continues to improve. For the year ended December 31, 2021, the Company’s allowance for current expected credit losses related to Variable Consideration Receivables decreased by $ 0.8 million . This decrease is principally due to the reversal of previously recorded credit loss expense as a result of an improving outlook for theater operators following the reopening of theaters and the resumption of normal film release schedules as the theatrical exhibition industry begins to recover from the COVID-19 pandemic, partially offset by new provisions recorded in the period.

Lease Arrangements

Lease Arrangements	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Lease Arrangements	7. Lease Arrangements (a) IMAX Corporation as a Lessee The Company’s operating lease arrangements principally involve office and warehouse space. Office equipment is generally purchased outright. Leases with an initial term of less than 12 months are not recorded on the Consolidated Balance Sheets and the related lease expense is recognized on a straight-line basis over the lease term. Most of the Company’s leases include one or more options to renew, with renewal terms that can extend the lease term from one to five years or more. The Company has determined that it is reasonably certain that the renewal options on its warehouse leases will be exercised based on previous history, its current understanding of future business needs, and its level of investment in leasehold improvements, among other factors. The incremental borrowing rate used in the calculation of the Company’s lease liabilities is based on the location of each leased property. None of the Company’s leases include options to purchase the leased property. The depreciable lives of right-of-use assets and related leasehold improvements are limited by the expected lease term. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company rents or subleases certain office space to third parties, which have a remaining term of less than 12 months and are not expected to be renewed. In 2022, the Company entered into a finance lease arrangement involving equipment used to facilitate the delivery of live events to certain IMAX locations. The lease arrangement includes an option for the Company to purchase the equipment at the end of the lease term that is reasonably certain to be exercised. The resulting right-of-use assets are being depreciated from the lease commencement dates over the useful life of the underlying equipment. The incremental borrowing rate used in the calculation of the lease liabilities is based on the rate of interest the Company would have to pay to borrow on a collateralized basis over a similar term. For the years ended December 31, 2022, 2021, and 2020 the components of lease expense recorded within Selling, General and Administrative Expenses are as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Operating lease cost: Amortization of operating lease assets 2,734 2,791 3,114 Interest on operating lease liabilities 825 937 1,052 Short-term and variable lease costs 616 713 540 Finance lease cost: Amortization of finance lease assets 171 N/A N/A Interest on finance lease liabilities 22 N/A N/A Total lease cost $ 4,368 $ 4,441 $ 4,706 For the years ended December 31, 2022, 2021, and 2020, supplemental cash and non-cash information related to leases is as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating leases $ 3,783 $ 3,839 $ 3,743 Finance leases $ 948 N/A N/A Supplemental disclosure of noncash leasing activities: Right-of-use assets obtained in exchange for operating lease obligations $ 3,068 $ 1,047 $ 563 Right-of-use assets obtained in exchange for finance lease obligations $ 1,990 N/A N/A As of December 31, 2022 and 2021, supplemental balance sheet information related to leases is as follows: December 31, (In thousands of U.S. Dollars) 2022 2021 Assets Balance Sheet Location Operating lease right-of-use assets Property, plant and equipment $ 12,341 $ 12,132 Finance lease right-of-use assets Property, plant and equipment $ 1,876 N/A Liabilities Balance Sheet Location Operating lease liabilities Accrued and other liabilities $ 14,641 $ 14,691 Finance lease liabilities (1) Accrued and other liabilities $ 1,011 N/A (1) Recorded net of a $ 0.9 million upfront payment made upon execution of the finance lease arrangement. As of December 31, 2022 and 2021, the weighted-average remaining lease term and weighted-average interest rate associated with the Company’s leases are as follows: December 31, 2022 2021 Operating leases: Weighted-average remaining lease term (years) 6.0 7.0 Weighted-average discount rate 5.90 % 5.97 % Finance leases: Weighted-average remaining lease term (years) 4.7 N/A Weighted-average discount rate 6.00 % N/A As of December 31, 2022, the maturities of the Company’s operating and finance lease liabilities are as follows: (In thousands of U.S. Dollars) Operating Leases Finance Leases 2023 $ 3,639 $ 508 2024 3,017 508 2025 2,429 — 2026 2,069 — 2027 2,094 — Thereafter 4,171 — Total lease payments $ 17,419 $ 1,016 Less: interest expense ( 2,778 ) ( 5 ) Present value of lease liabilities $ 14,641 $ 1,011 (b) IMAX Corporation as a Lessor The Company provides IMAX Systems to customers through long-term lease arrangements that for accounting purposes are classified as sales-type leases. Under these arrangements, in exchange for providing the IMAX System, the Company earns fixed upfront and ongoing consideration. Certain arrangements that are legal sales are also classified as sales-type leases as certain clauses within the arrangements limit transfer of title or provide the Company with conditional rights to the system. The customer’s rights under the Company’s sales-type lease arrangements are described in Note 3 (o). Under the Company’s sales-type lease arrangements, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s lease portfolio terms are typically non-cancellable for 10 to 20 years with renewal provisions from inception. The Company’s sales-type lease arrangements do not contain a guarantee of residual value at the end of the lease term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and an extended warranty generally after the first year of the lease until the end of the lease term. The customer is responsible for obtaining insurance coverage for the IMAX System commencing on the date specified in the arrangement’s shipping terms and ending on the date the IMAX System is returned to the Company. The Company also provides IMAX Systems to customers through joint revenue sharing arrangements. Under the traditional form of these arrangements, in exchange for providing the IMAX System under a long-term lease, the Company earns rent based on a percentage of contingent box office receipts and, in some cases, concession revenues, rather than requiring the customer to pay a fixed upfront fee or annual minimum payments. Under certain other joint revenue sharing arrangements, known as hybrid arrangements, the customer is responsible for making fixed upfront payments prior to the delivery and installation of the IMAX System. Under joint revenue sharing arrangements, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s joint revenue sharing arrangements are typically non-cancellable for 10 years or longer with renewal provisions. Title to the IMAX System under a joint revenue sharing arrangement generally does not transfer to the customer. The Company’s joint revenue sharing arrangements do not contain a guarantee of residual value at the end of the lease term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and an extended warranty throughout the term. The customer is responsible for obtaining insurance coverage for the IMAX System commencing on the date specified in the arrangement’s shipping terms and ending on the date the IMAX System is returned to the Company. The following lease payments are expected to be received by the Company for its sales-type leases and joint revenue sharing arrangements in each of the next five years and thereafter following the December 31, 2022 balance sheet date: (In thousands of U.S. Dollars) Sales-Type Joint Revenue 2023 $ 3,245 $ 172 2024 3,158 69 2025 3,038 27 2026 2,823 — 2027 2,760 — Thereafter 14,702 — Total $ 29,726 $ 268 (See Note 7 for additional information related to the net investment in leases related to the Company’s sales-type lease arrangements.)

Variable Consideration from Con

Variable Consideration from Contracts with Customers	12 Months Ended
	Dec. 31, 2022
Change in Contract with Customer, Asset [Abstract]
Variable Consideration from Contracts with Customers	8. Variable Consideration from Contracts with Customers The arrangement for the sale of an IMAX System includes indexed minimum payment increases over the term of the arrangement, as well as the potential for additional payments owed by the customer if certain minimum box office receipt thresholds are exceeded. In addition, hybrid sales arrangements include amounts owed by the customer based on a percentage of their box office receipts over the term of the arrangement. These contract provisions are considered to be variable consideration. An estimate of the present value of such variable consideration is recognized as revenue upon the transfer of control of the System Obligation to the customer, subject to constraints to ensure that there is not a risk of significant revenue reversal. This estimate is based on management’s box office projections for the individual IMAX System, which are developed using historical data for the location and, if necessary, comparable theaters and territories. (See Note 3(o) for a more detailed discussion of the Company’s accounting policy related to variable consideration.) The following table summarizes the activity related to variable consideration from contracts with customers for the years ended December 31, 2022, 2021, and 2020: (In thousands of U.S. Dollars) Balance as of January 1, 2020 $ 40,040 Variable consideration for newly recognized sales 5,550 Accretion to finance income 2,133 Transferred to receivables from variable consideration assets ( 5,310 ) Movement in allowance for credit losses ( 1,887 ) Balance as of December 31, 2020 40,526 Variable consideration for newly recognized sales 4,696 Accretion to finance income 1,985 Transferred to receivables from variable consideration assets ( 3,794 ) Movement in allowance for credit losses (see Note 6) 805 Balance as of December 31, 2021 44,218 Variable consideration for newly recognized sales 7,109 Accretion to finance income 1,846 Transferred to receivables from variable consideration assets ( 9,621 ) Movement in allowance for credit losses (see Note 6) 472 Balance as of December 31, 2022 $ 44,024

Inventories

Inventories	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventories	9. Inventories As of December 31, (In thousands of U.S. Dollars) 2022 2021 Raw materials $ 25,365 $ 20,551 Work-in-process 2,034 1,406 Finished goods 4,135 4,967 $ 31,534 $ 26,924 As of December 31, 2022, Inventories include finished goods of $ 3.5 million (December 31, 2021 — $ 2.6 million ) for which title had passed to the customer, but the criteria for revenue recognition were not met as of the balance sheet date. The following table summarizes the activity for the Company’s inventory valuation allowance account for the years ended December 31, 2022, 2021 and 2020: Balance at Additions (1) Other deductions (2) Balance at (In thousands of U.S. Dollars) Year ended December 31, 2022 $ 4,897 $ 919 $ ( 77 ) $ 5,739 Year ended December 31, 2021 $ 5,752 $ 629 $ ( 1,484 ) $ 4,897 Year ended December 31, 2020 $ 3,216 $ 3,028 $ ( 492 ) $ 5,752 (1) Excludes a recovery of $ 0.2 million charged directly to the Consolidated Statements of Operations during the year ended December 31, 2022 (2021 and 2020 — expenses of $ 0.3 million , and $ 0.6 million , respectively). (2) Includes the write-off of amounts previously charged to valuation allowance.

Film Assets

Film Assets	12 Months Ended
	Dec. 31, 2022
Film, Capitalized Cost [Abstract]
Film Assets	10. Film Assets As of December 31, (In thousands of U.S. Dollars) 2022 2021 Completed and released films, net of accumulated amortization of $ 1,227 $ 2,292 $ 235,029 (2021 ― $ 218,148 ) Films in production 1,667 195 Films in development 2,383 1,754 $ 5,277 $ 4,241 The Company expects to amortize $ 5.2 million of the Film Assets balance within three years from December 31, 2022, including $ 4.9 million expected to be amortized in 2023, $ 0.2 million in 2024, and $ 0.1 million in 2025. In certain film arrangements, the Company co-produces a film with a third party with the third party retaining certain rights to the film. The amount of participation payments owed to third parties related to co-produced films as of December 31, 2022 is $ 3.8 million (December 31, 2021 — $ 3.3 million ) and is recorded on the Consolidated Balance Sheets within Accrued and Other Liabilities. In 2022, the Company recorded impairment losses of $ 0.8 million related to the write-down of DMR and documentary film assets (2021 — $ 0.2 million ). In 2020, the Company recorded impairment losses of $ 10.8 million principally to write-down the carrying value of certain documentary, alternative content film assets and DMR related film assets due to a decrease in projected box office totals and related revenues based on management’s regular quarterly recoverability assessments.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	11. Property, Plant and Equipment As of December 31, 2022 Accumulated Net Book (In thousands of U.S. Dollars) Cost Depreciation Value Equipment leased or held for use: System components (1)(2)(3) $ 345,960 $ 194,444 $ 151,516 Camera equipment 8,597 3,859 4,738 354,557 198,303 156,254 Assets under construction (4) 14,379 — 14,379 Right-of-use assets (5) 14,615 398 14,217 Other property, plant and equipment: Land 8,203 — 8,203 Buildings 81,053 31,519 49,534 Office and production equipment (6) 38,485 31,360 7,125 Leasehold improvements 7,959 4,775 3,184 135,700 67,654 68,046 $ 519,251 $ 266,355 $ 252,896 As of December 31, 2021 Accumulated Net Book (In thousands of U.S. Dollars) Cost Depreciation Value Equipment leased or held for use: System components (1)(2)(3) $ 346,517 $ 181,936 $ 164,581 Camera equipment 4,855 3,214 1,641 351,372 185,150 166,222 Assets under construction (4) 10,232 — 10,232 Right-of-use assets (5) 14,429 2,297 12,132 Other property, plant and equipment: Land 8,203 — 8,203 Buildings 80,973 28,873 52,100 Office and production equipment (6) 39,017 31,169 7,848 Leasehold improvements 8,110 4,494 3,616 136,303 64,536 71,767 $ 512,336 $ 251,983 $ 260,353 (1) Included in system components are assets with costs of $ 7.6 million (2021 — $ 7.6 million ) and accumulated depreciation of $ 7.2 million (2021 — $ 7.0 million ) that are leased to customers under operating leases. (2) Included in system components are assets with costs of $ 323.7 million (2021 — $ 324.3 million ) and accumulated depreciation of $ 177.9 million (2021 — $ 166.5 million ) that are used in joint revenue sharing arrangements. (3) In 2022, the Company recorded charges of $ 1.0 million (2021 — $ 0.4 million ; 2020 — $ 1.8 million) in Costs and Expenses Applicable to Technology Rentals mostly related to the write-down of leased xenon-based digital systems which were taken out of service in connection with customer upgrades to laser-based digital systems, as well as an IMAX System that was removed from its existing location. (4) Included in assets under construction are components with costs of $ 9.1 million (2021 — $ 9.2 million ) that will be utilized to construct assets to be used in joint revenue sharing arrangements. (5) The right-of-use assets primarily include operating leases for office and warehouse space. (6) Fully depreciated office and production equipment is still in use by the Company. In 2022, the Company identified and wrote off $ 3.5 million (2021 — $ 0.5 million ) of office and production equipment that is fully depreciated and no longer in use. In 2022, the Company recorded a charge of $ 0.1 million (2021 — $ 0.2 million ; 2020 — $ 0.2 million ) reflecting Property, Plant and Equipment that was no longer in use.

Other Assets

Other Assets	12 Months Ended
	Dec. 31, 2022
Other Assets [Abstract]
Other Assets	12. Other Assets As of December 31, (In thousands of U.S. Dollars) 2022 2021 Lease incentives provided to exhibitor customers, net of accumulated amortization $ 12,975 $ 14,834 Commissions and other deferred selling expenses 1,336 1,418 Other investments 1,000 1,000 Foreign currency derivatives 50 184 Other 304 363 $ 15,665 $ 17,799

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes (a) (Loss) Income Before Taxes by Jurisdiction (Loss) income before taxes by tax jurisdiction for the years ended December 31, 2022, 2021, and 2020 consists of the following: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Canada $ ( 55,623 ) $ ( 55,480 ) $ ( 104,166 ) United States 4,281 3,218 ( 6,437 ) China 11,466 53,792 ( 8,253 ) Ireland 24,070 829 ( 7,473 ) Other 6,037 8,628 ( 2,795 ) $ ( 9,769 ) $ 10,987 $ ( 129,124 ) (b) Income Tax (Expense) Benefit Income tax (expense) benefit for the years ended December 31, 2022, 2021, and 2020 consists of the following: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Income tax (expense) benefit – current: Canada $ ( 1,149 ) $ ( 915 ) $ 555 United States ( 274 ) ( 1,038 ) 488 China ( 4,437 ) ( 11,045 ) ( 1,980 ) Ireland ( 2,802 ) ( 1,358 ) ( 1,462 ) Other ( 3,519 ) ( 3,212 ) ( 487 ) Sub-total ( 12,181 ) ( 17,568 ) ( 2,886 ) Income tax (expense) benefit – deferred: Canada (1) 943 ( 231 ) ( 10,801 ) United States ( 131 ) ( 1,268 ) 867 China (2) 2,763 ( 381 ) ( 15,756 ) Ireland ( 1,562 ) ( 997 ) 2,161 Other 60 ( 119 ) ( 89 ) Sub-total 2,073 ( 2,996 ) ( 23,618 ) Total (3) $ ( 10,108 ) $ ( 20,564 ) $ ( 26,504 ) (1) A valuation allowance is recorded in jurisdictions where management has determined, based on the weight of all available evidence, both positive and negative, that a valuation allowance for deferred tax assets is required. For the year ended December 31, 2022, the Company recorded a $ 16.9 million valuation allowance against its deferred tax assets in Canada and China primarily as a result of uncertainties related to the long-term impact of the COVID-19 pandemic (2021 — $ 17.2 million ). The $ 16.9 million increase in the valuation allowance recorded in 2022 is reflected within Income Tax Expense in the Company’s Consolidated Statements of Operations. (2) T he Company's deferred tax liability of $ 17.6 million as of December 31, 2021 was for the estimated applicable foreign withholding taxes associated with historical earnings that were not indefinitely reinvested, which will become payable upon the repatriation of any such earnings. During the year ended December 31, 2022, $ 27.4 million of historical earnings from a subsidiary in China were distributed and, as a result, $ 2.7 million of foreign withholding taxes were paid to the relevant tax authorities. The remaining deferred tax liability on the Company’s Consolidated Balance Sheets as of December 31, 2022 is $ 14.9 million . (3) For the year ended December 31, 2022 , Income Tax (Expense) Benefit excludes a tax expense of $ 0.8 million included in Other Comprehensive (Loss) Income ( 2021 — benefit of $ 0.3 million; 2020 — benefit of $ 0.1 million ). (c) Reconciliation of Income Tax Expense to Statutory Rates For the years ended December 31, 2022, 2021, and 2020, the Company’s effective tax rate and income tax expense differs from the combined Canadian federal and provincial statutory income tax rates due to the following factors: Years Ended December 31, 2022 2021 2020 (In thousands of U.S. Dollars, except rates) Amount Rate Amount Rate Amount Rate Income tax benefit (expense) at combined statutory rates $ 2,596 26.5 % $ ( 2,912 ) 26.5 % $ 34,218 26.5 % Adjustments resulting from: Non-controlling interests share of partnership losses — 0.0 % ( 1 ) 0.0 % ( 1,229 ) ( 1.0 %) Increase in valuation allowance ( 16,848 ) ( 172.5 %) ( 14,722 ) 134.0 % ( 28,589 ) ( 22.1 %) Changes to tax reserves 1,643 16.8 % 3,508 ( 31.9 %) ( 2,699 ) ( 2.1 %) U.S. federal and state taxes ( 86 ) ( 0.9 %) ( 80 ) 0.7 % ( 250 ) ( 0.2 %) Withholding taxes ( 3,825 ) ( 39.2 %) ( 4,199 ) 38.2 % ( 20,943 ) ( 16.2 %) Income tax at different rates in foreign and other provincial jurisdictions 3,872 39.6 % 3,352 ( 30.5 %) ( 2,607 ) ( 2.0 %) Investment and other tax credits (non-refundable) 752 7.7 % 413 ( 3.8 %) 643 0.5 % Changes to deferred tax assets and liabilities resulting from audit and other tax return adjustments 2,278 23.3 % ( 5,336 ) 48.6 % ( 1,219 ) ( 0.9 %) Other non-deductible/non-taxable items ( 490 ) ( 4.9 %) ( 587 ) 5.4 % ( 3,829 ) ( 3.0 %) Income tax expense $ ( 10,108 ) ( 103.6 %) $ ( 20,564 ) 187.2 % $ ( 26,504 ) ( 20.5 %) (d) Deferred Tax Assets and Deferred Tax Liability As of December 31, 2022 and 2021, the Company’s deferred tax assets and deferred tax liability consists of the following: As of December 31, (In thousands of U.S. Dollars) 2022 2021 Net operating loss carryforwards $ 29,158 $ 21,219 Investment tax credit and other tax credit carryforwards 5,213 3,919 Write-downs of other assets 2,341 1,223 Excess of tax accounting basis in various assets 14,549 13,929 Accrued pension liability 5,375 6,901 Accrued share-based compensation 8,920 7,728 Income recognition on net investment in leases ( 3,344 ) ( 3,368 ) Other accrued reserves 10,552 8,369 Total deferred income tax assets 72,764 59,920 Valuation allowance ( 62,864 ) ( 46,014 ) Deferred income tax asset net of valuation allowance 9,900 13,906 Deferred tax liability ( 14,900 ) ( 17,642 ) Net deferred tax liability $ ( 5,000 ) $ ( 3,736 ) As of December 31, 2022, net deferred tax assets include a liability of $ 1.1 million (December 31, 2021 — liability of $ 0.3 million ) associated with amounts recognized within Accumulated Other Comprehensive (Loss) Income, including unrealized actuarial gains and losses related to the Company’s pension and other postretirement benefit plans and unrealized net gains and losses on cash flow hedging instruments. (e) Net Operating Loss Carryforwards Estimated Canadian net operating loss carryforwards of $ 129.4 million can be used to reduce taxable income through 2042 , China net operating losses of $ 5.1 million can be used to reduce taxable income through 2027 , and $ 8.9 million of Ireland net operating losses can be carried forward indefinitely. Investment tax credits and other tax credits of $ 5.5 million can be carried forward to reduce income taxes payable through to 2042 . (f) Indefinitely Reinvested Assertion Income taxes are accrued for the earnings of non-Canadian affiliates and associated companies unless management determines that such earnings will be indefinitely reinvested outside of Canada. In 2020, management completed a reassessment of its strategy with respect to the most efficient means of deploying the Company’s capital resources globally. Based on the results of this reassessment, management concluded that the historical earnings of certain foreign subsidiaries in excess of amounts required to sustain business operations would no longer be indefinitely reinvested. The Company's deferred tax liability of $ 17.6 million as of December 31, 2021 related to the estimated applicable foreign withholding taxes associated with these historical earnings. During the year ended December 31, 2022 , $ 27.4 million of historical earnings from a subsidiary in China were distributed and, as a result, $ 2.7 million of foreign withholding taxes were paid to the relevant tax authorities ( 2021 — $ 2.0 million). The remaining deferred tax liability on the Company’s Consolidated Balance Sheets as of December 31, 2022 is $ 14.9 million . (g) Valuation Allowance As of December 31, 2022, the Company’s Consolidated Balance Sheets include net deferred income tax assets of $ 9.9 million , net of a valuation allowance of $ 62.9 million (December 31, 2021 — $ 13.9 million , net of a valuation allowance of $ 46.0 million ). For the years ended December 31, 2022 and 2021, the Company recorded a valuation allowance of $ 16.9 million and $ 17.2 million , respectively, where management cannot determine that the tax benefits will be realizable based on available evidence. The $ 16.9 million increase in the valuation allowance recorded in 2022 is reflected within Income Tax Expense in the Company’s Consolidated Statements of Operations. The $ 17.2 million increase in the valuation allowance recorded in 2021 is reflected within Income Tax Expense in the Company’s Consolidated Statements of Operations ($ 14.7 million) and Shareholder's Equity on the Company's Consolidated Balance Sheets ($ 2.5 million). The valuation allowance is expected to reverse at the point in time when management determines it is more likely than not that the Company will incur sufficient tax liabilities to allow it to utilize the deferred tax assets against which the valuation allowance is recorded. (h) Uncertain Tax Positions As of December 31, 2022 and December 31, 2021, the Company had total tax reserves (including interest and penalties) of $ 12.3 million and $ 13.9 million , respectively, for various uncertain tax positions. While the Company believes it has adequately provided for all tax positions, amounts asserted by taxing authorities could differ from the Company's accrued liability. Accordingly, additional provisions on federal, provincial, state and foreign tax-related matters may be required in the future as revised estimates are made or the underlying matters are settled or otherwise resolved. For the year ended December 31, 2022, the Company recorded a net decrease of $ 2.2 million related to reserves (excluding interest and penalties) for income taxes (2021 — $ 2.1 million , 2020 — $ 0.6 million ). The Company has elected to classify interest and penalties related to income tax liabilities, when applicable, as part of the Income Tax Expense in its Consolidated Statements of Operations rather than Interest Expense. The Company expensed $ 0.6 million in potential interest and penalties associated with its provision for uncertain tax positions for the years ended December 31, 2022 (2021 — expensed $ 1.4 million ; 2020 — expensed $ 3.3 million ). The following table presents a reconciliation of the beginning and ending amount of tax reserves (excluding interest and penalties) for the years ended December 31, 2022, 2021, and 2020: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Balance at beginning of the year $ 11,939 $ 14,076 $ 14,718 Additions based on tax positions related to the current year 11 37 2,301 Reductions for tax positions of prior years ( 94 ) ( 991 ) — Reductions resulting from lapse of applicable statute of limitations and ( 2,123 ) ( 1,183 ) ( 2,943 ) Balance at the end of the year $ 9,733 $ 11,939 $ 14,076 The number of years with open tax audits varies depending on the tax jurisdiction. The Company's material taxing jurisdictions include Canada, the United States, Ireland, and China. In 2021, the Canadian tax authorities denied the Company’s deduction of certain foreign taxes accrued in 2015, but not yet paid as discussions with the local authorities are ongoing. This resulted in the payment of $ 8.9 million in income taxes and $ 1.6 million in associated interest to the Canadian tax authorities in the fourth quarter of 2021. The Company has filed a waiver with the Canadian tax authorities in respect of 2015 so that when the foreign taxes are paid, the Company would be entitled to receive a refund of the $ 8.9 million in tax, which is recorded on the Company’s Consolidated Balance Sheets within Accounts Receivable, and the $ 1.6 million in associated interest. The Company's 2017 through 2022 tax years remain subject to examination by the IRS for United States federal tax purposes, and the 2016 through 2021 tax years remain subject to examination by the appropriate governmental agencies for Canadian federal tax purposes. There are other on-going audits in various other jurisdictions that are not material to the Consolidated Financial Statements. The Company is subject to audit by tax authorities in the various jurisdictions in which it operates in the ordinary course of its business and believes that it has adequately reserved for the expected exposures in its accounts. During the fourth quarter of 2022, the Company received a Notice of Reassessment (the “Reassessment”) in the amount of $ 13.2 million (inclusive of interest). Although the CRA is continuing its audit and has requested additional information to continue its evaluation of the facts, a Reassessment was necessary as the time limitation for assessment as imposed under the relevant income tax treaty was set to expire before the audit could be completed. The Company believes that the matter will be resolved on a basis that is consistent with its filing position. (i) Income Tax Effect on Other Comprehensive (Loss) Income For the years ended December 31, 2022, 2021, and 2020, Income Tax (Expense) Benefit related to the components of Other Comprehensive (Loss) Income is as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Unrealized defined benefit plan actuarial (gain) loss $ ( 198 ) $ ( 37 ) $ 276 Unrealized postretirement benefit plans actuarial (gain) loss ( 762 ) ( 35 ) 92 Amortization of prior service cost ( 48 ) ( 48 ) ( 23 ) Unrealized change in cash flow hedging instruments 346 ( 123 ) ( 132 ) Realized change in cash flow hedging instruments ( 156 ) 446 ( 158 ) Reclassification of unrealized change in ineffective cash flow hedging instruments — 83 — $ ( 818 ) $ 286 $ 55

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	14. Goodwill and Other Intangible Assets (a) Goodwill As of December 31, 2022, the Company’s total Goodwill was $ 52.8 million , of which $ 13.8 million relates to the SSIMWAVE reporting unit, which was acquired on September 22, 2022, $ 19.1 million relates to the IMAX Systems reporting unit ( December 31, 2021 — $ 19.1 million), $ 13.5 million relates to the Joint Revenue Sharing Arrangements reporting unit ( December 31, 2021 — $ 13.5 million), and $ 6.4 million relates to the IMAX Maintenance reporting unit ( December 31, 2021 — $ 6.4 million). (See Note 5 for additional information related to the Company's acquisition of SSIMWAVE.) The Company performed a qualitative impairment test as of the annual assessment date, September 30, 2022, to evaluate whether it is more likely than not that the fair value of its reporting units was less than their respective carrying amounts. The Company concluded that it was not more likely than not that the fair value of its reporting units had been reduced below their respective carrying amounts. (b) Other Intangible Assets As of December 31, 2022 Accumulated Net Book (In thousands of U.S. Dollars) Cost Amortization Value Licenses and intellectual property $ 26,168 $ 15,232 $ 10,936 Internal use software 32,886 25,232 7,654 Developed technology 5,779 225 5,554 In process research and development 3,810 — 3,810 Patents and trademarks 13,031 9,771 3,260 Customer relationships 1,340 50 1,290 Other 769 535 234 $ 83,783 $ 51,045 $ 32,738 As of December 31, 2021 Accumulated Net Book (In thousands of U.S. Dollars) Cost Amortization Value Licenses and intellectual property $ 26,168 $ 13,642 $ 12,526 Internal use software 28,571 21,544 7,027 Patents and trademarks 12,834 9,406 3,428 Other 598 499 99 $ 68,171 $ 45,091 $ 23,080 During 2022 , the Company acquired $ 11.2 million of intangible assets through its acquisition of SSIMWAVE (see Note 5). In addition, during 2022, the Company capitalized $ 5.1 million related to the development of internal use software, as well as additions in patents and trademarks and other intangible assets (2021 — $ 4.1 million . The weighted average amortization period for these additions is 4.7 years (2021 — 2.3 years). The net book value of the other intangible assets capitalized in 2022 was $ 15.5 million as of December 31, 2022 (2021 — $ 3.9 million ). During 2022 , the Company incurred costs of $ 0.1 million to renew or extend the term of acquired patents and trademarks which were recorded in Selling, General and Administrative expenses ( 2021 — $ 0.1 million ). Fully amortized other intangible assets are still in use by the Company. In 2022, the Company identified and wrote off $ 0.1 million (2021 — $ 0.1 million ) of patents and trademarks that are no longer in use. The estimated amortization expense for each of the next five years following the December 31, 2022 balance sheet date is as follows: (In thousands of U.S. Dollars) 2023 $ ( 7,821 ) 2024 ( 7,636 ) 2025 ( 5,456 ) 2026 ( 3,059 ) 2027 ( 3,099 )

Borrowings

Borrowings	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Borrowings	15. Borrowings (a) Revolving Credit Facility Borrowings, Net As of December 31, 2022 and 2021, Revolving Credit Facility Borrowings, Net includes the following: December 31, December 31, (In thousands of U.S. Dollars) 2022 2021 Wells Fargo Credit Facility borrowings $ 25,000 $ — HSBC China Facility borrowings 12,496 — Bank of China Facility borrowings 374 3,612 Unamortized debt issuance costs ( 1,759 ) ( 1,140 ) Revolving Credit Facility Borrowings, net $ 36,111 $ 2,472 Wells Fargo Credit Agreement On March 25, 2022, the Company entered into a Sixth Amended and Restated Credit Agreement with Wells Fargo Bank, National Association, as agent (the “Agent”), and a syndicate of lenders party thereto (the “Credit Agreement”), which extended the maturity date of the credit facility under the Credit Agreement (the “Credit Facility”) from June 28, 2023 to March 25, 2027 . The Company's obligations under the Credit Agreement are guaranteed by certain of the Company's subsidiaries (the “Guarantors”), and are secured by first-priority security interests in substantially all of the assets of the Company and the Guarantors. The Credit Agreement has a revolving borrowing capacity of $ 300.0 million, and contains an uncommitted accordion feature allowing the Company to further increase its borrowing capacity to the greater of $ 440.0 million or by the Company's EBITDA for the four most recently ended fiscal quarters, subject to certain conditions, depending on the mix of revolving loans and/or term loans under the incremental facility and subject to conditions set forth in the Credit Agreement. The Credit Facility requires that the Company maintain a maximum Senior Secured Net Leverage Ratio (as defined in the Credit Agreement) of no greater than 3.25 :1.00 on the last day of each Fiscal Quarter. The Senior Secured Net Leverage Ratio is the ratio of Total Debt (as defined in the Credit Agreement), secured by liens, net of unrestricted cash and cash equivalents held outside of the People’s Republic of China to a maximum of $ 75.0 million, relative to Adjusted EBITDA per Credit Facility for the four prior quarters. The Company was in compliance with this requirement as of December 31, 2022 as the Senior Secured Net Leverage Ratio was 0.00 :1.00. Loans under the Credit Facility bear interest, at the Company's option, at (i) Term SOFR, Eurocurrency Rate or CDOR Rate plus a margin ranging from 1.00 % to 1.75 % per annum; or (ii) the U.S. base rate or the Canadian prime rate plus a margin ranging from 0.25 % to 1.00 % per annum, in each case depending on the Company's total leverage ratio. In no event will Term SOFR, Eurocurrency Rate or CDOR Rate be less than 0.00 % per annum. As of December 31, 2022, the Company’s borrowings of $ 25.0 million (December 31, 2021 — nil ) currently bear interest at Term SOFR, plus a margin of 1.75 % per annum based on the Company's total leverage ratio. The effective interest rate for the year ended December 31, 2022 was 5.64 % (2021 — 2.64 %). The Credit Agreement contains customary affirmative and negative covenants, including covenants that limit indebtedness, liens, asset sales, investments and restricted payments, in each case subject to negotiated exceptions and baskets. The Credit Agreement also contains customary representations, warranties and event of default provisions. The Company incurred fees of approximately $ 2.5 million in connection with the March 2022 amendment of the Credit Agreement, which are being amortized on a straight-line basis over the term of the Credit Agreement. In the first quarter of 2022, the Company expensed $ 0.4 million in unamortized deferred financing costs associated with lenders that are no longer parties to the Credit Agreement. On May 25, 2022, the Company delivered a “Designated Period” suspension notice to the Agent, and the Company, the Agent and the lenders under the Credit Agreement entered into a limited consent, which notice and limited consent evidenced and effectuated the termination of the Designated Period under the Credit Agreement. From and after the termination of the Designated Period, the $ 75.0 million minimum liquidity covenant in the Credit Agreement was no longer in effect. For the year ended December 31, 2022, the Company did no t have any letters of credit or advance payment guarantees outstanding under the Credit Facility. As of December 31, 2021, there were no amounts drawn under the previous credit facility, and the Company did no t have any letters of credit or advance payment guarantees outstanding under the previous credit facility. As of December 31, 2022 , the amount available for future borrowings under the Credit Facility was $ 275.0 million. Foreign Exchange Facility Within the Credit Facility, the Company is able to purchase foreign currency forward contracts and/or other swap arrangements. As of December 31, 2022, the net unrealized loss on the Company's outstanding foreign currency forward contracts was $( 0.6 ) million , representing the amount by which the notional value of these forward contracts exceeded their fair value (December 31, 2021 — net unrealized gain of $ 0.1 million). As of December 31, 2022, the notional value of the Company's outstanding foreign currency forward contracts was $ 24.7 million (December 31, 2021 — $ 26.7 million ). Bank of China Facility In June 2022, IMAX (Shanghai) Multimedia Technology Co., Ltd. (“IMAX Shanghai”), one of the Company's majority-owned subsidiaries in China, renewed its unsecured revolving facility with Bank of China for up to 200.0 million Chinese Renminbi (“RMB”) ($ 28.7 million), including RMB 10.0 million ($ 1.4 million) for letters of guarantee, to fund ongoing working capital requirements (the “Bank of China Facility”). The Bank of China Facility expires in September 2023 . As of December 31, 2022, RMB 2.6 million ( $ 0.4 million ) of borrowings were outstanding under the Bank of China Facility and outstanding letters of guarantee were RMB 2.8 million ( $ 0.4 million ). As of December 31, 2021, outstanding Bank of China Facility borrowings were RMB 23.0 million ( $ 3.6 million ) and outstanding letters of guarantee were RMB 2.8 million ( $ 0.5 million ). As of December 31, 2022, the amount available for future borrowings under the Bank of China Facility was RMB 187.4 million ( $ 26.9 million ) and the amount available for letters of guarantee was RMB 7.2 million ( $ 1.0 million ). The amount available for future borrowings under the Bank of China Facility is not subject to a standby fee. The effective interest rate for the year ended December 31, 2022 was 4.12 % (2021 — 4.31 % ). HSBC China Facility In June 2022, IMAX Shanghai entered into an unsecured revolving facility for up to RMB 200.0 million ($ 28.7 million) with HSBC Bank (China) Company Limited, Shanghai Branch to fund ongoing working capital requirements (the “HSBC China Facility”). As of December 31, 2022, RMB 87.0 million ($ 12.5 million) of borrowings were outstanding under the HSBC China facility. As of December 31, 2022, the amount available for future borrowings under the HSBC China Facility was RMB 113.0 million ( $ 16.2 million ). The effective interest rate for the year ended December 31, 2022 was 3.91 % . NBC Facility In October 2019, the Company entered into a $ 5.0 million facility with National Bank of Canada (the “NBC Facility”) fully insured by Export Development Canada for use solely in conjunction with the issuance of performance guarantees and letters of credit. The NBC Facility will expire on June 30, 2023 , and is renewable on the same terms and conditions on an annual basis. The Company did no t have any letters of credit or advance payment guarantees outstanding as of December 31, 2022 and 2021 under the NBC Facility. (b) Convertible Notes and Other Borrowings, Net As of December 31, 2022 and December 31, 2021, Convertible Notes and Other Borrowings, Net includes the following: December 31, December 31, (In thousands of U.S. Dollars) 2022 2021 Convertible Notes $ 230,000 $ 230,000 Unamortized discounts and debt issuance costs ( 4,870 ) ( 6,359 ) Convertible Notes, net 225,130 223,641 Federal Economic Development Loan 2,812 N/A Unaccreted interest benefit ( 1,030 ) N/A Federal Economic Development Loan, net 1,782 N/A Convertible Notes and Other Borrowings, net $ 226,912 $ 223,641 Convertible Notes On March 19, 2021, the Company issued $ 230.0 million of 0.500 % Convertible Senior Notes due 2026 (the “Convertible Notes”) in a private placement conducted pursuant to Rule 144A under the Securities Act of 1933, as amended. The net proceeds from the issuance of the Convertible Notes were $ 223.7 million, after deducting the initial purchasers’ discounts and commissions. In addition, the Company paid $ 1.2 million of debt issuance costs associated with the Convertible Notes. The Company used a portion of the net proceeds from the issuance of the Convertible Notes to make a partial repayment of previous outstanding revolving credit facility borrowings, and used the remainder for working capital or other general corporate purposes. The Convertible Notes are senior unsecured obligations of the Company and bear interest at a rate of 0.500 % per annum on the principal of $ 230.0 million, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2021 . The Convertible Notes will mature on April 1, 2026 , unless they are redeemed or repurchased by the Company or converted on an earlier date. Holders of the Convertible Notes have the right to convert their Convertible Notes in certain circumstances and during specified periods. Before January 1, 2026, holders of the Convertible Notes have the right to convert their Convertible Notes only upon the occurrence of certain events. From and after January 1, 2026, holders of the Convertible Notes may convert their Convertible Notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as applicable, cash or a combination of cash (in an amount no less than the principal amount of the Convertible Notes being converted) and common shares, at its election, based on the applicable conversion rates. The initial conversion rate is 34.7766 common shares per $ 1,000 principal amount of Convertible Notes, which represents an initial conversion price of approximately $ 28.75 per common share, and is subject to adjustment upon the occurrence of certain events. The Convertible Notes are redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after April 6, 2024 and on or before the 40th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest, if any, but only if the last reported sale price per share of the Company’s common stock exceeds 130 % of the conversion price for a specified period of time. In addition, calling any Convertible Notes for redemption will constitute a “make-whole fundamental change” with respect to such notes, in which case the conversion rate applicable to the conversion of such notes will be increased in certain circumstances if such notes are converted after they are called for redemption . In addition, upon the occurrence of a “fundamental change” (as defined below), holders may require the Company to repurchase their Convertible Notes at a cash repurchase price equal to the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest, if any. Subject to the terms and conditions of the indenture governing the Convertible Notes, a “fundamental change” means, among other things, an event resulting in (i) a change of control, (ii) a transfer of all or substantially all of the assets of the Company, (iii) a merger, (iv) liquidation or dissolution of the Company, or (v) delisting of the Company’s common shares from a national securities exchange. The Company recorded the Convertible Notes entirely as a liability in the Consolidated Balance Sheets, net of initial purchasers' discounts and commissions and other debt issuance costs, with interest expense reflecting the cash coupon plus the amortization of the discounts and capitalized costs. Additionally, under the "if-converted" method, because the principal amount of the Convertible Notes is settled in cash and the conversion spread is settleable in the Company's common shares, diluted earnings per share is calculated by including the net number of incremental shares that would be issued upon conversion of the Convertible Notes, using the average market price during the period. Accordingly, the application of the "if-converted" method may reduce the Company's reported diluted earnings per share. In connection with the pricing of the Convertible Notes, the Company entered into privately negotiated capped call transactions (the “Capped Call Transactions”) with certain financial institutions. The Capped Call Transactions are expected to reduce potential dilution resulting from the common shares the Company is required to issue and/or to offset any potential cash payments the Company is required to make in excess of the principal amount of the Convertible Notes in the event that the market price per share of the Company’s common shares is greater than the strike price of the Capped Call Transactions with such reduction and/or offset subject to a cap. The Capped Call Transactions have an initial cap price of $ 37.2750 per share of the Company’s common shares, which represents a premium of 75 % over the last reported sale price of the common shares when they were priced on March 16, 2021, and are subject to certain adjustments under the terms of the Capped Call Transactions. Collectively, the Capped Call Transactions cover, subject to anti-dilution adjustments substantially similar to those applicable to the Convertible Notes, the number of the Company’s common shares underlying the Convertible Notes. The cost of the Capped Call Transactions was approximately $ 19.1 million. The Capped Call Transactions are separate transactions, are not part of the terms of the Convertible Notes and will not affect any holder’s rights under the Convertible Notes. Holders of the Convertible Notes will not have any rights with respect to the Capped Call Transactions. The Capped Call Transactions meet all of the applicable criteria for equity classification in accordance with ASC 815-10-15-74(a), “Derivatives and Hedging—Embedded Derivatives—Certain Contracts Involving an Entity’s Own Equity,” and, as a result, the related $ 19.1 million cost was recorded as a reduction to Other Equity within Shareholders’ Equity on the Company’s Consolidated Statements of Shareholders’ Equity and Consolidated Balance Sheets. Federal Economic Development Loan SSIMWAVE entered into a contribution agreement with the Federal Economic Development Agency for Southern Ontario (the “Federal Economic Development Loan” ) on May 29, 2019, under which SSIMWAVE may receive up to $ 4.2 million Canadian Dollars ( “CAD” ) ($ 3.1 million) by way of repayable contributions toward certain eligible projects costs. The contributions under the agreement cover 35 % of the eligible and supported costs of SSIMWAVE between January 10, 2019 and December 31, 2022. The contributions are repayable over 60 months , with repayments estimated to begin in January 2024 , with an annual interest rate of 0 %. As of December 31, 2022, SSIMWAVE has received contributions of CAD $ 3.8 million ( $ 2.8 million ) from the Federal Economic Development Loan. The benefit of the interest free loan has been determined by calculating the present value of the payments using a market-based interest rate and comparing this to the proceeds received. The benefit is being recorded as the interest free benefit of government funding within Interest Income on the Company's Consolidated Statements of Operations. No benefit was recorded during the year ended December 31, 2022, as the Company did not receive any funding since the date of acquisition. The obligation is being accreted to its maturity amount, resulting in an interest accretion expense of less than $ 0.1 million in 2022 and is being recorded within Interest Expense on the Company's Consolidated Statements of Operations. As of December 31, 2022, the Federal Economic Development Loan has a carrying value of $ 1.8 million , net of unaccreted interest benefit and is recorded within Convertible Notes and Other Borrowings, Net on the Company's Consolidated Balance Sheets.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments	16. Commitments In the ordinary course of its business, the Company enters into contractual agreements with third parties that include non-cancelable payment obligations, for which it is liable in future periods. These arrangements can include terms binding the Company to minimum payments and/or penalties if it terminates the agreement for any reason other than an event of default as described by the agreement. The following table presents a summary of the Company’s contractual obligations and commitments as of December 31, 2022: Payments Due by Period (In thousands of U.S. Dollars) Total Less Than One Year 1 to 3 years 3 to 5 years Thereafter Purchase obligations (1) $ 37,884 $ 34,419 $ 3,183 $ 37 $ 245 Pension obligations (2) 20,295 — — 20,295 — Operating lease obligations (3) 18,013 3,905 5,825 4,137 4,146 Finance lease obligations 1,016 508 508 — — Wells Fargo Facility 25,000 — — 25,000 — HSBC Facility 12,496 12,496 — — — Bank of China Facility 374 374 — — — Federal Economic Development Loan (4) 2,812 — 1,250 1,250 312 Convertible Notes (5) 234,025 1,150 2,300 230,575 — Postretirement benefits obligations 2,504 104 210 220 1,970 $ 354,419 $ 52,956 $ 13,276 $ 281,514 $ 6,673 (1) Represents total payments to be made under binding commitments with suppliers and outstanding payments to be made for supplies ordered, but yet to be invoiced. (2) The Company has an unfunded defined benefit pension plan covering its Chief Executive Officer. (See Note 24 .) (3) Represents total minimum annual rental payments due under the Company’s operating leases. (See Note 7 .) (4) The Federal Economic Development Loan will be repayable over 60 months, with repayments estimated to begin in January 2024. (See Note 15 (b).) (5) The Convertible Notes bear interest at a rate of 0.500 % per annum on the principal of $ 230.0 million, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2021 . The Convertible Notes will mature on April 1, 2026 , unless earlier repurchased, redeemed or converted. (See Note 15 (b).) The Company compensates its sales force with both fixed and variable compensation. Commissions on the sale or lease of IMAX Systems are payable in graduated amounts from the time of collection of the customer’s first payment to the Company up to the collection of the customer’s last initial payment. As of December 31, 2022, $ 2.2 million (December 31, 2021 — $ 1.1 million ) of commissions have been accrued and will be payable in future periods.

Contingencies and Guarantees

Contingencies and Guarantees	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Guarantees	17. Contingencies and Guarantees The Company is involved in lawsuits, claims, and proceedings, including those identified below, which arise in the ordinary course of business. Management is required to assess the likelihood of any adverse judgments or outcomes related to these legal contingencies, as well as potential ranges of probable or reasonably possible losses. The Company records a provision for a liability when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The determination of the amount of any liability recorded or disclosed is reviewed at least quarterly based on a careful analysis of each individual exposure with, in some cases, the assistance of outside legal counsel, taking into account the impact of negotiations, settlements, rulings, and other pertinent information related to the case. The amount of liabilities recorded or disclosed for these contingencies may change in the future due to changes in management's judgments resulting from new developments or changes in settlement strategy. Any resulting adjustment to the liabilities recorded by the Company could have a material adverse effect on its results of operations, cash flows, and financial position in the period or periods in which such changes in judgment occur. The Company believes it has adequate provisions for any such matters. The Company expenses legal costs relating to its lawsuits, claims and proceedings as incurred. (i) In January 2004, the Company and IMAX Theatre Services Ltd., a subsidiary of the Company, commenced an arbitration seeking damages before the International Court of Arbitration of the International Chamber of Commerce (the “ICC”) with respect to the breach by Electronic Media Limited (“EML”) of its December 2000 agreement with the Company. In June 2004, the Company commenced a related arbitration before the ICC against EML's affiliate, E-City Entertainment (I) PVT Limited (“E-City”). On March 27, 2008, the arbitration panel issued a final award in favor of the Company in the amount of $ 11.3 millio n, consisting of past and future rents owed to the Company, plus interest and costs, as well as an additional $ 2,512 each day in interest from October 1, 2007 until the date the award is paid . In July 2008, E-City commenced a proceeding in Mumbai, India seeking to prevent recognition of the ICC award in India. On March 10, 2017, the Supreme Court dismissed E-City's petition. On March 29, 2017, the Company filed an Execution Application in the Bombay High Court seeking to enforce the ICC award against E-City and several related parties, which award the Company calculates to be $ 25.3 million, inclusive of interest, as of December 31, 2022. That matter is currently pending. The Company has also taken steps to enforce the ICC final award outside of India. In December 2011, the Ontario Superior Court of Justice issued an order recognizing the final award and requiring E-City to pay the Company $ 30,000 to cover the costs of the application , and in May 2012, the New York Supreme Court recognized the Canadian judgment and entered it as a New York judgment. The Company intends to continue pursuing its rights and seeking to enforce the award, although no assurances can be given with respect to the ultimate outcome. (ii) On November 11, 2013, Giencourt Investments, S.A. (“Giencourt”) initiated arbitration before the International Centre for Dispute Resolution in Miami, Florida, based on alleged breaches by the Company of its theater agreement and related license agreement with Giencourt. On February 7, 2017, the panel issued a Partial Final Award and on July 21, 2017, the panel issued a Final Award (collectively, the “Award”), which held that the parties had reached a binding settlement, and therefore the panel did not reach a decision regarding the merits of the dispute. On December 3, 2020, the District Judge entered a final judgment (the “Final Judgment”) against the Company in the total amount of $ 11.3 million as damages under the Award. As of December 31, 2020, the Company's Consolidated Balance Sheets included a liability within Accrued and Other Liabilities of $ 11.3 million related to the Final Judgment, consisting of $ 7.2 million related to amounts collected from or owed to Giencourt principally in respect of theater systems that were not delivered and $ 4.1 million in respect of the remaining amounts owed under the Final Judgment. On June 23, 2021, the Company entered into a final settlement agreement with Giencourt to fully resolve all disputes between the parties in the United States and Ontario (the “Settlement Agreement” ). In the second quarter of 2021, the Company paid Giencourt $ 9.5 million as required by the terms of the Settlement Agreement. As a result of the Settlement Agreement, the Final Judgment has been vacated, all litigation between the parties in all jurisdictions has been dismissed and full and final releases have been exchanged by the parties. Accordingly, upon entry in the Settlement Agreement on June 23, 2021, the remaining $ 1.8 million liability recorded within Accrued and Other Liabilities was reversed and a corresponding $ 1.8 million benefit was recorded in the Company's Consolidated Statements of Operations within Legal Judgment and Arbitration Awards in the second quarter of 2021. (iii) In addition to the matters described above, the Company is currently involved in other legal proceedings or governmental inquiries which, in the opinion of the Company's management, will not materially affect the Company's financial position or future operating results, although no assurance can be given with respect to the ultimate outcome of any such proceedings. (iv) In the normal course of business, the Company enters into agreements that may contain features that meet the definition of a guarantee. A guarantee is a contract (including an indemnity) that contingently requires the Company to make payments (either in cash, financial instruments, other assets, shares of its stock, or provision of services) to a third party based on (a) changes in an underlying interest rate, foreign exchange rate, equity or commodity instrument, index or other variable, that is related to an asset, a liability or an equity security of the counterparty, (b) failure of another party to perform under an obligating agreement or (c) failure of another third party to pay its indebtedness when due. Financial Guarantees Certain subsidiaries of the Company have provided significant financial guarantees to third parties under the Credit Agreement (see Note 15). Product Warranties The Company’s accrual for product warranties, which is recorded within Accrued and Other Liabilities in the Consolidated Balance Sheets, was $ nil as of December 31, 2022 and 2021, respectively. Director/Officer Indemnifications The Company’s by-laws contain an indemnification of its directors/officers, former directors/officers, and persons who have acted at its request to be a director/officer of an entity in which the Company is a shareholder or creditor, to indemnify them, to the extent permitted by the Canada Business Corporations Act , against expenses (including legal fees), judgments, fines and any amounts actually and reasonably incurred by them in connection with any action, suit or proceeding in which the directors and/or officers are sued as a result of their service, if they acted honestly and in good faith with a view to the best interests of the Company. In addition, the Company has entered into indemnification agreements with each of its directors in order to effectuate the foregoing. The nature of the indemnification prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay to counterparties. The Company has purchased directors’ and officers’ liability insurance. No amount has been accrued in the Company's Consolidated Balance Sheets as of December 31, 2022 and December 31, 2021 with respect to this indemnity. Other Indemnification Agreements In the normal course of its operations, the Company provides indemnifications to counterparties in transactions such as: IMAX System lease and sale agreements and the supervision of installation or servicing of IMAX Systems; film production, exhibition and distribution agreements; real property lease agreements; and employment agreements. These indemnification agreements require the Company to compensate the counterparties for costs incurred as a result of litigation claims that may be suffered by the counterparty as a consequence of the transaction or the Company’s breach or non-performance under these agreements. While the terms of these indemnification agreements vary based upon the contract, they normally extend for the life of the agreements. A small number of agreements do not provide for any limit on the maximum potential amount of indemnification; however, virtually all of the IMAX System lease and sale agreements limit such maximum potential liability to the purchase price of the system. The fact that the maximum potential amount of indemnification required by the Company is not specified in some cases prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay to counterparties. Historically, the Company has no t made any significant payments under such indemnifications and no amounts have been accrued in the Consolidated Financial Statements with respect to the contingent aspect of these indemnities.

Capital Stock

Capital Stock	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Capital Stock	18. Capital Stock (a) Authorized Common Shares The authorized capital of the Company consists of an unlimited number of common shares. The following is a summary of the rights, privileges, restrictions, and conditions of the common shares. The holders of common shares are entitled to receive dividends, if and when declared by the directors of the Company, subject to the rights of the holders of any other class of shares of the Company entitled to receive dividends in priority to the common shares. The holders of the common shares are entitled to one vote for each common share held at all meetings of the shareholders. (b) Settlements of Share-Based Compensation During the years ended December 31, 2022, 2021, and 2020 , the Company settled the exercise of stock options and the vesting of RSUs with its common shares. These settlements were either through newly issued common shares from treasury or through the purchase of common shares in the open market by the IMAX LTIP trustee. The following table summarizes the settlement of stock option and RSU transactions: Years Ended December 31, 2022 2021 2020 Stock options Issued from treasury — 41,613 — Plan trustee purchases — — — Total stock options exercised — 41,613 — RSUs Issued from treasury 596,277 531,629 42,982 Plan trustee purchases — 723 386,297 Shares withheld for tax withholdings 203,956 157,546 24,714 Total RSUs vested 800,233 689,898 453,993 (c) Share-Based Compensation The Company issues share-based compensation to eligible employees, directors, and consultants under the IMAX LTIP and the China LTIP, as summarized below. On June 3, 2020, the Company’s shareholders approved the IMAX LTIP at its Annual and Special Meeting. Awards under the IMAX LTIP may consist of stock options, RSUs, PSUs, and other awards. Stock options are no longer granted under the Company’s previously approved Stock Option Plan (“SOP”). For the year ended December 31, 2022, share-based compensation expense totaled $ 27.0 million (2021 — $ 25.6 million ; 2020 — $ 21.5 million ) and is reflected in the following accounts in the Consolidated Statements of Operations: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Cost and expenses applicable to revenues $ 1,156 $ 1,490 $ 691 Selling, general and administrative expenses 25,438 23,776 20,652 Research and development 419 348 150 $ 27,013 $ 25,614 $ 21,493 As of December 31, 2022, the Company has reserved a total of 5,788,499 (December 31, 2021 — 5,807,445 ) common shares for future issuance under the IMAX LTIP. Of this amount, 3,604,739 common shares are reserved for the future exercise of stock options (December 31, 2021 — 3,736,157 ), 931,716 common shares are reserved for the future vesting of PSUs (December 31, 2021 — 613,405 ), and 1,252,044 common shares are reserved for the future vesting of RSUs (December 31, 2021 — 1,457,883 ). As of December 31, 2022, stock options in respect of 3,523,335 (December 31, 2021 — 3,488,107 ) common shares were vested and exercisable. IMAX LTIP and SOP Stock Options The Company’s policy is to issue new common shares from treasury or shares purchased in the open market to satisfy stock options which are exercised. The Company no longer intends to issue new stock option awards. The Company utilizes a Binomial Model to determine the fair value of stock option awards on the grant date. The fair value determined by the Binomial Model is affected by the Company’s stock price, as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the Company’s expected stock price volatility over the term of the award, and actual and projected employee stock option exercise behaviors. The Binomial Model also considers the expected exercise multiple which is the multiple of exercise price to grant price at which exercises are expected to occur on average. Option-pricing models were developed for use in estimating the value of traded options that have no vesting or hedging restrictions and are fully transferable. Because the Company’s employee stock options have certain characteristics that are significantly different from traded options, and because changes in the subjective assumptions can materially affect the estimated value, in management’s opinion, the Binomial Model best provides a fair measure of the fair value of the Company’s employee stock options. All stock option awards are granted at the fair market value of the Company’s common shares on the date of grant. The fair market value of a common share on a given date is based on the higher of the closing price of a common share on either: (i) the grant date or (ii) the most recent trading date if the grant date is not a trading date on the New York Stock Exchange (“NYSE”) or such national exchange as may be designated by the Company’s Board of Directors. The stock options vest within 4 years and expire 10 years or less from the date of grant. The SOP and IMAX LTIP provide for double-trigger accelerated vesting in the event of a change in control, as defined in each plan. The Company recorded the following expenses related to stock options issued to employees and directors under the IMAX LTIP and SOP: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Stock option expense $ 572 $ 1,064 $ 1,847 For the year ended December 31, 2022, the Company’s Consolidated Statements of Operations includes an income tax benefit of $ 0.1 million related to stock option expense (2021 — $ 0.1 million ; 2020 — $ 0.1 million ). As of December 31, 2022, 2021, and 2020, unrecognized share-based compensation expense related to non-vested employee stock options is as follows: As of December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Expense related to non-vested employee stock options $ 86 $ 662 $ 2,029 As of 2022, 2021, and 2020, unrecognized share-based compensation expense related to non-vested employee stock options is expected to be recognized over the following weighted-average periods: As of December 31, 2022 2021 2020 Weighted average period (in years) 0.2 1.1 1.8 During the years ended December 31, 2022, 2021 and 2020, the Company did not grant any stock options. The following table summarizes the stock option activity under the SOP and IMAX LTIP for the years ended December 31, 2022, 2021, and 2020: Weighted Average Exercise Number of Shares Price Per Share 2022 2021 2020 2022 2021 2020 Stock options outstanding, beginning of year 3,736,157 4,892,962 5,732,209 $ 26.61 $ 26.81 $ 26.82 Granted — — — — — — Exercised — ( 41,613 ) — — 21.23 — Forfeited ( 796 ) ( 88,934 ) ( 34,678 ) 22.49 22.49 22.49 Expired ( 126,569 ) ( 903,038 ) ( 786,086 ) 33.61 28.31 27.07 Cancelled ( 4,053 ) ( 123,220 ) ( 18,483 ) 27.92 26.68 27.97 Stock options outstanding, end of year 3,604,739 3,736,157 4,892,962 26.36 26.61 26.81 Stock options exercisable, end of year 3,523,335 3,488,107 4,311,761 26.45 26.93 27.30 As of December 31, 2022, 3,604,739 options outstanding included both fully vested and unvested options with a weighted average exercise price of $ 26.36 , an aggregate intrinsic value of $nil and a weighted average remaining contractual life of 3.3 years. The intrinsic value of options exercised in 2022 was $nil (2021 — $ 0.1 million ; 2020 — $nil). IMAX LTIP Restricted Share Units RSUs have been granted to employees and directors under the IMAX LTIP. Each RSU represents a contingent right to receive a common share and is the economic equivalent of one common share. The grant date fair value of each RSU is equal to the share price of the Company’s stock at the grant date or the average closing price of the Company’s common stock for five days prior to the date of grant. For the years ended December 31, 2022, 2021, and 2020, the Company recorded the following expenses related to RSUs issued to employees and directors in the IMAX LTIP: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 RSU expenses $ 15,498 $ 15,555 $ 13,761 The Company’s actual tax expense realized for the tax deductions related to the vesting of RSUs was $ 0.9 million for the year ended December 31, 2022 (2021 — benefit of $ 0.6 million ; 2020 — benefit of $ 0.3 million ). The Company’s accrued liability for granted RSUs was $ 0.8 million as of December 31, 2022 (December 31, 2021 — $ 2.6 million ). Total share-based compensation expense related to non-vested RSUs not yet recognized and the weighted average period over which the awards are expected to be recognized are as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Expense related to non-vested RSUs not yet recognized $ 17,457 $ 15,913 $ 17,343 Weighted average period awards are expected to be recognized (in years) 1.5 1.6 1.9 The following table summarizes the activity in respect of RSUs issued under the IMAX LTIP for the years ended December 31, 2022, 2021, and 2020: Number of Awards Weighted Average Grant Date Fair 2022 2021 2020 2022 2021 2020 RSUs outstanding, beginning of year 1,457,883 1,564,838 1,065,347 $ 19.16 $ 18.33 $ 23.17 Granted 708,313 831,123 1,050,385 19.31 21.03 15.35 Vested and settled ( 800,231 ) ( 689,872 ) ( 453,993 ) 19.10 19.46 22.71 Forfeited ( 113,921 ) ( 248,206 ) ( 96,901 ) 20.39 19.38 18.81 RSUs outstanding, end of year 1,252,044 1,457,883 1,564,838 19.16 19.16 18.33 Historically, RSUs granted under the IMAX LTIP have vested between immediately and three years from the grant date. In connection with the second amendment and restatement of the IMAX LTIP at the Company’s annual and special meeting of the shareholders on June 3, 2020, the IMAX LTIP plan retained the minimum one-year vesting period on future RSU grants, with a carve-out for an aggregate of no more than 5 % of the total number of common shares authorized for issuance under the plan that may vest on a shorter schedule. Vesting of the RSUs is subject to continued employment or service with the Company. The following table summarizes the number of RSUs issued from the carve-out balance: Approved under the June 3, 2020 amended and restated IMAX LTIP 885,000 Issued during previous years ( 482,912 ) Issued during 2022 ( 59,030 ) Outstanding, December 31, 2022 343,058 Restricted Share Units to Non-Employees During the years ended December 31, 2022, 2021 and 2020 , the Company did no t grant any stock options to non-employees. The Company did no t record any expenses for the year ended December 31, 2022 related to RSU grants issued to advisors and strategic partners of the Company (2021 ― $nil; 2020 ― $ 0.1 million). IMAX LTIP Performance Stock Units Summary In 2020, the Company expanded its share-based compensation program to include PSUs. The Company grants two types of PSUs awards, one which vests based on a combination of employee service and the achievement of certain EBITDA-based targets and one which vests based on a combination of employee service and the achievement of total shareholder return (“TSR”) targets. The achievement of the EBITDA and TSR targets in these PSUs is determined over a three-year performance period. At the conclusion of the three-year performance period, the number of PSUs that ultimately vest can range from 0 % to a maximum vesting opportunity of 175 % of the initial award, depending upon actual performance versus the established EBITDA and stock-price targets. The grant date fair value of PSUs with EBITDA-based targets is equal to the closing price of the Company’s common shares on the date of grant or the average closing price of the Company’s common shares for five days prior to the date of grant. The grant date fair value of PSUs with TSR targets is determined on the grant date using a Monte Carlo simulation, which is a valuation model that considers the likelihood of achieving the TSR targets embedded in the award (“Monte Carlo Model”). The compensation expense attributable to each type of PSU is recognized on a straight-line basis over the requisite service period. The fair value determined by the Monte Carlo Model is affected by the Company’s share price, as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, market conditions as of the grant date, the Company’s expected share price volatility over the term of the awards, and other relevant data. The compensation expense is fixed on the date of grant based on the fair value of the PSUs granted. The amount and timing of compensation expense recognized for PSUs with EBITDA-based targets is dependent upon management's assessment of the likelihood of achieving these targets. If, as a result of management’s assessment, it is projected that a greater number of PSUs will vest than previously anticipated, a life-to-date adjustment to increase compensation expense is recorded in the period that such determination is made. Conversely, if, as a result of management’s assessment, it is projected that a lower number of PSUs will vest than previously anticipated, a life-to-date adjustment to decrease compensation expense is recorded in the period that such determination is made. For the years ended December 31, 2022, 2021, and 2020, the Company recorded the following expenses related to outstanding PSUs, which includes adjustments reflecting management’s estimate of the number of PSUs with EBITDA-based targets expected to vest: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 PSU expenses $ 8,306 $ 5,322 $ 2,563 The Company’s actual tax benefits realized for the tax deductions related to the vesting of PSUs was $nil for the year ended December 31, 2022 (2021 ― $nil; 2020 ― $nil). As of December 31, 2022 , total unrecognized share-based compensation expense related to unvested PSUs and the weighted average period over which the expense is expected to be recognized is $ 10.8 million and 1.8 years, respectively. The following table summarizes the activity in respect of PSUs issued under the IMAX LTIP: Number of Awards Weighted Average Grant Date 2022 2021 2020 2022 2021 2020 PSUs outstanding, beginning of year 613,405 361,844 — $ 18.21 $ 15.68 $ — Granted 359,138 309,574 370,265 20.34 20.77 15.66 Forfeited ( 40,827 ) ( 58,013 ) ( 8,421 ) 19.90 16.11 4.84 PSUs outstanding, end of year 931,716 613,405 361,844 18.96 18.21 15.68 As of December 31, 2022 , the maximum number of shares of common stock that may be issued with respect to PSUs outstanding is 1,630,503 , assuming full achievement of the EBITDA and stock-price targets. China Long-Term Incentive Plan Each stock option (“China Option”), RSU, or PSU issued under the China LTIP represents an opportunity to participate economically in the future growth and value creation of IMAX China. In connection with the IMAX China IPO and in accordance with the China LTIP, IMAX China adopted a post-IPO share option plan and a post-IPO restricted stock unit plan. Pursuant to these plans, IMAX China has issued additional China Options, China LTIP Performance Stock Units (“China PSUs”), and China LTIP Restricted Share Units (“China RSUs”). For the years ended December 31, 2022, 2021, and 2020, share-based compensation expense related to China Options, China RSUs and China PSUs was as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Expense China Options $ 91 $ 285 $ 875 China RSUs 2,284 2,810 2,093 China PSUs 262 578 208 Total $ 2,637 $ 3,673 $ 3,176 In 2022, IMAX China modified the terms of certain fully vested stock options to extend their contractual life by one year and recorded an associated expense of $ 0.1 million ( 2021 ― $ 0.1 million; 2020 ― $ 0.7 million). Issuer Purchases of Equity Securities On April 28, 2022 and July 28, 2022, the Company’s Board of Directors approved a 12-month extension to its share repurchase program through June 30, 2023 and an increase of $ 200.0 million in the share repurchase program, respectively. With the increase of $ 200.0 million, the Company's total share repurchase authority is $ 400.0 million under the current share repurchase program. As of December 31, 2022 , the Company has $ 193.4 million available under its approved repurchase program. The repurchases may be made either in the open market or through private transactions, including repurchases made pursuant a plan intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, subject to market conditions, applicable legal requirements, and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time. In 2022, the Company repurchased 5,401,852 (2021 ― 841,331 ) common shares at an average price of $ 15.19 per share (2021 ― $ 16.51 per share), for a total of $ 82.0 million (2021 ― $ 13.9 million ), excluding commissions, of which 140,000 were common shares (2021 ― nil ) where settlement occurred subsequent to December 31, 2022, at an average price of $ 14.45 per share, for a total of $ 2.0 million, excluding commissions. Subsequent to December 31, 2022 and through February 21, 2023, the Company completed repurchases through a 10b5-1 program of 109,477 shares at an average price of $ 14.87 per share, for a total cost of $ 1.6 million, excluding commissions. The following table summarizes the Company's share repurchases during the years ended December 31, 2022 and 2021: Total Number of Shares Repurchased Average Price Paid Per Share (in thousands of U.S. Dollars) 2022 2021 2022 2021 Shares repurchased 5,401,852 841,331 $ 15.19 $ 16.51 For the years ended December 31, 2022 and 2021 , there were no shares purchases in the administration of employee share based plans. As of December 31, 2022, the IMAX LTIP trustee held nil shares. Any shares held with the trustee are recorded at cost and are reported as a reduction against Capital Stock on the Company’s Consolidated Balance Sheets. In 2021, IMAX China’s shareholders granted its Board of Directors a general mandate authorizing the Board, subject to applicable laws, to repurchase shares of IMAX China not to exceed 10 % of the total number of issued shares as of May 6, 2021 ( 34,835,824 shares). This program expired on the date of the 2022 Annual General Meeting of IMAX China on June 23, 2022. During the 2022 Annual General Meeting, shareholders approved the repurchase of shares of IMAX China not to exceed 10 % of the total number of issued shares as of June 23, 2022 ( 34,063,480 shares). This program will be valid until the 2023 Annual General Meeting of IMAX China. The repurchases may be made in the open market or through other means permitted by applicable laws. IMAX China has no obligation to repurchase its shares and the share repurchase program may be suspended or discontinued by IMAX China at any time. In 2022, IMAX China repurchased 2,961,800 (2021 ― 6,664,700 ) common shares at an average price of HKD 8.00 per share (U.S. $ 1.02 per share) for a total of HKD 23.7 million or U.S. $ 3.0 million (2021 ― HKD 11.68 per share or U.S. $ 1.50 per share, for a total of HKD 77.8 million or U.S. $ 10.0 million ). The change in non-controlling interest as a result of common shares repurchased by IMAX China is recorded within Non-Controlling Interest in the Consolidated Balance Sheets and the Consolidated Statements of Shareholders’ Equity. The difference between the consideration paid and the ownership interest obtained as a result of IMAX China share repurchases is recorded within Other Equity in the Consolidated Balance Sheets and the Consolidated Statements of Shareholders’ Equity (see Note 3(a)). The following table summarizes the IMAX China's share repurchases during the years ended December 31, 2022 and 2021: Total Number of Shares Repurchased Average Price Paid Per Share (in thousands of U.S. Dollars) 2022 2021 2022 2021 Shares repurchased 2,961,800 6,664,700 $ 1.02 $ 1.50 (d) Basic and Diluted Weighted Average Shares Outstanding The following table reconciles the denominator of the basic and diluted weighted average share computations: Years Ended December 31, (In thousands) 2022 2021 2020 Issued and outstanding, beginning of period 58,654 58,921 61,176 Weighted average number of shares (repurchased) issued, net ( 1,980 ) 205 ( 1,939 ) Weighted average number of shares outstanding - basic and diluted 56,674 59,126 59,237 For the year ended December 31, 2022, the calculation of diluted earnings per share excludes 4,523,121 (2021 and 2020 ― 6,131,792 and 6,999,667 , respectively) shares that are issuable upon the vesting of 637,120 RSUs (2021 and 2020 ― 1,457,883 and 1,564,838 , respectively), the vesting of 281,262 PSUs (2021 and 2020 ― 937,752 and 541,867 respectively), and the exercise of 3,604,739 stock options (2021 and 2020 ― 3,736,157 and 4,892,962 , respectively), as the effect would be anti-dilutive. The calculation of diluted weighted average shares outstanding for the year ended December 31, 2022 also excludes any shares potentially issuable upon the conversion of the Convertible Notes as the average market price of the Company’s common shares during the period of time they were outstanding was less than the conversion price of the Convertible Notes. (See Note 15(b).) (e) Statutory Surplus Reserve Pursuant to the corporate law of the People’s Republic of China (the “PRC”), entities registered in the PRC are required to maintain certain statutory reserves, which are appropriated from after-tax profits, after offsetting accumulated losses from prior years, before dividends can be declared or paid to equity holders. The Company’s PRC subsidiaries are required to appropriate 10 % of statutory net profits to statutory surplus reserves, upon distribution of their after-tax profits. The Company’s PRC subsidiaries may discontinue the appropriation of statutory surplus reserves when the aggregate sum of the statutory surplus reserve is more than 50 % of their registered capital. The statutory surplus reserve is non-distributable other than during liquidation and may only be used to fund losses from prior years, to expand production operations, or to increase the capital of the subsidiaries. In addition, the subsidiaries may make further contribution to the discretional surplus reserve using post-tax profits in accordance with resolutions of the Board of Directors. In 2021, one of the Company's PRC subsidiaries declared and paid dividends of RMB 131.6 million ($ 20.4 million). In the third quarter of 2021, upon passage of the requisite resolution of the Board of Directors, a statutory surplus reserve of RMB 36.4 million ($ 5.6 million) was recorded within Shareholders' Equity as an appropriation of the retained earnings of the Company's PRC subsidiaries, of which $ 3.9 million is attributable to the Company's common shareholders and $ 1.7 million is attributable to non-controlling shareholders. The statutory surplus reserve of RMB 36.4 million ($ 5.6 million) has reached 50 % of its PRC subsidiaries' registered capital. No additional statutory surplus reserve was recorded by the Company's PRC subsidiaries for the year ended December 31, 2022 .

Consolidated Statements of Op_2

Consolidated Statements of Operations Supplemental Information	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Consolidated Statements of Operations Supplemental Information	19. Consolidated Statements of Operations Supplemental Information (a) Selling Expenses The following table summarizes the Company’s selling expenses, including sales commissions and marketing and other, which are recognized within Costs and Expenses Applicable to Revenues in the Consolidated Statements of Operations, for the years ended December 31, 2022, 2021 and 2020: Years Ended December 31, 2022 2021 2020 (In thousands of U.S. Dollars) Sales Marketing and Other Sales Marketing and Other Sales Marketing and Other Technology sales (1) $ 479 $ 810 $ 1,885 $ 989 $ 1,278 $ 1,077 Image enhancement and maintenance services (2) — 20,284 — 8,923 — 4,306 Technology rentals (3) 85 663 399 1,109 908 510 Total $ 564 $ 21,757 $ 2,284 $ 11,021 $ 2,186 $ 5,893 (1) Sales commissions paid prior to the recognition of the related revenue are deferred and recognized upon the client acceptance of the IMAX System. Direct advertising and marketing costs for each IMAX System are expensed as incurred. (2) Film exploitation costs, including advertising and marketing costs are expensed as incurred. (3) Sales commissions related to joint revenue sharing arrangements accounted for operating leases are recognized in the month they are earned by the salesperson, which is typically the month in which the IMAX System is installed. Direct advertising and marketing costs for each IMAX System are expensed as incurred. (b) Foreign Exchange Included in Selling, General and Administrative Expenses for the year ended December 31, 2022 is a net loss of $( 3.2 ) million resulting from changes in exchange rates related to foreign currency denominated monetary assets and liabilities, primarily due to the weakening of the RMB against the USD, as compared to a net gain of $ 1.3 million and a net gain of $ 0.8 million for the years ended December 31, 2021 and 2020, respectively. See Note 23(c) for additional information. (c) Collaborative Arrangements Joint Revenue Sharing Arrangements See Note 7 for a description of the material terms of the Company's collaborative joint revenue sharing arrangements. The accounting policy for the Company's joint revenue sharing arrangements is disclosed in Note 3(o). Revenue attributable to transactions arising between the Company and its customers under joint revenue sharing arrangements are recorded within Revenues – Technology Sales (for hybrid joint revenue sharing arrangements) and Revenues – Technology Rentals (for traditional joint revenue sharing arrangements). For the year ended December 31, 2022, such revenues totaled $ 66.6 million (2021 — $ 51.6 million ; 2020 — $ 19.9 million ). (See Note 21(a) for a disaggregated presentation of the Company’s revenues.) IMAX DMR In an IMAX DMR arrangement, the Company receives a percentage of the box office receipts from a third party who owns the copyright to a film in exchange for converting the film into IMAX DMR format and distributing it through the IMAX network . The fee earned by the Company in a typical IMAX DMR arrangement averages approximately 12.5 % of box office receipts (i.e. gross box office receipts less applicable sales taxes), except for within Greater China, where the Company receives a lower percentage of net box office receipts for certain Hollywood films. The accounting policy for the Company's IMAX DMR arrangements is disclosed in Note 3(o). Revenue attributable to transactions arising between the Company and its customers under IMAX DMR arrangements are included in Revenues – Image Enhancement and Maintenance Services. For the year ended December 31, 2022, such revenues totaled $ 94.9 million (2021 — $ 70.7 million ; 2020 — $ 28.3 million ). (See Note 21(a) for a disaggregated presentation of the Company’s revenues.) Co-Produced Film Arrangements In certain film arrangements, the Company co-produces a film with a third party whereby the third party retains the copyright and certain other rights to the film. In some cases, the Company obtains exclusive theatrical distribution rights to the film. Under these arrangements, both parties contribute to the funding of the production, distribution and exploitation costs associated with the film. As of December 31, 2022 , the Company is party to one co-produced film arrangement, which represents the VIE total assets balance of $ 1.5 million and liabilities balance of $ 0.2 million and three other co-produced film arrangements, the terms of which are similar. The accounting policies relating to co-produced film arrangements are disclosed in Notes 3(a) and 3(o). In 2022, an expense of $ 0.8 million (2021 — $ 0.4 million ; 2020 — $ 2.0 million ) attributable to transactions between the Company and other parties involved in the production of the films have been included in Costs and Expenses Applicable to Revenues – Image Enhancement and Maintenance Services. In 2017, the Company participated in one significant co-produced television arrangement. This arrangement was not a VIE. For the year ended December 31, 2022, revenues of $ 0.3 million (2021 — $ 0.2 million ; 2020 — $ 0.3 million ) and Costs and Expenses Applicable to Revenues of $nil (2021 — $ nil ; 2020 — $ nil ) attributable to this collaborative arrangement were recorded within Revenue – Image Enhancement and Maintenance Services and Costs and Expenses Applicable to Revenues – Image Enhancement and Maintenance Services.

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows Supplemental Information	12 Months Ended
	Dec. 31, 2022
Supplemental Cash Flow Elements [Abstract]
Consolidated Statements of Cash Flows Supplemental Information	20. Consolidated Statements of Cash Flows Supplemental Information (a) Changes in other operating assets and liabilities Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Decrease (Increase) in: Financing receivables $ 5,411 $ ( 7,637 ) $ ( 10,568 ) Prepaid expenses ( 1,892 ) ( 3,230 ) ( 979 ) Variable consideration receivables 667 ( 2,905 ) ( 2,361 ) Other assets 968 1,003 ( 4,747 ) Increase (Decrease) in: Accounts payable 8,496 ( 4,752 ) 414 Accrued and other liabilities ( 12,849 ) 15,167 ( 6,399 ) $ 801 $ ( 2,354 ) $ ( 24,640 ) (b) Cash payments made on account Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Income taxes (1) $ 13,963 $ 18,475 $ 4,763 Interest $ 715 $ 3,251 $ 5,773 (1) In 2021 , the Canadian tax authorities denied the Company’s deduction of certain foreign taxes accrued in 2015, but not yet paid as discussions with the local authorities are ongoing. This resulted in the payment of $ 8.9 million in income taxes and $ 1.6 million in associated interest to the Canadian tax authorities in the fourth quarter of 2021. The Company has filed a waiver with the Canadian tax authorities in respect of 2015 so that when the foreign taxes are paid, the Company would be entitled to receive a refund of the $ 8.9 million in tax, which is recorded on the Company’s Consolidated Balance Sheets within Accounts Receivable, and the $ 1.6 million in associated interest. (c) Depreciation and amortization Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Film assets $ 16,881 $ 16,316 $ 8,838 Property, plant and equipment: Equipment supporting joint revenue sharing arrangements 22,165 22,320 24,930 Other property, plant and equipment (1) 9,757 9,479 11,225 Other intangible assets (2) 6,103 6,079 6,565 Other assets (3) 1,755 1,888 1,146 Total $ 56,661 $ 56,082 $ 52,704 (1) Includes the amortization of laser projection systems, camera, and lens upgrades recorded in Research and Development on the Statements of Operations of $ 0.6 million in the year ended December 31, 2022 (2021 — $ 0.8 million; 2020 — $ 0.9 million). (2) Includes the amortization of licenses and intellectual property recorded in Research and Development on the Consolidated Statements of Operations of $ 1.3 million in the year ended December 31, 2022 (2021 — $ 1.3 million; 2020 — $ 1.3 million). (3) Includes the amortization of lessee incentives provided by the Company to its customers under joint revenue sharing arrangements. (d) Write-downs, including asset impairments Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Other assets (1) $ 4,470 $ — $ 1,151 Inventories (2) 741 890 3,632 Property, plant and equipment: Equipment supporting joint revenue sharing arrangements (3) 973 364 1,784 Other property, plant and equipment 57 217 174 Other intangible assets 87 142 184 Film assets (4) 848 151 10,804 $ 7,176 $ 1,764 $ 17,729 (1) In 2022 , the Company recognized a full impairment of its RMB 30.0 million ($ 4.5 million) investment in the film Mozart from Space based on projected box office results and distribution costs. (See Note 23(e).) In 2020 , the Company recorded a write-down of $ 1.2 million in Asset Impairments related to content-related assets which became impaired in the year. No such write-downs including asset impairments were incurred in 2021. (2) In 2022 , the Company recorded write-downs of $ 0.9 million, net of a recovery of $ 0.2 million in Costs and Expenses Applicable to Technology Sales. The write-downs recorded during the year ended December 31, 2022 include $ 0.4 million related to excess and damaged inventory and $ 0.3 million recorded to reduce the carrying value of service parts held in Russia . For the years ended December 31, 2021 and 2020 , the Company recorded write-downs of $ 0.9 million and $ 3.6 million, respectively, in Costs and Expenses Applicable to Technology Sales to reduce the carrying value of excess inventory. (3) In 2022 , the Company recorded charges of $ 1.0 million ( 2021 — $ 0.4 million; 2020 — $ 1.8 million) in Costs and Expenses Applicable to Technology Rentals mostly related to the write-downs of leased xenon-based digital systems which were taken out of service in connection with exhibitor customer upgrades to laser-based digital systems, as well as an IMAX System that was removed from its existing location. (4) In 2022 , the Company recorded impairment losses of $ 0.8 million ( 2021 — $ 0.2 million) related to the write-down of DMR and documentary film assets. In 2020, the Company recorded impairment losses of $ 10.8 million principally to write-down the carrying value of certain documentary, alternative content film assets and DMR related film assets due to a decrease in projected box office totals and related revenues based on management’s regular quarterly recoverability assessments. (e) Significant non-cash investing activities Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Net increase (decrease) in accruals related to: Investment in equipment supporting joint revenue sharing arrangements $ 790 $ 1,009 $ ( 1,888 ) Acquisition of other intangible assets 30 ( 891 ) 792 Purchases of property, plant and equipment (1) 311 ( 188 ) 158 $ 1,131 $ ( 70 ) $ ( 938 ) (1) See Note 7 for supplemental disclosure of noncash leasing activities. (f) Significant non-cash financing activities In the fourth quarter of 2022, the Company recognized a $ 2.0 million liability related to repurchase of its common shares, which were not settled as of December 31, 2022 and were related on the Consolidated Balance Sheets within Accrued and Other Liabilities.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	12 Months Ended
	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	21. Revenue from Contracts with Customers (a) Disaggregated Information About Revenue The following tables summarize the Company’s revenues by type and reportable segment for the years ended December 31, 2022, 2021, and 2020: Year Ended December 31, 2022 Revenue from Contracts with Customers (In thousands of U.S. Dollars) Fixed Variable Revenue from Lease Finance Income Total Technology sales IMAX Systems (1) $ 43,704 $ 7,268 $ 3,479 $ — $ 54,451 Joint Revenue Sharing Arrangements, fixed fees — — 4,804 — 4,804 Other Theater Business 6,255 — — — 6,255 All Other 3,546 102 — — 3,648 Sub-total 53,505 7,370 8,283 — 69,158 Image enhancement and maintenance services IMAX DMR — 94,867 — — 94,867 IMAX Maintenance 56,608 — — — 56,608 Film Distribution 554 2,598 — — 3,152 Film Post-Production 3,783 — — — 3,783 All Other 1,178 1,791 — — 2,969 Sub-total 62,123 99,256 — — 161,379 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 61,768 — 61,768 All Other — — 18 — 18 Sub-total — — 61,786 — 61,786 Finance income IMAX Systems — — — 8,482 8,482 Total $ 115,628 $ 106,626 $ 70,069 $ 8,482 $ 300,805 Year Ended December 31, 2021 Revenue from Contracts with Customers (In thousands of U.S. Dollars) Fixed Variable Revenue from Lease Finance Income Total Technology sales IMAX Systems (1) $ 37,900 $ 5,576 $ 11,392 $ — $ 54,868 Joint Revenue Sharing Arrangements, fixed fees — — 5,406 — 5,406 Other Theater Business 2,363 — — — 2,363 All Other 3,475 41 — — 3,516 Sub-total 43,738 5,617 16,798 — 66,153 Image enhancement and maintenance services IMAX DMR — 70,659 — — 70,659 IMAX Maintenance 53,339 — — — 53,339 Film Distribution 205 1,259 — — 1,464 Film Post-Production 4,260 — — — 4,260 All Other 377 1,049 — — 1,426 Sub-total 58,181 72,967 — — 131,148 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 46,184 — 46,184 All Other — — 606 — 606 Sub-total — — 46,790 — 46,790 Finance income IMAX Systems — — — 10,792 10,792 Total $ 101,919 $ 78,584 $ 63,588 $ 10,792 $ 254,883 Year Ended December 31, 2020 Revenue from Contracts with Customers (In thousands of U.S. Dollars) Fixed Variable Revenue from Lease Finance Income Total Technology sales IMAX Systems (1) $ 33,869 $ 5,799 $ 4,271 $ — $ 43,939 Joint Revenue Sharing Arrangements, fixed fees — — 2,056 — 2,056 Other Theater Business 1,666 — — — 1,666 All Other 1,957 110 — — 2,067 Sub-total 37,492 5,909 6,327 — 49,728 Image enhancement and maintenance services IMAX DMR — 28,265 — — 28,265 IMAX Maintenance 21,999 — — — 21,999 Film Distribution 3,000 1,841 — — 4,841 Film Post-Production 3,878 — — — 3,878 All Other — 335 — — 335 Sub-total 28,877 30,441 — — 59,318 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 17,841 — 17,841 Sub-total — — 17,841 — 17,841 Finance income IMAX Systems — — — 10,116 10,116 Total $ 66,369 $ 36,350 $ 24,168 $ 10,116 $ 137,003 (1) Includes revenues earned from sale and sales-type lease arrangements involving new and upgraded IMAX Systems, as well as the impact of renewals and amendments to existing system arrangements. (b) Deferred Revenue IMAX System sale and lease arrangements include a requirement for the Company to provide maintenance services over the life of the arrangement, subject to a consumer price index adjustment each year. In circumstances where customers prepay the entire term’s maintenance fee, additional payments are due to the Company for the years after its extended warranty and maintenance obligations expire. Payments upon renewal each year are either prepaid or made in arrears and can vary in frequency from monthly to annually. As of December 31, 2022, $ 21.0 million of consideration has been deferred in relation to outstanding maintenance services to be provided on existing maintenance contracts (December 31, 2021 — $ 20.2 million and 2020 — $ 21.6 million). Maintenance revenue is recognized evenly over the contract term which coincides with the period over which maintenance services are provided. In the event of customer default, any payments made by the customer may be retained by the Company. In instances where the Company receives consideration prior to satisfying its performance obligations, the recognition of revenue is deferred. The majority of the deferred revenue balance relates to payments received by the Company for IMAX Systems where control of the system has not transferred to the customer. The deferred revenue balance related to an individual system increases as progress payments are made and is then derecognized when control of the system is transferred to the customer. Recognition dates are variable and depend on numerous factors, including some outside of the Company’s control.

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Segment Reporting	22. Segment Reporting The Company’s Chief Executive Officer (“CEO”) is its Chief Operating Decision Maker (“CODM”), as such term is defined under U.S. GAAP. The CODM, along with other members of management, assess segment performance based on segment revenues and gross margins. Selling, general and administrative expenses, research and development costs, the amortization of intangible assets, provision for (reversal of) current expected credit losses, certain write-downs, interest income, interest expense, and income tax (expense) benefit are not allocated to the Company’s segments. The Company has the following reportable segments: (i) IMAX DMR; (ii) Joint Revenue Sharing Arrangements (“JRSA”); (iii) IMAX Systems; (iv) IMAX Maintenance; (v) Other Theater Business; (vi) Film Distribution; and (vii) Film Post-Production. The Company's activities that do not meet the criteria to be considered a reportable segment are disclosed within All Other. The Company organizes its reportable segments into the following three categories , identified by the nature of the product sold or service provided : (i) IMAX Technology Network, which earns revenue based on contingent box office receipts and includes the IMAX DMR segment and contingent rent from the JRSA segment; (ii) IMAX Technology Sales and Maintenance, which includes results from the IMAX Systems, IMAX Maintenance and Other Theater Business segments, as well as fixed revenues from the JRSA segment; and (iii) Film Distribution and Post-Production, which includes activities related to the distribution of large-format documentary films, primarily to institutional theaters, and the distribution of exclusive experiences ranging from live performances to interactive events with leading artists and creators (through the Film Distribution segment) and the provision of film post-production and quality control services. The Company presents its segment information at a disaggregated level to provide more relevant information to the users of its financial statements. Transactions between the IMAX DMR segment and the Film Post-Production segment are valued at exchange value. Inter-segment profits are eliminated upon consolidation, as well as for the disclosures below. In the first quarter of 2022, the Company's internal reporting was updated to reclassify the results of IMAX Enhanced ® , an initiative to bring The IMAX Experience ® into the home, out of the New Business Initiatives segment and into All Other for segment reporting purposes. IMAX Enhanced was the only component of the New Business Initiatives segment. Prior period comparatives have been reclassified to conform with the current period presentation. In the first quarter of 2023, the Company has updated its internal reporting, including the information provided to the CODM to assess segment performance and allocate resources, and, as a result, will update its reportable segments in its quarterly report on Form 10-Q for the period ending March 31, 2023. Following these changes, the Company will have two reportable segments: (i) Technology Products and Services, which will principally include the sale, lease, and maintenance of IMAX Systems, previously included within the JRSA, IMAX Systems, IMAX Maintenance, Other Theater Business segments, and (ii) Content Solutions, which will principally include content enhancement and distribution services, previously included within the IMAX DMR, Film Distribution and Film Post-Production segments. The Company’s activities that do not meet the criteria to be considered a reportable segment will be reported within All Other. (a) Segment Financial Information The following table presents the Company’s revenue and gross margin (margin loss) by category and reportable segment for the years ended December 31, 2022, 2021, and 2020: Years Ended December 31, Revenue (1) Gross Margin (Margin Loss) (In thousands of U.S. Dollars) 2022 2021 2020 2022 2021 2020 IMAX Technology Network IMAX DMR $ 94,867 $ 70,659 $ 28,265 $ 57,964 $ 44,782 $ 13,731 JRSA, contingent rent 61,768 46,184 17,841 37,394 21,761 ( 9,500 ) 156,635 116,843 46,106 95,358 66,543 4,231 IMAX Technology Sales and Maintenance IMAX Systems (2) 62,933 65,660 54,055 35,129 34,981 24,816 JRSA, fixed fees 4,804 5,406 2,056 589 1,343 529 IMAX Maintenance 56,608 53,339 21,999 27,109 27,572 3,068 Other Theater Business (3) 6,255 2,363 1,666 807 398 ( 438 ) 130,600 126,768 79,776 63,634 64,294 27,975 Film Distribution and Post-Production Film Distribution (4) 3,152 1,464 4,841 ( 7,668 ) ( 1,121 ) ( 9,840 ) Post-Production 3,783 4,260 3,878 1,540 1,969 ( 358 ) 6,935 5,724 8,719 ( 6,128 ) 848 ( 10,198 ) Sub-total for reportable segments 294,170 249,335 134,601 152,864 131,685 22,008 All Other (5) 6,635 5,548 2,402 3,491 2,721 ( 468 ) Total $ 300,805 $ 254,883 $ 137,003 $ 156,355 $ 134,406 $ 21,540 The following table presents the Company’s assets by category and reportable segment, reconciled to consolidated assets, as of December 31, 2022 and 2021: As of December 31, (In thousands of U.S. Dollars) 2022 2021 IMAX Technology Network IMAX DMR $ 48,755 $ 48,299 JRSA, contingent rent 193,403 196,789 IMAX Technology Sales and Maintenance IMAX Systems 255,458 249,672 JRSA, fixed fees 26,574 27,930 IMAX Maintenance 48,764 38,530 Other Theater Business 110 82 Film Distribution and Post-Production Film Distribution 11,545 7,185 Post-Production 32,406 31,575 Sub-total for reportable segments 617,015 600,062 All Other (5) 29,686 1,420 Corporate and other non-segment specific assets 174,453 281,765 Total $ 821,154 $ 883,247 The following table presents the Company’s amortization by category and reportable segment, and on a consolidated basis, for the years ended December 31, 2022, 2021, and 2020: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 IMAX Technology Network IMAX DMR $ 16,367 $ 15,917 $ 10,269 JRSA, contingent rent 23,920 24,208 26,076 IMAX Technology Sales and Maintenance IMAX Systems 169 2,076 3,548 IMAX Maintenance — — 213 Film Distribution and Post-Production Film Distribution 2,423 600 1,213 Post-Production — 924 1,281 Sub-total for reportable segments 42,879 43,725 42,600 All Other (5) 309 — 11 Corporate and other non-segment specific assets 13,473 12,357 10,093 Total $ 56,661 $ 56,082 $ 52,704 The following table presents the Company’s write-downs, including asset impairments and credit loss expense (reversal), by category and reportable segment, and on a consolidated basis, for the years ended December 31, 2022, 2021, and 2020: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 IMAX Technology Network IMAX DMR $ 29 $ 151 $ 1,057 JRSA, contingent rent 973 364 1,784 IMAX Technology Sales and Maintenance IMAX Systems 150 837 2,872 IMAX Maintenance 591 53 510 Film Distribution and Post-Production Film Distribution (4) 819 — 9,997 Post-Production — — — Sub-total for reportable segments 2,562 1,405 16,220 All Other (5) — — 52 Corporate and other non-segment specific assets (6) 13,161 ( 3,592 ) 20,065 Total $ 15,723 $ ( 2,187 ) $ 36,337 The following table presents the Company’s purchases of fixed assets within the Consolidated Statements of Cash Flows by category and reportable segment for the years ended December 31, 2022, 2021, and 2020: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 IMAX Technology Network IMAX DMR $ — $ — $ — JRSA, contingent rent 19,803 10,094 6,654 IMAX Technology Sales and Maintenance IMAX Systems 2,574 621 50 IMAX Maintenance 4 25 — Film Distribution and Post-Production Film Distribution 4,126 1,599 — Post-Production 1,195 609 456 Sub-total for reportable segments 27,702 12,948 7,160 All Other (5) 9 — — Corporate and other non-segment specific assets 516 736 191 Total $ 28,227 $ 13,684 $ 7,351 (1) The Company’s largest customer represents 12 % of total Revenues as of December 31, 2022 (2021 ― 10 % ; 2020 ― 16 % ). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of December 31, 2022 and 2021 . (2) The revenue from this segment includes the initial upfront payments and the present value of fixed minimum payments from sale and sales-type lease arrangements of IMAX Systems, as well as the present value of estimated variable consideration from sales of IMAX Systems. To a lesser extent, the revenue from this segment also includes finance income associated with these revenue streams. (3) The revenue from this segment principally includes after-market sales of IMAX projection system parts and 3D glasses. (4) For the year ended December 31, 2022 , the Company recorded an impairment loss of $ 0.8 million related to the write-down of documentary film assets. During the year ended December 31, 2020 , Film Distribution segment results were significantly influenced by impairment losses of $ 10.0 million, to write-down the carrying value of certain documentary and alternative content film assets due to a decrease in projected box office totals and related revenues based on management’s regular quarterly recoverability assessments. No such impairment losses were incurred in 2021. (5) All Other includes the results from IMAX Enhanced, SSIMWAVE, and other ancillary activities. In the first quarter of 2022, the Company's internal reporting was updated to reclassify the results of IMAX Enhanced out of the New Business Initiatives segment into All Other for segment reporting purposes. Prior period comparatives have been revised to conform with the current period presentation. (See Note 5 for additional information related to the Company's acquisition of SSIMWAVE. ) (6) During the year ended December 31, 2022 , includes provision of current expected credit losses of $ 8.5 million ( 2021 ― net reversal of $ 4.0 million; 2020 ― provision of $ 18.6 million). (See Note 6 .) In 2022, the Company recognized a full impairment of its RMB 30.0 million ($ 4.5 million) investment in the film Mozart from Space based on projected box office results and distribution costs. (See Note 23(e).) In 2020, the Company recorded a write-down of $ 1.2 million in Asset Impairments related to content-related assets which became impaired in the year. No such impairment losses were incurred in 2021. These amounts are excluded from the measurement of the Company’s segment performance. (b) Geographic Information Revenue by geographic area is based on the location of the customer. Revenue related to IMAX DMR is presented based upon the geographic location of the IMAX System that exhibit the remastered films. IMAX DMR revenue is generated through contractual relationships with studios and other third parties and these may not be in the same geographical location as the IMAX System. The following table summarizes the Company’s revenues by geographic area for the years ended December 31, 2022, 2021, and 2020: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 United States $ 107,734 $ 73,499 $ 30,157 Greater China 73,330 112,801 52,331 Asia (excluding Greater China) 47,145 23,682 20,090 Western Europe 40,245 20,942 13,683 Latin America 9,418 3,601 6,114 Canada 7,550 3,266 1,365 Russia/the CIS & Ukraine (1) 2,849 7,308 2,927 Rest of the World 12,534 9,784 10,336 Total $ 300,805 $ 254,883 $ 137,003 (1) In addition to Russia, the CIS includes Azerbaijan, Belarus, Kazakhstan, and Kyrgyzstan. Commencing i n March 2022, in response to the ongoing conflict between Russia and Ukraine and resulting sanctions, the Company suspended its operations in Russia and Belarus. As of December 31, 2022, the IMAX network includes 54 systems in Russia, eight systems in Ukraine, and one system in Belarus. No single country in the Rest of the World, Western Europe, Latin America, and Asia (excluding Greater China) classifications comprise more than 10% of total revenue. The following table presents the breakdown of Property, Plant and Equipment by geography as of December 31, 2022 and 2021: As of December 31, (In thousands of U.S. Dollars) 2022 2021 United States $ 94,505 $ 91,856 Greater China 86,665 100,182 Canada 36,385 32,643 Western Europe 20,132 21,684 Asia (excluding Greater China) 10,471 9,463 Rest of the World 4,738 4,525 Total $ 252,896 $ 260,353

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2022
Investments, All Other Investments [Abstract]
Financial Instruments	23. Financial Instruments (a) Financial Instruments The Company maintains cash with various major financial institutions. The Company’s cash is invested with highly rated financial institutions. The Company’s $ 97.4 million balance of cash and cash equivalents as of December 31, 2022 (December 31, 2021 — $ 189.7 million ) includes $ 79.7 million in cash held outside of Canada (December 31, 2021 — $ 102.1 million ), of which $ 43.7 million was held in the PRC (December 31, 2021 — $ 76.3 million ). (b) Fair Value Measurements The carrying values of the Company’s Cash and Cash Equivalents, Accounts Receivable, Accounts Payable, and Accrued Liabilities due within one year approximate their fair values due to the short-term maturity of these instruments. Including these instruments, the Company’s financial instruments consist of the following: As of December 31, 2022 As of December 31, 2021 (In thousands of U.S. Dollars) Carrying Estimated Carrying Estimated Level 1 Cash and cash equivalents (1) $ 97,401 $ 97,401 $ 189,711 $ 189,711 Equity securities (2) 1,035 1,035 1,087 1,087 Level 2 Net financed sales receivables (3) $ 101,052 $ 100,059 $ 112,657 $ 112,662 Net investment in sales-type leases (3) 28,332 27,972 28,392 28,407 Equity securities (1) 1,000 1,000 1,000 1,000 COLI (4) 3,398 3,398 3,275 3,275 Foreign exchange contracts — designated forwards (2) ( 649 ) ( 649 ) 79 79 Wells Fargo Credit Facility borrowings (1) ( 25,000 ) ( 25,000 ) — — HSBC China Facility borrowings (1) ( 12,496 ) ( 12,496 ) — — Bank of China Facility borrowings (1) ( 374 ) ( 374 ) ( 3,612 ) ( 3,612 ) Federal Economic Development Loan (3) ( 1,782 ) ( 1,782 ) N/A N/A Convertible Notes (5) ( 230,000 ) ( 196,717 ) ( 230,000 ) ( 223,100 ) Level 3 Interest in film classified as a financial instrument (6) $ — $ — $ — $ — (1) Recorded at cost, which approximates fair value. (2) Fair value is determined using quoted prices in active markets. (3) Fair value is estimated based on discounting future cash flows at currently available interest rates with comparable terms. (4) Measured at cash surrender value, which approximates fair value. (5) Fair value is determined using quoted market prices that are observable in the market or that could be derived from observable market data. (6) Recorded at amortized cost less impairment losses. Inputs used in the calculation of estimated fair value include management's projection of future box office and ancillary receipts for the film net of distribution costs and other costs in accordance with the investment agreement. See 23 (e) below. (c) Foreign Exchange Risk Management The Company is exposed to market risk from changes in foreign currency rates. A majority of the Company’s revenues is denominated in U.S. Dollars while a significant portion of its costs and expenses is denominated in Canadian Dollars. A portion of the Company’s net U.S. Dollar cash is converted to Canadian Dollars to fund Canadian Dollar expenses through the spot market. In China and Japan, the Company has ongoing operating expenses related to its operations in RMB and Japanese Yen, respectively. Net cash flows are converted to and from U.S. Dollars through the spot market. The Company also has cash receipts under leases denominated in RMB, Japanese Yen, Canadian Dollars, and Euros which are converted to U.S. Dollars through the spot market. In addition, because IMAX films generate box office in 87 different countries, unfavorable exchange rates between applicable local currencies and the U.S. Dollar could have an impact on box office receipts and the Company’s revenues and results of operations. The Company’s policy is to not use any financial instruments for trading or other speculative purposes. The Company has entered into a series of foreign currency forward contracts to manage the risks associated with the volatility of foreign currencies. Certain of these foreign currency forward contracts met the criteria required for hedge accounting under the Derivatives and Hedging Topic of the FASB ASC at inception, and continue to meet hedge effectiveness tests as of December 31, 2022 (the “Foreign Currency Hedges”), with settlement dates throughout 2023 . Foreign currency derivatives are recognized and measured in the Consolidated Balance Sheets at fair value. Changes in the fair value (i.e., gains or losses) are recognized in the Consolidated Statements of Operations except for derivatives designated and qualifying as foreign currency cash flow hedging instruments. The Company currently has cash flow hedging instruments associated with Selling, General and Administrative Expenses. For foreign currency cash flow hedging instruments related to Selling, General and Administrative Expenses, the effective portion of the gain or loss in a hedge of a forecasted transaction is reported in Accumulated Other Comprehensive (Loss) Income and reclassified to the Consolidated Statements of Operations when the forecasted transaction occurs. Any ineffective portion is recognized immediately in the Consolidated Statements of Operations. The following tabular disclosures reflect the impact that derivative instruments and hedging activities have on the Company’s Consolidated Financial Statements: Notional value of foreign exchange contracts : As of December 31, (In thousands of U.S. Dollars) 2022 2021 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards $ 24,707 $ 26,702 Fair value of derivatives in foreign exchange contracts : As of December 31, (In thousands of U.S. Dollars) Balance Sheet Location 2022 2021 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards Other assets $ 50 $ 184 Accrued and other liabilities ( 699 ) ( 105 ) $ ( 649 ) $ 79 Derivatives in foreign currency hedging relationships are as follows : Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Foreign exchange contracts Derivative (Loss) Gain — Forwards Recognized in OCI (Effective Portion) $ ( 1,323 ) $ 468 $ 550 Location of Derivative (Loss) Gain Reclassified from AOCI Years Ended December 31, (In thousands of U.S. Dollars) (Effective Portion) 2022 2021 2020 Foreign exchange contracts Selling, general and — Forwards administrative expenses $ ( 596 ) $ 1,707 $ ( 578 ) Inventories — — ( 26 ) $ ( 596 ) $ 1,707 $ ( 604 ) Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Foreign exchange contracts Derivative Gain Recognized — Forwards In and out of OCI (Effective Portion) $ — $ — $ 17 Non-designated derivatives in foreign currency relationships are as follows : Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Foreign exchange contracts Derivative Gain Reclassified — Forwards From AOCI (Ineffective Portion) $ — $ ( 318 ) $ — Years Ended December 31, (In thousands of U.S. Dollars) Location of Derivative Gain 2022 2021 2020 Foreign exchange contracts Selling, general and — Forwards administrative expenses $ — $ 398 $ 344 The Company's estimated net amount of the existing loss as of December 31, 2022 is $ ( 0.6 ) million , which is expected to be reclassified to earnings within the next twelve months. (d) Investments in Equity Securities As of December 31, 2022, the Consolidated Balance Sheets includes $ 1.0 million (December 31, 2021 — $ 1.1 million ) of investments in equity securities. On January 17, 2019, IMAX China (Hong Kong), Limited, a wholly-owned subsidiary of IMAX China, as an investor entered into a cornerstone investment agreement with Maoyan Entertainment (“Maoyan”) (as the issuer) and Morgan Stanley Asia Limited (as a sponsor, underwriter and the underwriters’ representative). Pursuant to this agreement, IMAX China (Hong Kong), Limited agreed to invest $ 15.2 million to subscribe for a certain number of shares of Maoyan at the final offer price pursuant to the global offering of the share capital of Maoyan, and this investment would be subject to a lock-up period of six months following the date of the global offering. On February 4, 2019, Maoyan completed its global offering, upon which, IMAX China (Hong Kong), Limited became a less than 1 % shareholder in Maoyan. In February 2021, IMAX China (Hong Kong), Limited sold all of its 7,949,000 shares of Maoyan for gross proceeds of $ 17.8 million, and recognized $ 5.2 million gain in the Consolidated Statements of Operations. The Company has an investment of $ 1.0 million (December 31, 2021 — $ 1.0 million ) in the shares of an exchange traded fund. This investment is classified as an equity investment. As of December 31, 2022, the Company held investments in the preferred shares of enterprises which meet the criteria for classification as an equity security carried at historical cost, net of impairment charges. The carrying value of these equity security investments was $ 1.0 million as of December 31, 2022 (December 31, 2021 — $ 1.0 million ) and is recorded in Other Assets. (e) Interest in Film On January 10, 2022, IMAX (Shanghai) Culture and Technology Co., Ltd, a wholly-owned subsidiary of IMAX China, entered into a joint film investment agreement with Wanda Film (Horgos) Co. Ltd. to invest RMB 30.0 million ($ 4.7 million) in the movie Mozart from Space , which was released on July 15, 2022. Pursuant to the investment agreement, IMAX (Shanghai) Culture and Technology Co., Ltd. has the right to receive a share of the profits or losses of the film distribution. IMAX (Shanghai) Culture and Technology Co., Ltd.'s commitment is limited to its investment and has no further obligation if the actual movie production cost exceeds the original budget. The investment meets the criteria for classification as a financial asset. The investment is measured at amortized cost less impairment losses and is recorded within Other Assets in the Consolidated Balance Sheets. During the second quarter of 2022 , the Company recognized a full impairment of its RMB 30.0 million ($ 4.5 million) investment in Mozart from Space based on projected box office results and distribution costs.

Employees Pension and Postretir

Employees Pension and Postretirement Benefits	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Employees Pension and Postretirement Benefits	24. Employee's Pension and Postretirement Benefits (a) Defined Benefit Plan The Company has an unfunded defined benefit pension plan, the Supplemental Executive Retirement Plan (the “SERP” ), covering its CEO, Richard L. Gelfond. Under the terms of the SERP, if Mr. Gelfond's employment is terminated other than for cause (as defined in his employment agreement), he is entitled to receive SERP benefits in the form of a lump sum payment. SERP benefit payments to Mr. Gelfond are subject to a deferral for six months after the termination of his employment, at which time Mr. Gelfond will be entitled to receive interest on the deferred amount credited at the applicable federal rate for short-term obligations. Pursuant to an amendment to his employment agreement dated September 19, 2022, the term of Mr. Gelfond's employment was extended through December 31, 2025, although Mr. Gelfond has not informed the Company that he intends to retire at that time. Under the terms of his employment agreement, as amended, the total benefit payable to Mr. Gelfond under the SERP is fixed at $ 20.3 million. As of December 31, 2022 and 2021, the projected benefit obligation for SERP are as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 Projected benefit obligation: Obligation, beginning of period $ 20,056 $ 20,116 Interest cost 160 72 Actuarial gain ( 2,901 ) ( 132 ) Obligation, end of period and unfunded status $ 17,315 $ 20,056 As of December 31, 2022, 2021, and 2020, the following amounts related to the SERP were recorded on the Company’s Consolidated Balance Sheets within Accumulated Other Comprehensive (Loss) Income and will be recognized as components of net periodic benefit cost in future periods: As of December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Unrealized actuarial gain $ ( 3,580 ) $ ( 679 ) $ ( 547 ) Unamortized prior service cost — 184 369 Net periodic benefit costs to be recognized in future periods $ ( 3,580 ) $ ( 495 ) $ ( 178 ) For the years ended December 31, 2022, 2021, and 2020, the components of pension expense related to the SERP were as follows: Years ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Interest cost $ 160 $ 72 $ 379 Amortization of prior service cost 184 185 87 Pension expense $ 344 $ 257 $ 466 The following assumptions were used to determine the SERP obligation and any related costs as of and for the years ended December 31, 2022, 2021, and 2020: As of December 31, 2022 2021 2020 Discount rate 4.55 % 0.80 % 0.36 % Lump sum interest rate: First 25 years N/A N/A N/A First 20 years N/A N/A N/A Thereafter N/A N/A N/A Cost of living adjustment on benefits N/A N/A N/A No contributions were made for the SERP during 2022. The Company expects interest costs of $ 0.8 million to be recognized as a component of pension cost for the year ended December 31, 2023. (b) Defined Contribution Pension Plan The Company also maintains defined contribution plans for its employees, including its executive officers. The Company makes contributions to these plans on behalf of employees in an amount up to 5 % of their base salary subject to certain prescribed maximums. During 2022, the Company contributed and recorded expense of $ 1.1 million (2021 — $ 1.1 million ; 2020 — $ 1.1 million ) to its Canadian plan and $ 0.7 million (2021 — $ 0.5 million ; 2020 — $ 0.6 million ) to its defined contribution employee plan under Section 401(k) of the U.S. Internal Revenue Code. (c) Postretirement Benefits - Executives The Company has an unfunded postretirement plan for Mr. Gelfond and Bradley J. Wechsler, former Chairman of the Company’s Board of Directors (the “Executive Postretirement Benefit Plan”). The Executive Postretirement Benefit Plan provides that the Company will maintain health benefits for Messrs. Gelfond and Wechsler until they become eligible for Medicare and, thereafter, the Company will provide Medicare supplemental coverage as selected by Messrs. Gelfond and Wechsler. Mr. Wechsler retired from the Company’s Board of Directors on June 9, 2021. The Company maintained Mr. Wechsler’s health benefits through December 31, 2021, and thereafter is providing him with Medicare supplemental coverage or its equivalent value. As of December 31, 2022 and 2021, the Company’s Consolidated Balance Sheets include the following amounts within Accrued and Other Liabilities related to the Executive Postretirement Benefit Plan: As of December 31, (In thousands of U.S. Dollars) 2022 2021 Projected benefit obligation: Obligation, beginning of year $ 662 $ 710 Interest cost 18 16 Benefits paid ( 8 ) ( 16 ) Actuarial gain ( 215 ) ( 48 ) Obligation, end of year and unfunded status $ 457 $ 662 For the years ended December 31, 2022, 2021, and 2020, the components of pension expense related to the Executive Postretirement Benefit Plan were as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Interest cost $ 18 $ 16 $ 20 Amortization of actuarial gain — — ( 17 ) Pension expense $ 18 $ 16 $ 3 As of December 31, 2022, 2021, and 2020, the following amounts related to the Executive Postretirement Benefit Plan were recorded on the Company’s Consolidated Balance Sheets within Accumulated Other Comprehensive (Loss) Income and will be recognized as components of net pension cost in future periods: As of December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Unrealized actuarial (gain) loss $ ( 242 ) $ ( 27 ) $ 21 As of December 31, 2022, 2021, and 2020, the weighted average assumptions used to determine the benefit obligation related to the Executive Postretirement Benefit Plan are as follows: As of December 31, 2022 2021 2020 Discount rate 5.01 % 2.71 % 2.36 % For the years ended December 31, 2022, 2021, and 2020, the weighted average assumptions used to determine the net postretirement benefit expense related to the Executive Postretirement Benefit Plan are as follows: Years Ended December 31, 2022 2021 2020 Discount rate 2.71 % 2.36 % 3.13 % The following benefit payments are expected to be made as per the current plan assumptions for the Executive Postretirement Benefit Plan in each of the next five years and thereafter following the December 31, 2022 balance sheet date: (In thousands of U.S. Dollars) 2023 $ 10 2024 10 2025 11 2026 23 2027 24 Thereafter 888 Total $ 966 (d) Postretirement Benefits – Canadian Employees The Company has an unfunded postretirement plan for its Canadian employees meeting specific eligibility requirements (the “Canadian Postretirement Benefit Plan”). The Company will provide eligible participants, upon retirement, with health and welfare benefits. As of December 31, 2022 and 2021, the Company’s Consolidated Balance Sheets include the following amounts within Accrued and Other Liabilities related to the Canadian Postretirement Benefit Plan: As of December 31, (In thousands of U.S. Dollars) 2022 2021 Projected benefit obligations: Obligation, beginning of year $ 1,702 $ 1,862 Interest cost 46 42 Benefits paid ( 155 ) ( 118 ) Actuarial gain ( 539 ) ( 92 ) Unrealized foreign exchange (gain) loss ( 78 ) 8 Obligation, end of year and unfunded status $ 976 $ 1,702 For the years ended December 31, 2022, 2021, and 2020, the components of pension expense related to the Canadian Postretirement Benefit Plan were as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Interest cost $ 46 $ 42 $ 47 Pension expense $ 46 $ 42 $ 47 The Company expects interest costs of less than $ 0.1 million to be recognized as a component of benefit cost for the year ended December 31, 2023. As of December 31, 2022, 2021, and 2020, the following amounts related to the Canadian Postretirement Benefit Plan were recorded on the Company’s Consolidated Balance Sheets within Accumulated Other Comprehensive (Loss) Income and will be recognized as components of net pension cost in future periods: As of December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Unrealized actuarial (gain) loss $ ( 354 ) $ 185 $ 277 As December 31, 2022, 2021, and 2020, the weighted average assumptions used to determine the benefit obligation related to the Canadian Postretirement Benefit Plan are as follows: As of December 31, 2022 2021 2020 Discount rate 5.00 % 2.80 % 2.30 % For the years ended December 31, 2022, 2021, and 2020, the weighted average assumptions used to determine the net postretirement benefit expense related to the Canadian Postretirement Benefit Plan are as follows: Years Ended December 31, 2022 2021 2020 Discount rate 2.80 % 2.30 % 3.05 % The following benefit payments are expected to be made as per the current plan assumptions for the Canadian Postretirement Benefit Plan in each of the next five years and thereafter following the December 31, 2022 balance sheet date: (In thousands of U.S. Dollars) 2023 $ 94 2024 94 2025 95 2026 87 2027 86 Thereafter 1,082 Total $ 1,538 (e) Deferred Compensation Benefit Plan The Company maintained a nonqualified deferred compensation benefit plan (the “Retirement Plan”) covering the former CEO of IMAX Entertainment and Senior Executive Vice President of the Company. Under the terms of the Retirement Plan, the benefits were due to vest in full if the executive incurred a separation from service from the Company (as defined therein). In 2018, the executive incurred a separation from service from the Company, and as such, the Retirement Plan benefits became fully vested as of December 31, 2018. As of December 31, 2022, the benefit obligation related to the Retirement Plan was $ 3.9 million (December 31, 2021 — $ 3.8 million ) and is recorded on the Company’s Consolidated Balance Sheets within Accrued and Other Liabilities. As the Retirement Plan is fully vested, the benefit obligation is measured at the present value of the benefits expected to be paid in the future with the accretion of interest recognized in the Consolidated Statements of Operations within Retirement Benefits Non-Service Expense. The Retirement Plan is funded by an investment in company-owned life insurance (“COLI”), which is recorded at its fair value on the Company’s Consolidated Balance Sheets within Prepaid Expenses. As of December 31, 2022, fair value of the COLI asset was $ 3.4 million (December 31, 2021 — $ 3.3 million ). Gains and losses resulting from changes in the cash surrender value of the COLI asset are recognized in the Consolidated Statements of Operations within Realized and Unrealized Investment Gains (Losses).

Government Assistance

Government Assistance	12 Months Ended
	Dec. 31, 2022
Government Assistance [Abstract]
Government Assistance	25. Government Assistance (a) COVID-19 Relief The Company has applied for and received financial support under COVID relief legislation that has been enacted in the countries in which it operates. For the year ended December 31, 2022 , the Company recognized $ 0.4 million ( 2021 — $ 3.8 million; 2020 — $ 7.1 million) in benefits principally from the Hardest-Hit Businesses Recovery program, and recorded such amounts as reductions to Selling, General and Administrative Expenses ($ 0.3 million) and Costs and Expenses Applicable to Revenues ($ 0.1 million). For the years ended December 31, 2021 and 2020, the Company recognized $ 3.8 million and $ 7.1 million, respectively, in benefits from various COVID-19 government relief programs, and recorded such amounts as reductions to Selling, General and Administrative Expenses ($ 2.9 million and $ 6.0 million, respectively), Costs and Expenses Applicable to Revenues ($ 0.9 million and $ 1.0 million, respectively) and Research and Development ($ nil and $ 0.1 million, respectively). These benefits are principally under the Canada Emergency Wage Subsidy program (“CEWS” program), which expired in October 2021. (b) Federal Economic Development Loan SSIMWAVE entered into a contribution agreement with the Federal Economic Development Agency for Southern Ontario (the “Federal Economic Development Loan” on May 29, 2019, under which SSIMWAVE may receive up to $ 4.2 million CAD ($ 3.1 million) by way of repayable contributions toward certain eligible projects costs. The contributions under the agreement cover 35 % of the eligible and supported costs of SSIMWAVE between January 10, 2019 and December 31, 2022. The contributions are repayable over 60 months , with repayments estimated to begin in January 2024 , with an annual interest rate of 0 %. As of December 31, 2022, SSIMWAVE has received contributions of CAD $ 3.8 million ( $ 2.8 million ) from the Federal Economic Development Loan. As of December 31, 2022, the Federal Economic Development Loan has a carrying value of $ 1.8 million , net of unaccreted interest benefit and is recorded within Convertible Notes and Other Borrowings, Net on the Company's Consolidated Balance Sheets.

Non-Controlling Interests

Non-Controlling Interests	12 Months Ended
	Dec. 31, 2022
Temporary Equity Disclosure [Abstract]
Non-Controlling Interests	26. Non-Controlling Interests (a) IMAX China Non-Controlling Interest As of December 31, 2022, the Company indirectly owns 71.73 % of IMAX China, whose shares trade on the Hong Kong Stock Exchange (December 31, 2021 — 71.11 % ). IMAX China remains a consolidated subsidiary of the Company. The balance of non-controlling interest in IMAX China as of December 31, 2022 is $ 65.7 million (December 31, 2021 — $ 73.5 million). The net income attributable to non-controlling interest of IMAX China for the year ended December 31, 2022 is $ 3.0 million (2021 — income of $ 12.8 million ; 2020 — loss of $( 8.6 ) million ). (b) Other Non-Controlling Interests The Company’s Original Film Fund was established in 2014 to co-finance a portfolio of 10 original large-format films. The initial investment in the Original Film Fund was committed by a third party in the amount of $ 25.0 million, with the possibility of contributing additional funds. The Company has contributed $ 9.0 million to the Original Film Fund since 2014, and has reached its maximum contribution. Through December 31, 2022, the Original Film Fund has invested $ 22.3 million toward the development of original films. The related production, financing and distribution agreement includes put and call rights relating to change of control of the rights, title and interest in the co-financed pictures. (c) Non-Controlling Interest in Temporary Equity The following summarizes the movement of the non-controlling interest in temporary equity, in the Original Film Fund for the years ended December 31, 2022, 2021 and 2020: (In thousands of U.S. Dollars) Balance as of January 1, 2020 $ 5,908 Return of capital to non-controlling interests ( 10 ) Net loss ( 5,139 ) Balance as of December 31, 2020 759 Net loss ( 1 ) Balance as of December 31, 2021 758 Net loss ( 36 ) Balance as of December 31, 2022 $ 722

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principles of Consolidation	(a) Principles of Consolidation The Consolidated Financial Statements include the accounts of the Company together with its consolidated subsidiaries, except for subsidiaries which have been identified as variable interest entities (“VIEs”) where the Company is not the primary beneficiary. All intercompany accounts and transactions have been eliminated. The Company has evaluated its various variable interests to determine whether they are VIEs as required by U.S. GAAP. The Company has interests in ten film production companies, which have been identified as VIEs. The Company is the primary beneficiary of and consolidates five of these entities as it has the power to direct the activities that most significantly impact the economic performance of the VIE, and it has the obligation to absorb losses or the right to receive benefits from the respective VIE that could potentially be significant. The majority of the assets relating to these production companies are held by the IMAX Original Film Fund (the “Original Film Fund”) as described in Note 26 (b). The Company does not consolidate the other five film production companies because it does not have the power to direct their activities and it does not have the obligation to absorb the majority of the expected losses or the right to receive expected residual returns. The Company uses the equity method of accounting for these entities, which are not material to the Company’s Consolidated Financial Statements. A loss in value of an equity method investment that is other than temporary is recognized as a charge in the Consolidated Statements of Operations. As of December 31, 2022 and 2021, total assets and liabilities of the Company's consolidated VIEs are as follows: December 31, December 31, (In thousands of U.S. Dollars) 2022 2021 Total assets $ 1,523 $ 1,576 Total liabilities $ 248 $ 259
Estimates and Assumptions	(b) Estimates and Assumptions The preparation of financial statements and related disclosures in accordance with U.S. GAAP requires management to make judgments, assumptions, and estimates that affect the amounts reported in the Company’s Consolidated Financial Statements and accompanying notes. Management’s judgments, assumptions, and estimates are based on historical experience, future expectations and other factors that are believed to be reasonable as of the date of the Consolidated Financial Statements. Actual results may ultimately differ from management’s original estimates, as future events and circumstances sometimes do not develop as expected, and the differences may be material. Significant estimates made by management include, but are not limited to: (i) the allocation of the transaction price in an IMAX System arrangement to distinct performance obligations; (ii) the amount of variable consideration to be earned on sales of IMAX Systems based on projections of future box office performance; (iii) expected credit losses on accounts receivable, financing receivables, and variable consideration receivables; (iv) provisions for the write-down of excess and obsolete inventory; (v) the fair values of the reporting units used in assessing the recoverability of goodwill; (vi) the cash flow projections used in testing the recoverability of long-lived assets such as the theater system equipment supporting joint revenue sharing arrangements; (vii) the economic lives of the theater system equipment supporting joint revenue sharing arrangements; (viii) the useful lives of intangible assets; (ix) the ultimate revenue forecasts used to test the recoverability of film assets; (x) the discount rates used to determine the present value of financing receivables and lease liabilities, as well as to determine the fair values of the Company’s reporting units for the purpose of assessing the recoverability of goodwill; (xi) pension plan assumptions; (xii) estimates related to the fair value and projected vesting of share-based payment awards; (xiii) the valuation of deferred income tax assets; (xiv) reserves related to uncertain tax positions; and (xv) the allocation of the purchase price for the acquisition of SSIMWAVE Inc. and its wholly-owned subsidiary (together, “SSIMWAVE”). The COVID-19 pandemic and the measures to prevent its spread have impacted the Company’s business and the global economy, as described in Note 2. Although management is encouraged by the broad reopening of the IMAX network, the continued progress towards the resumption of normal theater operations, normal film release schedules, and recent box office results, there continues to be risk and uncertainty relating to the judgments, assumptions, and estimates used by management in preparing the Company's Consolidated Financial Statements. Commencing in March 2022, in response to numerous sanctions imposed by the United States, Canada and the European Union on companies transacting in Russia and Belarus resulting from ongoing conflict between Russia and Ukraine, the Company suspended its operations in Russia and Belarus. As of December 31, 2022 , the IMAX network includes 54 systems in Russia, eight systems in Ukraine, and one system in Belarus, and the Company's backlog includes 14 systems in Russia, one system in Ukraine, and five systems in Belarus with a total fixed contracted value of $ 22.9 million. In the first quarter of 2022, the Company recorded provisions for potential credit losses against substantially all of its receivables in Russia due to uncertainties associated with the ongoing conflict and resulting sanctions. These receivables relate to existing sale agreements as the Company is not party to any joint revenue sharing arrangements in these countries. In addition, beginning in the first quarter of 2022, exhibitors in Russia, Ukraine, and Belarus were placed on nonaccrual status for maintenance revenue and finance income. Most multiplexes in Ukraine have reopened since the conflict began and the Company remains optimistic that its full network in Ukraine will ultimately resume operations. The Company continues to closely monitor the evolving impacts of this conflict (including the sanctions imposed by the United States, Canada and the European Union) and its effects on the global economy and the Company. (See Note 6 for more information on the impact of the ongoing Russia-Ukraine conflict and resulting sanctions on the Company's receivables and current expected credit losses.) On September 7, 2022, Cineworld Group plc (“Cineworld”), the parent company of Regal, and certain of its subsidiaries and Regal CineMedia Holdings, LLC, filed petitions for reorganization under Chapter 11 of the United States Bankruptcy Code in the Southern District of Texas. The Company had an unsecured pre-petition claim of $ 11.4 million related to receivables from the entities included in the reorganization proceedings. On October 21, 2022, the Company was ratified by the bankruptcy court as a critical vendor of Cineworld, allowing the Company to collect pre-petition amounts owed to it by Cineworld, and requiring Cineworld to stay current on the Company’s post-petition receivables. On November 8, 2022, IMAX Corporation entered into a trade agreement with Cineworld (the “Trade Agreement”), pursuant to which Cineworld affirmed the amount of the receivables owed to the Company and agreed to a payment plan under which all amounts due will be settled over the period from November 9, 2022 to April 12, 2023. As of February 20, 2023, the Company had received payments of $ 7.2 million from Cineworld in accordance with the terms of the Trade Agreement. Based on its evaluation of its contracts with Cineworld, its assessment of the reorganization and its discussions with Cineworld to date, the Company has determined that no additional provision for expected credit losses is required. The Company also does not expect to see a material impact on its IMAX network with Cineworld resulting from this reorganization. There can, however, be no guarantees as to the ultimate outcome of a Chapter 11 proceeding.
Cash and Cash Equivalents	(c) Cash and Cash Equivalents The Company considers all highly liquid investments convertible to a known amount of cash and with an original maturity of three months or less to be cash equivalents.
Receivable	(d) Receivables The Company develops an estimate of expected credit losses by class of receivable and customer type through a calculation that utilizes historical loss rates which are then adjusted for specific receivables that are judged to have a higher-than-normal risk profile after considering management’s internal credit quality classifications, as well as macro-economic and industry risk factors. The write-off of any billed receivable balance requires the approval of management. (See Note 6 for more information related to the Company’s receivables and current expected credit losses.)
Inventories	(e) Inventories Inventories are carried at the lower of cost, determined on an average cost basis, and net realizable value except for raw materials, which are carried at the lower of cost and replacement cost. Finished goods and work-in-process includes the cost of raw materials, direct labor, theater design costs, and an applicable share of manufacturing overhead costs. The costs related to IMAX Systems under sale and sales-type lease arrangements are transferred from Inventories to Costs and Expenses Applicable to Revenues – Technology Sales in the period when the sale is recognized in the Consolidated Statements of Operations. The costs related to IMAX Systems under joint revenue sharing arrangements are transferred from Inventories to assets under construction in Property, Plant and Equipment when allocated to a signed joint revenue sharing arrangement. The Company records write-downs for excess and obsolete inventory based upon management’s judgments regarding future events and business conditions, including the anticipated installation dates for the current backlog of theater system contracts, contracts in negotiation, technological developments, growth prospects within the customers’ ultimate marketplace and anticipated market acceptance of the Company’s current and pending theater IMAX Systems. Finished goods inventories includes IMAX Systems for which title has passed to the Company’s customer in situations when the IMAX System has been delivered to the customer, but the criteria for revenue recognition were not met as of the balance sheet date.
Film Assets	(f) Film Assets Film Assets consist of: (i) capitalized costs associated with the digital remastering of films where the copyright is owned by a third party, including labor and allocated overhead, and (ii) capitalized costs associated with the production of films, including labor, allocated overhead, and the cost of acquiring film rights. Production financing provided by third parties that acquire substantive rights in the film is recorded as a reduction of the cost of the film. Capitalized film costs are amortized and participation costs are accrued to Costs and Expenses Applicable to Revenues using the individual-film-forecast method, which amortizes such costs in the same ratio as the associated ultimate revenue. Estimates of ultimate revenues are prepared on a title-by-title basis and reviewed regularly by management and revised where necessary to reflect the most current information. Ultimate revenues reflect management’s estimates of future revenue over a period not to exceed ten years following the date of the film’s initial release. The recoverability of the Company’s film assets is dependent upon the commercial acceptance of the underlying films and the resulting level of box office results and, in certain situations, ancillary revenues. If management’s projections of future net cash flows resulting from the exploitation of a film indicate that the carrying value of the film asset is not recoverable, the film asset is written down to its fair value. Film exploitation costs, including advertising and marketing, are recorded in Costs and Expenses Applicable to Revenues – Image Enhancement and Maintenance Services as incurred, except for those costs that are made after recognizing revenue, which are recorded when the related revenues are recognized.
Property, Plant and Equipment	(g) Property, Plant and Equipment Property, Plant and Equipment is recorded at cost and is depreciated on a straight-line basis over the estimated useful lives of the underlying assets as follows: Theater system components (1) — Over the equipment’s expected useful life ( 7 to 20 years) Camera equipment — Over a period between 5 to 10 years Buildings — Over a period between 20 to 25 years Office and product equipment — Over a period between 3 to 5 years Leasehold improvements — Over the shorter of the initial term of the underlying lease plus any reasonably assured renewal periods, and the useful life of the asset (1) Includes equipment under joint revenue sharing arrangements. The cost of IMAX System components and related equipment expected to be used in future joint revenue sharing arrangements, including related direct labor costs and an allocation of direct production costs, are recorded within assets under construction until the underlying IMAX System is installed and in working condition. These assets are depreciated to Costs and Expenses Applicable to Revenues on a straight-line basis over the lesser of the term of the joint revenue sharing arrangement and the equipment’s expected useful life. The estimated useful lives of the system components and related equipment used in joint revenue sharing arrangements are reviewed periodically to determine if any adjustments are required. Property, Plant and Equipment is grouped at the lowest level for which identifiable cash flows are largely independent and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset (or asset group) may not be recoverable. In such situations, the asset (or asset group) is considered impaired when estimated future cash flows (undiscounted and without interest charges) resulting from the use of the asset (or asset group) and its eventual disposition are less than the carrying value of the asset (or asset group). In such situations, the asset (or asset group) is written down to its fair value, which is the present value of the estimated future cash flows. Factors that are considered when evaluating such assets for impairment include a current expectation that it is more likely than not that the long-lived asset will be sold significantly before the end of its useful life, a significant decrease in the market price of the long-lived asset, and a significant change in the extent or manner in which the long-lived asset is being used.
Investment in Equity Securities	(h) Investment in Equity Securities Equity securities with readily determinable fair values are reported at fair value with changes in fair value recorded within Realized and Unrealized Investment Gains (Losses) in the Consolidated Statements of Operations.
Other Assets	(i) Other Assets Other Assets principally includes lease incentives provided to certain exhibitor customers under joint revenue sharing arrangements classified as an operating lease, as well as sales commissions and other deferred selling expenses that directly relate to the acquisition of the revenue generating contract and are incremental to the Company’s other expenses. To a much lesser extent, Other Assets also includes various investments and foreign currency derivatives. Capitalized lease incentives are amortized on a straight-line basis over the term of the lease as a reduction to rental revenue. Sales commissions and other selling expenses paid prior to the recognition of the related revenue are deferred and recognized within Costs and Expenses Applicable to Revenues upon the client acceptance of the IMAX System or the abandonment of the sale arrangement. Foreign currency derivatives are accounted for at fair value using quoted prices in active markets. In periods when there are no outstanding borrowings under the Company’s revolving credit facility arrangements, any related debt issuance costs are recorded within Other Assets and amortized on a straight-line basis over the term of the facility. In periods when there are outstanding borrowings under the Company’s revolving credit facility arrangements, any related debt issuance costs are reclassified to reduce the principal amount of outstanding borrowings and amortized on a straight-line basis over the term of the facility. (See Note 15 for information related to the Company’s borrowings.)
Goodwill	(j) Goodwill Goodwill represents the excess of the purchase price paid over the fair value of net assets acquired in a business combination. Goodwill is not amortized, but is tested annually for impairment at the reporting unit level in the fourth quarter of the year and between annual tests if indicators of potential impairment exist. These indicators could include a decline in the Company’s stock price and market capitalization, a significant change in the outlook for the reporting unit's business, including projections of future box office results and IMAX System installations, lower than expected operating results, increased competition, legal factors, or the sale or disposition of a significant portion of a reporting unit. For reporting units with goodwill, an impairment loss is recognized for the amount by which the reporting unit's carrying value, including goodwill, exceeds its fair value. The carrying value of each reporting unit is based on a systematic and rational allocation of certain assets and liabilities. The fair value of each reporting unit is assessed using a discounted cash flow model based on management’s current short-term forecast and estimated long-term projections, against which various sensitivity analyses are performed. The discount rates used in the cash flow model are derived based on the Company’s estimated weighted average cost of capital. These estimates and the likelihood of future changes in these estimates depend on a number of underlying variables and a range of possible outcomes.
Other Intangible Assets	(k) Other Intangible Assets Other intangible assets with finite lives are generally amortized on a straight-line basis over estimated useful lives ranging from 4 to 20 years, except for intangible assets that have an identifiable pattern of consumption of the economic benefit of the asset. Such intangible assets are amortized over the consumption pattern. Research and development acquired in a business combination is measured at fair value using market-participant assumptions and is initially classified as an indefinite-lived intangible asset. The in-process intangible research and development (IPR&D) assets are considered indefinite-lived until the abandonment or completion of the associated research and development efforts. If the acquired IPR&D project is abandoned, the related intangible would be written off or impaired. Once the IPR&D activities are completed, management would determine the useful lives and the methods of amortization of the related intangible assets. The Company capitalizes costs associated with internally developed and/or purchased software systems for internal use that have reached the application development stage. Capitalized costs include external direct costs of materials and services utilized in developing or obtaining internal-use software and payroll and payroll-related expenses for employees who are directly associated with and devote time to the internal-use software project. Capitalization of such costs begins when the preliminary project stage is complete and ceases no later than the point at which the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages are charged to expense. These capitalized costs are amortized on a straight-line basis over the estimated useful life. Intangible Assets are grouped at the lowest level for which identifiable cash flows are largely independent and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset (or asset group) may not be recoverable. In such situations, the asset (or asset group) is considered impaired when estimated future cash flows (undiscounted and without interest charges) resulting from the use of the asset (or asset group) and its eventual disposition are less than the carrying value of the asset (or asset group). In such situations, the asset (or asset group) is written down to its fair value, which is the present value of the estimated future cash flows. Factors that are considered when evaluating intangible assets for impairment include a current expectation that it is more likely than not that the intangible asset will be sold significantly before the end of its useful life, a significant decrease in the market price of the intangible asset, and a significant change in the extent or manner in which the intangible asset is being used.
Deferred Revenue	(l) Deferred Revenue In instances where the Company receives consideration prior to satisfying its performance obligations, the recognition of revenue is deferred. The majority of the Deferred Revenue balance relates to payments received by the Company for IMAX Systems where control of the system has not transferred to the customer. The Deferred Revenue balance related to an individual location increases as progress payments are made and is then derecognized when control of the system is transferred to the customer. To a lesser extent, the Deferred Revenue balance also relates to situations when an exhibitor customer pays the contractual maintenance fee prior to the recognition of revenue.
Statutory Surplus Reserve	(m) Statutory Surplus Reserve Pursuant to the corporate law of the People’s Republic of China (the “PRC”), entities registered in the PRC are required to maintain certain statutory reserves, which are appropriated from after-tax profits, after offsetting accumulated losses from prior years, before dividends can be declared or paid to equity holders. The Company’s PRC subsidiaries are required to appropriate 10 % of statutory net profits to statutory surplus reserves, upon distribution of their after-tax profits. The Company’s PRC subsidiaries may discontinue the appropriation of statutory surplus reserves when the aggregate sum of the statutory surplus reserve is more than 50 % of their registered capital. The statutory surplus reserve is non-distributable other than during liquidation and may only be used to fund losses from prior years, to expand production operations, or to increase the capital of the subsidiaries. In addition, the subsidiaries may make further contribution to a discretionary surplus reserve using post-tax profits in accordance with resolutions of the Board of Directors.
Income Taxes	(n) Income Taxes Income taxes are accounted for under the liability method whereby deferred income tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the accounting and tax bases of assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates or laws is recognized in the Company’s Consolidated Financial Statements in the period in which the change is enacted. Investment tax credits are recognized as a reduction of income tax expense. The Company assesses the realization of deferred income tax assets and based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable in the current period. In assessing the need for a valuation allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning strategies. If management determines that sufficient negative evidence exists, then management will consider recording a valuation allowance against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, management’s projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with the benefit of hindsight, to be inaccurate, it could prove more difficult to support the realization of these deferred tax assets. As a result, an additional valuation allowance could be required, which would have an adverse impact on the Company’s effective income tax rate and results. Conversely, if, after recording a valuation allowance, management determines that sufficient positive evidence exists in the jurisdiction in which a valuation allowance is recorded, the Company may reverse all or a portion of the valuation allowance in that jurisdiction. In such situations, the adjustment made to the deferred tax asset would have a favorable impact on the Company’s effective income tax rate and results in the period such determination was made. The Company is subject to ongoing tax exposures, examinations and assessments in various jurisdictions. Tax benefits are recognized only when it is more likely than not, based on the technical merits, that the benefits will be sustained on examination. Tax benefits that meet the more likely than not recognition threshold are measured using a probability weighting of the largest amount of tax benefit that has greater than 50% likelihood of being realized upon settlement. Whether the more likely than not recognition threshold is met for a particular tax benefit is a matter of judgment based on the individual facts and circumstances evaluated in light of all available evidence as of the balance sheet date. Although management believes that the Company has adequately accounted for its uncertain tax positions, tax audits can result in subsequent assessments where the ultimate resolution may result in the Company owing additional taxes above what was originally recognized in its financial statements. Tax reserves for uncertain tax positions are adjusted by the Company to reflect its best estimate of the outcome of examinations and assessments and in light of changing facts and circumstances, such as the completion of a tax audit, expiration of a statute of limitations, the refinement of an estimate, and interest accruals associated with the uncertain tax positions until they are resolved. Some of these adjustments require significant judgment in estimating the timing and amount of the additional tax expense.
Revenue Recognition	(o) Revenue Recognition IMAX Systems The Company evaluates each of the performance obligations in an IMAX System arrangement to determine which are considered distinct, either individually or in a group, for accounting purposes and which of the deliverables represent separate performance obligations. The Company’s “System Obligation” consists of the following: (i) an IMAX System, which includes the projector, sound system, screen system and, if applicable, a 3D glasses cleaning machine; (ii) services associated with the IMAX System, including theater design support, the supervision of installation services, and projectionist training; and (iii) a license to use the IMAX brand to market the theater. The System Obligation, as a group, is a distinct performance obligation. The Company is not responsible for the physical installation of the equipment in the customer’s facility; however, it supervises the installation by the customer. The customer has the right to use the IMAX brand from the date the Company and the customer enter into an arrangement. IMAX System arrangements also include a requirement for the Company to provide maintenance services and an extended warranty over the life of the arrangement in exchange for an annual maintenance fee, which is subject to a consumer price index increase on renewal each year. Consideration related to the provision of maintenance services is included in the allocation of the transaction price to the separate performance obligations in the arrangement at contract inception, as discussed in more detail below. The Company’s maintenance services are a stand ready obligation and, as a result, are recognized on a straight-line basis over the contract term. The transaction price in an IMAX System arrangement is allocated to each good or service that is identified as a separate performance obligation based on estimated standalone selling prices. This allocation is based on observable prices when the Company sells the goods or services separately. The Company has established standalone prices for the System Obligation and maintenance and extended warranty services, as well as for film license arrangements. The Company uses an adjusted market assessment approach for separate performance obligations that do not have standalone selling prices or third-party evidence of estimated standalone selling prices. The Company considers multiple factors including its historical pricing practices, product class, market competition and geography. IMAX System arrangements involve either the lease or the sale of an IMAX System. The transaction price for the System Obligation, other than for IMAX Systems delivered pursuant to joint revenue sharing arrangements, consist of upfront or initial payments made before and after the final installation of the system and ongoing payments throughout the term of the arrangement. The Company estimates the transaction price, including an estimate of future variable consideration, received in exchange for the goods delivered or services rendered. The arrangement for the sale of an IMAX System includes indexed minimum payment increases over the term of the arrangement, as well as the potential for additional payments owed by the exhibitor customer if certain minimum box office receipt thresholds are exceeded. In addition, hybrid sales arrangements include amounts owed by the exhibitor customer based on a percentage of their box office receipts over the term of the arrangement. These contract provisions are considered to be variable consideration. An estimate of the present value of such variable consideration is recognized as revenue upon the transfer of control of the System Obligation to the customer, subject to constraints to ensure that there is not a risk of significant revenue reversal. This estimate is based on management’s box office projections for the individual location, which are developed using historical data for the location and, if necessary, comparable theaters and territories (see “Constraints on the Recognition of Variable Consideration” below). Transfer of control of the System Obligation occurs at the earlier of client acceptance of the installation of the IMAX System, including projectionist training, and the opening of the theater to the public, as discussed in more detail below. IMAX System arrangements are non-cancellable unless the Company fails to perform its obligations. In the absence of a material default by the Company, there is no right to any remedy for the customer under the Company’s arrangements. If a material default by the Company exists, the customer has the right to terminate the arrangement and seek a refund only if the customer provides notice to the Company of a material default and only if the Company does not cure the default within a specified period. Sales Arrangements For IMAX System arrangements that qualify as a sale, the transaction price allocated to the System Obligation is recognized in the Consolidated Statements of Operations upon the transfer of control of the system to the customer, which is when all of the following conditions have been met: (i) the projector, sound system, and screen system have been installed and are in full working condition, (ii) the 3D glasses cleaning machine, if applicable, has been delivered, (iii) projectionist training has been completed, and (iv) the earlier of (a) the receipt of written customer acceptance certifying the completion of installation and run-in testing of the equipment and the completion of projectionist training or (b) the public opening of the IMAX System. The initial revenue recognized in a sales arrangement consists of payments made before and in connection with the installation of the IMAX System and the present value of any future payments, including ongoing fixed minimum payments, which are subject to indexed increases over the term of the arrangement, and potential additional payments owed by the customer if certain minimum box office receipt thresholds are exceeded. In addition, hybrid sales arrangements include amounts owed by the customer based on a percentage of their box office receipts over the term of the arrangement. Potential payments based on the future box office receipts of the customer are considered to be variable consideration. An estimate of the present value of such variable consideration is recognized as revenue upon the transfer of control of the System Obligation to the customer, subject to constraints to ensure that there is not a risk of significant revenue reversal (see “Constraints on the Recognition of Variable Consideration” below). The Company has also agreed, on occasion, to sell equipment under lease or at the end of a lease term. The transaction price agreed to for these lease buyouts is reflected in the Company’s Consolidated Statements of Operations within Revenues – Technology Sales. Taxes assessed by governmental authorities that are both imposed on and concurrent with the specific revenue-producing transactions and collected by the Company have been excluded from the measurement of the transaction prices discussed above. Constraints on the Recognition of Variable Consideration The recognition of variable consideration involves a significant amount of judgment. Variable consideration is recognized subject to appropriate constraints to avoid a significant reversal of revenue in future periods. The Company reviews its variable consideration assets on at least a quarterly basis considering recent box office performance and, when applicable, updated box office projections for future periods. The relevant accounting guidance identifies the following examples of situations when constraining the amount of variable consideration is appropriate: • The amount of consideration is highly susceptible to factors outside the entity’s influence; • The uncertainty about the amount of consideration is not expected to be resolved for a long period of time; • The Company’s experience (or other evidence) with similar types of contracts is limited, or that experience has limited predictive value; and • The entity has a practice of either offering a broad range of price concessions or changing the payment terms and conditions of similar contracts in similar circumstances. As discussed above, the Company’s significant streams of variable consideration relate to arrangements for the sale of IMAX Systems which include indexed minimum payment increases over the term of the arrangement, as well as the potential for additional payments owed by the customer if certain minimum box office receipt thresholds are exceeded. In addition, hybrid sales arrangements include variable consideration based on a percentage of the customer’s box office receipts over the term of the arrangement. Variable consideration related to indexed minimum payment increases is outside of the Company’s control, but the movement in the rates is historically well documented and economic trends in inflation are easily accessible. For each contract subject to an indexed minimum payment increase, the Company estimates the most likely amount using published indices. The amount of the estimated minimum payment increase is then recorded at its present value as of the date of recognition using the customer’s implied borrowing rate. Variable consideration related to the level of the customer’s box office receipts is outside of the Company’s control as it is dependent upon the future commercial success of the films released to the IMAX network. The estimated variable consideration initially recognized by the Company is based on management’s box office projections for the location, which are developed using historical box office data for that location and, if necessary, comparable locations and territories. Using this data, management applies its understanding of these exhibition markets to estimate the most likely amount of variable consideration to be earned over the term of the arrangement. Management then applies a constraint to this estimate by reducing the projection by a percentage factor for locations or markets with no or limited historical box office experience. In cases where direct historical experience can be observed, average historical box office results, eliminating significant outliers, is used. The resulting amount of variable consideration is then recorded at its present value as of the date of recognition using a risk-weighted discount rate.
Revenue Recognition Leases	Lease Arrangements As a lessor, the Company provides IMAX Systems to customers through long-term lease arrangements. Under these arrangements, in exchange for providing the IMAX System, the Company earns fixed upfront and ongoing consideration. A lease arrangement that transfers substantially all of the benefits and risks incident to ownership of the IMAX System is classified as a sales-type lease; otherwise the lease is classified as an operating lease. Prior to commencement of the lease term, the Company may modify certain payment terms or make concessions. If these circumstances occur, the Company reassesses the classification of the lease based on the modified terms and conditions. For sales-type leases, the revenue allocated to the System Obligation is recognized when the lease term commences, which the Company deems to be when all of the following conditions have been met: (i) the projector, sound system, and screen system have been installed and are in full working condition, (ii) the 3D glasses cleaning machine, if applicable, has been delivered, (iii) projectionist training has been completed, and (iv) the earlier of (a) the receipt of the written customer acceptance certifying the completion of installation and run-in testing of the equipment and the completion of projectionist training or (b) the public opening of the theater, provided collectability is reasonably assured. The initial revenue recognized for sales-type leases consists of the initial payments received and the present value of future initial payments and fixed minimum ongoing payments computed at the interest rate implicit in the lease. Contingent payments in excess of the fixed minimum payments are recognized when reported by theater operators, provided collectability is reasonably assured. For joint revenue sharing arrangements that are classified as operating leases, initial payments and fixed minimum ongoing payments are recognized as revenue on a straight-line basis over the lease term. For these leases, the lease term is considered to commence when all of the following conditions have been met: (i) the projector, sound system and screen system have been installed and are in full working condition; (ii) the 3D glasses cleaning machine, if applicable, has been delivered; (iii) projectionist training has been completed; and (iv) the earlier of (a) the receipt of written customer acceptance certifying the completion of installation and run-in testing of the equipment and the completion of projectionist training or (b) the public opening of the theater. Contingent payments in excess of fixed minimum ongoing payments are recognized as revenue when reported by theater operators, provided collectability is reasonably assured.
Revenue Recognition Finance Income	Finance Income Finance Income is recognized over the term of the sales-type lease or financed sale receivable, provided collectability is reasonably assured. A theater operator that is classified within the “All Transactions Suspended” category under the Company’s internal credit quality guidelines is placed on nonaccrual status and Finance Income recognition related to the location is stopped. While the recognition of Finance Income is suspended, payments received from a customer are applied against the outstanding balance owed. If payments are sufficient to cover any unreserved receivables, a recovery of provision taken on the billed amount, if applicable, is recorded to the extent of the residual cash received. Once the collectability issues are resolved and the customer has returned to being in good standing, the Company will resume recognition of Finance Income.
Improvements and Modifications	Improvements and Modifications Improvements and modifications to an IMAX System after installation are treated as a separate performance obligation, if and when the Company is requested to perform these services. Revenue is recognized for these services once they have been provided.
Costs and Expenses Applicable to Revenues - Technology Sales	Costs and Expenses Applicable to Revenues – Technology Sales Costs and Expenses Applicable to Revenues – Technology Sales relates to sale and sales-type leases of IMAX Systems and other equipment, and includes the cost of the equipment and costs related to project management, design, delivery and installation supervision services, as applicable. The costs related to IMAX Systems under sale and sales-type lease arrangements are transferred from Inventories to Costs and Expenses Applicable to Revenues in the period when the sale is recognized in the Consolidated Statements of Operations. Sales commissions and other selling expenses that directly relate to the acquisition of the revenue generating contract and are incremental to the Company’s other expenses are deferred and recognized in the Consolidated Statements of Operations upon the client acceptance of the IMAX System. The Company may have warranty obligations at or after the time revenue is recognized which require the replacement of certain parts that do not affect the functionality of the theater system or services. The costs for warranty obligations for known issues are accrued as charges to Costs and Expenses Applicable to Revenues – Technology Sales at the time revenue is recognized based on the Company’s past historical experience and cost estimates.
Costs and Expenses Applicable to Revenues - Technology Rentals	Costs and Expenses Applicable to Revenues – Technology Rentals Costs and Expenses Applicable to Revenues – Technology Rentals relates to joint revenue sharing arrangements classified as operating leases, and primarily includes the depreciation of IMAX System components and related equipment used in the joint revenue sharing arrangement. Impairment losses, if any, are also included in Costs and Expenses Applicable to Revenues – Technology Rentals. Sales commissions related to these arrangements are deferred and recognized as Costs and Expenses Applicable to Revenues – Technology Rentals in the month they are earned by the salesperson, which is typically the month of installation. Direct advertising and marketing costs for each location are charged to Costs and Expenses Applicable to Revenues – Technology Rentals as incurred.
Terminations, Consensual Buyouts and Concessions	Terminations, Consensual Buyouts and Concessions The Company enters into IMAX System arrangements with customers that contain customer payment obligations prior to the scheduled installation of the IMAX System. During the period of time between signing and the installation of the IMAX System, which may extend several years, certain customers may be unable to, or may elect not to, proceed with the system installation for a number of reasons including business considerations, or the inability to obtain certain consents, approvals or financing. Once the determination is made that the customer will not proceed with installation, the arrangement may be terminated under the default provisions of the arrangement or by mutual agreement between the Company and the customer (a “consensual buyout”). Terminations by default are situations when a customer does not meet the payment obligations under an arrangement and the Company retains the amounts paid by the customer. Under a consensual buyout, the Company and the customer agree, in writing, to a settlement and to release each other of any further obligations under the arrangement or an arbitrated settlement is reached. Any initial payments retained or additional payments received by the Company are recognized as revenue when the settlement arrangements are executed and the cash is received, respectively. In addition, the Company may agree with a customer to convert its obligations for one type of IMAX System configuration that has not yet been installed to an arrangement to acquire or lease a different type of IMAX System. The Company considers these situations to be the termination of the original arrangement and the origination of a new arrangement. The Company may offer certain incentives to customers to complete IMAX System transactions including payment concessions or free services and products such as film licenses or 3D glasses. Reductions in, and deferral of, payments are taken into account in determining the transaction price either by a direct reduction in the sales price or a reduction of payments to be discounted. Free products and services are accounted for as separate performance obligations.
Maintenance And Extended Warranty Services	Maintenance and Extended Warranty Services Maintenance and extended warranty services may be provided under an arrangement with multiple performance obligations or as a separately priced contract. Revenues related to these services are deferred and recognized on a straight-line basis over the contract period and are recognized within Revenues – Image Enhancement and Maintenance Services in the Consolidated Statements of Operations. Maintenance and extended warranty services include maintenance of the customer’s equipment and replacement parts. Under certain maintenance arrangements, maintenance services may include additional training services to the customer’s technicians. All costs associated with this maintenance and extended warranty program are expensed as incurred. A loss on maintenance and extended warranty services is recognized if the expected cost of providing the services under the contract exceeds the related deferred revenue. As the maintenance services are a stand ready obligation with the cost of providing the service expected to increase throughout the term, revenue is recognized over the term of the arrangement such that increased amounts are recognized in later periods.
Films Revenue Recognition	IMAX DMR Services In an IMAX DMR arrangement, the Company receives a percentage of the box-office receipts from a third party who owns the copyright to a film in exchange for converting the film into IMAX DMR format and distributing it through the IMAX network. In these arrangements, although the Company does not hold rights to the intellectual property in the form of the film content, it is compensated for the application of its intellectual property in the form of its patented DMR processes to create new intellectual property in the form of an IMAX DMR version of film. Revenues associated with IMAX DMR arrangements qualify for the variable consideration exemption for sales- or usage-based royalties in the relevant accounting guidance and are recognized within Revenues – Image Enhancement and Maintenance Services in the period when the corresponding box office sales occur. Losses on IMAX DMR services are recognized as Costs and Expenses Applicable to Revenues – Image Enhancement and Maintenance Services in the period when it is determined that the Company’s estimate of total revenues to be realized by the remastered film will not exceed the corresponding cost of IMAX DMR services. Film Production Services In certain film arrangements, the Company produces a film financed by third parties whereby the third party retains the copyright, and the Company obtains exclusive distribution rights. Under these arrangements, the Company is entitled to receive a fixed fee or retain, as a fee, the excess of gross revenue over the cost of the production (the “production fee”). The third party receives a portion of the revenues received by the Company from distributing the film, which is charged to Costs and Expenses Applicable to Revenues – Image Enhancement and Maintenance Services. Production fees are deferred and recognized as a reduction in the cost of the film based on the ratio of the Company’s distribution revenues recognized in the current period to the ultimate distribution revenues expected from the film. Film exploitation costs, including advertising and marketing, are recorded in Costs and Expenses Applicable to Revenues – Image Enhancement and Maintenance Services as incurred, except for those costs that are made after recognizing revenue, which are recorded when the related revenues are recognized. Revenue from film production services where the Company does not hold the associated distribution rights are recognized in Revenues – Image Enhancement and Maintenance Services when performance obligations associated with the contractual service are satisfied. Losses on film production services are recognized as Costs and Expenses Applicable to Revenues – Image Enhancement and Maintenance Services in the period when it is determined that the Company’s estimate of total revenues to be realized by the Company will not exceed estimated total production costs to be expended on the film production. Film Distribution Services In a Film Distribution arrangement, the Company distributes large-format documentary films, primarily to institutional locations, and distributes exclusive entertainment experiences ranging from live performances to interactive events with leading artists and creators. Revenue from the licensing of films qualifies for the variable consideration exemption for sales- or usage-based royalties in the relevant accounting guidance and is recognized within Revenues – Image Enhancement and Maintenance Services when all performance obligations have been satisfied, which includes the completion and delivery of the film and the commencement of the license period. In situations when film license fees are based on a percentage of box-office receipts, revenue is recognized when box-office receipts are reported by the exhibitor. Film exploitation costs, including advertising and marketing, are expensed as incurred within Costs and Expenses Applicable to Revenues – Image Enhancement and Maintenance Services. Film Post-Production Services Revenues from post-production film services are recognized within Revenues – Image Enhancement and Maintenance Services when performance of the contracted services is completed. Software License and Subscription Services Through SSIMWAVE, the Company provides term licenses, which give customers the right to use its software for a specific period, and perpetual licenses, which give customers the right to use its software for an indefinite period. For both types of licenses, the associated revenue is recognized at the point in time when the customer can use and benefit from the software, which is generally upon delivery to the customer or upon commencement of the renewal term. For licenses that are deployed and hosted at the customer site, revenue is recognized upon delivery of the software to the customer or upon commencement of the renewal term. For licenses where the software is provided through a hosting arrangement, if the customer does not have a contractual right to take possession of the underlying software without significant penalty, or it is not feasible for the customer to run the software on its own hardware or contract a third party to host the services, the arrangement is accounted for as a service transaction whereby the Company has a stand-ready obligation to provide the software over the license period. Therefore, the related revenue is recognized ratably over the license period, as control of service is transferred to the customer. SSIMWAVE's software license arrangements for both term and perpetual licenses typically include maintenance and support services which provide technical support and unspecified updates and upgrades on a when-and-if-available basis. The contractual term of the arrangement to provide maintenance and support services for perpetual licenses is renewable, generally on an annual basis, at the option of the customer. Maintenance and support services represent stand-ready obligations for which revenue is recognized ratably over the term of the arrangements. Revenues from licenses and maintenance and support services are recognized within Revenues – Image Enhancement and Maintenance Services.
Leases	(p) Leases As a lessee, the Company’s lease arrangements principally involve office and warehouse space, which are classified as operating leases. The corresponding operating lease right-of-use (“ROU”) assets and liabilities are recorded within Property, Plant and Equipment and Accrued and Other Liabilities in the Company’s Consolidated Balance Sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term. Operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The incremental borrowing rate used in the calculation of the Company’s lease liabilities is based on the location of each leased property. None of the Company’s leases include options to purchase the leased property. Most of the Company’s leases include one or more options to renew, with renewal terms that can extend the lease term from one to five years or more. The Company has determined that it is reasonably certain that the renewal options on its warehouse leases will be exercised based on previous history, its current understanding of future business needs, and its level of investment in the leasehold improvements, among other factors. The depreciable lives of ROU assets and related leasehold improvements are limited by the expected lease term. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company rents or subleases certain office space to third parties, which have a remaining term of less than 12 months and are not expected to be renewed. When there are modifications to the lease agreements, the Company remeasures the lease liabilities to reflect changes to lease payments and recognizes the amount of the remeasurement of the lease liability as an adjustment to the ROU assets. Amortization of ROU assets and interest on lease liabilities are included within Selling, General and Administrative Expenses in the Company’s Consolidated Statements of Operations. (See Note 7 for additional information related to the Company’s operating leases.)
Research and Development Expense	(q) Research and Development Research and development costs, which are expensed as incurred, primarily include projector and sound parts, labor, consulting fees, allocation of overheads, and other related materials which pertain to the Company’s development of new products and services. Research and development costs pertaining to fixed and intangible assets that have alternative future uses are capitalized and amortized under their related policies.
Foreign Currency Translations	(r) Foreign Currency Translation Monetary assets and liabilities that are denominated in a currency other than the Company's functional currency are translated into the relevant functional currency using the exchange rate prevailing at the end of the period. Foreign exchange translation gains and losses are included in the determination of earnings in the period in which they arise. Assets and liabilities recorded in foreign currencies are translated at the exchange rate on the balance sheet date. Revenues, expenses, gains, and losses recorded in foreign currencies are translated using the exchange rates prevailing during the period in which they are recognized. Translation adjustments resulting from this process are recorded to Other Comprehensive (Loss) Income and reported on the Company’s Consolidated Balance Sheets within Accumulated Other Comprehensive (Loss) Income until the subsidiary is sold or liquidated, at which point the adjustments are recognized in Consolidated Statements of Operations. Foreign currency derivatives are recognized and measured in the Consolidated Balance Sheets at their fair value. Changes in the fair value (i.e., gains or losses) are recognized in the Consolidated Statements of Operations except for derivatives designated and qualifying as foreign currency hedging instruments. For foreign currency hedging instruments, the gain or loss related to the effective portion of the hedge of a forecasted transaction is reported within Other Comprehensive (Loss) Income and reclassified to the Consolidated Statements of Operations when the forecasted transaction occurs. Any ineffective portion is recognized immediately in the Consolidated Statements of Operations.
Share-Based Compensation	(s) Share-Based Compensation The Company issues share-based compensation to eligible employees, directors, and consultants under the IMAX Corporation Second Amended and Restated Long-Term Incentive Plan (as may be amended, the “IMAX LTIP”) and the China Long-Term Incentive Plan (the “China LTIP”) as summarized in Note 18. The IMAX LTIP is the Company’s governing document and awards to employees, directors, and consultants under this plan may consist of stock options, restricted share units (“RSUs”), performance stock units (“PSUs”) and other awards. A separate stock option plan, the China LTIP, was adopted by a subsidiary of the Company in October 2012. The Company measures share-based compensation expense using the grant date fair value of the award (see below), which is recognized as an expense in the Consolidated Statements of Operations on a straight-line basis over the requisite service period. Share-based compensation expense is not adjusted for estimated forfeitures but is instead adjusted when and if actual forfeitures occur. Stock Options The Company utilizes a lattice-binomial option-pricing model (“Binomial Model”) to determine the fair value of stock option awards on the grant date. The fair value determined by the Binomial Model is affected by the Company’s stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the Company’s expected stock price volatility over the term of the award, and actual and projected employee stock option exercise behaviors. The Binomial Model also considers the expected exercise multiple which is the multiple of exercise price to grant price at which exercises are expected to occur on average. Option-pricing models were developed for use in estimating the value of traded options that have no vesting or hedging restrictions and are fully transferable. Because the Company’s employee stock options have certain characteristics that are significantly different from traded options, and because changes in the subjective assumptions can materially affect the estimated value, in management’s opinion, the Binomial Model best provides a fair measure of the fair value of the Company’s employee stock options. The Company stratifies its employees into homogeneous groups in order to calculate the grant date fair value of stock options using the Binomial Model. As a result, ranges of assumptions are used for the expected life of the option. The Company uses historical data to estimate option exercise behavior within the Binomial Model and various groups of employees that have similar historical exercise behavior are grouped together for valuation purposes. The expected volatility rate is estimated based on a blended volatility method which takes into consideration the Company’s historical share price volatility, the Company’s implied volatility which is determined in reference to observed current market prices for the Company’s traded options and the Company’s peer group volatility. (See Note 18(c) for the assumptions used to determine the fair value of the Company’s stock options.) Restricted Share Units The fair value of RSU awards is equal to the closing price of the Company’s common stock on the date of grant or the average closing price of the Company’s common shares for five days prior to the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as compensation expense over the requisite service period in the Company’s Consolidated Statements of Operations. The Company’s RSUs are classified as equity. Performance Stock Units The Company grants two types of PSU awards, one which vests based on a combination of employee service and the achievement of certain EBITDA-based targets and one which vests based on a combination of employee service and the achievement of total shareholder return (“TSR”) targets. The achievement of the EBITDA and TSR targets in these PSUs is determined over a three-year performance period. At the conclusion of the three-year performance period, the number of PSUs that ultimately vest can range from 0 % to a maximum vesting opportunity of 175 % of the initial award, depending upon actual performance versus the established EBITDA and share-price targets. The Company’s PSUs are classified as equity. The grant date fair value of PSUs with EBITDA-based targets is equal to the closing price of the Company’s common shares on the date of grant or the average closing price of the Company’s common shares for five days prior to the date of grant. The grant date fair value of PSUs with TSR targets is determined on the grant date using a Monte Carlo simulation, which is a valuation model that considers the likelihood of achieving the TSR targets embedded in the award (“Monte Carlo Model”). The compensation expense attributable to each type of PSU is recognized on a straight-line basis over the requisite service period. The fair value determined by the Monte Carlo Model is affected by the Company’s share price, as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, market conditions as of the grant date, the Company’s expected share price volatility over the term of the awards, and other relevant data. The compensation expense is fixed on the date of grant based on the dollar value of the PSUs granted. The amount and timing of compensation expense recognized for PSUs with EBITDA-based targets is dependent upon management's assessment of the likelihood and timing of achieving these targets. If, as a result of management’s assessment, it is projected that a greater number of PSUs will vest than previously anticipated, a life-to-date adjustment to increase compensation expense is recorded in the period such determination is made. Conversely, if, as a result of management’s assessment, it is projected that a lower number of PSUs will vest than previously anticipated, a life-to-date adjustment to decrease compensation expense is recorded in the period such determination is made. Share-Based Payment Awards to Non-Employees Share-based payment awards for services provided by non-employees are measured at grant date fair value of the equity instruments that the Company is obligated to issue when the service has been rendered and any other conditions necessary to earn the right to benefit from the instruments have been satisfied. The grant date is the date which the Company and the non-employees reach a mutual understanding of the key terms and conditions of the share-based payment awards. When there are performance conditions related to the vesting of the share-based awards, the Company assesses the probability of vesting at each reporting date and adjusts the compensation costs based on the probability assessment.
Pension and Other Postretirement Plans	(t) Pension Plans and Postretirement Benefits The Company has a defined benefit pension plan, the Supplemental Executive Retirement Plan (the “SERP”). As the Company’s SERP is unfunded, as of December 31, 2022, a liability is recognized for the benefit obligation. Assumptions used in computing the defined benefit obligations are reviewed annually by management in consultation with its actuaries and adjusted for current conditions. Actuarial gains or losses and prior service costs or credits that arise during the period but are not recognized as components of net periodic benefits cost are recognized as a component of Other Comprehensive (Loss) Income. Amounts recognized in Accumulated Other Comprehensive (Loss) Income including unrecognized actuarial gains or losses and prior service costs are adjusted as they are subsequently recognized in the Consolidated Statements of Operations as components of net periodic benefit cost. Prior service costs resulting from the pension plan inception or amendments are amortized over the expected future service life of the employees, cumulative actuarial gains and losses in excess of 10 % of the projected benefit obligation are amortized over the expected average remaining service life of the employees, and current service costs are expensed when earned. The remaining weighted average future service life of the employee used in computing the defined benefit obligation for the year ended December 31, 2022 was 3.0 years . For defined contribution pension plans, required contributions by the Company are recorded as an expense within Selling, General and Administrative Expenses in the Company’s Consolidated Statements of Operations. A liability is recognized for the unfunded accumulated benefit obligation of the postretirement benefits plan. Assumptions used in computing the accumulated benefit obligation are reviewed by management in consultation with its actuaries and adjusted for current conditions. Net benefit cost is split between operating income and non-operating income, where only the service cost is included in income from operations and the non-service components are included in Retirement Benefits Non-Service Expenses. Actuarial gains and losses are recognized as a component of Other Comprehensive (Loss) Income. Amounts recognized in Accumulated Other Comprehensive (Loss) Income including unrecognized actuarial gains or losses are adjusted as they are subsequently recognized within Retirement Benefits Non-Service Expense in the Consolidated Statements of Operations.
Guarantees, Indemnifications and Warranties	(u) Guarantees In situations when the Company acts as a guarantor, at the inception of a guarantee, it recognizes a liability for the fair value of the underlying guarantee. Disclosures as required under the relevant accounting guidance have been included in Note 17 .
Recently Issued Accounting Standards Not Yet Adopted	Adoption of New Accounting Policies In July 2021, the FASB issued ASU No. 2021-05, “Leases (Topic 842): Lessors - Certain Leases with Variable Lease Payments” (“ASU 2021-05”), which requires sales-type or direct financing leases that have variable payments (that do not depend on a rate or an index) and result in a day-one loss to be classified as operating leases. When a lease is classified as operating, the lessor does not recognize a net investment in the lease, does not derecognize the underlying asset, and, therefore, does not recognize a selling profit or loss. The amendments are effective for annual periods beginning after December 15, 2021 including interim periods within those periods. Early adoption is permitted. The Company adopted ASU 2021-05 for the year ended December 31, 2022 and adoption did no t have a material impact on the Company's Consolidated Financial Statements. In October 2021, the FASB issued ASU No. 2021-08, “2021-08: Business Combinations (Topic 850): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (“ASU 2021-08” ). ASU 2021-08 requires that an acquirer recognize and measure contract assets and contract liabilities (e.g., deferred revenue) acquired in a business combination in accordance with Topic 606, as opposed to at fair value. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, including interim periods within those periods. Early adoption is permitted. The Company elected to early adopt ASU 2021-08 in the third quarter of 2022 in connection with its acquisition of SSIMWAVE Inc. (see Note 5). In November 2021, the FASB issued ASU No. 2021-10, “2021-10: Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance” (“ASU 2021-10”). The amendments in ASU 2021-10 require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The amendments are effective for annual periods beginning after December 15, 2021. Early adoption is permitted. The Company adopted ASU 2021-10 for the year ended December 31, 2022 and has provided the required disclosures in Note 25. Recently Issued FASB Accounting Standard Codification Updates Not Yet Adopted In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”). The purpose of ASU 2020-04 is to provide optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2020-04 is effective for all entities from the beginning of an interim period that includes the issuance date of the ASU. An entity may elect to apply ASU 2020-04 prospectively through December 31, 2022. In October 2022, the FASB extended the temporary accounting relief to December 31, 2024 from the current sunset date of December 31, 2022. As of December 31, 2022, the Company is not party to any third party contracts that reference the London Interbank Offered Rate (LIBOR). Accordingly, the Company does not expect ASU 2020-04 to have a material effect on its Consolidated Financial Statements. In March 2022, the FASB issued ASU No. 2022-02, “2022-02: Financial Instruments—Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures” (“ASU 2022-02”). ASU 2022-02 amends and eliminates the accounting guidance for Troubled Debt Restructurings by creditors, while enhancing disclosure requirements for certain loan refinancings and restructurings by creditors when a borrower is experiencing financial difficulty and requires for public business entities, to disclose current-period gross write offs by year of origination for financing receivables and net investments in leases. ASU 2022-02 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. The Company will adopt ASU 2022-02 for the first quarter of 2023 and is in the process of evaluating the accounting and disclosure impact, if any, on the Company's Consolidated Financial Statements. The Company considers the applicability and impact of all recently issued FASB accounting standard codification updates. Accounting standard updates that are not noted above were assessed and determined to be not applicable or not significant to the Company’s Consolidated Financial Statements for the year ended December 31, 2022.
Credit Risk	The Company’s internal credit quality classifications for theater operators are as follows: • Good Standing — The theater operator continues to be in good standing as payments and reporting are received on a regular basis. • Credit Watch — The theater operator has demonstrated a delay in payments, but continues to be in active communication with the Company. Theater operators placed on Credit Watch are subject to enhanced monitoring. In addition, depending on the size of the outstanding balance, length of time in arrears, and other factors, future transactions may need to be approved by management. These receivables are in better condition than those in the Pre-Approved Transactions Only category, but are not in as good condition as the receivables in the Good Standing category. • Pre-Approved Transactions Only — The theater operator has demonstrated a delay in payments with little or no communication with the Company. All services and shipments to the theater operator must be reviewed and approved by management. These receivables are in better condition than those in the All Transactions Suspended category, but are not in as good condition as the receivables in the Credit Watch category. In certain situations, a theater operator may be placed on nonaccrual status and all revenue recognition related to the theater may be suspended, including the accretion of Finance Income for Financing Receivables. • All Transactions Suspended — The theater operator is severely delinquent, non-responsive or not negotiating in good faith with the Company. Once a theater operator is classified within the All Transactions Suspended category, the theater is placed on nonaccrual status and all revenue recognitions related to the theater are suspended, including the accretion of Finance Income for Financing Receivables.
Segment Reporting	The Company has the following reportable segments: (i) IMAX DMR; (ii) Joint Revenue Sharing Arrangements (“JRSA”); (iii) IMAX Systems; (iv) IMAX Maintenance; (v) Other Theater Business; (vi) Film Distribution; and (vii) Film Post-Production. The Company's activities that do not meet the criteria to be considered a reportable segment are disclosed within All Other. The Company organizes its reportable segments into the following three categories , identified by the nature of the product sold or service provided : (i) IMAX Technology Network, which earns revenue based on contingent box office receipts and includes the IMAX DMR segment and contingent rent from the JRSA segment; (ii) IMAX Technology Sales and Maintenance, which includes results from the IMAX Systems, IMAX Maintenance and Other Theater Business segments, as well as fixed revenues from the JRSA segment; and (iii) Film Distribution and Post-Production, which includes activities related to the distribution of large-format documentary films, primarily to institutional theaters, and the distribution of exclusive experiences ranging from live performances to interactive events with leading artists and creators (through the Film Distribution segment) and the provision of film post-production and quality control services.
Fair Value of Financial Instruments	The carrying values of the Company’s Cash and Cash Equivalents, Accounts Receivable, Accounts Payable, and Accrued Liabilities due within one year approximate their fair values due to the short-term maturity of these instruments. Including these instruments, the Company’s financial instruments consist of the following: As of December 31, 2022 As of December 31, 2021 (In thousands of U.S. Dollars) Carrying Estimated Carrying Estimated Level 1 Cash and cash equivalents (1) $ 97,401 $ 97,401 $ 189,711 $ 189,711 Equity securities (2) 1,035 1,035 1,087 1,087 Level 2 Net financed sales receivables (3) $ 101,052 $ 100,059 $ 112,657 $ 112,662 Net investment in sales-type leases (3) 28,332 27,972 28,392 28,407 Equity securities (1) 1,000 1,000 1,000 1,000 COLI (4) 3,398 3,398 3,275 3,275 Foreign exchange contracts — designated forwards (2) ( 649 ) ( 649 ) 79 79 Wells Fargo Credit Facility borrowings (1) ( 25,000 ) ( 25,000 ) — — HSBC China Facility borrowings (1) ( 12,496 ) ( 12,496 ) — — Bank of China Facility borrowings (1) ( 374 ) ( 374 ) ( 3,612 ) ( 3,612 ) Federal Economic Development Loan (3) ( 1,782 ) ( 1,782 ) N/A N/A Convertible Notes (5) ( 230,000 ) ( 196,717 ) ( 230,000 ) ( 223,100 ) Level 3 Interest in film classified as a financial instrument (6) $ — $ — $ — $ — (1) Recorded at cost, which approximates fair value. (2) Fair value is determined using quoted prices in active markets. (3) Fair value is estimated based on discounting future cash flows at currently available interest rates with comparable terms. (4) Measured at cash surrender value, which approximates fair value. (5) Fair value is determined using quoted market prices that are observable in the market or that could be derived from observable market data. (6) Recorded at amortized cost less impairment losses. Inputs used in the calculation of estimated fair value include management's projection of future box office and ancillary receipts for the film net of distribution costs and other costs in accordance with the investment agreement. See 23 (e) below.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
VIEs Total Assets and Liabilities	As of December 31, 2022 and 2021, total assets and liabilities of the Company's consolidated VIEs are as follows: December 31, December 31, (In thousands of U.S. Dollars) 2022 2021 Total assets $ 1,523 $ 1,576 Total liabilities $ 248 $ 259
Summary of Estimated Useful Lives	Property, Plant and Equipment is recorded at cost and is depreciated on a straight-line basis over the estimated useful lives of the underlying assets as follows: Theater system components (1) — Over the equipment’s expected useful life ( 7 to 20 years) Camera equipment — Over a period between 5 to 10 years Buildings — Over a period between 20 to 25 years Office and product equipment — Over a period between 3 to 5 years Leasehold improvements — Over the shorter of the initial term of the underlying lease plus any reasonably assured renewal periods, and the useful life of the asset (1) Includes equipment under joint revenue sharing arrangements.

Acquisition (Tables)

Acquisition (Tables)	12 Months Ended
	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Subject to Revision Upon Completion of Valuation Procedures	The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed as of December 31, 2022. (In thousands of U.S. Dollars) Purchase Price : Cash payments $ 19,521 IMAX Share Consideration 1,947 Earn-Out Payment 1,750 Total Purchase Price $ 23,218 Allocation of Purchase Price : Cash and cash equivalents $ 3,582 Accounts receivable 158 Property, plant and equipment 409 Intangible assets (see Note 14) 11,189 Other assets 293 Accounts payable and accrued liabilities ( 1,092 ) Deferred revenue ( 1,300 ) Federal economic development loan, net of unaccreted interest benefit ( 1,772 ) Deferred tax liability ( 2,037 ) Goodwill (see Note 14) 13,788 Total Purchase Price $ 23,218
Schedule of Allocation of Fair Value of Identifiable Intangible Assets	The allocation of the fair value of identified intangible assets is as follows: (In thousands of U.S. Dollars) Fair Value Weighted Average Useful Life Patent and trademarks 100 2 Years Customer relationships 1,340 7 Years Developed technology 5,779 4 to 7 Years In-process research and development 3,810 Not yet in use Non-compete agreement 160 4 Years Total identifiable intangible assets $ 11,189

Receivables (Tables)

Receivables (Tables)	12 Months Ended
	Dec. 31, 2022
Receivables [Abstract]
Summary of Allowance For Credit Losses Related to Accounts Receivable	The following tables summarize the activity in the allowance for credit losses related to Accounts Receivable for the years ended December 31, 2022 and 2021: Year Ended December 31, 2022 (In thousands of U.S. Dollars) Theater Studios Other Total Beginning balance $ 8,867 $ 1,994 $ 1,085 $ 11,946 Current period provision (reversal), net 2,687 ( 128 ) 585 3,144 Write-offs ( 43 ) ( 128 ) ( 394 ) ( 565 ) Foreign exchange ( 367 ) ( 39 ) — ( 406 ) Ending balance $ 11,144 $ 1,699 $ 1,276 $ 14,119 Year Ended December 31, 2021 (In thousands of U.S. Dollars) Theater Studios Other Total Beginning balance $ 8,368 $ 4,481 $ 1,446 $ 14,295 Current period provision (reversal), net 793 ( 1,913 ) ( 332 ) ( 1,452 ) Write-offs ( 357 ) ( 551 ) ( 19 ) ( 927 ) Foreign exchange 63 ( 23 ) ( 10 ) 30 Ending balance $ 8,867 $ 1,994 $ 1,085 $ 11,946
Schedule of Financing Receivables	. As of December 31, 2022 and 2021, financing receivables consist of the following: December 31, December 31, (In thousands of U.S. Dollars) 2022 2021 Net investment in leases Gross minimum payments due under sales-type leases $ 29,727 $ 29,953 Unearned finance income ( 619 ) ( 763 ) Present value of minimum payments due under sales-type leases 29,108 29,190 Allowance for credit losses ( 776 ) ( 798 ) Net investment in leases 28,332 28,392 Financed sales receivables Gross minimum payments due under financed sales 141,337 152,315 Unearned finance income ( 29,340 ) ( 34,244 ) Present value of minimum payments due under financed sales 111,997 118,071 Allowance for credit losses ( 10,945 ) ( 5,414 ) Net financed sales receivables 101,052 112,657 Total financing receivables $ 129,384 $ 141,049 Net financed sales receivables due within one year $ 32,366 $ 29,115 Net financed sales receivables due after one year 68,686 83,542 Total financed sales receivables $ 101,052 $ 112,657
Schedule of Weighted-average Remaining Lease Term and Weighted-average Interest Rate	As of December 31, 2022 and 2021, the weighted-average remaining lease term and weighted-average interest rate associated with the Company’s sales-type lease arrangements and financed sale receivables, as applicable, are as follows: December 31, December 31, 2022 2021 Weighted-average remaining lease term (in years) Sales-type lease arrangements 9.0 9.6 Weighted-average interest rate Sales-type lease arrangements 8.23 % 6.56 % Financed sales receivables 8.79 % 8.79 %
Schedule of Net Investment In Leases by Credit Quality Indicator	The tables below provide information on the Company’s net investment in leases by credit quality indicator as of December 31, 2022 and 2021. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. (In thousands of U.S. Dollars) By Origination Year As of December 31, 2022 2022 2021 2020 2019 2018 Prior Total Net investment in leases: Credit quality classification: In good standing $ 4,148 $ 6,969 $ 2,494 $ 1,977 $ — $ 1,016 $ 16,604 Credit Watch — — — — — — — Pre-approved transactions — 3,089 1,162 5,401 2,451 — 12,103 Transactions suspended — — — — — 401 401 Total net investment in leases $ 4,148 $ 10,058 $ 3,656 $ 7,378 $ 2,451 $ 1,417 $ 29,108 (In thousands of U.S. Dollars) By Origination Year As of December 31, 2021 2021 2020 2019 2018 2017 Prior Total Net investment in leases: Credit quality classification: In good standing $ 11,030 $ 3,991 $ 7,973 $ 2,574 $ 823 $ 1,928 $ 28,319 Credit Watch — — — — — — — Pre-approved transactions — — — — — — — Transactions suspended — — — — — 871 871 Total net investment in leases $ 11,030 $ 3,991 $ 7,973 $ 2,574 $ 823 $ 2,799 $ 29,190
Schedule of Financed Sale Receivables by Credit Quality Indicator	The tables below provide information on the Company’s financed sale receivables by credit quality indicator as of December 31, 2022 and 2021. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. (In thousands of U.S. Dollars) By Origination Year As of December 31, 2022 2022 2021 2020 2019 2018 Prior Total Financed sales receivables: Credit quality classification: In good standing $ 10,252 $ 8,643 $ 6,280 $ 8,541 $ 9,854 $ 39,912 $ 83,482 Credit Watch — — — — — 1,152 1,152 Pre-approved transactions — 2,318 1,399 1,134 1,449 9,243 15,543 Transactions suspended 272 664 142 1,269 1,197 8,276 11,820 Total financed sales receivables $ 10,524 $ 11,625 $ 7,821 $ 10,944 $ 12,500 $ 58,583 $ 111,997 (In thousands of U.S. Dollars) By Origination Year As of December 31, 2021 2021 2020 2019 2018 2017 Prior Total Financed sales receivables: Credit quality classification: In good standing $ 12,520 $ 8,251 $ 10,593 $ 13,278 $ 12,615 $ 47,950 $ 105,207 Credit Watch — — — — 321 1,292 1,613 Pre-approved transactions — — 743 418 2,098 3,650 6,909 Transactions suspended — — 335 — 680 3,327 4,342 Total financed sales receivables $ 12,520 $ 8,251 $ 11,671 $ 13,696 $ 15,714 $ 56,219 $ 118,071
Schedule of Aging Analysis for Net Investment in Leases and Financed Sale Receivables	The following tables provide an aging analysis for the Company’s net investment in leases and financed sale receivables as of December 31, 2022 and 2021: As of December 31, 2022 (In thousands of U.S. Dollars) Accrued 30-89 90+ Billed Unbilled Recorded Allowance Net Net investment in leases $ 237 $ 216 $ 2,593 $ 3,046 $ 26,062 $ 29,108 $ ( 776 ) $ 28,332 Financed sales receivables 2,269 1,307 12,793 16,369 95,628 111,997 ( 10,945 ) 101,052 Total $ 2,506 $ 1,523 $ 15,386 $ 19,415 $ 121,690 $ 141,105 $ ( 11,721 ) $ 129,384 As of December 31, 2021 (In thousands of U.S. Dollars) Accrued 30-89 90+ Billed Unbilled Recorded Allowance Net Net investment in leases $ 225 $ 156 $ 1,267 $ 1,648 $ 27,542 $ 29,190 $ ( 798 ) $ 28,392 Financed sales receivables 1,750 989 8,378 11,117 106,954 118,071 ( 5,414 ) 112,657 Total $ 1,975 $ 1,145 $ 9,645 $ 12,765 $ 134,496 $ 147,261 $ ( 6,212 ) $ 141,049
Schedule of Net Investment in Leases and Financed Sale Receivables with Billed Amounts Past Due Continues to Accrue Finance Income	The following tables provide information about the Company’s net investment in leases and financed sale receivables with billed amounts past due for which it continues to accrue finance income as of December 31, 2022 and 2021. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. As of December 31, 2022 (In thousands of U.S. Dollars) Accrued 30-89 Days 90+ Days Billed Unbilled Allowance Net Net investment in leases $ 190 $ 181 $ 2,593 $ 2,964 $ 17,070 $ ( 230 ) $ 19,804 Financed sales receivables 1,550 1,115 10,814 13,479 43,172 ( 1,587 ) 55,064 Total $ 1,740 $ 1,296 $ 13,407 $ 16,443 $ 60,242 $ ( 1,817 ) $ 74,868 As of December 31, 2021 (In thousands of U.S. Dollars) Accrued 30-89 Days 90+ Days Billed Unbilled Allowance Net Net investment in leases $ 143 $ 132 $ 825 $ 1,100 $ 12,619 $ ( 176 ) $ 13,543 Financed sales receivables 959 729 6,190 7,878 41,439 ( 1,413 ) 47,904 Total $ 1,102 $ 861 $ 7,015 $ 8,978 $ 54,058 $ ( 1,589 ) $ 61,447
Schedule of Net Investment in Leases and Financed Sale Receivables on Nonaccrual Status	The following table provides information about the Company’s net investment in leases and financed sale receivables that are on nonaccrual status as of December 31, 2022 and 2021: As of December 31, 2022 As of December 31, 2021 (In thousands of U.S. Dollars) Recorded Allowance Net Recorded Allowance Net Net investment in leases $ 401 $ ( 401 ) $ — $ 871 $ ( 309 ) $ 562 Net financed sales receivables 27,364 ( 9,589 ) 17,775 8,642 ( 2,357 ) 6,285 Total $ 27,765 $ ( 9,990 ) $ 17,775 $ 9,513 $ ( 2,666 ) $ 6,847
Summary of Allowance for Credit Losses Related to Net Investment in Leases and Financed Sale Receivables	The following tables summarize the activity in the allowance for credit losses related to the Company’s net investment in leases and financed sale receivables for years ended December 31, 2022 and 2021: Year Ended December 31, 2022 Net Investment Financed (In thousands of U.S. Dollars) in Leases Sales Receivables Beginning balance $ 798 $ 5,414 Current period provision, net 5 5,783 Foreign exchange ( 27 ) ( 252 ) Ending balance $ 776 $ 10,945 Year Ended December 31, 2021 Net Investment Net Financed (In thousands of U.S. Dollars) in Leases Sales Receivables Beginning balance $ 557 $ 7,274 Current period provision (reversal), net 235 ( 1,947 ) Foreign exchange 6 87 Ending balance $ 798 $ 5,414
Summary of Allowance For Credit Losses Related to Variable Consideration Receivables	The following table summarizes the activity in the Allowance for Credit Losses related to Variable Consideration Receivables for the years ended December 31, 2022 and 2021: Year Ended December 31, (In thousands of U.S. Dollars) 2022 2021 Beginning balance $ 1,082 $ 1,887 Current period reversal, net ( 440 ) ( 787 ) Foreign Exchange ( 32 ) ( 18 ) Ending balance $ 610 $ 1,082

Lease Arrangements (Tables)

Lease Arrangements (Tables)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Components of Operating Lease Expense	For the years ended December 31, 2022, 2021, and 2020 the components of lease expense recorded within Selling, General and Administrative Expenses are as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Operating lease cost: Amortization of operating lease assets 2,734 2,791 3,114 Interest on operating lease liabilities 825 937 1,052 Short-term and variable lease costs 616 713 540 Finance lease cost: Amortization of finance lease assets 171 N/A N/A Interest on finance lease liabilities 22 N/A N/A Total lease cost $ 4,368 $ 4,441 $ 4,706
Supplemental Cash and Non-Cash Flow Information Related to Leases	For the years ended December 31, 2022, 2021, and 2020, supplemental cash and non-cash information related to leases is as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating leases $ 3,783 $ 3,839 $ 3,743 Finance leases $ 948 N/A N/A Supplemental disclosure of noncash leasing activities: Right-of-use assets obtained in exchange for operating lease obligations $ 3,068 $ 1,047 $ 563 Right-of-use assets obtained in exchange for finance lease obligations $ 1,990 N/A N/A
Lessee Operating Lease Balance Sheet Amounts and Lines	As of December 31, 2022 and 2021, supplemental balance sheet information related to leases is as follows: December 31, (In thousands of U.S. Dollars) 2022 2021 Assets Balance Sheet Location Operating lease right-of-use assets Property, plant and equipment $ 12,341 $ 12,132 Finance lease right-of-use assets Property, plant and equipment $ 1,876 N/A Liabilities Balance Sheet Location Operating lease liabilities Accrued and other liabilities $ 14,641 $ 14,691 Finance lease liabilities (1) Accrued and other liabilities $ 1,011 N/A (1) Recorded net of a $ 0.9 million upfront payment made upon execution of the finance lease arrangement.
Lessee Leases Weighted Average Remaining Lease Term and Weighted Average Interest Rate	As of December 31, 2022 and 2021, the weighted-average remaining lease term and weighted-average interest rate associated with the Company’s leases are as follows: December 31, 2022 2021 Operating leases: Weighted-average remaining lease term (years) 6.0 7.0 Weighted-average discount rate 5.90 % 5.97 % Finance leases: Weighted-average remaining lease term (years) 4.7 N/A Weighted-average discount rate 6.00 % N/A
Lessee Operating and Finance Lease, Maturity	As of December 31, 2022, the maturities of the Company’s operating and finance lease liabilities are as follows: (In thousands of U.S. Dollars) Operating Leases Finance Leases 2023 $ 3,639 $ 508 2024 3,017 508 2025 2,429 — 2026 2,069 — 2027 2,094 — Thereafter 4,171 — Total lease payments $ 17,419 $ 1,016 Less: interest expense ( 2,778 ) ( 5 ) Present value of lease liabilities $ 14,641 $ 1,011
Schedule of Maturities of Lease Receivables	The following lease payments are expected to be received by the Company for its sales-type leases and joint revenue sharing arrangements in each of the next five years and thereafter following the December 31, 2022 balance sheet date: (In thousands of U.S. Dollars) Sales-Type Joint Revenue 2023 $ 3,245 $ 172 2024 3,158 69 2025 3,038 27 2026 2,823 — 2027 2,760 — Thereafter 14,702 — Total $ 29,726 $ 268

Variable Consideration from C_2

Variable Consideration from Contracts with Customers (Tables)	12 Months Ended
	Dec. 31, 2022
Change in Contract with Customer, Asset [Abstract]
Summary of Variable Consideration from Contracts With Customers	The following table summarizes the activity related to variable consideration from contracts with customers for the years ended December 31, 2022, 2021, and 2020: (In thousands of U.S. Dollars) Balance as of January 1, 2020 $ 40,040 Variable consideration for newly recognized sales 5,550 Accretion to finance income 2,133 Transferred to receivables from variable consideration assets ( 5,310 ) Movement in allowance for credit losses ( 1,887 ) Balance as of December 31, 2020 40,526 Variable consideration for newly recognized sales 4,696 Accretion to finance income 1,985 Transferred to receivables from variable consideration assets ( 3,794 ) Movement in allowance for credit losses (see Note 6) 805 Balance as of December 31, 2021 44,218 Variable consideration for newly recognized sales 7,109 Accretion to finance income 1,846 Transferred to receivables from variable consideration assets ( 9,621 ) Movement in allowance for credit losses (see Note 6) 472 Balance as of December 31, 2022 $ 44,024

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventories	As of December 31, (In thousands of U.S. Dollars) 2022 2021 Raw materials $ 25,365 $ 20,551 Work-in-process 2,034 1,406 Finished goods 4,135 4,967 $ 31,534 $ 26,924
Summary of Inventory Valuation Allowance Account	The following table summarizes the activity for the Company’s inventory valuation allowance account for the years ended December 31, 2022, 2021 and 2020: Balance at Additions (1) Other deductions (2) Balance at (In thousands of U.S. Dollars) Year ended December 31, 2022 $ 4,897 $ 919 $ ( 77 ) $ 5,739 Year ended December 31, 2021 $ 5,752 $ 629 $ ( 1,484 ) $ 4,897 Year ended December 31, 2020 $ 3,216 $ 3,028 $ ( 492 ) $ 5,752 (1) Excludes a recovery of $ 0.2 million charged directly to the Consolidated Statements of Operations during the year ended December 31, 2022 (2021 and 2020 — expenses of $ 0.3 million , and $ 0.6 million , respectively). (2) Includes the write-off of amounts previously charged to valuation allowance.

Film Assets (Tables)

Film Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Film, Capitalized Cost [Abstract]
Film Assets	As of December 31, (In thousands of U.S. Dollars) 2022 2021 Completed and released films, net of accumulated amortization of $ 1,227 $ 2,292 $ 235,029 (2021 ― $ 218,148 ) Films in production 1,667 195 Films in development 2,383 1,754 $ 5,277 $ 4,241

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	As of December 31, 2022 Accumulated Net Book (In thousands of U.S. Dollars) Cost Depreciation Value Equipment leased or held for use: System components (1)(2)(3) $ 345,960 $ 194,444 $ 151,516 Camera equipment 8,597 3,859 4,738 354,557 198,303 156,254 Assets under construction (4) 14,379 — 14,379 Right-of-use assets (5) 14,615 398 14,217 Other property, plant and equipment: Land 8,203 — 8,203 Buildings 81,053 31,519 49,534 Office and production equipment (6) 38,485 31,360 7,125 Leasehold improvements 7,959 4,775 3,184 135,700 67,654 68,046 $ 519,251 $ 266,355 $ 252,896 As of December 31, 2021 Accumulated Net Book (In thousands of U.S. Dollars) Cost Depreciation Value Equipment leased or held for use: System components (1)(2)(3) $ 346,517 $ 181,936 $ 164,581 Camera equipment 4,855 3,214 1,641 351,372 185,150 166,222 Assets under construction (4) 10,232 — 10,232 Right-of-use assets (5) 14,429 2,297 12,132 Other property, plant and equipment: Land 8,203 — 8,203 Buildings 80,973 28,873 52,100 Office and production equipment (6) 39,017 31,169 7,848 Leasehold improvements 8,110 4,494 3,616 136,303 64,536 71,767 $ 512,336 $ 251,983 $ 260,353 (1) Included in system components are assets with costs of $ 7.6 million (2021 — $ 7.6 million ) and accumulated depreciation of $ 7.2 million (2021 — $ 7.0 million ) that are leased to customers under operating leases. (2) Included in system components are assets with costs of $ 323.7 million (2021 — $ 324.3 million ) and accumulated depreciation of $ 177.9 million (2021 — $ 166.5 million ) that are used in joint revenue sharing arrangements. (3) In 2022, the Company recorded charges of $ 1.0 million (2021 — $ 0.4 million ; 2020 — $ 1.8 million) in Costs and Expenses Applicable to Technology Rentals mostly related to the write-down of leased xenon-based digital systems which were taken out of service in connection with customer upgrades to laser-based digital systems, as well as an IMAX System that was removed from its existing location. (4) Included in assets under construction are components with costs of $ 9.1 million (2021 — $ 9.2 million ) that will be utilized to construct assets to be used in joint revenue sharing arrangements. (5) The right-of-use assets primarily include operating leases for office and warehouse space. (6) Fully depreciated office and production equipment is still in use by the Company. In 2022, the Company identified and wrote off $ 3.5 million (2021 — $ 0.5 million ) of office and production equipment that is fully depreciated and no longer in use.

Other Assets (Tables)

Other Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Other Assets [Abstract]
Schedule of Other Assets	As of December 31, (In thousands of U.S. Dollars) 2022 2021 Lease incentives provided to exhibitor customers, net of accumulated amortization $ 12,975 $ 14,834 Commissions and other deferred selling expenses 1,336 1,418 Other investments 1,000 1,000 Foreign currency derivatives 50 184 Other 304 363 $ 15,665 $ 17,799

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of (Loss) Income Before Taxes by Jurisdiction	(a) (Loss) Income Before Taxes by Jurisdiction (Loss) income before taxes by tax jurisdiction for the years ended December 31, 2022, 2021, and 2020 consists of the following: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Canada $ ( 55,623 ) $ ( 55,480 ) $ ( 104,166 ) United States 4,281 3,218 ( 6,437 ) China 11,466 53,792 ( 8,253 ) Ireland 24,070 829 ( 7,473 ) Other 6,037 8,628 ( 2,795 ) $ ( 9,769 ) $ 10,987 $ ( 129,124 )
Schedule of Income Tax (Expense) Benefit	(b) Income Tax (Expense) Benefit Income tax (expense) benefit for the years ended December 31, 2022, 2021, and 2020 consists of the following: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Income tax (expense) benefit – current: Canada $ ( 1,149 ) $ ( 915 ) $ 555 United States ( 274 ) ( 1,038 ) 488 China ( 4,437 ) ( 11,045 ) ( 1,980 ) Ireland ( 2,802 ) ( 1,358 ) ( 1,462 ) Other ( 3,519 ) ( 3,212 ) ( 487 ) Sub-total ( 12,181 ) ( 17,568 ) ( 2,886 ) Income tax (expense) benefit – deferred: Canada (1) 943 ( 231 ) ( 10,801 ) United States ( 131 ) ( 1,268 ) 867 China (2) 2,763 ( 381 ) ( 15,756 ) Ireland ( 1,562 ) ( 997 ) 2,161 Other 60 ( 119 ) ( 89 ) Sub-total 2,073 ( 2,996 ) ( 23,618 ) Total (3) $ ( 10,108 ) $ ( 20,564 ) $ ( 26,504 ) (1) A valuation allowance is recorded in jurisdictions where management has determined, based on the weight of all available evidence, both positive and negative, that a valuation allowance for deferred tax assets is required. For the year ended December 31, 2022, the Company recorded a $ 16.9 million valuation allowance against its deferred tax assets in Canada and China primarily as a result of uncertainties related to the long-term impact of the COVID-19 pandemic (2021 — $ 17.2 million ). The $ 16.9 million increase in the valuation allowance recorded in 2022 is reflected within Income Tax Expense in the Company’s Consolidated Statements of Operations. (2) T he Company's deferred tax liability of $ 17.6 million as of December 31, 2021 was for the estimated applicable foreign withholding taxes associated with historical earnings that were not indefinitely reinvested, which will become payable upon the repatriation of any such earnings. During the year ended December 31, 2022, $ 27.4 million of historical earnings from a subsidiary in China were distributed and, as a result, $ 2.7 million of foreign withholding taxes were paid to the relevant tax authorities. The remaining deferred tax liability on the Company’s Consolidated Balance Sheets as of December 31, 2022 is $ 14.9 million . (3) For the year ended December 31, 2022 , Income Tax (Expense) Benefit excludes a tax expense of $ 0.8 million included in Other Comprehensive (Loss) Income ( 2021 — benefit of $ 0.3 million; 2020 — benefit of $ 0.1 million ).
Schedule of Reconciliation of Income Tax Expense to Statutory Rates	(c) Reconciliation of Income Tax Expense to Statutory Rates For the years ended December 31, 2022, 2021, and 2020, the Company’s effective tax rate and income tax expense differs from the combined Canadian federal and provincial statutory income tax rates due to the following factors: Years Ended December 31, 2022 2021 2020 (In thousands of U.S. Dollars, except rates) Amount Rate Amount Rate Amount Rate Income tax benefit (expense) at combined statutory rates $ 2,596 26.5 % $ ( 2,912 ) 26.5 % $ 34,218 26.5 % Adjustments resulting from: Non-controlling interests share of partnership losses — 0.0 % ( 1 ) 0.0 % ( 1,229 ) ( 1.0 %) Increase in valuation allowance ( 16,848 ) ( 172.5 %) ( 14,722 ) 134.0 % ( 28,589 ) ( 22.1 %) Changes to tax reserves 1,643 16.8 % 3,508 ( 31.9 %) ( 2,699 ) ( 2.1 %) U.S. federal and state taxes ( 86 ) ( 0.9 %) ( 80 ) 0.7 % ( 250 ) ( 0.2 %) Withholding taxes ( 3,825 ) ( 39.2 %) ( 4,199 ) 38.2 % ( 20,943 ) ( 16.2 %) Income tax at different rates in foreign and other provincial jurisdictions 3,872 39.6 % 3,352 ( 30.5 %) ( 2,607 ) ( 2.0 %) Investment and other tax credits (non-refundable) 752 7.7 % 413 ( 3.8 %) 643 0.5 % Changes to deferred tax assets and liabilities resulting from audit and other tax return adjustments 2,278 23.3 % ( 5,336 ) 48.6 % ( 1,219 ) ( 0.9 %) Other non-deductible/non-taxable items ( 490 ) ( 4.9 %) ( 587 ) 5.4 % ( 3,829 ) ( 3.0 %) Income tax expense $ ( 10,108 ) ( 103.6 %) $ ( 20,564 ) 187.2 % $ ( 26,504 ) ( 20.5 %)
Deferred Tax Assets and Deferred Tax Liability	(d) Deferred Tax Assets and Deferred Tax Liability As of December 31, 2022 and 2021, the Company’s deferred tax assets and deferred tax liability consists of the following: As of December 31, (In thousands of U.S. Dollars) 2022 2021 Net operating loss carryforwards $ 29,158 $ 21,219 Investment tax credit and other tax credit carryforwards 5,213 3,919 Write-downs of other assets 2,341 1,223 Excess of tax accounting basis in various assets 14,549 13,929 Accrued pension liability 5,375 6,901 Accrued share-based compensation 8,920 7,728 Income recognition on net investment in leases ( 3,344 ) ( 3,368 ) Other accrued reserves 10,552 8,369 Total deferred income tax assets 72,764 59,920 Valuation allowance ( 62,864 ) ( 46,014 ) Deferred income tax asset net of valuation allowance 9,900 13,906 Deferred tax liability ( 14,900 ) ( 17,642 ) Net deferred tax liability $ ( 5,000 ) $ ( 3,736 )
Reconciliation of Beginning and Ending Amount of Tax Reserves (excluding interest and penalties)	The following table presents a reconciliation of the beginning and ending amount of tax reserves (excluding interest and penalties) for the years ended December 31, 2022, 2021, and 2020: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Balance at beginning of the year $ 11,939 $ 14,076 $ 14,718 Additions based on tax positions related to the current year 11 37 2,301 Reductions for tax positions of prior years ( 94 ) ( 991 ) — Reductions resulting from lapse of applicable statute of limitations and ( 2,123 ) ( 1,183 ) ( 2,943 ) Balance at the end of the year $ 9,733 $ 11,939 $ 14,076
Income Tax (Expense) Benefit in Other Comprehensive Income	For the years ended December 31, 2022, 2021, and 2020, Income Tax (Expense) Benefit related to the components of Other Comprehensive (Loss) Income is as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Unrealized defined benefit plan actuarial (gain) loss $ ( 198 ) $ ( 37 ) $ 276 Unrealized postretirement benefit plans actuarial (gain) loss ( 762 ) ( 35 ) 92 Amortization of prior service cost ( 48 ) ( 48 ) ( 23 ) Unrealized change in cash flow hedging instruments 346 ( 123 ) ( 132 ) Realized change in cash flow hedging instruments ( 156 ) 446 ( 158 ) Reclassification of unrealized change in ineffective cash flow hedging instruments — 83 — $ ( 818 ) $ 286 $ 55

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Other Intangible Assets	As of December 31, 2022 Accumulated Net Book (In thousands of U.S. Dollars) Cost Amortization Value Licenses and intellectual property $ 26,168 $ 15,232 $ 10,936 Internal use software 32,886 25,232 7,654 Developed technology 5,779 225 5,554 In process research and development 3,810 — 3,810 Patents and trademarks 13,031 9,771 3,260 Customer relationships 1,340 50 1,290 Other 769 535 234 $ 83,783 $ 51,045 $ 32,738 As of December 31, 2021 Accumulated Net Book (In thousands of U.S. Dollars) Cost Amortization Value Licenses and intellectual property $ 26,168 $ 13,642 $ 12,526 Internal use software 28,571 21,544 7,027 Patents and trademarks 12,834 9,406 3,428 Other 598 499 99 $ 68,171 $ 45,091 $ 23,080
Summary of Estimated Amortization Expenses	The estimated amortization expense for each of the next five years following the December 31, 2022 balance sheet date is as follows: (In thousands of U.S. Dollars) 2023 $ ( 7,821 ) 2024 ( 7,636 ) 2025 ( 5,456 ) 2026 ( 3,059 ) 2027 ( 3,099 )

Borrowings (Tables)

Borrowings (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Revolving Credit Facility Borrowings	As of December 31, 2022 and 2021, Revolving Credit Facility Borrowings, Net includes the following: December 31, December 31, (In thousands of U.S. Dollars) 2022 2021 Wells Fargo Credit Facility borrowings $ 25,000 $ — HSBC China Facility borrowings 12,496 — Bank of China Facility borrowings 374 3,612 Unamortized debt issuance costs ( 1,759 ) ( 1,140 ) Revolving Credit Facility Borrowings, net $ 36,111 $ 2,472 Wells Fargo
Summary of Convertible Notes and Other Borrowings, Net	As of December 31, 2022 and December 31, 2021, Convertible Notes and Other Borrowings, Net includes the following: December 31, December 31, (In thousands of U.S. Dollars) 2022 2021 Convertible Notes $ 230,000 $ 230,000 Unamortized discounts and debt issuance costs ( 4,870 ) ( 6,359 ) Convertible Notes, net 225,130 223,641 Federal Economic Development Loan 2,812 N/A Unaccreted interest benefit ( 1,030 ) N/A Federal Economic Development Loan, net 1,782 N/A Convertible Notes and Other Borrowings, net $ 226,912 $ 223,641 Convertible Notes

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Summary of Company's Contractual Obligations and Commitments	The following table presents a summary of the Company’s contractual obligations and commitments as of December 31, 2022: Payments Due by Period (In thousands of U.S. Dollars) Total Less Than One Year 1 to 3 years 3 to 5 years Thereafter Purchase obligations (1) $ 37,884 $ 34,419 $ 3,183 $ 37 $ 245 Pension obligations (2) 20,295 — — 20,295 — Operating lease obligations (3) 18,013 3,905 5,825 4,137 4,146 Finance lease obligations 1,016 508 508 — — Wells Fargo Facility 25,000 — — 25,000 — HSBC Facility 12,496 12,496 — — — Bank of China Facility 374 374 — — — Federal Economic Development Loan (4) 2,812 — 1,250 1,250 312 Convertible Notes (5) 234,025 1,150 2,300 230,575 — Postretirement benefits obligations 2,504 104 210 220 1,970 $ 354,419 $ 52,956 $ 13,276 $ 281,514 $ 6,673 (1) Represents total payments to be made under binding commitments with suppliers and outstanding payments to be made for supplies ordered, but yet to be invoiced. (2) The Company has an unfunded defined benefit pension plan covering its Chief Executive Officer. (See Note 24 .) (3) Represents total minimum annual rental payments due under the Company’s operating leases. (See Note 7 .) (4) The Federal Economic Development Loan will be repayable over 60 months, with repayments estimated to begin in January 2024. (See Note 15 (b).) (5) The Convertible Notes bear interest at a rate of 0.500 % per annum on the principal of $ 230.0 million, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2021 . The Convertible Notes will mature on April 1, 2026 , unless earlier repurchased, redeemed or converted. (See Note 15 (b).)

Capital Stock (Tables)

Capital Stock (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Changes During the Year	The following table summarizes the settlement of stock option and RSU transactions: Years Ended December 31, 2022 2021 2020 Stock options Issued from treasury — 41,613 — Plan trustee purchases — — — Total stock options exercised — 41,613 — RSUs Issued from treasury 596,277 531,629 42,982 Plan trustee purchases — 723 386,297 Shares withheld for tax withholdings 203,956 157,546 24,714 Total RSUs vested 800,233 689,898 453,993
Share-Based Compensation Expense	Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Cost and expenses applicable to revenues $ 1,156 $ 1,490 $ 691 Selling, general and administrative expenses 25,438 23,776 20,652 Research and development 419 348 150 $ 27,013 $ 25,614 $ 21,493
Stock Option Plan	The Company recorded the following expenses related to stock options issued to employees and directors under the IMAX LTIP and SOP: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Stock option expense $ 572 $ 1,064 $ 1,847
Non vested stock options	As of December 31, 2022, 2021, and 2020, unrecognized share-based compensation expense related to non-vested employee stock options is as follows: As of December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Expense related to non-vested employee stock options $ 86 $ 662 $ 2,029 As of 2022, 2021, and 2020, unrecognized share-based compensation expense related to non-vested employee stock options is expected to be recognized over the following weighted-average periods: As of December 31, 2022 2021 2020 Weighted average period (in years) 0.2 1.1 1.8
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes the stock option activity under the SOP and IMAX LTIP for the years ended December 31, 2022, 2021, and 2020: Weighted Average Exercise Number of Shares Price Per Share 2022 2021 2020 2022 2021 2020 Stock options outstanding, beginning of year 3,736,157 4,892,962 5,732,209 $ 26.61 $ 26.81 $ 26.82 Granted — — — — — — Exercised — ( 41,613 ) — — 21.23 — Forfeited ( 796 ) ( 88,934 ) ( 34,678 ) 22.49 22.49 22.49 Expired ( 126,569 ) ( 903,038 ) ( 786,086 ) 33.61 28.31 27.07 Cancelled ( 4,053 ) ( 123,220 ) ( 18,483 ) 27.92 26.68 27.97 Stock options outstanding, end of year 3,604,739 3,736,157 4,892,962 26.36 26.61 26.81 Stock options exercisable, end of year 3,523,335 3,488,107 4,311,761 26.45 26.93 27.30
RSU Expenses	RSUs have been granted to employees and directors under the IMAX LTIP. Each RSU represents a contingent right to receive a common share and is the economic equivalent of one common share. The grant date fair value of each RSU is equal to the share price of the Company’s stock at the grant date or the average closing price of the Company’s common stock for five days prior to the date of grant. For the years ended December 31, 2022, 2021, and 2020, the Company recorded the following expenses related to RSUs issued to employees and directors in the IMAX LTIP: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 RSU expenses $ 15,498 $ 15,555 $ 13,761
RSU Unrecognized Expenses	Total share-based compensation expense related to non-vested RSUs not yet recognized and the weighted average period over which the awards are expected to be recognized are as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Expense related to non-vested RSUs not yet recognized $ 17,457 $ 15,913 $ 17,343 Weighted average period awards are expected to be recognized (in years) 1.5 1.6 1.9
Restricted Stock Units Issued under the IMAX LTIP	The following table summarizes the activity in respect of RSUs issued under the IMAX LTIP for the years ended December 31, 2022, 2021, and 2020: Number of Awards Weighted Average Grant Date Fair 2022 2021 2020 2022 2021 2020 RSUs outstanding, beginning of year 1,457,883 1,564,838 1,065,347 $ 19.16 $ 18.33 $ 23.17 Granted 708,313 831,123 1,050,385 19.31 21.03 15.35 Vested and settled ( 800,231 ) ( 689,872 ) ( 453,993 ) 19.10 19.46 22.71 Forfeited ( 113,921 ) ( 248,206 ) ( 96,901 ) 20.39 19.38 18.81 RSUs outstanding, end of year 1,252,044 1,457,883 1,564,838 19.16 19.16 18.33
RSU Carve out Balance	The following table summarizes the number of RSUs issued from the carve-out balance: Approved under the June 3, 2020 amended and restated IMAX LTIP 885,000 Issued during previous years ( 482,912 ) Issued during 2022 ( 59,030 ) Outstanding, December 31, 2022 343,058
PSU Expenses	For the years ended December 31, 2022, 2021, and 2020, the Company recorded the following expenses related to outstanding PSUs, which includes adjustments reflecting management’s estimate of the number of PSUs with EBITDA-based targets expected to vest: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 PSU expenses $ 8,306 $ 5,322 $ 2,563
Performance Stock Units Activity under the IMAX LTIP	The following table summarizes the activity in respect of PSUs issued under the IMAX LTIP: Number of Awards Weighted Average Grant Date 2022 2021 2020 2022 2021 2020 PSUs outstanding, beginning of year 613,405 361,844 — $ 18.21 $ 15.68 $ — Granted 359,138 309,574 370,265 20.34 20.77 15.66 Forfeited ( 40,827 ) ( 58,013 ) ( 8,421 ) 19.90 16.11 4.84 PSUs outstanding, end of year 931,716 613,405 361,844 18.96 18.21 15.68
China LTIP Activity	For the years ended December 31, 2022, 2021, and 2020, share-based compensation expense related to China Options, China RSUs and China PSUs was as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Expense China Options $ 91 $ 285 $ 875 China RSUs 2,284 2,810 2,093 China PSUs 262 578 208 Total $ 2,637 $ 3,673 $ 3,176
Summary of Share Repurchases	The following table summarizes the Company's share repurchases during the years ended December 31, 2022 and 2021: Total Number of Shares Repurchased Average Price Paid Per Share (in thousands of U.S. Dollars) 2022 2021 2022 2021 Shares repurchased 5,401,852 841,331 $ 15.19 $ 16.51
Basic and Diluted Per-share Computations	The following table reconciles the denominator of the basic and diluted weighted average share computations: Years Ended December 31, (In thousands) 2022 2021 2020 Issued and outstanding, beginning of period 58,654 58,921 61,176 Weighted average number of shares (repurchased) issued, net ( 1,980 ) 205 ( 1,939 ) Weighted average number of shares outstanding - basic and diluted 56,674 59,126 59,237
IMAX China
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Summary of Share Repurchases	The following table summarizes the IMAX China's share repurchases during the years ended December 31, 2022 and 2021: Total Number of Shares Repurchased Average Price Paid Per Share (in thousands of U.S. Dollars) 2022 2021 2022 2021 Shares repurchased 2,961,800 6,664,700 $ 1.02 $ 1.50

Consolidated Statements of Op_3

Consolidated Statements of Operations Supplemental Information (Tables)	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Selling Expenses, Including Sales Commissions and Marketing and Other Expenses	The following table summarizes the Company’s selling expenses, including sales commissions and marketing and other, which are recognized within Costs and Expenses Applicable to Revenues in the Consolidated Statements of Operations, for the years ended December 31, 2022, 2021 and 2020: Years Ended December 31, 2022 2021 2020 (In thousands of U.S. Dollars) Sales Marketing and Other Sales Marketing and Other Sales Marketing and Other Technology sales (1) $ 479 $ 810 $ 1,885 $ 989 $ 1,278 $ 1,077 Image enhancement and maintenance services (2) — 20,284 — 8,923 — 4,306 Technology rentals (3) 85 663 399 1,109 908 510 Total $ 564 $ 21,757 $ 2,284 $ 11,021 $ 2,186 $ 5,893 (1) Sales commissions paid prior to the recognition of the related revenue are deferred and recognized upon the client acceptance of the IMAX System. Direct advertising and marketing costs for each IMAX System are expensed as incurred. (2) Film exploitation costs, including advertising and marketing costs are expensed as incurred. (3) Sales commissions related to joint revenue sharing arrangements accounted for operating leases are recognized in the month they are earned by the salesperson, which is typically the month in which the IMAX System is installed. Direct advertising and marketing costs for each IMAX System are expensed as incurred.

Consolidated Statements of Ca_3

Consolidated Statements of Cash Flows Supplemental Information (Tables)	12 Months Ended
	Dec. 31, 2022
Supplemental Cash Flow Elements [Abstract]
Summary of Changes in Other Operating Assets and Liabilities	Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Decrease (Increase) in: Financing receivables $ 5,411 $ ( 7,637 ) $ ( 10,568 ) Prepaid expenses ( 1,892 ) ( 3,230 ) ( 979 ) Variable consideration receivables 667 ( 2,905 ) ( 2,361 ) Other assets 968 1,003 ( 4,747 ) Increase (Decrease) in: Accounts payable 8,496 ( 4,752 ) 414 Accrued and other liabilities ( 12,849 ) 15,167 ( 6,399 ) $ 801 $ ( 2,354 ) $ ( 24,640 )
Cash Payments	Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Income taxes (1) $ 13,963 $ 18,475 $ 4,763 Interest $ 715 $ 3,251 $ 5,773 (1) In 2021 , the Canadian tax authorities denied the Company’s deduction of certain foreign taxes accrued in 2015, but not yet paid as discussions with the local authorities are ongoing. This resulted in the payment of $ 8.9 million in income taxes and $ 1.6 million in associated interest to the Canadian tax authorities in the fourth quarter of 2021. The Company has filed a waiver with the Canadian tax authorities in respect of 2015 so that when the foreign taxes are paid, the Company would be entitled to receive a refund of the $ 8.9 million in tax, which is recorded on the Company’s Consolidated Balance Sheets within Accounts Receivable, and the $ 1.6 million in associated interest.
Summary of Depreciation and Amortization	Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Film assets $ 16,881 $ 16,316 $ 8,838 Property, plant and equipment: Equipment supporting joint revenue sharing arrangements 22,165 22,320 24,930 Other property, plant and equipment (1) 9,757 9,479 11,225 Other intangible assets (2) 6,103 6,079 6,565 Other assets (3) 1,755 1,888 1,146 Total $ 56,661 $ 56,082 $ 52,704 (1) Includes the amortization of laser projection systems, camera, and lens upgrades recorded in Research and Development on the Statements of Operations of $ 0.6 million in the year ended December 31, 2022 (2021 — $ 0.8 million; 2020 — $ 0.9 million). (2) Includes the amortization of licenses and intellectual property recorded in Research and Development on the Consolidated Statements of Operations of $ 1.3 million in the year ended December 31, 2022 (2021 — $ 1.3 million; 2020 — $ 1.3 million). (3) Includes the amortization of lessee incentives provided by the Company to its customers under joint revenue sharing arrangements.
Write Downs, Net of Recoveries	Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Other assets (1) $ 4,470 $ — $ 1,151 Inventories (2) 741 890 3,632 Property, plant and equipment: Equipment supporting joint revenue sharing arrangements (3) 973 364 1,784 Other property, plant and equipment 57 217 174 Other intangible assets 87 142 184 Film assets (4) 848 151 10,804 $ 7,176 $ 1,764 $ 17,729 (1) In 2022 , the Company recognized a full impairment of its RMB 30.0 million ($ 4.5 million) investment in the film Mozart from Space based on projected box office results and distribution costs. (See Note 23(e).) In 2020 , the Company recorded a write-down of $ 1.2 million in Asset Impairments related to content-related assets which became impaired in the year. No such write-downs including asset impairments were incurred in 2021. (2) In 2022 , the Company recorded write-downs of $ 0.9 million, net of a recovery of $ 0.2 million in Costs and Expenses Applicable to Technology Sales. The write-downs recorded during the year ended December 31, 2022 include $ 0.4 million related to excess and damaged inventory and $ 0.3 million recorded to reduce the carrying value of service parts held in Russia . For the years ended December 31, 2021 and 2020 , the Company recorded write-downs of $ 0.9 million and $ 3.6 million, respectively, in Costs and Expenses Applicable to Technology Sales to reduce the carrying value of excess inventory. (3) In 2022 , the Company recorded charges of $ 1.0 million ( 2021 — $ 0.4 million; 2020 — $ 1.8 million) in Costs and Expenses Applicable to Technology Rentals mostly related to the write-downs of leased xenon-based digital systems which were taken out of service in connection with exhibitor customer upgrades to laser-based digital systems, as well as an IMAX System that was removed from its existing location. (4) In 2022 , the Company recorded impairment losses of $ 0.8 million ( 2021 — $ 0.2 million) related to the write-down of DMR and documentary film assets. In 2020, the Company recorded impairment losses of $ 10.8 million principally to write-down the carrying value of certain documentary, alternative content film assets and DMR related film assets due to a decrease in projected box office totals and related revenues based on management’s regular quarterly recoverability assessments.
Significant Non-cash Investing Activities	Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Net increase (decrease) in accruals related to: Investment in equipment supporting joint revenue sharing arrangements $ 790 $ 1,009 $ ( 1,888 ) Acquisition of other intangible assets 30 ( 891 ) 792 Purchases of property, plant and equipment (1) 311 ( 188 ) 158 $ 1,131 $ ( 70 ) $ ( 938 ) (1) See Note 7 for supplemental disclosure of noncash leasing activities. (f) Significant non-cash financing activities In the fourth quarter of 2022, the Company recognized a $ 2.0 million liability related to repurchase of its common shares, which were not settled as of December 31, 2022 and were related on the Consolidated Balance Sheets within Accrued and Other Liabilities.

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	12 Months Ended
	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue by Segment	The following tables summarize the Company’s revenues by type and reportable segment for the years ended December 31, 2022, 2021, and 2020: Year Ended December 31, 2022 Revenue from Contracts with Customers (In thousands of U.S. Dollars) Fixed Variable Revenue from Lease Finance Income Total Technology sales IMAX Systems (1) $ 43,704 $ 7,268 $ 3,479 $ — $ 54,451 Joint Revenue Sharing Arrangements, fixed fees — — 4,804 — 4,804 Other Theater Business 6,255 — — — 6,255 All Other 3,546 102 — — 3,648 Sub-total 53,505 7,370 8,283 — 69,158 Image enhancement and maintenance services IMAX DMR — 94,867 — — 94,867 IMAX Maintenance 56,608 — — — 56,608 Film Distribution 554 2,598 — — 3,152 Film Post-Production 3,783 — — — 3,783 All Other 1,178 1,791 — — 2,969 Sub-total 62,123 99,256 — — 161,379 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 61,768 — 61,768 All Other — — 18 — 18 Sub-total — — 61,786 — 61,786 Finance income IMAX Systems — — — 8,482 8,482 Total $ 115,628 $ 106,626 $ 70,069 $ 8,482 $ 300,805 Year Ended December 31, 2021 Revenue from Contracts with Customers (In thousands of U.S. Dollars) Fixed Variable Revenue from Lease Finance Income Total Technology sales IMAX Systems (1) $ 37,900 $ 5,576 $ 11,392 $ — $ 54,868 Joint Revenue Sharing Arrangements, fixed fees — — 5,406 — 5,406 Other Theater Business 2,363 — — — 2,363 All Other 3,475 41 — — 3,516 Sub-total 43,738 5,617 16,798 — 66,153 Image enhancement and maintenance services IMAX DMR — 70,659 — — 70,659 IMAX Maintenance 53,339 — — — 53,339 Film Distribution 205 1,259 — — 1,464 Film Post-Production 4,260 — — — 4,260 All Other 377 1,049 — — 1,426 Sub-total 58,181 72,967 — — 131,148 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 46,184 — 46,184 All Other — — 606 — 606 Sub-total — — 46,790 — 46,790 Finance income IMAX Systems — — — 10,792 10,792 Total $ 101,919 $ 78,584 $ 63,588 $ 10,792 $ 254,883 Year Ended December 31, 2020 Revenue from Contracts with Customers (In thousands of U.S. Dollars) Fixed Variable Revenue from Lease Finance Income Total Technology sales IMAX Systems (1) $ 33,869 $ 5,799 $ 4,271 $ — $ 43,939 Joint Revenue Sharing Arrangements, fixed fees — — 2,056 — 2,056 Other Theater Business 1,666 — — — 1,666 All Other 1,957 110 — — 2,067 Sub-total 37,492 5,909 6,327 — 49,728 Image enhancement and maintenance services IMAX DMR — 28,265 — — 28,265 IMAX Maintenance 21,999 — — — 21,999 Film Distribution 3,000 1,841 — — 4,841 Film Post-Production 3,878 — — — 3,878 All Other — 335 — — 335 Sub-total 28,877 30,441 — — 59,318 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 17,841 — 17,841 Sub-total — — 17,841 — 17,841 Finance income IMAX Systems — — — 10,116 10,116 Total $ 66,369 $ 36,350 $ 24,168 $ 10,116 $ 137,003 (1) Includes revenues earned from sale and sales-type lease arrangements involving new and upgraded IMAX Systems, as well as the impact of renewals and amendments to existing system arrangements.

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Segment Reporting Information by Category and Reportable Segment	The following table presents the Company’s revenue and gross margin (margin loss) by category and reportable segment for the years ended December 31, 2022, 2021, and 2020: Years Ended December 31, Revenue (1) Gross Margin (Margin Loss) (In thousands of U.S. Dollars) 2022 2021 2020 2022 2021 2020 IMAX Technology Network IMAX DMR $ 94,867 $ 70,659 $ 28,265 $ 57,964 $ 44,782 $ 13,731 JRSA, contingent rent 61,768 46,184 17,841 37,394 21,761 ( 9,500 ) 156,635 116,843 46,106 95,358 66,543 4,231 IMAX Technology Sales and Maintenance IMAX Systems (2) 62,933 65,660 54,055 35,129 34,981 24,816 JRSA, fixed fees 4,804 5,406 2,056 589 1,343 529 IMAX Maintenance 56,608 53,339 21,999 27,109 27,572 3,068 Other Theater Business (3) 6,255 2,363 1,666 807 398 ( 438 ) 130,600 126,768 79,776 63,634 64,294 27,975 Film Distribution and Post-Production Film Distribution (4) 3,152 1,464 4,841 ( 7,668 ) ( 1,121 ) ( 9,840 ) Post-Production 3,783 4,260 3,878 1,540 1,969 ( 358 ) 6,935 5,724 8,719 ( 6,128 ) 848 ( 10,198 ) Sub-total for reportable segments 294,170 249,335 134,601 152,864 131,685 22,008 All Other (5) 6,635 5,548 2,402 3,491 2,721 ( 468 ) Total $ 300,805 $ 254,883 $ 137,003 $ 156,355 $ 134,406 $ 21,540 The following table presents the Company’s assets by category and reportable segment, reconciled to consolidated assets, as of December 31, 2022 and 2021: As of December 31, (In thousands of U.S. Dollars) 2022 2021 IMAX Technology Network IMAX DMR $ 48,755 $ 48,299 JRSA, contingent rent 193,403 196,789 IMAX Technology Sales and Maintenance IMAX Systems 255,458 249,672 JRSA, fixed fees 26,574 27,930 IMAX Maintenance 48,764 38,530 Other Theater Business 110 82 Film Distribution and Post-Production Film Distribution 11,545 7,185 Post-Production 32,406 31,575 Sub-total for reportable segments 617,015 600,062 All Other (5) 29,686 1,420 Corporate and other non-segment specific assets 174,453 281,765 Total $ 821,154 $ 883,247 The following table presents the Company’s amortization by category and reportable segment, and on a consolidated basis, for the years ended December 31, 2022, 2021, and 2020: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 IMAX Technology Network IMAX DMR $ 16,367 $ 15,917 $ 10,269 JRSA, contingent rent 23,920 24,208 26,076 IMAX Technology Sales and Maintenance IMAX Systems 169 2,076 3,548 IMAX Maintenance — — 213 Film Distribution and Post-Production Film Distribution 2,423 600 1,213 Post-Production — 924 1,281 Sub-total for reportable segments 42,879 43,725 42,600 All Other (5) 309 — 11 Corporate and other non-segment specific assets 13,473 12,357 10,093 Total $ 56,661 $ 56,082 $ 52,704 The following table presents the Company’s write-downs, including asset impairments and credit loss expense (reversal), by category and reportable segment, and on a consolidated basis, for the years ended December 31, 2022, 2021, and 2020: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 IMAX Technology Network IMAX DMR $ 29 $ 151 $ 1,057 JRSA, contingent rent 973 364 1,784 IMAX Technology Sales and Maintenance IMAX Systems 150 837 2,872 IMAX Maintenance 591 53 510 Film Distribution and Post-Production Film Distribution (4) 819 — 9,997 Post-Production — — — Sub-total for reportable segments 2,562 1,405 16,220 All Other (5) — — 52 Corporate and other non-segment specific assets (6) 13,161 ( 3,592 ) 20,065 Total $ 15,723 $ ( 2,187 ) $ 36,337 The following table presents the Company’s purchases of fixed assets within the Consolidated Statements of Cash Flows by category and reportable segment for the years ended December 31, 2022, 2021, and 2020: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 IMAX Technology Network IMAX DMR $ — $ — $ — JRSA, contingent rent 19,803 10,094 6,654 IMAX Technology Sales and Maintenance IMAX Systems 2,574 621 50 IMAX Maintenance 4 25 — Film Distribution and Post-Production Film Distribution 4,126 1,599 — Post-Production 1,195 609 456 Sub-total for reportable segments 27,702 12,948 7,160 All Other (5) 9 — — Corporate and other non-segment specific assets 516 736 191 Total $ 28,227 $ 13,684 $ 7,351 (1) The Company’s largest customer represents 12 % of total Revenues as of December 31, 2022 (2021 ― 10 % ; 2020 ― 16 % ). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of December 31, 2022 and 2021 . (2) The revenue from this segment includes the initial upfront payments and the present value of fixed minimum payments from sale and sales-type lease arrangements of IMAX Systems, as well as the present value of estimated variable consideration from sales of IMAX Systems. To a lesser extent, the revenue from this segment also includes finance income associated with these revenue streams. (3) The revenue from this segment principally includes after-market sales of IMAX projection system parts and 3D glasses. (4) For the year ended December 31, 2022 , the Company recorded an impairment loss of $ 0.8 million related to the write-down of documentary film assets. During the year ended December 31, 2020 , Film Distribution segment results were significantly influenced by impairment losses of $ 10.0 million, to write-down the carrying value of certain documentary and alternative content film assets due to a decrease in projected box office totals and related revenues based on management’s regular quarterly recoverability assessments. No such impairment losses were incurred in 2021. (5) All Other includes the results from IMAX Enhanced, SSIMWAVE, and other ancillary activities. In the first quarter of 2022, the Company's internal reporting was updated to reclassify the results of IMAX Enhanced out of the New Business Initiatives segment into All Other for segment reporting purposes. Prior period comparatives have been revised to conform with the current period presentation. (See Note 5 for additional information related to the Company's acquisition of SSIMWAVE. ) (6) During the year ended December 31, 2022 , includes provision of current expected credit losses of $ 8.5 million ( 2021 ― net reversal of $ 4.0 million; 2020 ― provision of $ 18.6 million). (See Note 6 .) In 2022, the Company recognized a full impairment of its RMB 30.0 million ($ 4.5 million) investment in the film Mozart from Space based on projected box office results and distribution costs. (See Note 23(e).) In 2020, the Company recorded a write-down of $ 1.2 million in Asset Impairments related to content-related assets which became impaired in the year. No such impairment losses were incurred in 2021. These amounts are excluded from the measurement of the Company’s segment performance.
Geographic Information	The following table summarizes the Company’s revenues by geographic area for the years ended December 31, 2022, 2021, and 2020: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 United States $ 107,734 $ 73,499 $ 30,157 Greater China 73,330 112,801 52,331 Asia (excluding Greater China) 47,145 23,682 20,090 Western Europe 40,245 20,942 13,683 Latin America 9,418 3,601 6,114 Canada 7,550 3,266 1,365 Russia/the CIS & Ukraine (1) 2,849 7,308 2,927 Rest of the World 12,534 9,784 10,336 Total $ 300,805 $ 254,883 $ 137,003 (1) In addition to Russia, the CIS includes Azerbaijan, Belarus, Kazakhstan, and Kyrgyzstan. Commencing i n March 2022, in response to the ongoing conflict between Russia and Ukraine and resulting sanctions, the Company suspended its operations in Russia and Belarus. As of December 31, 2022, the IMAX network includes 54 systems in Russia, eight systems in Ukraine, and one system in Belarus.
Schedule of Property Plant and Equipment By Geographic Areas	The following table presents the breakdown of Property, Plant and Equipment by geography as of December 31, 2022 and 2021: As of December 31, (In thousands of U.S. Dollars) 2022 2021 United States $ 94,505 $ 91,856 Greater China 86,665 100,182 Canada 36,385 32,643 Western Europe 20,132 21,684 Asia (excluding Greater China) 10,471 9,463 Rest of the World 4,738 4,525 Total $ 252,896 $ 260,353

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2022
Derivative Instruments Gain Loss [Line Items]
Fair Value of Financial Instruments	The carrying values of the Company’s Cash and Cash Equivalents, Accounts Receivable, Accounts Payable, and Accrued Liabilities due within one year approximate their fair values due to the short-term maturity of these instruments. Including these instruments, the Company’s financial instruments consist of the following: As of December 31, 2022 As of December 31, 2021 (In thousands of U.S. Dollars) Carrying Estimated Carrying Estimated Level 1 Cash and cash equivalents (1) $ 97,401 $ 97,401 $ 189,711 $ 189,711 Equity securities (2) 1,035 1,035 1,087 1,087 Level 2 Net financed sales receivables (3) $ 101,052 $ 100,059 $ 112,657 $ 112,662 Net investment in sales-type leases (3) 28,332 27,972 28,392 28,407 Equity securities (1) 1,000 1,000 1,000 1,000 COLI (4) 3,398 3,398 3,275 3,275 Foreign exchange contracts — designated forwards (2) ( 649 ) ( 649 ) 79 79 Wells Fargo Credit Facility borrowings (1) ( 25,000 ) ( 25,000 ) — — HSBC China Facility borrowings (1) ( 12,496 ) ( 12,496 ) — — Bank of China Facility borrowings (1) ( 374 ) ( 374 ) ( 3,612 ) ( 3,612 ) Federal Economic Development Loan (3) ( 1,782 ) ( 1,782 ) N/A N/A Convertible Notes (5) ( 230,000 ) ( 196,717 ) ( 230,000 ) ( 223,100 ) Level 3 Interest in film classified as a financial instrument (6) $ — $ — $ — $ — (1) Recorded at cost, which approximates fair value. (2) Fair value is determined using quoted prices in active markets. (3) Fair value is estimated based on discounting future cash flows at currently available interest rates with comparable terms. (4) Measured at cash surrender value, which approximates fair value. (5) Fair value is determined using quoted market prices that are observable in the market or that could be derived from observable market data. (6) Recorded at amortized cost less impairment losses. Inputs used in the calculation of estimated fair value include management's projection of future box office and ancillary receipts for the film net of distribution costs and other costs in accordance with the investment agreement. See 23 (e) below.
Notional Amount of Derivative	The following tabular disclosures reflect the impact that derivative instruments and hedging activities have on the Company’s Consolidated Financial Statements: Notional value of foreign exchange contracts : As of December 31, (In thousands of U.S. Dollars) 2022 2021 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards $ 24,707 $ 26,702
Fair Value of Foreign Exchange Contracts	Fair value of derivatives in foreign exchange contracts : As of December 31, (In thousands of U.S. Dollars) Balance Sheet Location 2022 2021 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards Other assets $ 50 $ 184 Accrued and other liabilities ( 699 ) ( 105 ) $ ( 649 ) $ 79
Derivatives in Foreign Currency Hedging Relationships	Derivatives in foreign currency hedging relationships are as follows : Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Foreign exchange contracts Derivative (Loss) Gain — Forwards Recognized in OCI (Effective Portion) $ ( 1,323 ) $ 468 $ 550 Location of Derivative (Loss) Gain Reclassified from AOCI Years Ended December 31, (In thousands of U.S. Dollars) (Effective Portion) 2022 2021 2020 Foreign exchange contracts Selling, general and — Forwards administrative expenses $ ( 596 ) $ 1,707 $ ( 578 ) Inventories — — ( 26 ) $ ( 596 ) $ 1,707 $ ( 604 ) Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Foreign exchange contracts Derivative Gain Recognized — Forwards In and out of OCI (Effective Portion) $ — $ — $ 17
Not Designated as Hedging Instrument [Member]
Derivative Instruments Gain Loss [Line Items]
Derivatives in Foreign Currency Hedging Relationships	Non-designated derivatives in foreign currency relationships are as follows : Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Foreign exchange contracts Derivative Gain Reclassified — Forwards From AOCI (Ineffective Portion) $ — $ ( 318 ) $ — Years Ended December 31, (In thousands of U.S. Dollars) Location of Derivative Gain 2022 2021 2020 Foreign exchange contracts Selling, general and — Forwards administrative expenses $ — $ 398 $ 344

Employees Pension and Postret_2

Employees Pension and Postretirement Benefits (Tables)	12 Months Ended
	Dec. 31, 2022
SERP Benefits [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Summary of Amounts Accrued for the SERP	As of December 31, 2022 and 2021, the projected benefit obligation for SERP are as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 Projected benefit obligation: Obligation, beginning of period $ 20,056 $ 20,116 Interest cost 160 72 Actuarial gain ( 2,901 ) ( 132 ) Obligation, end of period and unfunded status $ 17,315 $ 20,056
Summary of Accumulated Other Comprehensive (Loss) Income and Components of Net Periodic Benefit Cost in Future Periods	As of December 31, 2022, 2021, and 2020, the following amounts related to the SERP were recorded on the Company’s Consolidated Balance Sheets within Accumulated Other Comprehensive (Loss) Income and will be recognized as components of net periodic benefit cost in future periods: As of December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Unrealized actuarial gain $ ( 3,580 ) $ ( 679 ) $ ( 547 ) Unamortized prior service cost — 184 369 Net periodic benefit costs to be recognized in future periods $ ( 3,580 ) $ ( 495 ) $ ( 178 )
Summary of Disclosure of Pension Expense	For the years ended December 31, 2022, 2021, and 2020, the components of pension expense related to the SERP were as follows: Years ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Interest cost $ 160 $ 72 $ 379 Amortization of prior service cost 184 185 87 Pension expense $ 344 $ 257 $ 466
Summary of Weighted Average Assumptions Used to Determine the Benefit Obligation and Expense	The following assumptions were used to determine the SERP obligation and any related costs as of and for the years ended December 31, 2022, 2021, and 2020: As of December 31, 2022 2021 2020 Discount rate 4.55 % 0.80 % 0.36 % Lump sum interest rate: First 25 years N/A N/A N/A First 20 years N/A N/A N/A Thereafter N/A N/A N/A Cost of living adjustment on benefits N/A N/A N/A
Postretirement Benefits Executives [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Summary of Amounts Accrued for the SERP	As of December 31, 2022 and 2021, the Company’s Consolidated Balance Sheets include the following amounts within Accrued and Other Liabilities related to the Executive Postretirement Benefit Plan: As of December 31, (In thousands of U.S. Dollars) 2022 2021 Projected benefit obligation: Obligation, beginning of year $ 662 $ 710 Interest cost 18 16 Benefits paid ( 8 ) ( 16 ) Actuarial gain ( 215 ) ( 48 ) Obligation, end of year and unfunded status $ 457 $ 662
Summary of Accumulated Other Comprehensive (Loss) Income and Components of Net Periodic Benefit Cost in Future Periods	As of December 31, 2022, 2021, and 2020, the following amounts related to the Executive Postretirement Benefit Plan were recorded on the Company’s Consolidated Balance Sheets within Accumulated Other Comprehensive (Loss) Income and will be recognized as components of net pension cost in future periods: As of December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Unrealized actuarial (gain) loss $ ( 242 ) $ ( 27 ) $ 21
Summary of Disclosure of Pension Expense	For the years ended December 31, 2022, 2021, and 2020, the components of pension expense related to the Executive Postretirement Benefit Plan were as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Interest cost $ 18 $ 16 $ 20 Amortization of actuarial gain — — ( 17 ) Pension expense $ 18 $ 16 $ 3
Summary of Weighted Average Assumptions Used to Determine the Benefit Obligation and Expense	As of December 31, 2022, 2021, and 2020, the weighted average assumptions used to determine the benefit obligation related to the Executive Postretirement Benefit Plan are as follows: As of December 31, 2022 2021 2020 Discount rate 5.01 % 2.71 % 2.36 % For the years ended December 31, 2022, 2021, and 2020, the weighted average assumptions used to determine the net postretirement benefit expense related to the Executive Postretirement Benefit Plan are as follows: Years Ended December 31, 2022 2021 2020 Discount rate 2.71 % 2.36 % 3.13 %
Summary of Benefit Payment are Expected in Next Five Year	The following benefit payments are expected to be made as per the current plan assumptions for the Executive Postretirement Benefit Plan in each of the next five years and thereafter following the December 31, 2022 balance sheet date: (In thousands of U.S. Dollars) 2023 $ 10 2024 10 2025 11 2026 23 2027 24 Thereafter 888 Total $ 966
Postretirement Benefits Canadian Employees [Member]
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]
Summary of Amounts Accrued for the SERP	As of December 31, 2022 and 2021, the Company’s Consolidated Balance Sheets include the following amounts within Accrued and Other Liabilities related to the Canadian Postretirement Benefit Plan: As of December 31, (In thousands of U.S. Dollars) 2022 2021 Projected benefit obligations: Obligation, beginning of year $ 1,702 $ 1,862 Interest cost 46 42 Benefits paid ( 155 ) ( 118 ) Actuarial gain ( 539 ) ( 92 ) Unrealized foreign exchange (gain) loss ( 78 ) 8 Obligation, end of year and unfunded status $ 976 $ 1,702
Summary of Accumulated Other Comprehensive (Loss) Income and Components of Net Periodic Benefit Cost in Future Periods	As of December 31, 2022, 2021, and 2020, the following amounts related to the Canadian Postretirement Benefit Plan were recorded on the Company’s Consolidated Balance Sheets within Accumulated Other Comprehensive (Loss) Income and will be recognized as components of net pension cost in future periods: As of December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Unrealized actuarial (gain) loss $ ( 354 ) $ 185 $ 277
Summary of Disclosure of Pension Expense	For the years ended December 31, 2022, 2021, and 2020, the components of pension expense related to the Canadian Postretirement Benefit Plan were as follows: Years Ended December 31, (In thousands of U.S. Dollars) 2022 2021 2020 Interest cost $ 46 $ 42 $ 47 Pension expense $ 46 $ 42 $ 47
Summary of Weighted Average Assumptions Used to Determine the Benefit Obligation and Expense	As December 31, 2022, 2021, and 2020, the weighted average assumptions used to determine the benefit obligation related to the Canadian Postretirement Benefit Plan are as follows: As of December 31, 2022 2021 2020 Discount rate 5.00 % 2.80 % 2.30 % For the years ended December 31, 2022, 2021, and 2020, the weighted average assumptions used to determine the net postretirement benefit expense related to the Canadian Postretirement Benefit Plan are as follows: Years Ended December 31, 2022 2021 2020 Discount rate 2.80 % 2.30 % 3.05 %
Summary of Benefit Payment are Expected in Next Five Year	The following benefit payments are expected to be made as per the current plan assumptions for the Canadian Postretirement Benefit Plan in each of the next five years and thereafter following the December 31, 2022 balance sheet date: (In thousands of U.S. Dollars) 2023 $ 94 2024 94 2025 95 2026 87 2027 86 Thereafter 1,082 Total $ 1,538

Non-Controlling Interests (Tabl

Non-Controlling Interests (Tables)	12 Months Ended
	Dec. 31, 2022
Temporary Equity Disclosure [Abstract]
Summary of Movement of the Non-controlling Interest in Temporary Equity in Original Film Fund	The following summarizes the movement of the non-controlling interest in temporary equity, in the Original Film Fund for the years ended December 31, 2022, 2021 and 2020: (In thousands of U.S. Dollars) Balance as of January 1, 2020 $ 5,908 Return of capital to non-controlling interests ( 10 ) Net loss ( 5,139 ) Balance as of December 31, 2020 759 Net loss ( 1 ) Balance as of December 31, 2021 758 Net loss ( 36 ) Balance as of December 31, 2022 $ 722

Description of the Business - A

Description of the Business - Additional Information (Details)	Dec. 31, 2022 TheaterSystem Destination Country Institutionallocation Multiplex	Dec. 31, 2021 Institutionallocation Multiplex TheaterSystem Destination Country
Description of Business (Textuals) [Abstract]
Number of theater systems operating | TheaterSystem	1,716	1,683
Number of Countries and Territories in which Entity Operates | Country	87	87
Number of commercial multiplexes | Multiplex	1,633	1,599
Number of commercial destinations | Destination	12	12
Number of institutional locations | Institutionallocation	71	72
IMAX China Noncontrolling Interest
Description of Business (Textuals) [Abstract]
Minority Interest Ownership Percentage By Company	71.73%	71.11%

Impact of COVID-19 Pandemic - A

Impact of COVID-19 Pandemic - Additional Information (Details)	Dec. 31, 2022
Impact of COVID-19 Pandemic [Member] | IMAX [Member] | Greater China [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Percentage of global theater network open	97%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands		12 Months Ended
	Feb. 20, 2023 USD ($)	Dec. 31, 2022 USD ($) Theater Lease	Sep. 07, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Significant Accounting Policies [Line Items]
Other equity | $		$ 185,678		$ 174,620
Non-controlling interests | $		65,691		73,531
Total shareholders' equity | $		$ 329,046		$ 429,614	$ 464,008
Number of variable interest entities		ten
Period of revenue estimation from initial film release		10 years
Fixed contracted theater value | $		$ 22,900
Percentage of statutory net profits to statutory surplus reserve to be appropriated		10%
Discontinuation of contribution, Aggregate sum of statutory surplus reserve more than its registered capital, percent		50%
Lessee, operating lease, existence of option to extend term		true
Lessee, operating lease, existence of option to extend description		The Company has determined that it is reasonably certain that the renewal options on its warehouse leases will be exercised based on previous history, its current understanding of future business needs, and its level of investment in the leasehold improvements, among other factors.
Lessee, operating lease, assumptions for discount rate		The incremental borrowing rate used in the calculation of the Company’s lease liabilities is based on the location of each leased property.
Leases include options to purchase leased property | Lease		0
Lessee, operating lease, existence of residual value		false
Lessee, operating lease, sublease options		The Company rents or subleases certain office space to third parties, which have a remaining term of less than 12 months and are not expected to be renewed.
Pension policy details		10%
Remaining weighted average service life of employee		3.0 years
Unsecured pre-petition claims related to receivable from bankruptcy entities | $			$ 11,400
CineworldGroupPlc | Trade Agreement [Member] | Subsequent Event
Significant Accounting Policies [Line Items]
Proceeds from receivables | $	$ 7,200
Russia [Member]
Significant Accounting Policies [Line Items]
Number of backlog theaters | Theater		14
Number of theaters | Theater		54
Ukraine [Member]
Significant Accounting Policies [Line Items]
Number of backlog theaters | Theater		1
Number of theaters | Theater		8
Belarus [Member]
Significant Accounting Policies [Line Items]
Number of backlog theaters | Theater		5
Number of theaters | Theater		1
Performance Share Units [Member]
Significant Accounting Policies [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period		3 years
Minimum [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Useful Life		4 years
Lessee, operating lease, renewal term		1 year
Minimum [Member] | Performance Share Units [Member]
Significant Accounting Policies [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage		0%
Maximum [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Useful Life		20 years
Lessee, operating lease, renewal term		5 years
Maximum [Member] | Performance Share Units [Member]
Significant Accounting Policies [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage		175%
Variable Interest Entity, Primary Beneficiary [Member]
Significant Accounting Policies [Line Items]
Number of variable interest entities primary beneficiary		five
Variable Interest Entity, Not Primary Beneficiary [Member]
Significant Accounting Policies [Line Items]
Number of variable interest entities not a primary beneficiary		five

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - VIEs Total Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Variable Interest Entity [Line Items]
Variable Interest Entity, Consolidated, Carrying Amount, Total Assets	$ 821,154	$ 883,247
Variable Interest Entity, Consolidated, Carrying Amount, Total Liabilities	491,386	452,875
Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Variable Interest Entity, Consolidated, Carrying Amount, Total Assets	1,523	1,576
Variable Interest Entity, Consolidated, Carrying Amount, Total Liabilities	$ 248	$ 259

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2022
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property, Plant And Equipment, Useful Life, Maximum	Over the shorter of the initial term of the underlying lease plus any reasonably assured renewal
Minimum [Member] | Theater System Components [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years	[1]
Minimum [Member] | Camera Equipment [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Minimum [Member] | Buildings [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Useful Life	20 years
Minimum [Member] | Office and Production Equipment [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member] | Theater System Components [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Useful Life	20 years	[1]
Maximum [Member] | Camera Equipment [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Maximum [Member] | Buildings [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Useful Life	25 years
Maximum [Member] | Office and Production Equipment [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
[1] Includes equipment under joint revenue sharing arrangements.

New Accounting Standards and _2

New Accounting Standards and Accounting Changes - Additional Information (Details)	Dec. 31, 2022
ASU 2021-05
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 01, 2022
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	true
ASU 2021-08
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jul. 01, 2022
Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false]	true
ASU 2021-10
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 01, 2022

Acquisition - Additional Inform

Acquisition - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended	12 Months Ended
	Sep. 22, 2022	Dec. 31, 2022	Dec. 31, 2022
Business Acquisition [Line Items]
Cash payments			$ 15,939
Professional fees			1,100
Purchase price allocation from goodwill		$ 11,200	11,200
SSIMWAVE Inc. [Member]
Business Acquisition [Line Items]
Business acquisition, date of acquisition agreement	Sep. 22, 2022
Total Purchase Price	$ 23,218
Cash payments	$ 19,521
Number of common shares issued	160,547
Business combination common shares with fair value	$ 1,947
Contingent consideration fair value	1,750
Business combination maximum amount of possible earn out payment paid to sellers in aggregate amount	2,000
Purchase price allocation from goodwill	11,189	11,200	11,200
Deferred tax liability	$ 2,037	2,000	$ 2,000
Additional payment to former shareholders		$ 100

Acquisition - Schedule of Subje

Acquisition - Schedule of Subject to Revision Upon Completion of Valuation Procedures (Details) - USD ($) $ in Thousands		12 Months Ended
	Sep. 22, 2022	Dec. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Cash payments		$ 15,939
Intangible assets		11,200
Goodwill		52,815	$ 39,027
SSIMWAVE Inc. [Member]
Business Acquisition [Line Items]
Cash payments	$ 19,521
IMAX Share Consideration	1,947
Earn-Out Payment	1,750
Total Purchase Price	23,218
Cash and cash equivalents	3,582
Accounts receivable	158
Property, plant and equipment	409
Intangible assets	11,189	11,200
Other assets	293
Accounts payable and accrued liabilities	(1,092)
Deferred revenue	(1,300)
Federal economic development loan, net of unaccreted interest benefit	(1,772)
Deferred tax liability	(2,037)	(2,000)
Goodwill	13,788	$ 13,800
Total Purchase Price	$ 23,218

Acquisition - Schedule of Alloc

Acquisition - Schedule of Allocation of Fair Value of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands		12 Months Ended
	Sep. 22, 2022	Dec. 31, 2022
Business Acquisition [Line Items]
Total identifiable intangible assets, Fair Value		$ 11,200
SSIMWAVE Inc. [Member]
Business Acquisition [Line Items]
Total identifiable intangible assets, Fair Value	$ 11,189	$ 11,200
SSIMWAVE Inc. [Member] | In-process Research and Development [Member]
Business Acquisition [Line Items]
Indefinite lived intangible assets, Fair Value	3,810
Acquired Indefinite Lived Intangible Assets Weighted Average Useful Life		Not yet in use
SSIMWAVE Inc. [Member] | Patent and Trademarks [Member]
Business Acquisition [Line Items]
Finite lived intangible assets, Fair Value	$ 100
Finite lived intangible assets, Weighted Average Useful Life	2 years
SSIMWAVE Inc. [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Finite lived intangible assets, Fair Value	$ 1,340
Finite lived intangible assets, Weighted Average Useful Life	7 years
SSIMWAVE Inc. [Member] | Developed Technology [Member]
Business Acquisition [Line Items]
Finite lived intangible assets, Fair Value	$ 5,779
SSIMWAVE Inc. [Member] | Developed Technology [Member] | Minimum [Member]
Business Acquisition [Line Items]
Finite lived intangible assets, Weighted Average Useful Life	4 years
SSIMWAVE Inc. [Member] | Developed Technology [Member] | Maximum [Member]
Business Acquisition [Line Items]
Finite lived intangible assets, Weighted Average Useful Life	7 years
SSIMWAVE Inc. [Member] | Non-compete Agreement [Member]
Business Acquisition [Line Items]
Finite lived intangible assets, Fair Value	$ 160
Finite lived intangible assets, Weighted Average Useful Life	4 years

Receivables - Summary of Allowa

Receivables - Summary of Allowance For Credit Losses Related to Accounts Receivable (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	$ 11,946	$ 14,295
Current period provision (reversal), net	3,144	(1,452)
Write-offs	(565)	(927)
Foreign exchange	(406)	30
Ending balance	14,119	11,946
Theatre Operators [Member]
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	8,867	8,368
Current period provision (reversal), net	2,687	793
Write-offs	(43)	(357)
Foreign exchange	(367)	63
Ending balance	11,144	8,867
Studios [Member]
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	1,994	4,481
Current period provision (reversal), net	(128)	(1,913)
Write-offs	(128)	(551)
Foreign exchange	(39)	(23)
Ending balance	1,699	1,994
Other [Member]
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	1,085	1,446
Current period provision (reversal), net	585	(332)
Write-offs	(394)	(19)
Foreign exchange		(10)
Ending balance	$ 1,276	$ 1,085

Receivables - Additional Inform

Receivables - Additional Information (Details) - USD ($)		12 Months Ended
	Feb. 20, 2023	Dec. 31, 2022	Dec. 31, 2021	Sep. 07, 2022
Current Expected Credit Losses [Line Items]
Unsecured pre-petition claims related to receivable from bankruptcy entities				$ 11,400,000
Finance income related to net investment in leases with billed amounts past due		$ 100,000	$ 100,000
Finance Income related to the net investment in leases in nonaccrual status		0	0
Finance income related to financed sale receivables with billed amounts past due		3,600,000	3,700,000
Finance Income related to the financed sales receivables in nonaccrual status		500,000	200,000
Theatre And Foreign Movie Studio [Member]
Current Expected Credit Losses [Line Items]
Increase (decrease) in allowance for current expected credit losses, accounts receivables		2,200,000	(2,300,000)
Additional reserve allowances		1,500,000
Theatre Operators [Member]
Current Expected Credit Losses [Line Items]
Increase (decrease) in allowance for current expected credit losses, variable consideration receivables		500,000	800,000
Theatre Operators [Member] | Variable Consideration Receivables [Member]
Current Expected Credit Losses [Line Items]
Increase (decrease) investment in leases and financed sale receivables provision for current expected credit losses		$ 5,500,000	$ 1,600,000
Trade Agreement [Member] | Cineworld Group Plc [Member] | Subsequent Event
Current Expected Credit Losses [Line Items]
Proceeds from receivables	$ 7,200,000

Receivables - Schedule of Finan

Receivables - Schedule of Financing Receivables (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Net investment in leases
Gross minimum payments due under sales-type leases	$ 29,727	$ 29,953
Unearned finance income	(619)	(763)
Present value of minimum payments due under sales-type leases	29,108	29,190
Allowance for credit losses	(776)	(798)
Net investment in leases	28,332	28,392
Financed sales receivables
Gross minimum payments due under financed sales	141,337	152,315
Unearned finance income	(29,340)	(34,244)
Present value of minimum payments due under financed sales	111,997	118,071
Allowance for credit losses	(10,945)	(5,414)
Net financed sales receivables	101,052	112,657
Total financing receivables	129,384	141,049
Net financed sales receivables due within one year	32,366	29,115
Net financed sales receivables due after one year	68,686	83,542
Net financed sales receivables	$ 101,052	$ 112,657

Receivables - Schedule of Weigh

Receivables - Schedule of Weighted-average Remaining Lease Term and Weighted-average Interest Rate (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Weighted-average remaining lease term (in years)
Sales-type lease arrangements	9 years	9 years 7 months 6 days
Weighted-average interest rate
Sales-type lease arrangements	8.23%	6.56%
Financed sales receivables	8.79%	8.79%

Receivables - Schedule of Net I

Receivables - Schedule of Net Investment In Leases by Credit Quality Indicator (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Net Investment In Lease Credit Quality Indicator [Line Items]
Net investment leases, By Origination Year, Current fiscal year	$ 4,148	$ 11,030
Net investment leases, By Origination Year, Before latest fiscal year	10,058	3,991
Net investment leases, By Origination Year, Two years before latest fiscal year	3,656	7,973
Net investment leases, By Origination Year, Three years before latest fiscal year	7,378	2,574
Net investment leases, By Origination Year, Four years before latest fiscal year	2,451	823
Net investment leases, By Origination Year, Prior	1,417	2,799
Net Investment in Lease, Total	29,108	29,190
In Good Standing [Member]
Net Investment In Lease Credit Quality Indicator [Line Items]
Net investment leases, By Origination Year, Current fiscal year	4,148	11,030
Net investment leases, By Origination Year, Before latest fiscal year	6,969	3,991
Net investment leases, By Origination Year, Two years before latest fiscal year	2,494	7,973
Net investment leases, By Origination Year, Three years before latest fiscal year	1,977	2,574
Net investment leases, By Origination Year, Four years before latest fiscal year		823
Net investment leases, By Origination Year, Prior	1,016	1,928
Net Investment in Lease, Total	16,604	28,319
Pre-Approved Transactions [Member]
Net Investment In Lease Credit Quality Indicator [Line Items]
Net investment leases, By Origination Year, Before latest fiscal year	3,089
Net investment leases, By Origination Year, Two years before latest fiscal year	1,162
Net investment leases, By Origination Year, Three years before latest fiscal year	5,401
Net investment leases, By Origination Year, Four years before latest fiscal year	2,451
Net Investment in Lease, Total	12,103
Transactions Suspended [Member]
Net Investment In Lease Credit Quality Indicator [Line Items]
Net investment leases, By Origination Year, Prior	401	871
Net Investment in Lease, Total	$ 401	$ 871

Receivables - Schedule of Fin_2

Receivables - Schedule of Financed Sale Receivables by Credit Quality Indicator (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Current fiscal year	$ 10,524	$ 12,520
Financed sales receivables, By Origination Year, Before lastest fiscal year	11,625	8,251
Financed sales receivables, By Origination Year, Two year before latest fiscal year	7,821	11,671
Financed sales receivables, By Origination Year, Three year before latest fiscal year	10,944	13,696
Financed sales receivables, By Origination Year, Four year before latest fiscal year	12,500	15,714
Financed sales receivables, By Origination Year, Prior	58,583	56,219
Financed sales receivables, Total	141,105	147,261
Financing Receivable [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, Total	111,997	118,071
In Good Standing [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Current fiscal year	10,252	12,520
Financed sales receivables, By Origination Year, Before lastest fiscal year	8,643	8,251
Financed sales receivables, By Origination Year, Two year before latest fiscal year	6,280	10,593
Financed sales receivables, By Origination Year, Three year before latest fiscal year	8,541	13,278
Financed sales receivables, By Origination Year, Four year before latest fiscal year	9,854	12,615
Financed sales receivables, By Origination Year, Prior	39,912	47,950
In Good Standing [Member] | Financing Receivable [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, Total	83,482	105,207
Credit Watch [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Four year before latest fiscal year		321
Financed sales receivables, By Origination Year, Prior	1,152	1,292
Credit Watch [Member] | Financing Receivable [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, Total	1,152	1,613
Pre-Approved Transactions [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Before lastest fiscal year	2,318
Financed sales receivables, By Origination Year, Two year before latest fiscal year	1,399	743
Financed sales receivables, By Origination Year, Three year before latest fiscal year	1,134	418
Financed sales receivables, By Origination Year, Four year before latest fiscal year	1,449	2,098
Financed sales receivables, By Origination Year, Prior	9,243	3,650
Pre-Approved Transactions [Member] | Financing Receivable [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, Total	15,543	6,909
Transactions Suspended [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Current fiscal year	272
Financed sales receivables, By Origination Year, Before lastest fiscal year	664
Financed sales receivables, By Origination Year, Two year before latest fiscal year	142	335
Financed sales receivables, By Origination Year, Three year before latest fiscal year	1,269
Financed sales receivables, By Origination Year, Four year before latest fiscal year	1,197	680
Financed sales receivables, By Origination Year, Prior	8,276	3,327
Transactions Suspended [Member] | Financing Receivable [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, Total	$ 11,820	$ 4,342

Receivables - Schedule of Aging

Receivables - Schedule of Aging Analysis for Net Investment in Leases and Financed Sale Receivables (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	$ 19,415	$ 12,765
Unbilled	121,690	134,496
Financed sales receivables, Total	141,105	147,261
Allowance for Credit Losses	(11,721)	(6,212)
Total financing receivables	129,384	141,049
Net Investment in Leases [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	3,046	1,648
Unbilled	26,062	27,542
Financed sales receivables, Total	29,108	29,190
Allowance for Credit Losses	(776)	(798)	$ (557)
Total financing receivables	28,332	28,392
Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	16,369	11,117
Unbilled	95,628	106,954
Financed sales receivables, Total	111,997	118,071
Allowance for Credit Losses	(10,945)	(5,414)	$ (7,274)
Total financing receivables	101,052	112,657
Accrued and Current [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	2,506	1,975
Accrued and Current [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	237	225
Accrued and Current [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	2,269	1,750
30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	1,523	1,145
30 to 89 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	216	156
30 to 89 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	1,307	989
Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	15,386	9,645
Equal To Greater Than 90 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	2,593	1,267
Equal To Greater Than 90 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	$ 12,793	$ 8,378

Receivables - Schedule of Net_2

Receivables - Schedule of Net Investment in Leases and Financed Sale Receivables with Billed Amounts Past Due Continues to Accrue Finance Income (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	$ 19,415	$ 12,765
Unbilled	121,690	134,496
Allowance for Credit Losses	(11,721)	(6,212)
Total financing receivables	129,384	141,049
Accrued and Current [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	2,506	1,975
30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,523	1,145
Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	15,386	9,645
Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	3,046	1,648
Unbilled	26,062	27,542
Allowance for Credit Losses	(776)	(798)	$ (557)
Total financing receivables	28,332	28,392
Net Investment in Leases [Member] | Accrued and Current [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	237	225
Net Investment in Leases [Member] | 30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	216	156
Net Investment in Leases [Member] | Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	2,593	1,267
Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	16,369	11,117
Unbilled	95,628	106,954
Allowance for Credit Losses	(10,945)	(5,414)	$ (7,274)
Total financing receivables	101,052	112,657
Net Financed Sales Receivables [Member] | Accrued and Current [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	2,269	1,750
Net Financed Sales Receivables [Member] | 30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,307	989
Net Financed Sales Receivables [Member] | Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	12,793	8,378
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	16,443	8,978
Unbilled	60,242	54,058
Allowance for Credit Losses	(1,817)	(1,589)
Total financing receivables	74,868	61,447
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Accrued and Current [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,740	1,102
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | 30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,296	861
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	13,407	7,015
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	2,964	1,100
Unbilled	17,070	12,619
Allowance for Credit Losses	(230)	(176)
Total financing receivables	19,804	13,543
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Investment in Leases [Member] | Accrued and Current [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	190	143
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Investment in Leases [Member] | 30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	181	132
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Investment in Leases [Member] | Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	2,593	825
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	13,479	7,878
Unbilled	43,172	41,439
Allowance for Credit Losses	(1,587)	(1,413)
Total financing receivables	55,064	47,904
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Financed Sales Receivables [Member] | Accrued and Current [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,550	959
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Financed Sales Receivables [Member] | 30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,115	729
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Financed Sales Receivables [Member] | Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	$ 10,814	$ 6,190

Receivables - Schedule of Net_3

Receivables - Schedule of Net Investment in Leases and Financed Sale Receivables on Nonaccrual Status (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Financing Receivable Nonaccrual Status [Line Items]
Recorded Receivable	$ 27,765	$ 9,513
Allowance for Credit Losses	(9,990)	(2,666)
Net	17,775	6,847
Net Investment in Leases [Member]
Financing Receivable Nonaccrual Status [Line Items]
Recorded Receivable	401	871
Allowance for Credit Losses	(401)	(309)
Net		562
Net Financed Sales Receivables [Member]
Financing Receivable Nonaccrual Status [Line Items]
Recorded Receivable	27,364	8,642
Allowance for Credit Losses	(9,589)	(2,357)
Net	$ 17,775	$ 6,285

Receivables - Summary of Allo_2

Receivables - Summary of Allowance for Credit Losses Related to Net Investment in Leases and Financed Sale Receivables (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Financing Receivable Allowance For Credit Losses [Line Items]
Beginning balance	$ 6,212
Ending balance	11,721	$ 6,212
Net Investment in Leases [Member]
Financing Receivable Allowance For Credit Losses [Line Items]
Beginning balance	798	557
Current period provision (reversal), net	5	235
Foreign exchange	(27)	6
Ending balance	776	798
Net Financed Sales Receivables [Member]
Financing Receivable Allowance For Credit Losses [Line Items]
Beginning balance	5,414	7,274
Current period provision (reversal), net	5,783	(1,947)
Foreign exchange	(252)	87
Ending balance	$ 10,945	$ 5,414

Receivables - Summary of Allo_3

Receivables - Summary of Allowance For Credit Losses Related to Variable Consideration Receivables (Details) - Theatre Operators [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	$ 1,082	$ 1,887
Current period reversal, net	(440)	(787)
Foreign Exchange	(32)	(18)
Ending balance	$ 610	$ 1,082

Lease Arrangements - Additional

Lease Arrangements - Additional Information (Details)	12 Months Ended
	Dec. 31, 2022 Lease
Leases [Line Items]
Lessee, operating lease description	The Company’s operating lease arrangements principally involve office and warehouse space. Office equipment is generally purchased outright. Leases with an initial term of less than 12 months are not recorded on the Consolidated Balance Sheets and the related lease expense is recognized on a straight-line basis over the lease term.
Lessee, operating lease, existence of option to extend term	true
Lessee, operating lease, existence of option to extend description	The Company has determined that it is reasonably certain that the renewal options on its warehouse leases will be exercised based on previous history, its current understanding of future business needs, and its level of investment in the leasehold improvements, among other factors.
Lessee, operating lease, assumptions for discount rate	The incremental borrowing rate used in the calculation of the Company’s lease liabilities is based on the location of each leased property.
Leases include options to purchase leased property	0
Lessee, operating lease, existence of residual value	false
Lessee, operating lease, sublease options	The Company rents or subleases certain office space to third parties, which have a remaining term of less than 12 months and are not expected to be renewed.
Lessor, sales-type lease description	The Company provides IMAX Systems to customers through long-term lease arrangements that for accounting purposes are classified as sales-type leases. Under these arrangements, in exchange for providing the IMAX System, the Company earns fixed upfront and ongoing consideration. Certain arrangements that are legal sales are also classified as sales-type leases as certain clauses within the arrangements limit transfer of title or provide the Company with conditional rights to the system.
Minimum [Member]
Leases [Line Items]
Lessee, operating lease, renewal term	1 year
Sales-type lease, lease term	10 years
Non-cancellable term of joint revenue sharing arrangements	10 years
Maximum [Member]
Leases [Line Items]
Lessee, operating lease, renewal term	5 years
Sales-type lease, lease term	20 years
Non-cancellable term of joint revenue sharing arrangements	or longer

Lease Arrangements - Components

Lease Arrangements - Components of Operating Lease Expense (Details) - Selling, General and Administrative Expenses [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Line Items]
Amortization of operating lease assets	$ 2,734	$ 2,791	$ 3,114
Interest on operating lease liabilities	825	937	1,052
Short-term and variable lease costs	616	713	540
Amortization of finance lease assets	171
Interest on finance lease liabilities	22
Total lease cost	$ 4,368	$ 4,441	$ 4,706

Lease Arrangements - Supplement

Lease Arrangements - Supplemental Cash and Non-Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating leases	$ 3,783	$ 3,839	$ 3,743
Finance leases	948
Supplemental Disclosure of Noncash Leasing Activities [Abstract]
Right-of-use assets obtained in exchange for operating lease obligations	3,068	$ 1,047	$ 563
Right-of-use assets obtained in exchange for finance lease obligations	$ 1,990

Lease Arrangements - Lessee Ope

Lease Arrangements - Lessee Operating Lease Balance Sheet Amounts and Lines (Details) - USD ($) $ in Thousands		Dec. 31, 2022	Dec. 31, 2021
Leases [Line Items]
Operating lease right-of-use assets		$ 12,341	$ 12,132
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]		Property, plant and equipment, net of accumulated depreciation	Property, plant and equipment, net of accumulated depreciation
Finance lease right-of-use assets		$ 1,876
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]		Property, Plant and Equipment, Net
Operating lease liabilities		$ 14,641	$ 14,691
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]		Accrued Liabilities and Other Liabilities	Accrued Liabilities and Other Liabilities
Finance lease liabilities	[1]	$ 1,011
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]		Accrued Liabilities and Other Liabilities
[1] Recorded net of a $ 0.9 million upfront payment made upon execution of the finance lease arrangement.

Lease Arrangements - Lessee O_2

Lease Arrangements - Lessee Operating Lease Balance Sheet Amounts and Lines (Parenthetical) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Leases [Abstract]
Upfront payment made upon execution of finance lease	$ 0.9

Lease Arrangements - Lessee Lea

Lease Arrangements - Lessee Leases Weighted Average Remaining Lease Term and Weighted Average Interest Rate (Details)	Dec. 31, 2022	Dec. 31, 2021
Operating Leases [Abstract]
Weighted-average remaining lease term (years)	6 years	7 years
Weighted-average discount rate	5.90%	5.97%
Finance Leases [Abstract]
Weighted-average remaining lease term (years)	4 years 8 months 12 days
Weighted-average discount rate	6%

Lease Arrangements - Lessee O_3

Lease Arrangements - Lessee Operating and Finance Lease, Maturity (Details) - USD ($) $ in Thousands		Dec. 31, 2022	Dec. 31, 2021
Lessee, Operating Lease, Liability, to be Paid [Abstract]
2023		$ 3,639
2024		3,017
2025		2,429
2026		2,069
2027		2,094
Thereafter		4,171
Total lease payments		17,419
Less: interest expense		(2,778)
Present value of lease liabilities		$ 14,641	$ 14,691
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]		Accrued and other liabilities	Accrued and other liabilities
Finance Lease, Liability, to be Paid [Abstract]
2023		$ 508
2024		508
Total lease payments		1,016
Less: interest expense		(5)
Present value of lease liabilities	[1]	$ 1,011
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]		Accrued Liabilities and Other Liabilities
[1] Recorded net of a $ 0.9 million upfront payment made upon execution of the finance lease arrangement.

Lease Arrangements - Schedule o

Lease Arrangements - Schedule of Maturities of Lease Receivables (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Sales-type leases
2023	$ 3,245
2024	3,158
2025	3,038
2026	2,823
2027	2,760
Thereafter	14,702
Total	29,726
Joint Revenue Sharing Arrangements
2023	172
2024	69
2025	27
Total	$ 268

Variable Consideration Receivab

Variable Consideration Receivable from Contracts With Customers - Summary of Variable Consideration Receivable from Contracts With Customers (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Change in Contract with Customer, Asset [Abstract]
Balance Beginning	$ 44,218	$ 40,526	$ 40,040
Variable consideration for newly recognized sales	7,109	4,696	5,550
Accretion to finance income	1,846	1,985	2,133
Transferred to receivables from variable consideration assets	(9,621)	(3,794)	(5,310)
Movement in allowance for credit losses	472	805	(1,887)
Balance Ending	$ 44,024	$ 44,218	$ 40,526

Inventories - Inventories (Deta

Inventories - Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Inventories
Raw materials	$ 25,365	$ 20,551
Work-in-process	2,034	1,406
Finished goods	4,135	4,967
Total	$ 31,534	$ 26,924

Inventories - Additional Inform

Inventories - Additional Information (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Inventories (Textuals) [Abstract]
Finished goods inventory with title passed to customer	$ 3.5	$ 2.6

Inventories - Summary of Invent

Inventories - Summary of Inventory Valuation Allowance Account (Details) - Inventory Valuation Allowance [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Inventory [Line Items]
Balance at beginning of year	$ 4,897	$ 5,752		$ 3,216
Additions charged to expenses	919	629	[1]	3,028	[1]
Other deductions	(77)	(1,484)	[2]	(492)	[2]
Balance at end of year	$ 5,739	$ 4,897		$ 5,752
[1] Excludes a recovery of $ 0.2 million charged directly to the Consolidated Statements of Operations during the year ended December 31, 2022 (2021 and 2020 — expenses of $ 0.3 million , and $ 0.6 million , respectively). Includes the write-off of amounts previously charged to valuation allowance.

Inventories - Summary of Inve_2

Inventories - Summary of Inventory Valuation Allowance Account (Parenthetical) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Inventory [Abstract]
Inventory expenses (recovery) charged to statement of operation	$ (0.2)	$ 0.3	$ 0.6

Film Assets - Film Assets (Deta

Film Assets - Film Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Film, Capitalized Cost [Abstract]
Completed and released films, net of accumulated amortization of $218,148 (2020 - $202,832)	$ 1,227	$ 2,292
Films in production	1,667	195
Films in development	2,383	1,754
Film Costs, Total	$ 5,277	$ 4,241

Film Assets - Film Assets (Pare

Film Assets - Film Assets (Parenthetical) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Film, Capitalized Cost [Abstract]
Accumulated amortization	$ 235,029	$ 218,148

Film Assets - Additional Inform

Film Assets - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Film Assets [Line Items]
Film costs expected to be amortized within three years from balance sheet date				$ 5.2
Amount of participation payments expected to be made to third parties in the next operating cycle				3.8	$ 3.3
Documentary film asset impairments				$ 0.8	$ 0.2	$ 10.8
Forecast [Member]
Film Assets [Line Items]
Film costs, amortized in next operating cycle	$ 0.1	$ 0.2	$ 4.9

Property, Plant and Equipment -

Property, Plant and Equipment - Property, Plant and Equipment (Details) - USD ($) $ in Thousands		Dec. 31, 2022	Dec. 31, 2021
Property, plant and equipment
Cost		$ 519,251	$ 512,336
Accumulated Depreciation		266,355	251,983
Net Book Value		252,896	260,353
System Components [Member]
Property, plant and equipment
Cost	[1],[2],[3]	345,960	346,517
Accumulated Depreciation	[1],[2],[3]	194,444	181,936
Net Book Value	[1],[2],[3]	151,516	164,581
Camera Equipment [Member]
Property, plant and equipment
Cost		8,597	4,855
Accumulated Depreciation		3,859	3,214
Net Book Value		4,738	1,641
Equipment leased or held for use [Member]
Property, plant and equipment
Cost		354,557	351,372
Accumulated Depreciation		198,303	185,150
Net Book Value		156,254	166,222
Asset under Construction [Member]
Property, plant and equipment
Cost	[4]	14,379	10,232
Accumulated Depreciation	[4]	0	0
Net Book Value	[4]	14,379	10,232
Right Of Use Assets
Property, plant and equipment
Cost	[5]	14,615	14,429
Accumulated Depreciation	[5]	398	2,297
Net Book Value	[5]	14,217	12,132
Land [Member]
Property, plant and equipment
Cost		8,203	8,203
Accumulated Depreciation		0	0
Net Book Value		8,203	8,203
Buildings [Member]
Property, plant and equipment
Cost		81,053	80,973
Accumulated Depreciation		31,519	28,873
Net Book Value		49,534	52,100
Office and Production Equipment [Member]
Property, plant and equipment
Cost	[6]	38,485	39,017
Accumulated Depreciation	[6]	31,360	31,169
Net Book Value	[6]	7,125	7,848
Leasehold Improvements [Member]
Property, plant and equipment
Cost		7,959	8,110
Accumulated Depreciation		4,775	4,494
Net Book Value		3,184	3,616
Other property, plant and equipment [Member]
Property, plant and equipment
Cost		135,700	136,303
Accumulated Depreciation		67,654	64,536
Net Book Value		$ 68,046	$ 71,767
[1] In 2022, the Company recorded charges of $ 1.0 million (2021 — $ 0.4 million ; 2020 — $ 1.8 million) in Costs and Expenses Applicable to Technology Rentals mostly related to the write-down of leased xenon-based digital systems which were taken out of service in connection with customer upgrades to laser-based digital systems, as well as an IMAX System that was removed from its existing location. Included in system components are assets with costs of $ 323.7 million (2021 — $ 324.3 million ) and accumulated depreciation of $ 177.9 million (2021 — $ 166.5 million ) that are used in joint revenue sharing arrangements. Included in system components are assets with costs of $ 7.6 million (2021 — $ 7.6 million ) and accumulated depreciation of $ 7.2 million (2021 — $ 7.0 million ) that are leased to customers under operating leases. Included in assets under construction are components with costs of $ 9.1 million (2021 — $ 9.2 million ) that will be utilized to construct assets to be used in joint revenue sharing arrangements. The right-of-use assets primarily include operating leases for office and warehouse space. Fully depreciated office and production equipment is still in use by the Company. In 2022, the Company identified and wrote off $ 3.5 million (2021 — $ 0.5 million ) of office and production equipment that is fully depreciated and no longer in use.

Property, Plant and Equipment_2

Property, Plant and Equipment - Property, Plant and Equipment (Parenthetical) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
System Components [Member]
Property, plant and equipment
Assets leased to customers under operating lease, Gross	$ 7.6	$ 7.6
Accumulated Depreciation, assets leased to customers under operating lease	7.2	7
Assets under joint revenue sharing arrangements included in Theater system components	323.7	324.3
Accumulated Depreciation , Assets under joint revenue sharing arrangements included in Theater system components	177.9	166.5
Theater system components written off in Costs and expenses	1	0.4	$ 1.8
Asset under Construction [Member]
Property, plant and equipment
Assets under joint revenue sharing arrangements included in Assets under construction	9.1	9.2
Office and Production Equipment [Member]
Property, plant and equipment
Fully amortized office and production equipment written off in the period	$ 3.5	$ 0.5

Property, Plant and Equipment_3

Property, Plant and Equipment - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Other property, plant and equipment [Member]
Property Plant And Equipment [Line Items]
Property plant and equipment write downs no longer in use	$ 0.1	$ 0.2	$ 0.2

Other Assets - Schedule of Othe

Other Assets - Schedule of Other Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Other Assets [Abstract]
Lease incentives provided to exhibitor customers, net of accumulated amortization	$ 12,975	$ 14,834
Commissions and other deferred selling expenses	1,336	1,418
Other investments	1,000	1,000
Foreign currency derivatives	50	184
Other	304	363
Other assets, total	$ 15,665	$ 17,799

Income Taxes - Schedule of (Los

Income Taxes - Schedule of (Loss) Income Before Taxes by Jurisdiction (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Taxes Disclosure [Line Items]
(Loss) income before taxes	$ (9,769)	$ 10,987	$ (129,124)
Canada [Member]
Income Taxes Disclosure [Line Items]
(Loss) income before taxes	(55,623)	(55,480)	(104,166)
United States [Member]
Income Taxes Disclosure [Line Items]
(Loss) income before taxes	4,281	3,218	(6,437)
China [Member]
Income Taxes Disclosure [Line Items]
(Loss) income before taxes	11,466	53,792	(8,253)
Ireland [Member]
Income Taxes Disclosure [Line Items]
(Loss) income before taxes	24,070	829	(7,473)
Other [Member]
Income Taxes Disclosure [Line Items]
(Loss) income before taxes	$ 6,037	$ 8,628	$ (2,795)

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax (Expense) Benefit (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Taxes Disclosure [Line Items]
Current income tax (expense) benefit, Total		$ (12,181)	$ (17,568)	$ (2,886)
Deferred income tax (expense) benefit, Total		2,073	(2,996)	(23,618)
Total	[1]	(10,108)	(20,564)	(26,504)
Canada [Member]
Income Taxes Disclosure [Line Items]
Current income tax (expense) benefit, Total		(1,149)	(915)	555
Deferred income tax (expense) benefit, Total	[2]	943	(231)	(10,801)
United States [Member]
Income Taxes Disclosure [Line Items]
Current income tax (expense) benefit, Total		(274)	(1,038)	488
Deferred income tax (expense) benefit, Total		(131)	(1,268)	867
China [Member]
Income Taxes Disclosure [Line Items]
Current income tax (expense) benefit, Total		(4,437)	(11,045)	(1,980)
Deferred income tax (expense) benefit, Total	[3]	2,763	(381)	(15,756)
Ireland [Member]
Income Taxes Disclosure [Line Items]
Current income tax (expense) benefit, Total		(2,802)	(1,358)	(1,462)
Deferred income tax (expense) benefit, Total		(1,562)	(997)	2,161
Other [Member]
Income Taxes Disclosure [Line Items]
Current income tax (expense) benefit, Total		(3,519)	(3,212)	(487)
Deferred income tax (expense) benefit, Total		$ 60	$ (119)	$ (89)
[1] For the year ended December 31, 2022 , Income Tax (Expense) Benefit excludes a tax expense of $ 0.8 million included in Other Comprehensive (Loss) Income ( 2021 — benefit of $ 0.3 million; 2020 — benefit of $ 0.1 million ). A valuation allowance is recorded in jurisdictions where management has determined, based on the weight of all available evidence, both positive and negative, that a valuation allowance for deferred tax assets is required. For the year ended December 31, 2022, the Company recorded a $ 16.9 million valuation allowance against its deferred tax assets in Canada and China primarily as a result of uncertainties related to the long-term impact of the COVID-19 pandemic (2021 — $ 17.2 million ). The $ 16.9 million increase in the valuation allowance recorded in 2022 is reflected within Income Tax Expense in the Company’s Consolidated Statements of Operations. he Company's deferred tax liability of $ 17.6 million as of December 31, 2021 was for the estimated applicable foreign withholding taxes associated with historical earnings that were not indefinitely reinvested, which will become payable upon the repatriation of any such earnings. During the year ended December 31, 2022, $ 27.4 million of historical earnings from a subsidiary in China were distributed and, as a result, $ 2.7 million of foreign withholding taxes were paid to the relevant tax authorities. The remaining deferred tax liability on the Company’s Consolidated Balance Sheets as of December 31, 2022 is $ 14.9 million .

Income Taxes - Schedule of In_2

Income Taxes - Schedule of Income Tax (Expense) Benefit (Parenthetical) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Taxes Disclosure [Line Items]
Deferred tax asset, valuation allowance	$ 62,864	$ 46,014
Deferred income tax asset, valuation allowance change	16,900	17,200
Deferred tax liability	14,900	17,642
Deferred income tax (benefit) expense	(2,073)	2,996	$ 23,618
Payment of foreign withholding taxes	2,700	2,000
Other comprehensive (loss) income, income tax effect	818	(286)	(55)
Canada [Member]
Income Taxes Disclosure [Line Items]
Deferred tax asset, valuation allowance	16,900	17,200
China [Member]
Income Taxes Disclosure [Line Items]
Deferred tax asset, valuation allowance	16,900	17,200
Foreign Country [Member]
Income Taxes Disclosure [Line Items]
Deferred income tax (benefit) expense	131	1,268	$ (867)
Foreign Country [Member] | China [Member]
Income Taxes Disclosure [Line Items]
Deferred income tax (benefit) expense	27,400
Shareholder's Equity [Member]
Income Taxes Disclosure [Line Items]
Deferred income tax asset, valuation allowance change		2,500
Income Tax Expense [Member]
Income Taxes Disclosure [Line Items]
Deferred income tax asset, valuation allowance change	$ 16,900	$ 14,700

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Income Tax Expense to Statutory Rates (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income tax (expense) benefit at combined statutory rates, Amount	$ 2,596	$ (2,912)	$ 34,218
NCI share of partnership losses, Amount		(1)	(1,229)
Increase in valuation allowance, Amount	(16,848)	(14,722)	(28,589)
Changes to tax reserves, Amount	1,643	3,508	(2,699)
U.S. federal and state taxes, Amount	(86)	(80)	(250)
Withholding taxes, Amount	(3,825)	(4,199)	(20,943)
Income tax at different rates in foreign and other provincial jurisdictions, Amount	3,872	3,352	(2,607)
Investment and other tax credits (non-refundable), Amount	752	413	643
Changes to deferred tax assets and liabilities resulting from audit and other tax return adjustments, Amount	2,278	(5,336)	(1,219)
Other non-deductible/non-taxable items, Amount	(490)	(587)	(3,829)
Income tax expense	$ (10,108)	$ (20,564)	$ (26,504)
Income tax (expense) benefit at combined statutory rates, Rate	26.50%	26.50%	26.50%
Non-controlling interests share of partnership losses, Rate	0%	0%	(1.00%)
Increase in valuation allowance, Rate	(172.50%)	134%	(22.10%)
Changes to tax reserves, Rate	16.80%	(31.90%)	(2.10%)
U.S. federal and state taxes, Rate	(0.90%)	0.70%	(0.20%)
Withholding taxes, Rate	(39.20%)	38.20%	(16.20%)
Income tax at different rates in foreign and other provincial jurisdictions, Rate	39.60%	(30.50%)	(2.00%)
Investment and other tax credits (non-refundable), Rate	7.70%	(3.80%)	0.50%
Changes to deferred tax assets and liabilities resulting from audit and other tax return adjustments, Rate	23.30%	48.60%	(0.90%)
Other non-deductible/non-taxable items, Rate	(4.90%)	5.40%	(3.00%)
Income tax expense	(103.60%)	187.20%	(20.50%)

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets and Deferred Tax Liability (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred Tax Assets, Net [Abstract]
Net operating loss carryforwards	$ 29,158	$ 21,219
Investment tax credit and other tax credit carryforwards	5,213	3,919
Write-downs of other assets	2,341	1,223
Excess of tax accounting basis in various assets	14,549	13,929
Accrued pension liability	5,375	6,901
Accrued share-based compensation	8,920	7,728
Income recognition on net investment in leases	(3,344)	(3,368)
Other accrued reserves	10,552	8,369
Total deferred income tax assets	72,764	59,920
Valuation allowance	(62,864)	(46,014)
Deferred income tax asset net of valuation allowance	9,900	13,906
Deferred tax liability	(14,900)	(17,642)
Net deferred tax liability	$ (5,000)	$ (3,736)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020
Income Tax Contingency [Line Items]
Deferred tax liability recognized within Accumulated Other Comprehensive (Loss) Income	$ 1,100	$ 300	$ 1,100		$ 300
Net Operating Loss Carryforwards, Limitations on Use			Estimated Canadian net operating loss carryforwards of $129.4 million can be used to reduce taxable income through 2042, China net operating losses of $5.1 million can be used to reduce taxable income through 2027, and $8.9 million of Ireland net operating losses can be carried forward indefinitely. Investment tax credits and other tax credits of $5.5 million can be carried forward to reduce income taxes payable through to 2042.
Investment tax credits and other tax credits, carryforwards	5,500		$ 5,500
Investment tax credits and other tax credit carryforward, expiration period			2042
Deferred tax liability	14,900	17,642	$ 14,900		17,642
Deferred income tax asset after valuation allowance	9,900	13,906	9,900		13,906
Deferred tax asset, valuation allowance	62,864	46,014	62,864		46,014
Deferred income tax asset, valuation allowance change			16,900		17,200
Deferred income tax (benefit) expense			(2,073)		2,996		$ 23,618
Payment of foreign withholding taxes			2,700		2,000
Provision for uncertain tax positions recorded to income tax provision			2,200		2,100		600
Total tax reserves (including interest and penalties)	12,300	13,900	12,300		13,900
Interest and penalty associated with tax reserves			600		1,400		3,300
Payment of income taxes		8,900	13,963	[1]	18,475	[1]	4,763	[1]
Income tax receivable	8,900		$ 8,900
Notice of reassessment received	13,200
Canada Revenue Agency [Member]
Income Tax Contingency [Line Items]
Net operating loss carryforwards, expiration period			2042
Net Operating Loss Carryforwards	129,400		$ 129,400
Payment of income taxes		1,600
Income tax receivable	1,600		$ 1,600
Canada Revenue Agency [Member] | Minimum [Member]
Income Tax Contingency [Line Items]
Open Tax Years by Major Tax Jurisdiction			2016
Canada Revenue Agency [Member] | Maximum [Member]
Income Tax Contingency [Line Items]
Open Tax Years by Major Tax Jurisdiction			2021
Internal Revenue Service (IRS) [Member] | Minimum [Member]
Income Tax Contingency [Line Items]
Open Tax Years by Major Tax Jurisdiction			2017
Internal Revenue Service (IRS) [Member] | Maximum [Member]
Income Tax Contingency [Line Items]
Open Tax Years by Major Tax Jurisdiction			2022
State Administration of Taxation, China [Member]
Income Tax Contingency [Line Items]
Net operating loss carryforwards, expiration period			2027
Net Operating Loss Carryforwards	5,100		$ 5,100
Revenue Commissioners, Ireland [Member]
Income Tax Contingency [Line Items]
Net Operating Loss Carryforwards	8,900		8,900
Impact of COVID-19 Pandemic [Member]
Income Tax Contingency [Line Items]
Deferred tax asset, valuation allowance	16,900	17,200	16,900		17,200
China [Member]
Income Tax Contingency [Line Items]
Deferred tax asset, valuation allowance	$ 16,900	17,200	16,900		17,200
Shareholder's Equity [Member]
Income Tax Contingency [Line Items]
Deferred income tax asset, valuation allowance change					2,500
Income Tax Expense [Member]
Income Tax Contingency [Line Items]
Deferred income tax asset, valuation allowance change			16,900		14,700
Foreign Country [Member]
Income Tax Contingency [Line Items]
Deferred income tax (benefit) expense			131		$ 1,268		$ (867)
Payment of income taxes		$ 8,900
Foreign Country [Member] | China [Member]
Income Tax Contingency [Line Items]
Deferred income tax (benefit) expense			$ 27,400
[1] In 2021 , the Canadian tax authorities denied the Company’s deduction of certain foreign taxes accrued in 2015, but not yet paid as discussions with the local authorities are ongoing. This resulted in the payment of $ 8.9 million in income taxes and $ 1.6 million in associated interest to the Canadian tax authorities in the fourth quarter of 2021. The Company has filed a waiver with the Canadian tax authorities in respect of 2015 so that when the foreign taxes are paid, the Company would be entitled to receive a refund of the $ 8.9 million in tax, which is recorded on the Company’s Consolidated Balance Sheets within Accounts Receivable, and the $ 1.6 million in associated interest.

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Beginning and Ending Amount of Tax Reserves (excluding interest and penalties) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of beginning and ending amount of tax reserves (excluding interest and penalties)
Balance at beginning of the year	$ 11,939	$ 14,076	$ 14,718
Additions based on tax positions related to the current year	11	37	2,301
Reductions for tax positions of prior years	(94)	(991)
Reductions resulting from lapse of applicable statute of limitations and administrative practices	(2,123)	(1,183)	(2,943)
Balance at the end of the year	$ 9,733	$ 11,939	$ 14,076

Income Taxes - Income Tax (Expe

Income Taxes - Income Tax (Expense) Benefit Included in the Other Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Unrealized defined benefit plan actuarial (gain) loss	$ (198)	$ (37)	$ 276
Unrealized postretirement benefit plans actuarial (gain) loss	(762)	(35)	92
Amortization of prior service cost	(48)	(48)	(23)
Unrealized change in cash flow hedging instruments	(346)	(123)	(132)
Realized change in cash flow hedging instruments	(156)	446	(158)
Reclassification of unrealized change in ineffective cash flow hedging instruments		83
Income tax effect on comprehensive (loss) income	$ (818)	$ 286	$ 55

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Sep. 22, 2022
Finite-Lived Intangible Assets [Line Items]
Net book value of patents and trademarks disposed of in the year	$ 100	$ 100
Goodwill	52,815	39,027
Intangible assets acquired	11,200
Capitalized other intangible assets, cost	83,783	68,171
Net book value of other intangible assets capitalized	$ 15,500	$ 3,900
Weighted average amortization period for additions to other intangible assets	4 years 8 months 12 days	2 years 3 months 18 days
Costs incurred to renew or extend the term of acquired patents and trademarks	$ 100	$ 100
Internal Use Software, Patents And Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Capitalized other intangible assets, cost	5,100	4,100
SSIMWAVE Inc. [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill	13,800		$ 13,788
Intangible assets acquired	11,200		$ 11,189
IMAX Systems Reporting Unit [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill	19,100	19,100
Joint Revenue Sharing Arrangements Reporting Unit [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill	13,500	13,500
IMAX Maintenance Reporting Unit [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 6,400	$ 6,400

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Summary of Other Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Other Intangible Assets
Other Intangible Assets, Cost	$ 83,783	$ 68,171
Other Intangible Assets, Accumulated Amortization	51,045	45,091
Other Intangible Assets, Net Book Value	32,738	23,080
Licenses and Intellectual Property [Member]
Other Intangible Assets
Other Intangible Assets, Cost	26,168	26,168
Other Intangible Assets, Accumulated Amortization	15,232	13,642
Other Intangible Assets, Net Book Value	10,936	12,526
Internal Use Software [Member]
Other Intangible Assets
Other Intangible Assets, Cost	32,886	28,571
Other Intangible Assets, Accumulated Amortization	25,232	21,544
Other Intangible Assets, Net Book Value	7,654	7,027
Developed Technology [Member]
Other Intangible Assets
Other Intangible Assets, Cost	5,779
Other Intangible Assets, Accumulated Amortization	225
Other Intangible Assets, Net Book Value	5,554
In Process Research and Development [Member]
Other Intangible Assets
Other Intangible Assets, Cost	3,810
Other Intangible Assets, Net Book Value	3,810
Patents and Trademarks [Member]
Other Intangible Assets
Other Intangible Assets, Cost	13,031	12,834
Other Intangible Assets, Accumulated Amortization	9,771	9,406
Other Intangible Assets, Net Book Value	3,260	3,428
Customer Relationships [Member]
Other Intangible Assets
Other Intangible Assets, Cost	1,340
Other Intangible Assets, Accumulated Amortization	50
Other Intangible Assets, Net Book Value	1,290
Other [Member]
Other Intangible Assets
Other Intangible Assets, Cost	769	598
Other Intangible Assets, Accumulated Amortization	535	499
Other Intangible Assets, Net Book Value	$ 234	$ 99

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Summary of Estimated Amortization Expenses (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Other Intangible Assets Additional Textuals [Abstract]
2023	$ (7,821)
2024	(7,636)
2025	(5,456)
2026	(3,059)
2027	$ (3,099)

Borrowings - Revolving Credit F

Borrowings - Revolving Credit Facility Borrowings, Net (Details) ¥ in Millions	Dec. 31, 2022 USD ($)	Dec. 31, 2022 CNY (¥)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 CNY (¥)
Wells Fargo Credit Facility [Member]
Bank indebtedness [Line Items]
Borrowings	$ 25,000,000		$ 0
Revolving Credit Facility [Member]
Bank indebtedness [Line Items]
Unamortized debt issuance costs	(1,759,000)		(1,140,000)
Revolving Credit Facility Borrowings, net	36,111,000		2,472,000
Bank of China Facility [Member]
Bank indebtedness [Line Items]
Borrowings	400,000	¥ 2.6	3,600,000	¥ 23
Bank of China Facility [Member] | Revolving Credit Facility [Member]
Bank indebtedness [Line Items]
Borrowings	374,000		$ 3,612,000
HSBC China Facility [Member]
Bank indebtedness [Line Items]
Borrowings	$ 12,496,000	¥ 87

Borrowings - Additional Informa

Borrowings - Additional Information (Details) ¥ in Millions				3 Months Ended	12 Months Ended			48 Months Ended
	May 25, 2022 USD ($)	Mar. 19, 2021 USD ($)	May 29, 2019 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2022 CNY (¥)	Dec. 31, 2022 CAD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2022 CNY (¥)	Dec. 31, 2021 CNY (¥)	Oct. 31, 2019 USD ($)	May 29, 2019 CAD ($)
Borrowings (Textual) [Abstract]
Credit facility description					On March 25, 2022, the Company entered into a Sixth Amended and Restated Credit Agreement with Wells Fargo Bank, National Association, as agent (the “Agent”), and a syndicate of lenders party thereto (the “Credit Agreement”), which extended the maturity date of the credit facility under the Credit Agreement (the “Credit Facility”) from June 28, 2023 to March 25, 2027. The Company's obligations under the Credit Agreement are guaranteed by certain of the Company's subsidiaries (the “Guarantors”), and are secured by first-priority security interests in substantially all of the assets of the Company and the Guarantors.
Credit facility maturity date					Mar. 25, 2027
Current borrowing capacity					$ 300,000,000			$ 300,000,000
Repayment of outstanding indebtedness					$ 3,600,000	$ 307,609,000
Line of credit facility covenant terms					The Credit Facility requires that the Company maintain a maximum Senior Secured Net Leverage Ratio (as defined in the Credit Agreement) of no greater than 3.25:1.00 on the last day of each Fiscal Quarter.
Letters of guarantee outstanding					$ 400,000	500,000		400,000	¥ 2.8				¥ 2.8
Amount borrowed					37,871,000	3,600,000	$ 287,610,000
Proceeds from issuance of convertible notes, net						223,675,000
Debt issuance costs paid					2,279,000	527,000	$ 1,073,000
Foreign Exchange Facility [Member]
Borrowings (Textual) [Abstract]
Unrealized gain (loss) on outstanding foreign currency forward contracts					(600,000)	100,000		(600,000)
Notional Amount of arrangements entered into					24,700,000	26,700,000		24,700,000
Convertible Notes [Member]
Borrowings (Textual) [Abstract]
Borrowings					230,000,000	230,000,000		230,000,000
Debt instrument, principal amount		$ 230,000,000			$ 230,000,000			$ 230,000,000
Debt instrument, annual interest rate		0.50%			0.50%			0.50%	0.50%	0.50%
Proceeds from issuance of convertible notes, net		$ 223,700,000
Debt issuance costs paid		$ 1,200,000
Debt instrument, frequency of periodic interest payment					semi-annually
Debt instrument, payment terms					The Convertible Notes are senior unsecured obligations of the Company and bear interest at a rate of 0.500% per annum on the principal of $230.0 million, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2021.
Debt instrument, date of first required payment					Oct. 01, 2021
Debt instrument, maturity date					Apr. 01, 2026
Debt instrument, convertible, terms of conversion feature					Holders of the Convertible Notes have the right to convert their Convertible Notes in certain circumstances and during specified periods. Before January 1, 2026, holders of the Convertible Notes have the right to convert their Convertible Notes only upon the occurrence of certain events. From and after January 1, 2026, holders of the Convertible Notes may convert their Convertible Notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as applicable, cash or a combination of cash (in an amount no less than the principal amount of the Convertible Notes being converted) and common shares, at its election, based on the applicable conversion rates. The initial conversion rate is 34.7766 common shares per $1,000 principal amount of Convertible Notes, which represents an initial conversion price of approximately $28.75 per common share, and is subject to adjustment upon the occurrence of certain events.
Debt instrument, initial conversion rate per $1,000 principal amount					34.7766
Convertible notes principal amount					$ 1,000			$ 1,000
Debt instrument, initial conversion price | $ / shares					$ 28.75			$ 28.75
Debt instrument, redemption, description					The Convertible Notes are redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after April 6, 2024 and on or before the 40th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest, if any, but only if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price for a specified period of time. In addition, calling any Convertible Notes for redemption will constitute a “make-whole fundamental change” with respect to such notes, in which case the conversion rate applicable to the conversion of such notes will be increased in certain circumstances if such notes are converted after they are called for redemption
Debt instrument, redemption start date					Apr. 06, 2024
Convertible Notes [Member] | Call Option [Member]
Borrowings (Textual) [Abstract]
Cap price of capped call transactions | $ / shares					37.2750			37.2750
Percentage of premium of cap price over last reported sale price per common share on March 16, 2021					75%
Cost of capped call transactions					$ 19,100,000
Reduction to other equity					$ 19,100,000
Bank of China Facility [Member]
Borrowings (Textual) [Abstract]
Credit facility description					In June 2022, IMAX (Shanghai) Multimedia Technology Co., Ltd. (“IMAX Shanghai”), one of the Company's majority-owned subsidiaries in China, renewed its unsecured revolving facility with Bank of China for up to 200.0 million Chinese Renminbi (“RMB”) ($28.7 million), including RMB 10.0 million ($1.4 million) for letters of guarantee, to fund ongoing working capital requirements (the “Bank of China Facility”).
Current borrowing capacity											$ 28,700,000	¥ 200
Borrowings					$ 400,000	$ 3,600,000		$ 400,000	¥ 2.6				¥ 23
Effective interest rate					4.12%	4.31%
Letters of guarantees borrowing capacity											1,400,000	10
Line of credit facility expiration period					2023-09
Remaining borrowing capacity					$ 26,900,000			26,900,000	187.4
HSBC China Facility [Member]
Borrowings (Textual) [Abstract]
Current borrowing capacity											$ 28,700,000	¥ 200
Borrowings					$ 12,496,000			12,496,000	87
Effective interest rate					3.91%
Remaining borrowing capacity					$ 16,200,000			16,200,000	113
Federal Economic Development Loan Payable [Member]
Borrowings (Textual) [Abstract]
Loans payable					2,812,000			2,812,000
Debt instrument, fair value					1,782,000			$ 1,782,000
Federal Economic Development Loan Payable [Member] | Interest Expense [Member]
Borrowings (Textual) [Abstract]
Interest accretion expense					100,000
Federal Economic Development Loan Payable [Member] | SSIMWAVE Inc. [Member]
Borrowings (Textual) [Abstract]
Debt instrument, annual interest rate			0%												0%
Percentage of contributions cover eligible and supported costs								35%
Contributions repayable months			60 months
Debt instrument repayment beginning month and year			2024-01
Loans payable					2,800,000			$ 2,800,000		$ 3,800,000
Letter of Credit | Bank of China Facility [Member]
Borrowings (Textual) [Abstract]
Remaining borrowing capacity					$ 1,000,000			1,000,000	¥ 7.2
NBC Facility [Member]
Borrowings (Textual) [Abstract]
Credit facility maturity date					Jun. 30, 2023
Current borrowing capacity														$ 5,000,000
Remaining borrowing capacity					$ 0	$ 0		0
Wells Fargo Credit Facility [Member]
Borrowings (Textual) [Abstract]
Borrowings					25,000,000	0		25,000,000
Letters of credit or advance payment guarantees					$ 0	$ 0		0
Line of credit facility covenant terms					The Credit Agreement contains customary affirmative and negative covenants, including covenants that limit indebtedness, liens, asset sales, investments and restricted payments, in each case subject to negotiated exceptions and baskets. The Credit Agreement also contains customary representations, warranties and event of default provisions.The Company incurred fees of approximately $2.5 million in connection with the March 2022 amendment of the Credit Agreement, which are being amortized on a straight-line basis over the term of the Credit Agreement. In the first quarter of 2022, the Company expensed $0.4 million in unamortized deferred financing costs associated with lenders that are no longer parties to the Credit Agreement.
Debt instrument net leverage ratio					0
Liquidity covenant minimum	$ 75,000,000
Interest rate description					Loans under the Credit Facility bear interest, at the Company's option, at (i) Term SOFR, Eurocurrency Rate or CDOR Rate plus a margin ranging from 1.00% to 1.75% per annum; or (ii) the U.S. base rate or the Canadian prime rate plus a margin ranging from 0.25% to 1.00% per annum, in each case depending on the Company's total leverage ratio. In no event will Term SOFR, Eurocurrency Rate or CDOR Rate be less than 0.00% per annum.
Effective interest rate					5.64%	2.64%
Fees incurred with amendments					$ 2,500,000
Unamortized deferred financing costs expenses				$ 400,000
Remaining borrowing capacity					$ 275,000,000			275,000,000
Wells Fargo Credit Facility [Member] | SOFR, Eurocurrency or CDOR Rate [Member]
Borrowings (Textual) [Abstract]
Interest rate margin percentage					1.75%
Interest rate maximum margin percentage					0%
Minimum [Member]
Borrowings (Textual) [Abstract]
Borrowing capacity under uncommitted accordion feature					$ 440,000,000			440,000,000
Minimum [Member] | Convertible Notes [Member]
Borrowings (Textual) [Abstract]
Percentage of last reported sale price per common share against conversion price for specific period of time					130%
Minimum [Member] | Wells Fargo Credit Facility [Member] | SOFR, Eurocurrency or CDOR Rate [Member]
Borrowings (Textual) [Abstract]
Interest rate margin percentage					1%
Minimum [Member] | Wells Fargo Credit Facility [Member] | U.S. Base Rate or Canadian Prime Rate [Member]
Borrowings (Textual) [Abstract]
Interest rate margin percentage					0.25%
Maximum [Member] | Federal Economic Development Loan Payable [Member] | SSIMWAVE Inc. [Member]
Borrowings (Textual) [Abstract]
Debt instrument, principal amount			$ 3,100,000												$ 4,200,000
Maximum [Member] | Wells Fargo Credit Facility [Member]
Borrowings (Textual) [Abstract]
Debt instrument net leverage ratio					3.25
Unrestricted cash and cash equivalents held outside of People's Republic of China					$ 75,000,000			$ 75,000,000
Maximum [Member] | Wells Fargo Credit Facility [Member] | SOFR, Eurocurrency or CDOR Rate [Member]
Borrowings (Textual) [Abstract]
Interest rate margin percentage					1.75%
Maximum [Member] | Wells Fargo Credit Facility [Member] | U.S. Base Rate or Canadian Prime Rate [Member]
Borrowings (Textual) [Abstract]
Interest rate margin percentage					1%

Borrowings - Summary of Convert

Borrowings - Summary of Convertible Notes and Other Borrowings, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Bank indebtedness [Line Items]
Revolving Credit Facility Borrowings, net	$ 226,912	$ 223,641
Convertible Notes and Other Borrowings, net	226,912	223,641
Convertible Notes [Member]
Bank indebtedness [Line Items]
Borrowings	230,000	230,000
Unamortized discounts and debt issuance costs	(4,870)	(6,359)
Revolving Credit Facility Borrowings, net	225,130	$ 223,641
Federal Economic Development Loan [Member]
Bank indebtedness [Line Items]
Loans payable	2,812
Unaccreted interest benefit	(1,030)
Debt instrument, fair value, Total	$ 1,782

Commitments - Summary of Compan

Commitments - Summary of Company's Contractual Obligations and Commitments (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Purchase obligations
Purchase obligations, Total	$ 37,884	[1]
Less Than One Year, Purchase obligations	34,419	[1]
1 to 3 years, Purchase obligations	3,183	[1]
3 to 5 years, Purchase obligations	37	[1]
Thereafter, Purchase obligations	245	[1]
Operating lease obligations
Total lease payments	17,419
Less Than One Year, Operating Leases	3,639
Thereafter, Operating Leases	4,171
Finance lease obligations
Total lease payments	1,016
Less Than One Year, Finance lease obligations	508
Total contractual obligations and commitments
Total contractual obligations and commitments, Total	354,419
Less Than One Year, Total contractual obligations and commitments	52,956
1 to 3 years, Total contractual obligations and commitments	13,276
3 to 5 years, Total contractual obligations and commitments	281,514
Thereafter, Total contractual obligations and commitments	6,673
Convertible Notes [Member]
Working Capital Facility
Convertible Notes, Total	234,025	[2]
Less Than One Year, Working Capital Facility	1,150	[2]
1 to 3 years, Working Capital Facility	2,300	[2]
3 to 5 years, Working Capital Facility	230,575	[2]
Thereafter, Working Capital Facility	0	[2]
Wells Fargo Credit Facility [Member]
Total contractual obligations and commitments
Total contractual obligations and commitments, Total	25,000
3 to 5 years, Total contractual obligations and commitments	25,000
HSBC Facility [Member]
Total contractual obligations and commitments
Total contractual obligations and commitments, Total	12,496
Less Than One Year, Total contractual obligations and commitments	12,496
Bank of China Facility [Member]
Total contractual obligations and commitments
Total contractual obligations and commitments, Total	374
Less Than One Year, Total contractual obligations and commitments	374
Federal Economic Development Loan Payable [Member]
Total contractual obligations and commitments
Total contractual obligations and commitments, Total	2,812	[3]
1 to 3 years, Total contractual obligations and commitments	1,250	[3]
3 to 5 years, Total contractual obligations and commitments	1,250	[3]
Thereafter, Total contractual obligations and commitments	312	[3]
Operating Lease Obligations
Operating lease obligations
Total lease payments	18,013	[4]
Less Than One Year, Operating Leases	3,905	[4]
1 to 3 years, Operating Leases	5,825	[4]
3 to 5 years, Operating Leases	4,137	[4]
Thereafter, Operating Leases	4,146	[4]
Finance Lease Obligations [Member]
Finance lease obligations
Total lease payments	1,016
Less Than One Year, Finance lease obligations	508
1 to 3 years, Finance lease obligations	508
Pension Obligations [Member]
Pension and Postretirement benefits obligations
Total expected future benefit payment	20,295	[5]
Less Than One Year	0	[5]
1 to 3 years	0	[5]
3 to 5 years	20,295	[5]
Thereafter	0	[5]
Postretirement Benefits Obligations [Member]
Pension and Postretirement benefits obligations
Total expected future benefit payment	2,504
Less Than One Year	104
1 to 3 years	210
3 to 5 years	220
Thereafter	$ 1,970
[1] Represents total payments to be made under binding commitments with suppliers and outstanding payments to be made for supplies ordered, but yet to be invoiced. The Convertible Notes bear interest at a rate of 0.500 % per annum on the principal of $ 230.0 million, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2021 . The Convertible Notes will mature on April 1, 2026 , unless earlier repurchased, redeemed or converted. (See Note 15 (b).) The Federal Economic Development Loan will be repayable over 60 months, with repayments estimated to begin in January 2024. (See Note 15 (b).) Represents total minimum annual rental payments due under the Company’s operating leases. (See Note 7 .) The Company has an unfunded defined benefit pension plan covering its Chief Executive Officer. (See Note 24 .)

Commitments - Summary of Comp_2

Commitments - Summary of Company's Contractual Obligations and Commitments (Parenthetical) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 19, 2021
Borrowings (Textual) [Abstract]
Credit facility description	On March 25, 2022, the Company entered into a Sixth Amended and Restated Credit Agreement with Wells Fargo Bank, National Association, as agent (the “Agent”), and a syndicate of lenders party thereto (the “Credit Agreement”), which extended the maturity date of the credit facility under the Credit Agreement (the “Credit Facility”) from June 28, 2023 to March 25, 2027. The Company's obligations under the Credit Agreement are guaranteed by certain of the Company's subsidiaries (the “Guarantors”), and are secured by first-priority security interests in substantially all of the assets of the Company and the Guarantors.
Convertible Notes [Member]
Borrowings (Textual) [Abstract]
Debt instrument, annual interest rate	0.50%	0.50%
Debt instrument, principal amount	$ 230,000,000	$ 230,000,000
Debt instrument, frequency of periodic interest payment	semi-annually
Debt instrument, payment terms	The Convertible Notes are senior unsecured obligations of the Company and bear interest at a rate of 0.500% per annum on the principal of $230.0 million, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2021.
Debt instrument, date of first required payment	Oct. 01, 2021
Debt instrument, maturity date	Apr. 01, 2026

Commitments - Additional Inform

Commitments - Additional Information (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Accrued commission on sale or lease of the theater systems payable in future periods	$ 2.2	$ 1.1

Contingencies and Guarantees -

Contingencies and Guarantees - Additional Information (Details) - USD ($)		12 Months Ended			51 Months Ended	95 Months Ended
	Dec. 03, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Mar. 27, 2008	Dec. 02, 2011	Jun. 30, 2021	Jun. 23, 2021
Contingencies And Guarantees Disclosure Textual [Abstract]
Final Award in favor of company					amount of $11.3 million, consisting of past and future rents owed to the Company, plus interest and costs, as well as an additional $2,512 each day in interest from October 1, 2007 until the date the award is paid	$30,000 to cover the costs of the application
Final Award amount issued					$ 11,300,000
Final Award additional interest					$ 2,512
Final Award settlement cost						$ 30,000
Award inclusive of interest		$ 25,300,000
Damages awarded	$ 11,300,000
Litigation liability related to Final Judgment				$ 11,300,000
Amounts collected in respect of theater systems not delivered				7,200,000
Legal judgment and arbitration awards (income) expense		0	$ (1,770,000)	$ 4,105,000
Litigation liability paid							$ 9,500,000
Litigation settlement expense reversed								$ 1,800,000
Benefit of legal judgement and arbitration awards							$ 1,800,000
Product warranty accrual		0	0
Indemnification of its directors/officers		0	0
Other Indemnification		$ 0	$ 0

Capital Stock - Summary of Sett

Capital Stock - Summary of Settlement of Stock Option and RSU Transactions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Plan trustee purchases	0	0
Cash proceeds from stock option exercises		$ 883
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued from treasury		41,613
Total stock options exercised		41,613
Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued from treasury	596,277	531,629	42,982
Plan trustee purchases		723	386,297
Shares withheld for tax withholdings	203,956	157,546	24,714
Total RSUs vested	800,233	689,898	453,993

Capital Stock - Additional Info

Capital Stock - Additional Information (Details) $ / shares in Units, $ / shares in Units, ¥ in Millions, $ in Millions	2 Months Ended	12 Months Ended
	Feb. 21, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2022 HKD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2021 HKD ($) $ / shares shares	Dec. 31, 2021 CNY (¥) shares	Dec. 31, 2020 USD ($) shares	Jul. 28, 2022 shares	Jun. 23, 2022 shares	Jun. 02, 2022 shares	Apr. 28, 2022 shares	Sep. 30, 2021 USD ($)	Sep. 30, 2021 CNY (¥)	May 06, 2021 shares	Dec. 31, 2019 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation costs recorded for the period | $		$ 27,000,000		$ 25,600,000			$ 21,500,000
Stock-based compensation expense | $		$ 27,013,000		$ 25,614,000			$ 21,493,000
Common stock, shares outstanding		54,148,614		58,653,642
Maximum number of shares of common stock may be issued for outstanding PSU		54,148,614		58,653,642
Common shares purchased in open market by trustee in connection with RSUs		0	0	0	0	0
Antidilutive shares issuable upon exercise of stock options and vesting of restricted share units and performance stock units		4,523,121	4,523,121	6,131,792	6,131,792	6,131,792	6,999,667
Percentage of statutory net profits to statutory surplus reserve to be appropriated		10%
Discontinuation of contribution, Aggregate sum of statutory surplus reserve more than its registered capital, percent		50%
Statutory surplus reserve appropriated		$ 0										$ 5,600,000	¥ 36.4
Dividends declared and paid				$ 20,400,000		¥ 131.6
Statutory surplus reserve to its subsidiaries registered capital percent												50%	50%
Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Repurchase of common shares	109,477
Stock Acquired, Average Cost per Share | $ / shares	$ 14.87
Repurchase of common shares, value | $	$ 1,600,000
IMAX China
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Details of the share repurchase program		In 2021, IMAX China’s shareholders granted its Board of Directors a general mandate authorizing the Board, subject to applicable laws, to repurchase shares of IMAX China not to exceed 10% of the total number of issued shares as of May 6, 2021 (34,835,824 shares). This program expired on the date of the 2022 Annual General Meeting of IMAX China on June 23, 2022. During the 2022 Annual General Meeting, shareholders approved the repurchase of shares of IMAX China not to exceed 10% of the total number of issued shares as of June 23, 2022 (34,063,480 shares). This program will be valid until the 2023 Annual General Meeting of IMAX China. The repurchases may be made in the open market or through other means permitted by applicable laws. IMAX China has no obligation to repurchase its shares and the share repurchase program may be suspended or discontinued by IMAX China at any time.	In 2021, IMAX China’s shareholders granted its Board of Directors a general mandate authorizing the Board, subject to applicable laws, to repurchase shares of IMAX China not to exceed 10% of the total number of issued shares as of May 6, 2021 (34,835,824 shares). This program expired on the date of the 2022 Annual General Meeting of IMAX China on June 23, 2022. During the 2022 Annual General Meeting, shareholders approved the repurchase of shares of IMAX China not to exceed 10% of the total number of issued shares as of June 23, 2022 (34,063,480 shares). This program will be valid until the 2023 Annual General Meeting of IMAX China. The repurchases may be made in the open market or through other means permitted by applicable laws. IMAX China has no obligation to repurchase its shares and the share repurchase program may be suspended or discontinued by IMAX China at any time.
Stock Repurchase Program Expiration Date		Jun. 23, 2022	Jun. 23, 2022	May 06, 2021	May 06, 2021	May 06, 2021
Repurchase of common shares		2,961,800	2,961,800	6,664,700	6,664,700	6,664,700
Stock Acquired, Average Cost per Share | (per share)		$ 1.02	$ 8	$ 1.50	$ 11.68
Repurchase of common shares, value		$ 3,000,000	$ 23.7	$ 10,000,000	$ 77.8
Stock Repurchase Program, maximum percentage of shares to be repurchased									10%					10%
Stock Repurchase Program, Authorized number of shares									34,063,480					34,835,824
Parent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Details of the share repurchase program		On April 28, 2022 and July 28, 2022, the Company’s Board of Directors approved a 12-month extension to its share repurchase program through June 30, 2023 and an increase of $200.0 million in the share repurchase program, respectively. With the increase of $200.0 million, the Company's total share repurchase authority is $400.0 million under the current share repurchase program. As of December 31, 2022, the Company has $193.4 million available under its approved repurchase program. The repurchases may be made either in the open market or through private transactions, including repurchases made pursuant a plan intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, subject to market conditions, applicable legal requirements, and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time.	On April 28, 2022 and July 28, 2022, the Company’s Board of Directors approved a 12-month extension to its share repurchase program through June 30, 2023 and an increase of $200.0 million in the share repurchase program, respectively. With the increase of $200.0 million, the Company's total share repurchase authority is $400.0 million under the current share repurchase program. As of December 31, 2022, the Company has $193.4 million available under its approved repurchase program. The repurchases may be made either in the open market or through private transactions, including repurchases made pursuant a plan intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, subject to market conditions, applicable legal requirements, and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time.
Stock Repurchase Program, Authorized Amount | $		$ 193,400,000
Stock Repurchase Program Expiration Date		Jun. 30, 2023	Jun. 30, 2023
Repurchase of common shares		5,401,852	5,401,852	841,331	841,331	841,331
Stock Acquired, Average Cost per Share | $ / shares		$ 15.19		$ 16.51
Repurchase of common shares, value | $		$ 82,000,000		$ 13,900,000
Stock Repurchase Program, Authorized number of shares								200,000,000			200,000,000
Statutory surplus reserve appropriated | $												$ 3,900,000
Non-controlling Interests [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Repurchase of common shares, value | $		$ 2,458,000		$ 5,797,000			$ 858,000
Statutory surplus reserve appropriated | $												$ 1,700,000
Settlement Occurred [Member] | Parent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Repurchase of common shares		140,000	140,000	0	0	0
Stock Acquired, Average Cost per Share | $ / shares		$ 14.45
Repurchase of common shares, value | $		$ 2,000,000
Maximum [Member] | Parent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Repurchase Program, Authorized Amount | $		$ 400,000,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reserved common shares for future issuance		5,788,499		5,807,445
Options outstanding		3,604,739		3,736,157			4,892,962								5,732,209
Options common shares were vested and exercisable		3,523,335		3,488,107
Income tax benefit from stock based compensation | $		$ 100,000		$ 100,000			$ 100,000
Options fully vested and unvested, weighted average exercise price | $ / shares		$ 26.36
Options fully vested and unvested, weighted average remaining contractual life		3 years 3 months 18 days	3 years 3 months 18 days
Intrinsic value of options exercised | $				0.1
Stock-based compensation expense | $		$ 572,000		$ 1,064,000			$ 1,847,000
Antidilutive shares issuable upon exercise of stock options and vesting of restricted share units and performance stock units		3,604,739	3,604,739	3,736,157	3,736,157	3,736,157	4,892,962
Employee Stock Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based awards vesting period		4 years	4 years
Stock based awards expiration period or remaining contractual life		10 years	10 years
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares outstanding		931,716		613,405			361,844
Stock based awards vesting period		3 years	3 years
RSU awards, granted to non-employees		359,138	359,138	309,574	309,574	309,574	370,265
Stock-based compensation expense | $		$ 8,306,000		$ 5,322,000			$ 2,563,000
Unrecognized share based compensation expense | $		$ 10,800,000
Weighted average term expense expected recognized		1 year 9 months 18 days	1 year 9 months 18 days
Antidilutive shares issuable upon exercise of stock options and vesting of restricted share units and performance stock units		281,262	281,262	937,752	937,752	937,752	541,867
Performance Stock Units [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage		175%	175%
Performance Stock Units [Member] | Maximum [Member] | EBITDA
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares of common stock may be issued for outstanding PSU		1,630,503
Performance Stock Units [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage		0%	0%
Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares outstanding		1,252,044		1,457,883			1,564,838								1,065,347
Restricted Stock Unit Economic Equivalent		1	1
Tax expense (benefits) realized | $		$ 900,000		$ (600,000)			$ (300,000)
Accrued liabilities | $		$ 800,000		$ 2,600,000
RSU that may vest on a shorter period		343,058								885,000
RSU awards, granted to non-employees		708,313	708,313	831,123	831,123	831,123	1,050,385
Stock-based compensation expense | $		$ 15,498,000		$ 15,555,000			$ 13,761,000
Common shares purchased in open market by trustee in connection with RSUs				723	723	723	386,297
Antidilutive shares issuable upon exercise of stock options and vesting of restricted share units and performance stock units		637,120	637,120	1,457,883	1,457,883	1,457,883	1,564,838
Restricted Share Units [Member] | Certain Advisor [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSU awards, granted to non-employees		0	0	0	0	0	0
Stock-based compensation expense | $		$ 0					$ 100,000
Restricted Share Units [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based awards vesting period		3 years	3 years
Percentage of common shares authorized		5%	5%
Restricted Share Units [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based awards vesting period		1 year	1 year
IMAX China Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense | $		$ 100,000		$ 100,000			$ 700,000
Vested stock options contractual life		1 year	1 year

Capital Stock - Share-Based Com

Capital Stock - Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 27,013	$ 25,614	$ 21,493
Cost and Expenses Applicable to Revenues [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	1,156	1,490	691
Selling, General and Administrative Expenses [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	25,438	23,776	20,652
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 419	$ 348	$ 150

Capital Stock - Expenses Relate

Capital Stock - Expenses Related to Stock Option Grants Issued to Employees and Directors (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 27,013	$ 25,614	$ 21,493
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 572	$ 1,064	$ 1,847

Capital Stock - Total Share-Bas

Capital Stock - Total Share-Based Compensation Expense Related to Non-Vested Employee Stock Options not yet Recognized (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense related to non-vested employee stock options	$ 86	$ 662	$ 2,029

Capital Stock - Weighted Averag

Capital Stock - Weighted Average Period over Which Awards Expected to be Recognized (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period (in years)	2 months 12 days	1 year 1 month 6 days	1 year 9 months 18 days

Capital Stock - Schedule of Sha

Capital Stock - Schedule of Share-based Compensation, Stock Options, Activity (Details) - Employee Stock Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options outstanding, beginning of year	3,736,157	4,892,962	5,732,209
Exercised		(41,613)
Forfeited	(796)	(88,934)	(34,678)
Expired	(126,569)	(903,038)	(786,086)
Cancelled	(4,053)	(123,220)	(18,483)
Stock options outstanding, end of year	3,604,739	3,736,157	4,892,962
Stock options exercisable, end of year	3,523,335	3,488,107	4,311,761
Stock options outstanding, weighted average exercise price per share, beginning of year	$ 26.61	$ 26.81	$ 26.82
Exercised, weighted average exercise price per share		21.23
Forfeited, weighted average exercise price per share	22.49	22.49	22.49
Expired, weighted average exercise price per share	33.61	28.31	27.07
Cancelled, weighted average exercise price per share	27.92	26.68	27.97
Stock options outstanding, weighted average exercise price per share, end of year	26.36	26.61	26.81
Stock options exercisable, weighted average exercise price per share, end of year	$ 26.45	$ 26.93	$ 27.30

Capital Stock - Expenses Rela_2

Capital Stock - Expenses Related to RSU Grants Issued to Employees and Directors in Plan (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 27,013	$ 25,614	$ 21,493
Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 15,498	$ 15,555	$ 13,761

Capital Stock - Total Share-B_2

Capital Stock - Total Share-Based Compensation Expense Related to Non-Vested RSUs not Yet Recognized and Weighted Average Period (Details) - Restricted Share Units [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense related to non-vested RSUs not yet recognized	$ 17,457	$ 15,913	$ 17,343
Weighted average period awards are expected to be recognized (in years)	1 year 6 months	1 year 7 months 6 days	1 year 10 months 24 days

Capital Stock - Restricted Stoc

Capital Stock - Restricted Stock Units Activity under the IMAX LTIP (Details) - Restricted Share Units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards outstanding, beginning of year	1,457,883	1,564,838	1,065,347
Granted	708,313	831,123	1,050,385
Vested and settled	(800,231)	(689,872)	(453,993)
Forfeited	(113,921)	(248,206)	(96,901)
Number of awards outstanding, end of year	1,252,044	1,457,883	1,564,838
Weighted average grant date fair value per share, beginning of year	$ 19.16	$ 18.33	$ 23.17
Granted, weighted average grant date fair value per share	19.31	21.03	15.35
Vested and settled, weighted average grant date fair value per share	19.10	19.46	22.71
Forfeited, weighted average grant date fair value per share	20.39	19.38	18.81
Weighted average grant date fair value per share, end of year	$ 19.16	$ 19.16	$ 18.33

Capital Stock - Summary of Numb

Capital Stock - Summary of Number of RSUs Issued From Carve-Out Balance (Details) - Restricted Share Units [Member] - shares	7 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSU carve out, balance beginning of period	885,000
RSUs issued from carve-out	(59,030)	(482,912)
RSU carve out, balance end of period	343,058

Capital Stock - Expenses Rela_3

Capital Stock - Expenses Related to PSUs Grants Issued to Employees and Directors in Plan (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 27,013	$ 25,614	$ 21,493
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 8,306	$ 5,322	$ 2,563

Capital Stock - Performance Sto

Capital Stock - Performance Stock Units Activity under the IMAX LTIP (Details) - Performance Stock Units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards outstanding, beginning of year	613,405	361,844
Granted	359,138	309,574	370,265
Forfeited	(40,827)	(58,013)	(8,421)
Number of awards outstanding, end of year	931,716	613,405	361,844
Weighted average grant date fair value per share, beginning of year	$ 18.21	$ 15.68
Granted, weighted average grant date fair value per share	20.34	20.77	$ 15.66
Forfeited, weighted average grant date fair value per share	19.90	16.11	4.84
Weighted average grant date fair value per share, end of year	$ 18.96	$ 18.21	$ 15.68

Capital Stock - Summary of Expe

Capital Stock - Summary of Expense Related to Award Type (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense	$ 27,000	$ 25,600	$ 21,500
China Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense	91	285	875
China RSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense	2,284	2,810	2,093
China PSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense	262	578	208
China Options, RSUs and PSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense	$ 2,637	$ 3,673	$ 3,176

Capital Stock - Summary of Shar

Capital Stock - Summary of Share Repurchases (Details)	12 Months Ended
	Dec. 31, 2022 $ / shares shares	Dec. 31, 2022 $ / shares shares	Dec. 31, 2021 $ / shares shares	Dec. 31, 2021 $ / shares shares
IMAX China
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total Number of Shares Repurchased	2,961,800	2,961,800	6,664,700	6,664,700
Average Price Paid Per Share | (per share)	$ 1.02	$ 8	$ 1.50	$ 11.68
Parent [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total Number of Shares Repurchased	5,401,852	5,401,852	841,331	841,331
Average Price Paid Per Share | $ / shares	$ 15.19		$ 16.51

Capital Stock - Basic and Dilut

Capital Stock - Basic and Diluted Weighted Average Share Computations (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Issued and outstanding, beginning of period	58,654	58,921	61,176
Weighted average number of shares (repurchased) issued , net	(1,980)	205	(1,939)
Weighted average number of shares outstanding - basic	56,674	59,126	59,237
Weighted average number of shares outstanding - diluted	56,674	59,126	59,237

Consolidated Statements of Op_4

Consolidated Statements of Operations Supplemental Information - Summary of Selling Expenses, Including Sales Commissions and Marketing and Other Expenses (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangements [Line Items]
Sales Commissions		$ 564	$ 2,284	$ 2,186
Marketing and Other		21,757	11,021	5,893
Technology Sales [Member]
Collaborative Arrangements [Line Items]
Sales Commissions	[1]	479	1,885	1,278
Marketing and Other	[1]	810	989	1,077
Image Enhancement and Maintenance Services [Member]
Collaborative Arrangements [Line Items]
Marketing and Other	[2]	20,284	8,923	4,306
Technology Rentals [Member]
Collaborative Arrangements [Line Items]
Sales Commissions	[3]	85	399	908
Marketing and Other	[3]	$ 663	$ 1,109	$ 510
[1] Sales commissions paid prior to the recognition of the related revenue are deferred and recognized upon the client acceptance of the IMAX System. Direct advertising and marketing costs for each IMAX System are expensed as incurred. Film exploitation costs, including advertising and marketing costs are expensed as incurred. Sales commissions related to joint revenue sharing arrangements accounted for operating leases are recognized in the month they are earned by the salesperson, which is typically the month in which the IMAX System is installed. Direct advertising and marketing costs for each IMAX System are expensed as incurred.

Consolidated Statements of Op_5

Consolidated Statements of Operations Supplemental Information - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) Film	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2017 Film
Foreign Exchange
Foreign exchange translation gain (loss)	$ (3,200)	$ 1,300	$ 800
Collaborative Arrangements
Average percentage of the box-office receipts of the film for recovering digital re-mastering cost	12.50%
Revenue attributable to transactions arising between the company and its customers under IMAX DMR arrangements	$ 94,900	70,700	28,300
Number of significant co-produced film arrangement | Film	1			1
Number of other co-produced film arrangements | Film	3
Variable Interest Entity, Consolidated, Carrying Amount, Total Assets	$ 821,154	883,247
Variable Interest Entity, Consolidated, Carrying Amount, Total Liabilities	491,386	452,875
Amounts attributable to transactions between the company and other parties involved in the production of films included in costs and expenses	800	400	2,000
Co-produced television collaborative arrangement revenue	300	200	300
Co-produced television collaborative arrangement costs and expenses		0	0
Variable Interest Entity, Primary Beneficiary [Member]
Collaborative Arrangements
Variable Interest Entity, Consolidated, Carrying Amount, Total Assets	1,523	1,576
Variable Interest Entity, Consolidated, Carrying Amount, Total Liabilities	248	259
Retrospective adoption of ASC Topic 606, Revenue from Contracts with Customers [Member]
Collaborative Arrangements
Revenues attributable to transactions arising between the company and its customers under joint revenue sharing arrangements	$ 66,600	$ 51,600	$ 19,900

Consolidated Statements of Ca_4

Consolidated Statements of Cash Flows Supplemental Information - Summary of Changes in Other Operating Assets and Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020
Decrease (Increase) in:
Financing receivables		$ 5,411		$ (7,637)		$ (10,568)
Prepaid expenses		(1,892)		(3,230)		(979)
Variable consideration receivables		667		(2,905)		(2,361)
Other assets		968		1,003		(4,747)
Increase (Decrease) in:
Accounts payable		8,496		(4,752)		414
Accrued and other liabilities		(12,849)		15,167		(6,399)
Changes in other non-cash operating assets and liabilities		801		(2,354)		(24,640)
Cash payments made on account of:
Income taxes	$ 8,900	13,963	[1]	18,475	[1]	4,763	[1]
Interest		$ 715		$ 3,251		$ 5,773
[1] In 2021 , the Canadian tax authorities denied the Company’s deduction of certain foreign taxes accrued in 2015, but not yet paid as discussions with the local authorities are ongoing. This resulted in the payment of $ 8.9 million in income taxes and $ 1.6 million in associated interest to the Canadian tax authorities in the fourth quarter of 2021. The Company has filed a waiver with the Canadian tax authorities in respect of 2015 so that when the foreign taxes are paid, the Company would be entitled to receive a refund of the $ 8.9 million in tax, which is recorded on the Company’s Consolidated Balance Sheets within Accounts Receivable, and the $ 1.6 million in associated interest.

Consolidated Statements of Ca_5

Consolidated Statements of Cash Flows Supplemental Information - Summary of Changes in Other Operating Assets and Liabilities (Parentheticals) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2022	[1]	Dec. 31, 2021	[1]	Dec. 31, 2020	[1]
Supplemental Cash Flow Elements [Line Items]
Payment of income taxes	$ 8,900	$ 13,963		$ 18,475		$ 4,763
Accounts Receivable Net Of Allowance For Credit Losses
Supplemental Cash Flow Elements [Line Items]
Payment of income taxes	8,900
Interest	1,600
Foreign Country [Member]
Supplemental Cash Flow Elements [Line Items]
Payment of income taxes	8,900
Interest	$ 1,600
[1] In 2021 , the Canadian tax authorities denied the Company’s deduction of certain foreign taxes accrued in 2015, but not yet paid as discussions with the local authorities are ongoing. This resulted in the payment of $ 8.9 million in income taxes and $ 1.6 million in associated interest to the Canadian tax authorities in the fourth quarter of 2021. The Company has filed a waiver with the Canadian tax authorities in respect of 2015 so that when the foreign taxes are paid, the Company would be entitled to receive a refund of the $ 8.9 million in tax, which is recorded on the Company’s Consolidated Balance Sheets within Accounts Receivable, and the $ 1.6 million in associated interest.

Consolidated Statements of Ca_6

Consolidated Statements of Cash Flows Supplemental Information - Summary of Depreciation and Amortization (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Summary of Depreciation and amortization
Film assets		$ 16,881	$ 16,316	$ 8,838
Property, plant and equipment:
Equipment supporting joint revenue sharing arrangements		22,165	22,320	24,930
Other property, plant and equipment	[1]	9,757	9,479	11,225
Other intangible assets	[2]	6,103	6,079	6,565
Other assets	[3]	1,755	1,888	1,146
Depreciation and amortization		$ 56,661	$ 56,082	$ 52,704
[1] Includes the amortization of laser projection systems, camera, and lens upgrades recorded in Research and Development on the Statements of Operations of $ 0.6 million in the year ended December 31, 2022 (2021 — $ 0.8 million; 2020 — $ 0.9 million). Includes the amortization of licenses and intellectual property recorded in Research and Development on the Consolidated Statements of Operations of $ 1.3 million in the year ended December 31, 2022 (2021 — $ 1.3 million; 2020 — $ 1.3 million). Includes the amortization of lessee incentives provided by the Company to its customers under joint revenue sharing arrangements.

Consolidated Statements of Ca_7

Consolidated Statements of Cash Flows Supplemental Information - Summary of Depreciation and Amortization (Parenthetical) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Supplemental Cash Flow Elements [Abstract]
Amortization of property, plant and equipment net in research and development	$ 0.6	$ 0.8	$ 0.9
Amortization of intangible assets net in research and development	$ 1.3	$ 1.3	$ 1.3

Consolidated Statements of Ca_8

Consolidated Statements of Cash Flows Supplemental Information - Write-downs, Net of Recoveries (Details) $ in Thousands, ¥ in Millions		12 Months Ended
		Dec. 31, 2022 USD ($)	Dec. 31, 2022 CNY (¥)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Write-downs
Other assets		$ 4,500	¥ 30	$ 0	$ 1,151	[1]
Inventories	[2]	741		890	3,632
Equipment supporting joint revenue sharing arrangements	[3]	973		364	1,784
Other property, plant and equipment		57		217	174
Other intangible assets		87		142	184
Film assets	[4]	848		151	10,804
Write-downs		$ 7,176		$ 1,764	$ 17,729
[1] In 2022 , the Company recognized a full impairment of its RMB 30.0 million ($ 4.5 million) investment in the film Mozart from Space based on projected box office results and distribution costs. (See Note 23(e).) In 2020 , the Company recorded a write-down of $ 1.2 million in Asset Impairments related to content-related assets which became impaired in the year. No such write-downs including asset impairments were incurred in 2021. In 2022 , the Company recorded write-downs of $ 0.9 million, net of a recovery of $ 0.2 million in Costs and Expenses Applicable to Technology Sales. The write-downs recorded during the year ended December 31, 2022 include $ 0.4 million related to excess and damaged inventory and $ 0.3 million recorded to reduce the carrying value of service parts held in Russia . For the years ended December 31, 2021 and 2020 , the Company recorded write-downs of $ 0.9 million and $ 3.6 million, respectively, in Costs and Expenses Applicable to Technology Sales to reduce the carrying value of excess inventory. In 2022 , the Company recorded charges of $ 1.0 million ( 2021 — $ 0.4 million; 2020 — $ 1.8 million) in Costs and Expenses Applicable to Technology Rentals mostly related to the write-downs of leased xenon-based digital systems which were taken out of service in connection with exhibitor customer upgrades to laser-based digital systems, as well as an IMAX System that was removed from its existing location. In 2022 , the Company recorded impairment losses of $ 0.8 million ( 2021 — $ 0.2 million) related to the write-down of DMR and documentary film assets. In 2020, the Company recorded impairment losses of $ 10.8 million principally to write-down the carrying value of certain documentary, alternative content film assets and DMR related film assets due to a decrease in projected box office totals and related revenues based on management’s regular quarterly recoverability assessments.

Consolidated Statements of Ca_9

Consolidated Statements of Cash Flows Supplemental Information - Write-downs, Net of Recoveries (Parenthetical) (Details) $ in Thousands, ¥ in Millions		12 Months Ended
		Dec. 31, 2022 USD ($)	Dec. 31, 2022 CNY (¥)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Supplemental Cash Flow Elements [Line Items]
Other assets write downs on impairment		$ 4,500	¥ 30	$ 0	$ 1,151	[1]
Theater system components written off in Costs and expenses		1,000		400	1,800
Write-downs for excess and obsolete inventory	[2]	741		890	3,632
Film assets write downs on impairment loss		800		$ 200	$ 10,800
Technology Sales [Member]
Supplemental Cash Flow Elements [Line Items]
Write-downs for excess and obsolete inventory		900
Write-downs net of a recovery		200
Excess and damaged inventory
Supplemental Cash Flow Elements [Line Items]
Write-downs for excess and obsolete inventory		400
Carrying value of service parts | Russia
Supplemental Cash Flow Elements [Line Items]
Write-downs for excess and obsolete inventory		$ 300
[1] In 2022 , the Company recognized a full impairment of its RMB 30.0 million ($ 4.5 million) investment in the film Mozart from Space based on projected box office results and distribution costs. (See Note 23(e).) In 2020 , the Company recorded a write-down of $ 1.2 million in Asset Impairments related to content-related assets which became impaired in the year. No such write-downs including asset impairments were incurred in 2021. In 2022 , the Company recorded write-downs of $ 0.9 million, net of a recovery of $ 0.2 million in Costs and Expenses Applicable to Technology Sales. The write-downs recorded during the year ended December 31, 2022 include $ 0.4 million related to excess and damaged inventory and $ 0.3 million recorded to reduce the carrying value of service parts held in Russia . For the years ended December 31, 2021 and 2020 , the Company recorded write-downs of $ 0.9 million and $ 3.6 million, respectively, in Costs and Expenses Applicable to Technology Sales to reduce the carrying value of excess inventory.

Consolidated Statements of C_10

Consolidated Statements of Cash Flows Supplemental Information - Significant Non-cash Investing Activities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net increase (decrease) in accruals related to:
Investment in equipment supporting joint revenue sharing arrangements	$ 790	$ 1,009	$ (1,888)
Acquisition of other intangible assets	30	(891)	792
Purchases of property, plant and equipment	311	(188)	158
Net accruals	$ 1,131	$ (70)	$ (938)

Condensed Consolidated Statemen

Condensed Consolidated Statements of Cash Flows Supplemental Information (Parenthetical) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]
Liability related to repurchase of common shares expense recognized not settled	$ 2

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Disaggregation of Revenue by Segment (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Revenues	[1]	$ 300,805	$ 254,883	$ 137,003
Fixed Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		115,628	101,919	66,369
Variable Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		106,626	78,584	36,350
Lease Arrangements [Member]
Disaggregation of Revenue [Line Items]
Revenues		70,069	63,588	24,168
Finance Income [Member]
Disaggregation of Revenue [Line Items]
Revenues		8,482	10,792	10,116
Technology Sales [Member]
Disaggregation of Revenue [Line Items]
Revenues		69,158	66,153	49,728
Technology Sales [Member] | Fixed Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		53,505	43,738	37,492
Technology Sales [Member] | Variable Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		7,370	5,617	5,909
Technology Sales [Member] | Joint Revenue Sharing Arrangements, Fixed Fees [Member]
Disaggregation of Revenue [Line Items]
Revenues		4,804	5,406	2,056
Technology Sales [Member] | Joint Revenue Sharing Arrangements, Fixed Fees [Member] | Fixed Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Technology Sales [Member] | Joint Revenue Sharing Arrangements, Fixed Fees [Member] | Variable Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Technology Sales [Member] | Other Theater Business [Member]
Disaggregation of Revenue [Line Items]
Revenues		6,255	2,363	1,666
Technology Sales [Member] | Other Theater Business [Member] | Fixed Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		6,255	2,363	1,666
Technology Sales [Member] | Other Theater Business [Member] | Variable Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Technology Sales [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Revenues		3,648	3,516	2,067
Technology Sales [Member] | Other [Member] | Fixed Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		3,546	3,475	1,957
Technology Sales [Member] | Other [Member] | Variable Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		102	41	110
Technology Sales [Member] | IMAX Systems [Member]
Disaggregation of Revenue [Line Items]
Revenues	[2]	54,451	54,868	43,939
Technology Sales [Member] | IMAX Systems [Member] | Fixed Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues	[2]	43,704	37,900	33,869
Technology Sales [Member] | IMAX Systems [Member] | Variable Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues	[2]	7,268	5,576	5,799
Technology Sales [Member] | Lease Arrangements [Member]
Disaggregation of Revenue [Line Items]
Revenues		8,283	16,798	6,327
Technology Sales [Member] | Lease Arrangements [Member] | Joint Revenue Sharing Arrangements, Fixed Fees [Member]
Disaggregation of Revenue [Line Items]
Revenues		4,804	5,406	2,056
Technology Sales [Member] | Lease Arrangements [Member] | Other Theater Business [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Technology Sales [Member] | Lease Arrangements [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Technology Sales [Member] | Lease Arrangements [Member] | IMAX Systems [Member]
Disaggregation of Revenue [Line Items]
Revenues	[2]	3,479	11,392	4,271
Technology Sales [Member] | Finance Income [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Technology Sales [Member] | Finance Income [Member] | Joint Revenue Sharing Arrangements, Fixed Fees [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Technology Sales [Member] | Finance Income [Member] | Other Theater Business [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Technology Sales [Member] | Finance Income [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Technology Sales [Member] | Finance Income [Member] | IMAX Systems [Member]
Disaggregation of Revenue [Line Items]
Revenues	[2]	0	0	0
Image Enhancement and Maintenance Services [Member]
Disaggregation of Revenue [Line Items]
Revenues		161,379	131,148	59,318
Image Enhancement and Maintenance Services [Member] | Fixed Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		62,123	58,181	28,877
Image Enhancement and Maintenance Services [Member] | Variable Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		99,256	72,967	30,441
Image Enhancement and Maintenance Services [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Revenues		2,969	1,426
Image Enhancement and Maintenance Services [Member] | Other [Member] | Fixed Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		1,178	377
Image Enhancement and Maintenance Services [Member] | Other [Member] | Variable Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		1,791	1,049
Image Enhancement and Maintenance Services [Member] | IMAX DMR [Member]
Disaggregation of Revenue [Line Items]
Revenues		94,867	70,659	28,265
Image Enhancement and Maintenance Services [Member] | IMAX DMR [Member] | Fixed Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Image Enhancement and Maintenance Services [Member] | IMAX DMR [Member] | Variable Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		94,867	70,659	28,265
Image Enhancement and Maintenance Services [Member] | Film Post-Production [Member]
Disaggregation of Revenue [Line Items]
Revenues		3,783	4,260	3,878
Image Enhancement and Maintenance Services [Member] | Film Post-Production [Member] | Fixed Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		3,783	4,260	3,878
Image Enhancement and Maintenance Services [Member] | Film Post-Production [Member] | Variable Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Image Enhancement and Maintenance Services [Member] | Film Distribution [Member]
Disaggregation of Revenue [Line Items]
Revenues		3,152	1,464	4,841
Image Enhancement and Maintenance Services [Member] | Film Distribution [Member] | Fixed Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		554	205	3,000
Image Enhancement and Maintenance Services [Member] | Film Distribution [Member] | Variable Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		2,598	1,259	1,841
Image Enhancement and Maintenance Services [Member] | IMAX Maintenance Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues		56,608	53,339	21,999
Image Enhancement and Maintenance Services [Member] | IMAX Maintenance Segment [Member] | Fixed Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		56,608	53,339	21,999
Image Enhancement and Maintenance Services [Member] | IMAX Maintenance Segment [Member] | Variable Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Image Enhancement and Maintenance Services [Member] | Lease Arrangements [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Image Enhancement and Maintenance Services [Member] | Lease Arrangements [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0
Image Enhancement and Maintenance Services [Member] | Lease Arrangements [Member] | IMAX DMR [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Image Enhancement and Maintenance Services [Member] | Lease Arrangements [Member] | Film Post-Production [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Image Enhancement and Maintenance Services [Member] | Lease Arrangements [Member] | Film Distribution [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Image Enhancement and Maintenance Services [Member] | Lease Arrangements [Member] | IMAX Maintenance Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Image Enhancement and Maintenance Services [Member] | Finance Income [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Image Enhancement and Maintenance Services [Member] | Finance Income [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0
Image Enhancement and Maintenance Services [Member] | Finance Income [Member] | IMAX DMR [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Image Enhancement and Maintenance Services [Member] | Finance Income [Member] | Film Post-Production [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Image Enhancement and Maintenance Services [Member] | Finance Income [Member] | Film Distribution [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Image Enhancement and Maintenance Services [Member] | Finance Income [Member] | IMAX Maintenance Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Technology Rentals [Member]
Disaggregation of Revenue [Line Items]
Revenues		61,786	46,790	17,841
Technology Rentals [Member] | Fixed Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Technology Rentals [Member] | Variable Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Technology Rentals [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Revenues		18	606	335
Technology Rentals [Member] | Other [Member] | Fixed Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Technology Rentals [Member] | Other [Member] | Variable Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	335
Technology Rentals [Member] | Joint Revenue Sharing Arrangements, Contingent Rent [Member]
Disaggregation of Revenue [Line Items]
Revenues		61,768	46,184	17,841
Technology Rentals [Member] | Joint Revenue Sharing Arrangements, Contingent Rent [Member] | Fixed Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Technology Rentals [Member] | Joint Revenue Sharing Arrangements, Contingent Rent [Member] | Variable Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Technology Rentals [Member] | Lease Arrangements [Member]
Disaggregation of Revenue [Line Items]
Revenues		61,786	46,790	17,841
Technology Rentals [Member] | Lease Arrangements [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Revenues		18	606	0
Technology Rentals [Member] | Lease Arrangements [Member] | Joint Revenue Sharing Arrangements, Contingent Rent [Member]
Disaggregation of Revenue [Line Items]
Revenues		61,768	46,184	17,841
Technology Rentals [Member] | Finance Income [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Technology Rentals [Member] | Finance Income [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Technology Rentals [Member] | Finance Income [Member] | Joint Revenue Sharing Arrangements, Contingent Rent [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Finance Income Segment [Member] | IMAX Systems [Member]
Disaggregation of Revenue [Line Items]
Revenues		8,482	10,792	10,116
Finance Income Segment [Member] | IMAX Systems [Member] | Fixed Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Finance Income Segment [Member] | IMAX Systems [Member] | Variable Consideration [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Finance Income Segment [Member] | Lease Arrangements [Member] | IMAX Systems [Member]
Disaggregation of Revenue [Line Items]
Revenues		0	0	0
Finance Income Segment [Member] | Finance Income [Member] | IMAX Systems [Member]
Disaggregation of Revenue [Line Items]
Revenues		$ 8,482	$ 10,792	$ 10,116
[1] The Company’s largest customer represents 12 % of total Revenues as of December 31, 2022 (2021 ― 10 % ; 2020 ― 16 % ). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of December 31, 2022 and 2021 . Includes revenues earned from sale and sales-type lease arrangements involving new and upgraded IMAX Systems, as well as the impact of renewals and amendments to existing system arrangements.

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Additional Information (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Maintenance Services [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue Remaining Performance Obligation	$ 21	$ 20.2	$ 21.6

Segment Reporting - Additional

Segment Reporting - Additional Information (Details) - Segment	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Segment Reporting (Textual) [Abstract]
Description of products and services from which each reportable segment derives its revenues		The Company has the following reportable segments: (i) IMAX DMR; (ii) Joint Revenue Sharing Arrangements (“JRSA”); (iii) IMAX Systems; (iv) IMAX Maintenance; (v) Other Theater Business; (vi) Film Distribution; and (vii) Film Post-Production. The Company's activities that do not meet the criteria to be considered a reportable segment are disclosed within All Other. The Company organizes its reportable segments into the following three categories, identified by the nature of the product sold or service provided
Disclosure on geographic areas, description of revenue from external customers		No single country in the Rest of the World, Western Europe, Latin America, and Asia (excluding Greater China) classifications comprise more than 10% of total revenue.
Forecast [Member]
Segment Reporting (Textual) [Abstract]
Number of reportable segments	2

Segment Reporting - Segment Rep

Segment Reporting - Segment Reporting Information by Category and Reportable Segment (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues
Revenue	[1]	$ 300,805	$ 254,883	$ 137,003
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		156,355	134,406	21,540
Assets
Assets		821,154	883,247
Amortization
Amortization		56,661	56,082	52,704
Write-downs, including asset impairments and credit loss expense
Write-downs, including asset impairments and credit loss expense		15,723	(2,187)	36,337
Purchase of property, plant and equipment
Purchases of fixed assets		28,227	13,684	7,351
IMAX DMR [Member]
Revenues
Revenue	[1]	94,867	70,659	28,265
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		57,964	44,782	13,731
Assets
Assets		48,755	48,299
Amortization
Amortization		16,367	15,917	10,269
Write-downs, including asset impairments and credit loss expense
Write-downs, including asset impairments and credit loss expense		29	151	1,057
JRSA, Contingent Rent [Member]
Revenues
Revenue	[1]	61,768	46,184	17,841
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		37,394	21,761	(9,500)
Assets
Assets		193,403	196,789
Amortization
Amortization		23,920	24,208	26,076
Write-downs, including asset impairments and credit loss expense
Write-downs, including asset impairments and credit loss expense		973	364	1,784
Purchase of property, plant and equipment
Purchases of fixed assets		19,803	10,094	6,654
IMAX Technology Network [Member]
Revenues
Revenue	[1]	156,635	116,843	46,106
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		95,358	66,543	4,231
IMAX Systems [Member]
Revenues
Revenue	[1],[2]	62,933	65,660	54,055
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[2]	35,129	34,981	24,816
Assets
Assets		255,458	249,672
Amortization
Amortization		169	2,076	3,548
Write-downs, including asset impairments and credit loss expense
Write-downs, including asset impairments and credit loss expense		150	837	2,872
Purchase of property, plant and equipment
Purchases of fixed assets		2,574	621	50
IMAX Maintenance Reporting Unit [Member]
Revenues
Revenue	[1]	56,608	53,339	21,999
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		27,109	27,572	3,068
Assets
Assets		48,764	38,530
Amortization
Amortization				213
Write-downs, including asset impairments and credit loss expense
Write-downs, including asset impairments and credit loss expense		591	53	510
Purchase of property, plant and equipment
Purchases of fixed assets		4	25
JRSA, Fixed Fees [Member]
Revenues
Revenue	[1]	4,804	5,406	2,056
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		589	1,343	529
Assets
Assets		26,574	27,930
Other Theater Business [Member]
Revenues
Revenue	[3]	6,255	2,363	1,666
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[3]	807	398	(438)
Assets
Assets		110	82
IMAX Technology Sales and Maintenance [Member]
Revenues
Revenue	[1]	130,600	126,768	79,776
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		63,634	64,294	27,975
Post-Production [Member]
Revenues
Revenue	[1]	3,783	4,260	3,878
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		1,540	1,969	(358)
Assets
Assets		32,406	31,575
Amortization
Amortization			924	1,281
Purchase of property, plant and equipment
Purchases of fixed assets		1,195	609	456
Film Distribution [Member]
Revenues
Revenue	[4]	3,152	1,464	4,841
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[4]	(7,668)	(1,121)	(9,840)
Assets
Assets		11,545	7,185
Amortization
Amortization		2,423	600	1,213
Write-downs, including asset impairments and credit loss expense
Write-downs, including asset impairments and credit loss expense	[4]	819		9,997
Purchase of property, plant and equipment
Purchases of fixed assets		4,126	1,599
Sub-total for Reportable Segments
Revenues
Revenue	[1]	294,170	249,335	134,601
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		152,864	131,685	22,008
Assets
Assets		617,015	600,062
Amortization
Amortization		42,879	43,725	42,600
Write-downs, including asset impairments and credit loss expense
Write-downs, including asset impairments and credit loss expense		2,562	1,405	16,220
Purchase of property, plant and equipment
Purchases of fixed assets		27,702	12,948	7,160
Reportable Segments [Member]
Revenues
Revenue	[1]	6,935	5,724	8,719
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		(6,128)	848	(10,198)
Other [Member]
Revenues
Revenue	[1],[5]	6,635	5,548	2,402
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[5]	3,491	2,721	(468)
Assets
Assets	[5]	29,686	1,420
Amortization
Amortization	[5]	309		11
Write-downs, including asset impairments and credit loss expense
Write-downs, including asset impairments and credit loss expense	[5]			52
Purchase of property, plant and equipment
Purchases of fixed assets	[5]	9
Corporate and other non-segment specific assets [Member]
Assets
Assets		174,453	281,765
Amortization
Amortization		13,473	12,357	10,093
Write-downs, including asset impairments and credit loss expense
Write-downs, including asset impairments and credit loss expense	[5],[6]	13,161	(3,592)	20,065
Purchase of property, plant and equipment
Purchases of fixed assets		$ 516	$ 736	$ 191
[1] The Company’s largest customer represents 12 % of total Revenues as of December 31, 2022 (2021 ― 10 % ; 2020 ― 16 % ). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of December 31, 2022 and 2021 . The revenue from this segment includes the initial upfront payments and the present value of fixed minimum payments from sale and sales-type lease arrangements of IMAX Systems, as well as the present value of estimated variable consideration from sales of IMAX Systems. To a lesser extent, the revenue from this segment also includes finance income associated with these revenue streams. The revenue from this segment principally includes after-market sales of IMAX projection system parts and 3D glasses. For the year ended December 31, 2022 , the Company recorded an impairment loss of $ 0.8 million related to the write-down of documentary film assets. During the year ended December 31, 2020 , Film Distribution segment results were significantly influenced by impairment losses of $ 10.0 million, to write-down the carrying value of certain documentary and alternative content film assets due to a decrease in projected box office totals and related revenues based on management’s regular quarterly recoverability assessments. For the year ended December 31, 2022 , the Company recorded an impairment loss of $ 0.8 million related to the write-down of documentary film assets. All Other includes the results from IMAX Enhanced, SSIMWAVE, and other ancillary activities. In the first quarter of 2022, the Company's internal reporting was updated to reclassify the results of IMAX Enhanced out of the New Business Initiatives segment into All Other for segment reporting purposes. Prior period comparatives have been revised to conform with the current period presentation. (See Note 5 for additional information related to the Company's acquisition of SSIMWAVE. During the year ended December 31, 2022 , includes provision of current expected credit losses of $ 8.5 million ( 2021 ― net reversal of $ 4.0 million; 2020 ― provision of $ 18.6 million). (See Note 6 .)

Segment Reporting - Segment R_2

Segment Reporting - Segment Reporting Information by Category and Reportable Segment (Parenthetical) (Details) $ in Thousands, ¥ in Millions	3 Months Ended		12 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2022 CNY (¥)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 CNY (¥)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Segment Reporting Information [Line Items]
Percentage of total revenues represented by largest customer			12%	12%	10%	16%
Segment Reporting (Textual) [Abstract]
Impairment loss					$ 0
Film assets write downs on impairment loss			$ 800		200	$ 10,800
Amortization of deferred financing costs			3,177		2,513	902
Other assets write downs on impairment			4,500	¥ 30	0	1,151	[1]
Wanda Film (Horgos) Co. Ltd [Member]
Segment Reporting (Textual) [Abstract]
Investment in film impairment	$ 4,500	¥ 30
Distribution [Member]
Segment Reporting (Textual) [Abstract]
Impairment loss						10,000
Corporate and other non-segment specific assets [Member]
Segment Reporting (Textual) [Abstract]
Write-downs, included in current expected credit loss expense			$ 8,500		$ 4,000	$ 18,600
[1] In 2022 , the Company recognized a full impairment of its RMB 30.0 million ($ 4.5 million) investment in the film Mozart from Space based on projected box office results and distribution costs. (See Note 23(e).) In 2020 , the Company recorded a write-down of $ 1.2 million in Asset Impairments related to content-related assets which became impaired in the year. No such write-downs including asset impairments were incurred in 2021.

Segment Reporting - Geographic

Segment Reporting - Geographic Information (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues From External Customers And Long Lived Assets [Line Items]
Revenue	[1]	$ 300,805	$ 254,883	$ 137,003
United States [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenue		107,734	73,499	30,157
Greater China [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenue		73,330	112,801	52,331
Asia (excluding Greater China) [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenue		47,145	23,682	20,090
Western Europe [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenue		40,245	20,942	13,683
Latin America [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenue		9,418	3,601	6,114
Canada [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenue		7,550	3,266	1,365
Russia/the CIS & Ukraine [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenue	[2]	2,849	7,308	2,927
Rest of the World [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenue		$ 12,534	$ 9,784	$ 10,336
[1] The Company’s largest customer represents 12 % of total Revenues as of December 31, 2022 (2021 ― 10 % ; 2020 ― 16 % ). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of December 31, 2022 and 2021 . In addition to Russia, the CIS includes Azerbaijan, Belarus, Kazakhstan, and Kyrgyzstan. Commencing i n March 2022, in response to the ongoing conflict between Russia and Ukraine and resulting sanctions, the Company suspended its operations in Russia and Belarus. As of December 31, 2022, the IMAX network includes 54 systems in Russia, eight systems in Ukraine, and one system in Belarus.

Segment Reporting - Geographi_2

Segment Reporting - Geographic Information (Parenthetical) (Details)	Dec. 31, 2022 System
RU
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of Systems	54
UA
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of Systems	8
BY
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of Systems	1

Segment Reporting - Schedule of

Segment Reporting - Schedule of Property Plant and Equipment By Geographic Areas (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment	$ 252,896	$ 260,353
United States [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment	94,505	91,856
Greater China [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment	86,665	100,182
Canada [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment	36,385	32,643
Western Europe [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment	20,132	21,684
Asia (excluding Greater China) [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment	10,471	9,463
Rest of the World [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property, plant and equipment	$ 4,738	$ 4,525

Financial Instruments - Additio

Financial Instruments - Additional Information (Details) $ in Thousands, ¥ in Millions	1 Months Ended	3 Months Ended		12 Months Ended
	Feb. 28, 2021 USD ($) shares	Jun. 30, 2022 USD ($)	Jun. 30, 2022 CNY (¥)	Dec. 31, 2022 USD ($) Country	Jan. 10, 2022 USD ($)	Jan. 10, 2022 CNY (¥)	Dec. 31, 2021 USD ($)
Financial Instruments (Textual) [Abstract]
Cash and cash equivalents				$ 97,401			$ 189,711
Cash held outside of Canada				$ 79,700			102,100
Number of countries that generate box office | Country				87
Foreign Exchange contract settlement date range				settlement dates throughout 2023
Estimated gains to be reclassified to earnings within the next twelve months				$ 600
Investment in equity securities				1,035			1,087
Investment in equity securities - cost				$ 15,200
Equity securities restrictions				lock-up period of six months
Wanda Film (Horgos) Co. Ltd [Member]
Financial Instruments (Textual) [Abstract]
Investments in film					$ 4,700	¥ 30
Investment in film impairment		$ 4,500	¥ 30
Fixed Income Securities [Member]
Financial Instruments (Textual) [Abstract]
Equity Investment, Debt Securities				$ 1,000			1,000
Preferred Stock [Member] | Other Assets [Member]
Financial Instruments (Textual) [Abstract]
Investment in equity securities				$ 1,000			1,000
Maoyan [Member]
Financial Instruments (Textual) [Abstract]
Number of shares sold | shares	7,949,000
Gross proceeds from sale of investment	$ 17,800
Realized gain on fair value of investment	$ 5,200
Maximum [Member]
Financial Instruments (Textual) [Abstract]
Equity securities percentage ownership				1%
China [Member]
Financial Instruments (Textual) [Abstract]
Cash held/undistributed earnings				$ 43,700			$ 76,300

Financial Instruments - Fair Va

Financial Instruments - Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands		Dec. 31, 2022	Dec. 31, 2021
Other Financial Instrument
Cash and cash equivalents		$ 97,401	$ 189,711
Net investment in sales-type leases		28,332	28,392
Credit Facility borrowings		(36,111)	(2,472)
Carrying Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 1 [Member]
Other Financial Instrument
Cash and cash equivalents	[1]	97,401	189,711
Equity securities	[2]	1,035	1,087
Carrying Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2
Other Financial Instrument
Net financed sales receivables	[3]	101,052	112,657
Net investment in sales-type leases	[3]	28,332	28,392
Equity securities	[1]	1,000	1,000
COLI	[4]	3,398	3,275
Convertible Notes	[5]	(230,000)	(230,000)
Carrying Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 | HSBC China Facility [Member]
Other Financial Instrument
Credit Facility borrowings	[1]	(12,496)
Carrying Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 | Bank of China Facility [Member]
Other Financial Instrument
Credit Facility borrowings	[1]	(374)	(3,612)
Carrying Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 | Federal Economic Development Loan [Member]
Other Financial Instrument
Credit Facility borrowings	[3]	(1,782)
Carrying Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 | Wells Fargo Credit Facility [Member]
Other Financial Instrument
Credit Facility borrowings	[1]	(25,000)
Carrying Amount, Fair Value Disclosure [Member] | Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2
Other Financial Instrument
Foreign exchange contracts forwards	[2]	(649)	79
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 1 [Member]
Other Financial Instrument
Cash and cash equivalents	[1]	97,401	189,711
Equity securities	[2]	1,035	1,087
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2
Other Financial Instrument
Net financed sales receivables	[3]	100,059	112,662
Net investment in sales-type leases	[3]	27,972	28,407
Equity securities	[1]	1,000	1,000
COLI	[4]	3,398	3,275
Convertible Notes	[5]	(196,717)	(223,100)
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 | HSBC China Facility [Member]
Other Financial Instrument
Credit Facility borrowings	[1]	(12,496)
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 | Bank of China Facility [Member]
Other Financial Instrument
Credit Facility borrowings	[1]	(374)	(3,612)
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 | Federal Economic Development Loan [Member]
Other Financial Instrument
Credit Facility borrowings	[3]	(1,782)
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 | Wells Fargo Credit Facility [Member]
Other Financial Instrument
Credit Facility borrowings	[1]	(25,000)
Estimate of Fair Value, Fair Value Disclosure [Member] | Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2
Other Financial Instrument
Foreign exchange contracts forwards	[2]	$ (649)	$ 79
[1] Recorded at cost, which approximates fair value. Fair value is determined using quoted prices in active markets. Fair value is estimated based on discounting future cash flows at currently available interest rates with comparable terms. Measured at cash surrender value, which approximates fair value. Fair value is determined using quoted market prices that are observable in the market or that could be derived from observable market data.

Financial Instruments - Notiona

Financial Instruments - Notional Amount of Derivative (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Foreign exchange contracts — Forwards	$ 24,707	$ 26,702

Financial Instruments - Fair _2

Financial Instruments - Fair Value of Foreign Exchange Contracts (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Derivatives Fair Value [Line Items]
Foreign currency derivatives	$ 50	$ 184
Not Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Derivative Liability, Fair Value	(649)	79
Other Assets [Member] | Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Foreign currency derivatives	50	184
Accrued and other liabilities [Member] | Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Derivative Liability, Fair Value	$ (699)	$ (105)

Financial Instruments - Derivat

Financial Instruments - Derivatives in Foreign Currency Hedging Relationships (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Derivative Instruments Gain Loss [Line Items]
Derivative (Loss) Gain Recognized in OCI (Effective Portion)	$ (1,323,000)	$ 468,000	$ 500,000
Derivative (Loss) Gain Reclassified from AOCI (Effective Portion) included in Selling, general and administrative expenses	(596,000)	1,707,000	(578,000)
Realized net loss (gain) from cash flow hedging instruments	(596,000)	1,707,000	(604,000)
Derivative Gain (Loss) Recognized In and Out of OCI (Effective Portion)	0	0	17,000
Fair Value Hedging [Member]
Derivative Instruments Gain Loss [Line Items]
Derivative (Loss) Gain Recognized in OCI (Effective Portion)	(1,323,000)	468,000	550,000
Inventories [Member]
Derivative Instruments Gain Loss [Line Items]
Realized net loss (gain) from cash flow hedging instruments	$ 0	$ 0	$ (26,000)

Financial Instruments - Non Des

Financial Instruments - Non Designated Derivatives in Foreign Currency Relationships (Details) - Not Designated as Hedging Instrument [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Derivative Instruments Gain Loss [Line Items]
Derivative Gain Reclassified From AOCI (Ineffective portion)		$ (318)
Foreign Exchange Contracts - Forwards [Member]
Derivative Instruments Gain Loss [Line Items]
Location of Derivative Gain	$ 0	$ 398	$ 344
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, General and Administrative Expense	Selling, General and Administrative Expense	Selling, General and Administrative Expense

Employee's Pension and Postreti

Employee's Pension and Postretirement Benefits - Additional Information (Details) - USD ($) $ in Thousands		12 Months Ended
	Sep. 19, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Deferred Compensation Plan [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Deferred compensation plan description		The Company maintained a nonqualified deferred compensation benefit plan (the “Retirement Plan”) covering the former CEO of IMAX Entertainment and Senior Executive Vice President of the Company. Under the terms of the Retirement Plan, the benefits were due to vest in full if the executive incurred a separation from service from the Company (as defined therein).
Deferred Compensation Plan [Member] | Accrued and Other Liabilities [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Benefit obligation recorded		$ 3,900	$ 3,800
Deferred Compensation Plan [Member] | Prepaid Expenses [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Company-owned life insurance		$ 3,400	3,300
SERP Benefits [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Defined benefit pension plan		The Company has an unfunded defined benefit pension plan, the Supplemental Executive Retirement Plan (the “SERP”), covering its CEO, Richard L. Gelfond.
Companies contribution and expenses		$ 0
Expected interest costs in the remainder of the year		800
Expected interest costs		$ 160	72	$ 379
Defined Contribution Plan [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Defined contribution plans for employees		The Company also maintains defined contribution plans for its employees, including its executive officers. The Company makes contributions to these plans on behalf of employees in an amount up to 5% of their base salary subject to certain prescribed maximums.
Maximum percentage of base salary contributed to Defined Contribution Plan by Company		5%
Canadian Plan [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Companies contribution and expenses		$ 1,100	1,100	1,100
Us Internal Revenue Code [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Companies contribution and expenses		700	500	600
Postretirement Benefits Canadian Employees [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Expected interest costs		46	$ 42	$ 47
Postretirement Benefits Canadian Employees [Member] | Maximum [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Expected interest costs		$ 100
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]		Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component
Richard L. Gelfond [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Benefit payable	$ 20,300

Employee's Pension and Postre_2

Employee's Pension and Postretirement Benefits - Summary of Amounts Accrued for the SERP (Details) - SERP Benefits [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Amounts Accrued
Obligation, beginning of period	$ 20,056	$ 20,116
Interest cost	160	72	$ 379
Actuarial gain	(2,901)	(132)
Obligation, end of period and unfunded status	$ 17,315	$ 20,056	$ 20,116

Employee's Pension and Postre_3

Employee's Pension and Postretirement Benefits - Summary of Accumulated Other Comprehensive (Loss) Income and Components of Net Periodic Benefit Cost in Future Periods (Details) - SERP Benefits [Member] - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Components of net periodic benefit cost in future periods
Unrealized actuarial (gain) loss	$ (3,580)	$ (679)	$ (547)
Unamortized prior service cost		184	369
Net periodic benefit costs to be recognized in future periods	$ (3,580)	$ (495)	$ (178)

Employee's Pension and Postre_4

Employee's Pension and Postretirement Benefits - Summary of Disclosure of Pension Expense (Details) - SERP Benefits [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net periodic benefit cost
Interest cost	$ 160	$ 72	$ 379
Amortization of prior service cost	$ 184	$ 185	$ 87
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Amortization of Prior Service Cost (Credit), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income Defined Benefit Plan Amortization Prior Service Cost Credit Arising During Period Before Tax	Other Comprehensive Income Defined Benefit Plan Amortization Prior Service Cost Credit Arising During Period Before Tax	Other Comprehensive Income Defined Benefit Plan Amortization Prior Service Cost Credit Arising During Period Before Tax
Pension expense	$ 344	$ 257	$ 466

Employee's Pension and Postre_5

Employee's Pension and Postretirement Benefits - Summary of Assumptions to Determine SERP Obligation and Any Related Costs (Details)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
SERP Benefits [Member]
Assumptions used to determine obligation and cost status
Discount rate	4.55%	0.80%	0.36%

Employee's Pension and Postre_6

Employee's Pension and Postretirement Benefits - Summary of Amounts Include within Accrued and Other Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Postretirement Benefits Executives [Member]
Defined Benefit Plan Disclosure [Line Items]
Obligation, beginning of period	$ 662	$ 710
Interest cost	18	16	$ 20
Benefits paid	(8)	(16)
Actuarial gain	(215)	(48)
Obligation, end of period and unfunded status	457	662	710
Postretirement Benefits Canadian Employees [Member]
Defined Benefit Plan Disclosure [Line Items]
Obligation, beginning of period	1,702	1,862
Interest cost	46	42	47
Benefits paid	(155)	(118)
Actuarial gain	(539)	(92)
Unrealized foreign exchange (gain) loss	(78)	8
Obligation, end of period and unfunded status	$ 976	$ 1,702	$ 1,862

Employee's Pension and Postre_7

Employee's Pension and Postretirement Benefits - Summary of Components of Pension Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Postretirement Benefits Executives [Member]
Defined Benefit Plan Disclosure [Line Items]
Interest cost	$ 18	$ 16	$ 20
Amortization of actuarial gain			$ (17)
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Immediate Recognition of Actuarial Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]			Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax
Pension expense	18	16	$ 3
Postretirement Benefits Canadian Employees [Member]
Defined Benefit Plan Disclosure [Line Items]
Interest cost	46	42	47
Pension expense	$ 46	$ 42	$ 47

Employee's Pension and Postre_8

Employee's Pension and Postretirement Benefits - Summary of Accumulated Other Comprehensive (Loss) Income and Components of Net Pension Cost in Future Periods (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Postretirement Benefits Executives [Member]
Components of net periodic benefit cost in future periods
Unrealized actuarial (gain) loss	$ (242)	$ (27)	$ 21
Postretirement Benefits Canadian Employees [Member]
Components of net periodic benefit cost in future periods
Unrealized actuarial (gain) loss	$ (354)	$ 185	$ 277

Employee's Pension and Postre_9

Employee's Pension and Postretirement Benefits - Summary of Weighted Average Assumptions Used to Determine the Benefit Obligation (Details)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Postretirement Benefits Executives [Member]
Assumptions used to determine obligation and cost status
Discount rate	5.01%	2.71%	2.36%
Postretirement Benefits Canadian Employees [Member]
Assumptions used to determine obligation and cost status
Discount rate	5%	2.80%	2.30%

Employee's Pension and Postr_10

Employee's Pension and Postretirement Benefits - Summary of Weighted Average Assumptions Used to Determine the Net Postretirement Benefit Expense (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Postretirement Benefits Executives [Member]
Assumptions used to determine obligation and cost status
Discount rate used in calculating net periodic benefit cost	2.71%	2.36%	3.13%
Postretirement Benefits Canadian Employees [Member]
Assumptions used to determine obligation and cost status
Discount rate used in calculating net periodic benefit cost	2.80%	2.30%	3.05%

Employee's Pension and Postr_11

Employee's Pension and Postretirement Benefits - Summary of Benefit Payment are Expected in Next Five Year (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Postretirement Benefits Executives [Member]
Pension and Postretirement benefits obligations
2023	$ 10
2024	10
2025	11
2026	23
2027	24
Thereafter	888
Total expected future benefit payment	966
Postretirement Benefits Canadian Employees [Member]
Pension and Postretirement benefits obligations
2023	94
2024	94
2025	95
2026	87
2027	86
Thereafter	1,082
Total expected future benefit payment	$ 1,538

Government Assistance - Additio

Government Assistance - Additional Information (Details)		12 Months Ended			48 Months Ended
	May 29, 2019 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 CAD ($)	May 29, 2019 CAD ($)
Impact of COVID-19 Pandemic [Member]
Government Assistance [Line Items]
Proceeds from government subsidies		$ 400,000	$ 3,800,000	$ 7,100,000
Impact of COVID-19 Pandemic [Member] | Selling, General and Administrative Expenses [Member]
Government Assistance [Line Items]
Proceeds from government subsidies		300,000	2,900,000	6,000,000
Impact of COVID-19 Pandemic [Member] | Costs and Expenses Applicable to Revenues [Member]
Government Assistance [Line Items]
Proceeds from government subsidies		100,000	900,000	1,000,000
Impact of COVID-19 Pandemic [Member] | Research and Development [Member]
Government Assistance [Line Items]
Proceeds from government subsidies			$ 0	$ 100,000
Federal Economic Development Loan Payable [Member]
Government Assistance [Line Items]
Loans payable		2,812,000			$ 2,812,000
Debt instrument, fair value		1,782,000			$ 1,782,000
SSIMWAVE Inc. [Member] | Federal Economic Development Loan Payable [Member]
Government Assistance [Line Items]
Percentage of contributions cover eligible and supported costs					35%
Contributions repayable months	60 months
Debt instrument repayment beginning month and year	2024-01
Debt instrument, annual interest rate	0%						0%
Loans payable		$ 2,800,000			$ 2,800,000	$ 3,800,000
SSIMWAVE Inc. [Member] | Maximum [Member] | Federal Economic Development Loan Payable [Member]
Government Assistance [Line Items]
Debt instrument, principal amount	$ 3,100,000						$ 4,200,000

Non-Controlling Interests - Add

Non-Controlling Interests - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2014 USD ($) Film
Redeemable Noncontrolling Interest [Line Items]
Non-controlling interests	$ 65,691	$ 73,531
Net income (loss) attributable to non-controlling interests	2,923	12,752	$ (13,711)
Investment in film assets	$ 19,598	$ 14,810	7,665
IMAX China Noncontrolling Interest
Redeemable Noncontrolling Interest [Line Items]
Minority Interest Ownership Percentage By Company	71.73%	71.11%
IMAX China
Redeemable Noncontrolling Interest [Line Items]
Non-controlling interests	$ 65,700	$ 73,500
Net income (loss) attributable to non-controlling interests	3,000	12,800	(8,600)
Other Noncontrolling Interest [Member]
Redeemable Noncontrolling Interest [Line Items]
Net income (loss) attributable to non-controlling interests	$ (36)	$ (1)	$ (5,139)
Non-controlling interest description	The Company’s Original Film Fund was established in 2014 to co-finance a portfolio of 10 original large-format films. The initial investment in the Original Film Fund was committed by a third party in the amount of $25.0 million, with the possibility of contributing additional funds. The Company has contributed $9.0 million to the Original Film Fund since 2014, and has reached its maximum contribution.
Number of expected original films | Film				10
Investment in film assets	$ 22,300
Other Noncontrolling Interest [Member] | Third Party [Member]
Redeemable Noncontrolling Interest [Line Items]
Film fund committed capital contribution				$ 25,000
Other Noncontrolling Interest [Member] | IMAX [Member]
Redeemable Noncontrolling Interest [Line Items]
Film fund contributions paid	$ 9,000

Non-Controlling Interests - Sum

Non-Controlling Interests - Summary of Movement of the Non-controlling Interest in Temporary Equity in Original Film Fund (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Non-controlling Interests
Net loss	$ 2,923	$ 12,752	$ (13,711)
Other Noncontrolling Interest [Member]
Non-controlling Interests
Beginning Balance	758	759	5,908
Return of capital to non-controlling interests			(10)
Net loss	(36)	(1)	(5,139)
Ending Balance	$ 722	$ 758	$ 759